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3Abstract
This thesis investigates the epidemiology of sequential pregnancies among HIV-positive
women in the United Kingdom and Ireland, and explores the health, therapeutic and
obstetric management, and pregnancy outcomes, of the women experiencing them. Data
from the UK and Ireland’s National Study of HIV in Pregnancy and Childhood (NSHPC) are
analysed. This is a well-established, active, comprehensive national surveillance study with
over 1500 pregnancies currently reported each year.
The findings demonstrate that a substantial and increasing proportion of pregnancies are
women’s second or subsequent since their HIV diagnosis (39% in 2009), with a rate of 6.7
(95% CI: 6.5-6.9) per 100 woman-years during 1990-2009. Analyses revealed potential
missed opportunities for the timely initiation of antiretroviral therapy (ART) in this group of
previously diagnosed women, both within and outside the context of pregnancy. Variations
in women’s engagement with HIV and pregnancy-related care are explored.
In the contemporary context of effective prevention of mother-to-child transmission
(PMTCT) interventions there are unanswered questions around the optimal management of
HIV-positive women of childbearing age. Exposure to short-course protease inhibitor-based
combination ART for PMTCT did not impact on response to therapy in subsequent
pregnancies, supporting current UK recommendations. However, analyses of the
immunological status and virological outcomes in second pregnancies to women not on
ART at conception suggest that initiating lifelong ART in pregnancy may have benefits for
maternal health and the risk of vertical transmission in future pregnancies. Adverse
pregnancy and perinatal outcomes are investigated among women’s repeat pregnancies,
which were for example, more likely to be conceived on ART than index pregnancies.
Finally, patterns in mode of delivery for women’s sequential births are explored.
The analyses presented in this thesis inform the evidence-base for the effective
management of HIV-positive women in the context of current and potential future
pregnancies.
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Chapter 1 Introduction
1.1 Overview of HIV
1.1.1 Global epidemiology of HIV
In 2012 an estimated 35.3 million adults were living with Human Immunodeficiency Virus (HIV)
worldwide, half of whom were women. Over the last decade there has been a 33% reduction in
the annual number of new infections among adults and children (from 3.4 million in 2001 to 2.3
million in 2012). This reflects the natural course of the epidemic, combined with the impact of
prevention measures, particularly behaviour change programmes which have resulted in the
adoption of safer sexual practices, together with expanded access to antiretroviral therapy
(ART). Although there have been recent increases in the number of people living with HIV, this
is due to the expansion of treatment programmes, and consequent reduction in HIV-related
deaths (which declined from 2.3 million in 2005 to 1.6 million in 2012). There are, however,
significant geographic variations. Globally, the highest prevalence of HIV is in sub-Saharan
Africa where 4.7% of adults aged 15-49 years were living with HIV in 2012, with particularly
high prevalence in the countries of Southern Africa (Figure 1.1) (UNAIDS, 2013).
There are variations across sub-Saharan Africa, but many countries are now experiencing
generalised epidemics (i.e. prevalence of HIV among the general population exceeds 1%
(World Health Organization, 2013)). In this region women are at disproportionate risk, now
accounting for 57% of all those living with HIV. Significant gender inequalities exist in many
areas making women particularly vulnerable to HIV, with factors such a gender-based violence,
poorer access to education and economic opportunities, as well as women’s greater
physiological vulnerability to HIV all thought to play a role (UNAIDS, 2013). Many other regions
of the world have epidemics that are concentrated among specific high risk groups which
include men who have sex with men (MSM), people who inject drugs and sex workers. In much
of Western Europe and the United States (US), migrants from high prevalence areas of the
world and MSM bear the greatest burden of HIV, while the epidemic in much of Central Asia
and Eastern Europe is particularly focused among injecting drug users and their sex partners
(Centers for Disease Control and Prevention, 2012; European Centre for Disease Prevention
and Control/ WHO Regional Office for Europe, 2013; UNAIDS, 2011b).
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Figure 1.1 Global HIV prevalence among adults, 2012
1.1.2 Epidemiology of HIV in the United Kingdom (UK)
In the UK1 there were an estimated 98,400 people living with HIV in 2012, one in five of whom
(21,900) were unaware of their status. Approximately one third (31,700) were women, and the
majority (82%) of diagnosed women are of childbearing age (15-49 years)2. There were 6360
new HIV diagnoses overall (1800 in women) during 2012. New diagnoses increased
substantially to a peak of almost 8000 in 2005 but have since been declining (Figure 1.2), as a
result of reductions in new diagnoses among heterosexuals originating from high prevalence
areas of the world. Diagnoses among MSM have, however, continued to increase and
accounted for just over half of diagnoses in 2012 (Aghaizu et al, 2013).
1 Data from Ireland are not collected as part of routine HIV surveillance by Public Health England (PHE),
therefore information is presented for the UK only.
2 The proportion of women who were of childbearing age was calculated among those with diagnosed HIV
attending HIV care during in 2012. Data obtained from (Aghaizu et al, 2013, Appendix 6).
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Figure 1.2 Annual new HIV and AIDS diagnoses and deaths, UK, 1981-2012
Source: (Aghaizu et al, 2013)
The overall prevalence of HIV among the UK population was 0.15% in 2012 (0.1% in women
and 0.2% in men), but is much higher in certain population groups with one in 20 MSM (0.47%)
living with HIV (one in 12 in London). Meanwhile, 5.1% of black African women and 2.6% of
black African men in the UK were living with HIV in 2012, reflecting the high prevalence of HIV
in sub-Saharan Africa. Black African women were less likely to have undiagnosed HIV than
men, most likely due to the effectiveness of the antenatal screening programme (which is
discussed further in Section 1.2.1 of this chapter). There are also geographic variations in
prevalence; 20% of local authorities (18 of which were in London) have been classed as ‘high
prevalence’ areas with ≥0.2% of the adult (15-59 year old) population living with diagnosed HIV 
(Aghaizu et al, 2013).
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1.1.3 Natural history and transmission
HIV is a retrovirus that causes Acquired Immunodeficiency Syndrome (AIDS). There are
currently two known types of HIV: HIV-1 and HIV-2. HIV-1 is both more virulent and more
infectious (Peeters et al, 2013). HIV-1 is the dominant type throughout most of the world while
HIV-2 is confined largely to West Africa (Lemey et al, 2003; Peeters et al, 2013). HIV-1 is
divided into four main groups, ‘M’ being the most common, and these groups are further
divided into a number of types and sub-types reflecting the high genetic variability of the virus
(Peeters et al, 2013).
HIV contains two copies of single-stranded ribonucleic acid (RNA), together with various
enzymes, including reverse transcriptase, integrase and protease, required for the
development of new virus particles. Glycoproteins (gp120 receptors) on the surface of the virus
particles enable virons to bind with CD4 lymphocytes (‘T helper cells’); viral RNA can
subsequently enter the nucleus of the host cell. From here viral RNA is converted to
deoxyribonucleic acid (DNA) by reverse transcriptase, and then enters the nucleus of the host
cell where it is spliced into the DNA of the host cell. When the host lymphocyte becomes
active, new virus particles are produced via the replication processes of the host cell. These
new virus particles subsequently bud off and infect other CD4 cells (Mortimer et al, 2001).
Through this process HIV systematically destroys CD4 cells (Pantaleo et al, 1993), thereby
causing a decline in the host’s immune function.
In the natural course of HIV disease, the initial ‘acute phase’ is characterised by rapid viral
replication and consequent sharp decline in CD4 T-lymphocyte cell count, hereafter referred to
as CD4 count. An immune response to HIV is elicited within the first three months which results
in some recovery in CD4 count and a substantial reduction in viral load. Then ensues a
clinically latent phase of around 10 years, during which there is a gradual decline in CD4 cells.
This continues until the immune system is weakened to such a degree that opportunistic
diseases begin to occur (Pantaleo et al, 1993). AIDS is defined as a CD4 count of <200 cells/µl
or the diagnosis of an AIDS-definition condition (World Health Organization, 2007)3. In the
absence of treatment, death from AIDS usually occurs within around two years (Lemp et al,
1990; Mocroft et al, 1997).
3 The WHO provides a comprehensive list of AIDS-defining conditions. Examples include
Pneumocystis pneumonia, active tuberculosis disease, HIV wasting syndrome, and Kaposi sarcoma (World
Health Organization, 2007).
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HIV can be present in bodily fluids including blood and blood products, semen, vaginal
secretions and breast milk. The virus can thus be transmitted through unprotected sex (the
most common route of transmission globally), receipt of infected blood, blood products or
organs, the use of contaminated needles and from mother to child (Adler, 2001). The likelihood
of transmission is highly dependent on the circulating viral load (Quinn et al, 2000;
Tovanabutra et al, 2002).
1.1.4 Diagnosis
There are several methods for the diagnosis of HIV, including both serological and virological
tests. Serologic methods detect antibodies to the virus and/or the p24 viral antigens (p24) in
the blood, while the presence of viral DNA and RNA can be detected by means of the
polymerase chain reaction (PCR) (Fearon, 2005). Current UK guidelines recommend the use
of serological assays which detect both antibodies and antigens simultaneously. HIV RNA viral
load tests are not recommended for diagnosis due to the potential for false-positive results
(British HIV Association et al, 2008).
In the UK, both the estimated proportion of HIV infections that remain undiagnosed (22% in
2012), and the proportion of infections diagnosed late4 (47% in 2012) (Aghaizu et al, 2013),
remain worryingly high. Individuals diagnosed at a late stage of disease have greater morbidity
and mortality (Aghaizu et al, 2013; Chadborn et al, 2006; May et al, 2011a). Furthermore,
undiagnosed and hence untreated infection presents a major barrier to HIV control at the
population level as the virus may, for example, be unwittingly passed on to sexual partners,
particularly in the presence of high viral loads (Marks et al, 2006). In light of this, concerted
efforts have been made to increase the uptake of HIV testing among high risk groups (Health
Protection Agency, 2011b). UK national guidelines for HIV testing published in 2008
recommend universal testing of adults presenting to general practice or other medical services
in areas where the prevalence exceeds 0.2%. Universal testing is also recommended in certain
settings such as sexual health clinics and antenatal services, and for all those falling into high
risk groups e.g. MSM and partners of diagnosed individuals (British HIV Association et al,
2008). More recently, innovative strategies such as the use of home sampling kits, available to
order online with samples sent to the laboratory for testing, have been implemented (Aghaizu
et al, 2013; Nardone et al, 2013).
4 Based on a ‘late diagnosis’ definition of CD4 <350 cell/µl within three months of HIV diagnosis (Aghaizu et al,
2013). The definition of late diagnosis (or presentation to care) has changed over time with a threshold of <200
cells/µl previously used in the UK (Chadborn et al, 2006).
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1.1.5 Treatment
The advent and impact of ART
There have been significant advances in the treatment of HIV since the first antiretroviral drug,
zidovudine, a nucleoside reverse transcriptase inhibitor (NRTI), was found to be effective
against HIV in 1987 (Fischl et al, 1987). With the subsequent identification of further agents
that prevent HIV viral replication, including both non-nucleoside reverse transcriptase inhibitors
(NNRTIs) and protease inhibitors (PIs), in the mid-1990’s it was demonstrated that treating
patients with a combination of antiretrovirals suppressed viral load more effectively than
zidovudine alone (Hammer et al, 1996). This hailed the advent of highly active antiretroviral
therapy (HAART), a combination of three or more antiretrovirals (also now known as
combination antiretroviral therapy (cART)), commonly consisting of two NRTIs and either an
NNRTI or a PI. There are now a number of different classes of antiretrovirals, each targeting a
different phase of the HIV lifecycle. The main classes and their mechanisms of action are
provided in Table 1.1. The most commonly used classes are NRTIs, NNRTIs and PIs.
Ritonavir, a PI, is prescribed alongside cART, not for its own antiretroviral activity but because
it inhibits the host enzyme that breaks down other PIs thus leading to higher concentrations
(“boosting”) of these drugs in the patient. The World Health Organization (WHO) recommends
that first line HIV therapy consists of two NRTIs plus one NNRTI (tenofovir and lamivudine or
emtricitabine) plus efavirenz, assuming no contraindications (World Health Organization,
2013). Meanwhile, UK guidelines for the treatment of adults recommend that two NRTIs are
combined with either an NNRTI, a ritonavir-boosted PI or an integrase inhibitor (INI), the
preferred regimen being tenofovir and emtricitabine plus either boosted atazanavir, boosted
darunavir, efavirenz or raltegravir (Williams et al, 2012).
cART has dramatically improved the lives of people living with HIV. With early diagnosis and
appropriate treatment, HIV-positive5 people can now have a near normal life expectancy (May
et al, 2011b; Nakagawa et al, 2012; Samji et al, 2013; van Sighem et al, 2010). Adherence to
treatment is paramount for maintaining high levels of viral suppression, though required levels
of adherence vary by regimen (Maggiolo et al, 2007; Nachega et al, 2007; Paterson et al,
2000; Shuter, 2008).
5 “HIV-positive” is largely used in place of “people (or women) living with HIV” in this thesis for brevity (both
refer to the diagnosed population).
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Table 1.1 Main classes of antiretrovirals
Drug class Mechanism of action Examples
Non-nucleoside reverse
transcriptase inhibitors
(NNRTIs)
Inhibit the function of the
reverse transcriptase enzyme
required for HIV replication
nevirapine (NVP), efavirenz
(EFV)
Nucleoside reverse
transcriptase inhibitors
(NRTIs)
Inhibit the function of the
reverse transcriptase enzyme
required for HIV replication
zidovudine (ZDV, AZT),
tenofovir (TDF),
emtricitabine (FTC), abacavir
(ABC), lamivudine (3TC),
stavudine (d4T)
Protease inhibitors (PIs) Block the protease enzyme atazanavir (ATV), darunavir
(DRV), nelfinavir (NFV)
Fusion (or entry) inhibitors Blocks the virus from entering
host CD4 lymphocytes
maraviroc (MVC)
Integrase inhibitors (INI) Blocks the intergrase enzyme raltegravir (RAL)
Source: Based on information from the US Department of Health and Human Sciences. Available at:
http://www.niaid.nih.gov/topics/HIVAIDS/Understanding/Treatment/pages/arvdrugclasses.aspx (Accessed
January 2014).
Drug resistance
Due to the rapid and error-prone replication of HIV, the development of resistance to
antiretrovirals is a major issue (Clavel et al, 2004; Tang et al, 2012). Resistance may be
transmitted, whereby an individual is infected with a resistant strain, or acquired, when an
individual develops resistance through drug selection pressure (Clavel et al, 2004; Tang et al,
2012). Resistance to PIs occurs less frequently than for NNRTIs as they have a higher ‘genetic
barrier’ to the development of resistance; several mutations are required for resistance to occur
(Clavel et al, 2004; de Mendoza et al, 2004; Tang et al, 2012). Meanwhile, resistance occurs
less frequently under cART regimens than with single or dual drug therapy since the high
levels of viral suppression maintained by cART minimise the replication of any resistant virus
that may emerge. Resistance mutations can, however, still occur in the presence of cART
(Clavel et al, 2004; Dolling et al, 2012; Paredes et al, 2010; Phillips et al, 2005).
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Timing of ART initiation
There is uncertainty and debate with regards to the optimal timing of ART initiation among HIV-
positive adults. Though the benefits of ART initiation among those with CD4 counts of <350
cells/µl are now widely agreed (European AIDS Cinical Society, 2013; Panel on Antiretroviral
Guidelines for Adults and Adolescents, 2013; Williams et al, 2012; World Health Organization,
2013), the benefits and risks of starting ART in asymptomatic people with higher CD4 counts
are uncertain. A recent review of national and international HIV treatment guidelines
highlighted the disparities in recommendations and the differing methodologies used to assess
the evidence-base (Sabin et al, 2013). Although current UK guidelines do not recommend ART
for those with CD4 counts of ≥350 cells/µl, except for some specific groups such as those with 
certain co-infections (Williams et al, 2012), they do allow for the continuation of ART after
pregnancy in women with CD4 counts of 350-500 cells/µl who wish to stay on treatment
(Taylor et al, 2012). Meanwhile, recent WHO guidelines recommend the initiation of ART when
CD4 counts fall to ≤500 cells/µl (the threshold was previously <350 cells/µl) (World Health 
Organization, 2013), and the latest European guidelines state that treatment may be
considered for those with CD4 counts of ≥350 cells/µl (European AIDS Cinical Society, 2013). 
Some guidelines now recommend treatment for all people living with HIV, even those with CD4
counts >500 cells/µl (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2013;
Thompson et al, 2012). The Strategic Timing of Antiretroviral Therapy (START) is a large,
international clinical trial currently underway to assess the risks and benefits of starting ART
among people with CD4 counts of >500 cells/µl (Babiker et al, 2013), the results of which
should contribute to the evidence-base.
HIV treatment as prevention
The effectiveness of cART in reducing viral load to undetectable levels has led to “HIV
treatment as prevention” becoming an area of active research and growing interest (Cohen et
al, 2007; Eaton et al, 2012; Granich et al, 2009; Hosseinipour et al, 2002; Montaner et al, 2006;
Montaner et al, 2010; World Health Organization, 2013). The move towards the earlier initiation
of ART, including new WHO recommendations (World Health Organization, 2013), is being
driven not only by the clinical benefits for the individual, but also evidence that people on
effective treatment with undetectable viral loads have a very low risk of onward transmission of
HIV (Cohen et al, 2011; Quinn et al, 2000; Tovanabutra et al, 2002)6. The trial by Cohen et al,
conducted in nine countries, was hailed as a major breakthrough in HIV prevention. Patients
with CD4 counts of 350-550 cells/µl in serodiscordant partnerships were randomised to either
6 Indeed, the title of the most recent (2013) WHO guideline on the use of antiretrovirals is “Consolidated
guidelines on the use of antiretroviral drugs for treating and preventing HIV infection”.
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immediate ART initiation or delayed initiation (at CD4 ≤250 cells/µl). Of the 28 transmissions 
that could be genetically linked to the HIV-positive partner, only one occurred in the immediate
therapy group (hazard ratio (HR): 0.04, 95% CI: 0.01-0.27). Current UK guidelines recommend
that patients are made aware that being on ART reduces the risk of passing HIV to their sexual
partners (Fidler et al, 2013).
1.2 HIV in pregnant women
1.2.1 Antenatal HIV screening
Ensuring that women living with HIV are diagnosed during, if not before, pregnancy is an
essential component of interventions for the prevention of vertical transmission, as well as
improving the woman’s prognosis7. During the 1990’s there were high levels of undiagnosed
HIV among pregnant women (an estimated two-thirds of pregnant women were undiagnosed in
1997), reflecting the low uptake of the existing ‘opt-in’ approach to HIV antenatal screening
(Gibb, 2000; Tookey et al, 1998). Recognising the importance of diagnosing HIV in pregnant
women, in 1999 the Department of Health for England introduced a policy to offer and
recommend a voluntary antenatal HIV test to all pregnant women with a target of 80% uptake
by the end of 2002 (NHS Executive, 1999). Similar policies were subsequently adopted in
Wales, Scotland and Northern Ireland. Uptake of antenatal HIV screening has risen
substantially since then with national uptake in England reaching 98% in 2012 (Figure 1.3)
(Public Health England, 2013a; Townsend et al, 2006).
7 As a consequence of earlier diagnosis (Aghaizu et al, 2013; Chadborn et al, 2006; May et al, 2011a).
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Figure 1.3 Trends in uptake of antenatal HIV screening in England, 2005-2012
Source: Based on data from Public Health England; data are collected through the National Antenatal
Infections Screening Monitoring (NAISM). Data tables for 2005-2012. Available at:
http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1245581538007 (Accessed December
2013).
1.2.2 Epidemiology of HIV in pregnant women in the UK and Ireland
In 2012, 0.19% of women tested through the voluntary antenatal scheme had a positive result,
and this has been relatively stable in recent years (Public Health England, 2013a). Meanwhile,
based on data from the neonatal dried blood spot survey (an unlinked anonymous survey of
maternal HIV infection using neonatal dried blood spots which therefore includes all women
giving birth, regardless of whether diagnosed or not) the estimated prevalence was 0.22%8.
Consistent with what is known about the distribution of HIV among the UK population, the
highest prevalence was in women from sub-Saharan Africa (2.3%) (Aghaizu et al, 2013).
By the end of 2012, over 16,000 pregnancies to diagnosed HIV-positive women had been
reported to the UK and Ireland National Study of HIV in Pregnancy and Childhood (NSHPC)
since surveillance began in 1989, with over 1500 reported each year since 2007 (National
8 The unlinked anonymous pregnant women surveys use leftover neonatal dried blood spots routinely taken
from newborns around 10 days after birth to test for maternal HIV infection. The survey includes >60% of births
in England (www.hpa.org.uk). The lower HIV prevalence estimate obtained based on the results of voluntary
antenatal screening (0.19%) is due to a combination of factors such as some previously diagnosed women not
being screened antenatally, while others may acquire HIV during pregnancy.
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Study of HIV in Pregnancy and Childhood, 2013). There have been major shifts in the
demographic profile of HIV-positive pregnant women since the early years of the HIV epidemic.
For example, there has been a decline in the proportion of women born in the UK or Ireland
(from 49% during 1990-1993 to 14% in 2007-2011), and in those who likely acquired their HIV
infection from their own or their partner’s injecting drug use (from 49% to 1.5% over the same
period). Meanwhile, the proportion who originated from sub-Saharan Africa increased
substantially (from 44% to 77%) (Townsend et al, 2014; Townsend et al, 2008b). There have
been significant increases over time in the proportion of women reported to the NSHPC who
were diagnosed prior to their current pregnancy, now accounting for over 80% of pregnancies
reported annually (Figure 1.4). In 2012, among those women diagnosed prior to their current
pregnancy, around 40% were diagnosed antenatally during a previous pregnancy, with a
further 40% having been diagnosed in a genitourinary medicine (GUM) clinic, and the
remaining 20% in other settings e.g. general practice (Byrne et al, 2013).
Figure 1.4 Trends in timing of maternal HIV diagnosis, UK and Ireland, 1998-2012
*Incomplete data due to reporting delays
Note: Based on year of delivery for live and stillbirths and expected date of delivery for other outcomes.
Source: National Study of HIV in Pregnancy and Childhood (NSHPC), data reported by end of December
2012.
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1.2.3 Mother-to-child transmission (MTCT) of HIV
HIV can be transmitted from mother to child in utero, during labour and delivery, and through
breastfeeding. In utero transmissions may occur via the placenta, particularly in the presence
of placental tears or disruption. Transmissions occurring during labour and delivery may result
from exposure of the infant to the virus in maternal blood and genital secretions in the birth
canal, ascent of infection from the vagina or cervix, and maternal-fetal transfusions during
contractions (Kourtis et al, 2010; Newell, 1998). In the absence of interventions, the risk of
MTCT was around 14-25% among non-breastfeeding populations in Western settings (The
Working Group on Mother-To-Child Transmission of HIV, 1995). The relative contributions of
antepartum, intra-partum and post-partum transmission are not entirely clear but in non-
breastfeeding populations most transmissions are thought to occur in late pregnancy or during
delivery (Kourtis et al, 2001).
Maternal HIV RNA level (“viral load”) is the pre-eminent risk factor for MTCT (Cooper et al,
2002; European Collaborative Study, 1999; Garcia et al, 1999; Mayaux et al, 1997; Mofenson
et al, 1999; Warszawski et al, 2008), and there is clear evidence that the risk of transmission
increases with increasing viral load. For example, a recent analysis of UK data reported a
transmission rate of 9.2% in women with delivery viral loads of ≥10,000 copies/ml compared 
with just 0.05% in women with undetectable (<50 copies/ml) viral loads (Townsend et al, 2014).
Viral load may be considered as a proxy for the potential risk of vertical transmission.
1.2.4 Prevention of mother-to-child transmission (PMTCT) of HIV
Antenatal ART
In 1994, a landmark randomised controlled trial demonstrated that zidovudine monotherapy
given to pregnant women and their newborns reduced the risk of MTCT of HIV by 68%
(Connor et al, 1994), an intervention which was then rapidly adopted. Meanwhile, the Ugandan
HIVNET 012 trial demonstrated that a single dose of intra-partum nevirapine (sdNVP) reduced
MTCT risk by 50% (Guay et al, 1999), and this was found to be beneficial when added to a
short-course of antenatal zidovudine (Lallemant et al, 2004). The use of sdNVP for PMTCT in
resource-limited settings is discussed further in Chapter 2, Section 2.5. The effectiveness
cART in preventing vertical transmission of HIV has been widely demonstrated (Siegfried et al,
2011), and is now generally the recommended regimen in resource-rich settings (Aebi-Popp et
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al, 2013b; Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal
Transmission, 2012; Taylor et al, 2012).
The aim of ART administered during pregnancy is to suppress viral replication, ideally reducing
maternal viral load to an undetectable level by the time of delivery; this is the mechanism
through which ART reduces the risk of vertical transmission (Siegfried et al, 2011). The
therapeutic management of HIV in pregnancy is complex, not least due to the many
physiological changes that women undergo during this period. These changes may alter the
pharmacokinetics of drugs, including absorption, distribution and metabolism (Abduljalil et al,
2012; Mirochnick et al, 2010). Achievement of an undetectable viral load by delivery is
dependent on a range of factors including baseline viral load, timing and duration ART, type of
drugs and dosing, drug pharmacokinetics (including the potential for differential penetration into
genital tract tissues), and adherence (Aziz et al, 2013; Dumond et al, 2007; Read et al, 2012;
Taylor et al, 2012).
Current British HIV Association (BHIVA) guidelines on the management of HIV in pregnancy
recommend short-term cART commenced after the first trimester, and discontinued after
delivery, for pregnant women not requiring treatment for their own health (Taylor et al, 2012).
Boosted-PI based cART is the recommended regimen for PMTCT (Taylor et al, 2012) owing to
the long half-life of NNRTIs which increases the risk of the development of drug resistance
following short-course therapy (Mackie et al, 2004). If NNRTI-based cART is used efavirenz or
nevirapine are the recommended drugs. In the UK and Ireland zidovudine monotherapy
remains an alternative to cART for women who do not require treatment for their own health,
have a baseline viral load of <10,000 copies/ml and plan to deliver by caesarean section
(Taylor et al, 2012), though the majority of women receive cART (Townsend et al, 2014). A
brief summary of how the key recommendations for the management of HIV have changed
over the last decade is provided in Appendix II.
The timing of antenatal ART initiation requires a balance of the risks and benefits to both
mother and child. This includes consideration of possible teratogenicity of first trimester ART
exposure, toxicities e.g. mitochondrial, the precipitation of pregnancy complications such as
pre-eclampsia, risk of adverse pregnancy outcomes such as preterm delivery, and women’s
health (Newell et al, 2013). International and national guidelines have evolved over time with a
more recent move towards the earlier initiation of antenatal ART among women not requiring
ART for their own health. The WHO now recommends that women start ART as early as 14
weeks gestation (World Health Organization, 2013), while in the US it is recommended women
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start at 12 weeks, with initiation during the first trimester also being an option taking into
consideration women’s health status (Panel on Treatment of HIV-Infected Pregnant Women
and Prevention of Perinatal Transmission, 2012). The 2012 UK guideline states that all women
should have commenced ART by 24 weeks, and at the start of the second trimester for those
with very high viral loads (>30,000 copies/ml) (Taylor et al, 2012). Prior to this the
recommended timing was 20-28 weeks according to the 2008 guideline (de Ruiter et al, 2008),
while the 2005 guideline provided a broader recommendation of ‘during the second trimester’
(Hawkins et al, 2005).
This shift reflects the growing evidence that longer duration of antenatal ART decreases the
risk of detectable viral load at delivery, and hence MTCT (Chibwesha et al, 2011; Denoeud-
Ndam et al, 2013; Hoffman et al, 2010; Patel et al, 2007; Rachas et al, 2013; Read et al, 2012;
Townsend et al, 2014; Warszawski et al, 2008). For example, an analysis of data on over 5000
mother-child pairs reported to the French Perinatal Cohort demonstrated a non-linear
association between antenatal ART duration and the risk of MTCT. There was a rapid decline
in risk during the first 12 weeks, with a much slower decline beyond this (Warszawski et al,
2008). Similarly, a recent analysis of the NSHPC data revealed that with each additional week
of antenatal ART the risk of MTCT rapidly declined over the first few weeks with a continued,
though slower, decline up to 15 weeks from initiation, though this varied by baseline viral load
(Townsend et al, 2014). Preterm birth is of concern here, particularly in women starting ART
late in pregnancy, since early delivery limits the duration of ART received. Meanwhile, in line
with the increasing proportion of pregnancies to women who were diagnosed prior to that
pregnancy (as was shown in Figure 1.4), an increasing proportion of women are conceiving on
ART (41% during 2007-2011) (Townsend et al, 2014), with similar trends documented in
Europe (Bailey et al, 2013; Floridia et al, 2006). For these women it is now recommended that
treatment should usually be continued throughout pregnancy (Taylor et al, 2012), in
accordance with other national (Panel on Treatment of HIV-Infected Pregnant Women and
Prevention of Perinatal Transmission, 2012) and international guidelines (World Health
Organization, 2013). Not only shorter durations of antenatal ART, but also treatment
interruptions during pregnancy, have been associated with an increased risk of MTCT (Galli et
al, 2009; Townsend et al, 2008a; Warszawski et al, 2008), thus continuation of regimens
initiated prior to pregnancy is desirable.
ART is generally well tolerated during pregnancy and is associated with relatively few maternal
toxicities (Tuomala et al, 2005; Watts et al, 2004). However, that is not to say that it is without
potential adverse consequences. cART in pregnancy has been linked with possible increased
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risks of pre-eclampsia, hypertension and gestational diabetes (Newell et al, 2013; Suy et al,
2006; Thorne et al, 2007a), while an increased risk of preterm delivery has been widely
documented (Short et al, 2014). With regard to infant outcomes, some studies have raised
concerns about increased risks of conditions such as anaemia in the newborn (El Beitune et al,
2006; Pacheco et al, 2006), mitochondrial disorders (Ross et al, 2012) and low birthweight
(Ekouevi et al, 2008; Machado et al, 2009) in exposed infants. Though the benefits of antenatal
ART are widely accepted to outweigh the risks (Newell et al, 2013; Thorne et al, 2007a;
Townsend et al, 2010b; Tuomala et al, 2005), it remains essential to carefully monitor and
minimise any potential short and long-term adverse consequences of antenatal ART. This
topic, including risks of congenital abnormalities among infants exposed to ART in utero is
discussed further in Chapter 2, Section 2.6.
Mode of delivery
The effectiveness of elective caesarean section in reducing the risk of MTCT was reported in
several European observational studies during the 1990’s (European Collaborative Study,
1994; Kind et al, 1998; Maguire et al, 1997; Mandelbrot et al, 1998), a finding which was
subsequently borne out in a meta-analysis of 15 prospective cohort studies in Europe and the
US in which elective caesarean section was associated with a 50% reduction in the risk of
transmission (The International Perinatal HIV Group, 1999). In the same year these
observational findings were upheld by the results of a randomised controlled trial in which 436
HIV-positive women were allocated to either a vaginal or elective caesarean section delivery,
around 65% of whom also received zidovudine prophylaxis. The risk of transmission was 3.4%
in infants delivered by caesarean section compared with 10.2% in those delivered vaginally
(p=0.009) (European Mode of Delivery Collaboration, 1999). Elective caesarean section was
thus recommended for PMTCT in resource-rich settings (Tovo et al, 1999).
In the current era, there is uncertainty regarding the additional benefit of elective caesarean
section in women on cART with low viral loads. Although some studies demonstrate a
protective effect (Boer et al, 2010; Ioannidis et al, 2001; Thorne et al, 2005), others have found
no significant benefit in those with undetectable viral loads delivering at term (Briand et al,
2013; Townsend et al, 2014; Warszawski et al, 2008), though some potential benefit among
those with low but detectable levels of the virus cannot be ruled out (Townsend et al, 2014).
There is, however, difficulty in conducting studies that are sufficiently powered to address this
question. In light of the very low vertical transmission rates in women on cART (Townsend et
al, 2014; von Linstow et al, 2010; Warszawski et al, 2008), there has been a move towards the
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normalisation of delivery for HIV-positive women over the last decade with many countries
allowing for vaginal deliveries in those on suppressive therapy (Aebi-Popp et al, 2013b).
However, the viral load threshold below which there is no additional benefit is unknown. This
uncertainty is reflected in variations in national and international guidelines. A recent review of
European guidelines reported that the threshold below which a vaginal delivery may be
considered was <50 copies/ml in 11 countries, <400 in three countries, and <1000 copies/ml in
five (Aebi-Popp et al, 2013b).
Despite comprehensive UK guidelines for the obstetric management of HIV in pregnancy,
which recognise the range and complexity of cases seen, there is a lack of specific
recommendations for the management of those experiencing a repeat delivery as a diagnosed
woman (Taylor et al, 2012).
Infant feeding
Since HIV infection can be passed from mother to child via breast milk (Dunn et al, 1992), the
avoidance of breastfeeding is recommended in countries where infant feeding formulas are
readily available, affordable, safe and acceptable (Taylor et al, 2012; World Health
Organization, 2010a). Although the risk of post-natal transmission by this route is significantly
reduced in women receiving cART during the breastfeeding period, some risk still remains (de
Vincenzi, 2011; Shapiro et al, 2010). In the UK additional support to formula feed should be
provided where necessary (Taylor et al, 2012)9.
Effectiveness of interventions
PMTCT is, on the whole, the great success story in HIV prevention. The use of antiretroviral
prophylaxis or treatment during the antenatal and intra-partum periods, and prophylaxis for the
neonate, combined with elective caesarean section delivery and the avoidance of
breastfeeding (Taylor et al, 2012) has reduced the MTCT rate in the UK and Ireland to very low
levels in recent years, with current rates being just 0.5% (based on data for 2010-11)
(Townsend et al, 2014). Dramatic declines, and currently low MTCT rates, have also been
documented in other resource-rich settings (Nesheim et al, 2013; Thorne et al, 2005; von
Linstow et al, 2010; Warszawski et al, 2008). Globally, there is a target set by the Joint United
Nations Programme on HIV/AIDS (UNAIDS), for the ‘virtual elimination’ of MTCT worldwide by
9 The UK guideline does state that in exceptional circumstances women on cART with repeated undetectable
viral loads who choose to breastfeed should be closely monitored (e.g. regular viral load monitoring) and
should cease breastfeeding at six months (Taylor et al, 2012).
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2015 (an MTCT rate of <5% in breastfeeding settings and <2% in non-breastfeeding settings)
(World Health Organization and UNICEF, 2012). Though much remains to be done, significant
progress has been made with antiretroviral coverage among pregnant women living with HIV
reaching 62% in 2012, while the number of children newly infected with HIV in 2012 was 35%
lower than in 2009 (UNAIDS, 2013).
It should, however, be remembered that even in resource-rich settings with highly effective
interventions, some transmissions do still occur, including in utero transmissions prior to
diagnosis or cART initiation. Furthermore, as has been noted, even in treated women, the
effectiveness of ART in reducing viral load to undetectable levels may vary (e.g. due to
variations in drug absorption). Women who have received sub-optimal care during pregnancy,
for example, insufficient antenatal ART are at particular risk of transmission (Bailey et al,
2011). In some cases this stems from women’s complex social circumstances (Modestini et al,
2013; National Study of HIV in Pregnancy and Childhood et al, 2007). Finally, it should be
noted that vertical transmission is multifactorial and there is no viral load level under which it
does not occur (Townsend et al, 2014; Warszawski et al, 2008).
1.2.5 Summary
Women account for over half of people living with HIV worldwide, and most of these (around
80% in the UK) are of childbearing age. With effective treatment HIV is now a chronic,
manageable, life-long condition. Over the last two decades dramatic improvements in the
health, quality of life and life expectancy of people living with HIV have given HIV-positive
women a greater opportunity for childbearing. There are now over 1500 pregnancies to
diagnosed women in the UK and Ireland annually, with over 16,000 reported since surveillance
began. Widespread antenatal screening, together with effective PMTCT interventions, have
resulted in MTCT rates of just 0.5% in recent years. However, questions remain regarding the
optimal management of diagnosed women of childbearing age, not only during pregnancy, but
more broadly, and within the context of potential future pregnancies. Indeed, a substantial and
increasing proportion of conceptions are occurring in diagnosed women, many of whom were
diagnosed antenatally during a previous pregnancy. Yet, UK guidelines offer little guidance on
the optimal strategies for the therapeutic and obstetric management of women experiencing
repeat pregnancies following their diagnosis, and it is not currently known how these women
are being managed or what their pregnancy outcomes are.
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Chapter 2 Literature review
This narrative review considers some key contemporary issues related to the health,
management and pregnancy outcomes of HIV-positive women of childbearing age, with an
emphasis on those of particular relevance to women who have had, or may in the future
experience, repeat pregnancies following their HIV diagnosis. The review focuses largely on
studies from resource-rich settings, although the broader literature, including data from
resource-limited settings, is cited where pertinent.
2.1 Methods
Literature searches were conducted in PubMed (http://www.ncbi.nlm.nih.gov/pubmed/). All
searches were restricted to English language papers published between 1990 and 2014.
Reference lists of key papers were hand-searched. Regular content alerts from key journals
(The Lancet, The Lancet Infectious Diseases, New England Journal of Medicine, AIDS, Journal
of Acquired Immunodeficiency Syndromes, Current Opinion in HIV and AIDS, and HIV
Medicine), were subscribed to, and a broad monthly content alert from Scopus
(http://www.scopus.com/) for any papers related to HIV was used to help identify any relevant
papers not identified through the more specific searches. Proceedings of the following key
conferences were searched: International AIDS Society, AIDS, Conference on Retroviruses
and Opportunistic Infections, BHIVA annual conferences. Organisation websites and internet
searches were used to identify relevant guidelines and data sources data (e.g. Office for
National Statistics, WHO, National Institute for Health and Clinical Excellence (NICE), Royal
College of Obstetricians and Gynaecologists (RCOG)). BHIVA guidelines for the management
of HIV, both in adults and in pregnant women specifically, published between 2000 and 2012
were all obtained and reviewed.
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2.2 Fertility of HIV-positive women
There is quite a substantial international literature on childbearing desires and fertility among
women living with HIV. Both Western and African studies are considered here given that the
majority of diagnosed women in the UK are migrants from sub-Saharan Africa and
“motherhood is personally, culturally, and historically rooted” (Kennedy et al, 2014). The
potential impact of HIV on fertility is outlined, and factors influencing childbearing desires and
fertility among people living with HIV explored10. The narrative then focuses on what is known
about the frequency and predictors of repeat pregnancies among diagnosed women in
resource-rich settings.
Impact of HIV on fertility
In the early years of the epidemic, HIV was associated with a poor prognosis, and in the
absence of interventions for PMTCT, declines in pregnancy rates and increases in terminations
were documented (Stephenson et al, 1996; van Benthem et al, 2000). The introduction of
cART is generally considered to have led to an increased pregnancy rate, and a reduction in
terminations in resource-rich settings (Blair et al, 2004; Sharma et al, 2007; Townsend et al,
2008b; van Benthem et al, 2000). Further to this, it is likely that low rates of MTCT (Thorne et
al, 2005; Townsend et al, 2014; von Linstow et al, 2010; Warszawski et al, 2008) combined
with greatly improved AIDS-free survival in more recent years (May et al, 2011b; Nakagawa et
al, 2012; Samji et al, 2013; van Sighem et al, 2010), have had an impact on HIV-positive
women’s fertility. Nonetheless, even in the cART era, there is evidence to suggest that the
fertility of HIV-positive women may differ to that of the general population. An analysis of the
US Women’s Interagency HIV Study data for 2002-2009 provided a pregnancy rate ratio of
0.60 (0.46–0.78) in HIV-positive compared with HIV-negative women, after adjusting for age,
parity and other relevant factors, while those with low CD4 counts had a significantly longer
time to first pregnancy than those with stronger immune systems (Linas et al, 2011). Similar
findings were reported in an earlier analysis (data for 1994-2002) of the same cohort, with
overall pregnancy rates among HIV-positive and HIV-negative women of 7.4 and 15.2 per 100
person-years respectively, and a significant difference being apparent during all time periods
studied. Interestingly, this earlier analysis revealed no difference in pregnancy rate before and
after the introduction of cART (Massad et al, 2004).
10 The main focus here is on HIV-positive women. However, some studies discussed included both men and
women.
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The biological mechanisms through which HIV may affect fertility are not well defined, and are
difficult to disentangle from the influence of social and cultural factors. Some studies have
found low CD4 counts and high HIV viral loads to be associated with amenorrhea and irregular
menstrual cycles (Cejtin et al, 2006; Chirgwin et al, 1996), while others have not found a
difference after adjusting for potential confounders of the association such as illicit drug use
(Ellerbrock et al, 1996). There has also been research into whether HIV may cause premature
ovarian ageing but the evidence is inconclusive (Kushnir et al, 2011). Meanwhile, HIV infection
in men has been associated with reduced semen quantity and quality (Nicopoullos et al, 2004),
which may impact on the fertility of women in seroconcordant partnerships. As well as these
possible direct effects on biological fertility, HIV may also have indirect effects, for example,
through co-morbidities such as sexually transmitted infections (STIs) (Kushnir et al, 2011).
Fertility among people living with HIV
There are a wide range of biological, social and cultural factors that influence reproductive
decision-making and fertility regardless of HIV. These may include existing family size, the
outcome of any previous pregnancies, social and cultural factors, age, childbearing desires,
partner’s views and family expectations. Among people living with HIV additional factors also
come into play including health status, issues of disclosure, concerns regarding their future
health, perceived risk of MTCT and information provided by health care providers (Bedimo-
Rung et al, 2005; Blair et al, 2004; Craft et al, 2007; Finocchario-Kessler et al, 2010; Fiore et
al, 2008; Kirshenbaum et al, 2004; Loutfy et al, 2009; Nattabi et al, 2009; Ogilvie et al, 2007;
Wilcher et al, 2009). However, childbearing desires, intentions and actual childbearing, though
clearly inter-related, are distinct concepts. The link between them is complex, and will be
moderated by a range of factors (Finocchario-Kessler et al, 2010; Loutfy et al, 2009). For
example, there is evidence that a high proportion of pregnancies among HIV-positive women
are unplanned or unintended11. Just over half of pregnancies to diagnosed women in Europe
(Fiore et al, 2008), and 56% in Canada (Loutfy et al, 2011) were unplanned or unintended.
Similarly, in a study in one UK city only 53% of women reported that their pregnancy was
planned, although only half of were aware of their HIV status at the time of that pregnancy
(Moses et al, 2012). Meanwhile, in a recent US study, 19% of diagnosed women had planned
their pregnancy, with the remainder either reporting ambivalence (58%) or that it was
unplanned (23%) (Rahangdale et al, 2014). On the other hand, those who desire children may
11 A wide range of terms are used to describe pregnancies (e.g. ‘planned’, ‘unplanned’, ‘wanted’, ‘unwanted’,
‘intended’, ‘unintended’). These terms are understood, interpreted and used by women in many ways (Barrett
et al, 2002; Fischer et al, 1999).
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experience difficulties conceiving, or make a conscious decision not to become pregnant for a
variety of reasons including their HIV status (Bedimo-Rung et al, 2005; Kushnir et al, 2011).
In the simplest terms, a prevailing message of published literature is that substantial
proportions people living with HIV desire, and intend, to have (more) children12 (Berhan et al,
2013; Cliffe et al, 2011; Cooper et al, 2009; Fiore et al, 2008; Gingelmaier et al, 2011; Heard et
al, 2007; Kaida et al, 2010; Kennedy et al, 2014; Loutfy et al, 2009; Myer et al, 2007; Nostlinger
et al, 2013), with levels of childbearing desires being similar to those of the general population
(Finocchario-Kessler et al, 2010; Ogilvie et al, 2007; Stanwood et al, 2007; Wesley, 2003).
Indeed, in a UK questionnaire-based survey of 450 women attending HIV clinics during 2003-
2004 three-quarters stated that they desired (more) children (Cliffe et al, 2011). With regard to
factors influencing childbearing desires, a recently published systematic review and meta-
analysis of 20 international studies among people living with HIV (three-quarters of which were
carried out in Africa) revealed that the most important predictors of childbearing desires were
being childless (pooled odds ratio (OR) compared with those who already had children: 2.96,
95% confidence interval (CI): 1.77-4.95) and younger age (pooled OR comparing those aged
<30 vs. ≥30 years: 2.31, 95% CI: 1.87-2.84) (Berhan et al, 2013). Number of living children also
has an influence, with fewer living children being associated with increased childbearing
desires (Chen et al, 2001; Myer et al, 2007; Nakayiwa et al, 2006). Having a partner has also
been found to be a predictor of desiring children in a number of studies (Cliffe et al, 2011;
Cooper et al, 2009; Heard et al, 2007; Laursen et al, 2013; Ogilvie et al, 2007), as has shorter
relationship duration (Myer et al, 2007; Stanwood et al, 2007). Meanwhile, studies in Western
settings have tended to report higher childbearing desires among those originating from Africa
(Bungener et al, 2000; Heard et al, 2007; Loutfy et al, 2009). Health concerns have been found
to be important in mitigating childbearing desires, with women reporting concerns about the
impact of pregnancy on their health, as well as worries about vertical transmission and the risk
of infecting their partners (Nattabi et al, 2009), with the availability of ART and PMTCT
interventions positively associated with fertility desires and intentions in some studies (Cliffe et
al, 2011; Cooper et al, 2009). For example, in the UK study by Cliffe et al, although a third of
women said they initially did not want children following their HIV diagnosis, 41% reported that
they had changed their mind following improvements in HIV treatment (Cliffe et al, 2011).
12 The definitions of childbearing desires and intent, and the way they were assessed varied widely between
studies. For example, in a Canadian study women who agreed with the statement “I expect to give birth to
children in the future” were classed as intending to have children (Ogilvie et al, 2007), while in the UK study
women responding “yes” to the question ‘‘Would you like any (more) children?’’ were defined as having fertility
intentions (Cliffe et al, 2011).
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Other studies have focused on factors associated with actual childbearing (or pregnancy),
which of course involves not only childbearing desires and intent but also biological factors and
practical considerations. However, predictors were similar to those of desiring children, as
shown in Box 2.1.
Box 2.1 Key predictors of pregnancy among HIV-positive women
Predictor Study reference
Younger maternal age
(Bedimo-Rung et al, 2005; Blair et al, 2004; Huntington et al,
2013; Kaida et al, 2013; Linas et al, 2011; Massad et al,
2004; Myer et al, 2010)
Null parity or lower parity (Fiore et al, 2008; Linas et al, 2011)
Black African ethnicity* (Huntington et al, 2013)
Higher maternal health status
(actual or perceived)
(Bedimo-Rung et al, 2005; Blair et al, 2004; Fiore et al,
2008; Huntington et al, 2013; Linas et al, 2011; Massad et
al, 2004; Myer et al, 2010)
*Among those living in a Western setting
Frequency and predictors of repeat pregnancies among HIV-positive women
As shown in Chapter 1, there have been significant increases in the number of pregnancies to
diagnosed women in the UK, with similar trends observed elsewhere. However, despite a
wealth of literature on HIV in pregnancy, little to date has been published specifically on the
frequency, trends or predictors of repeat pregnancies among diagnosed women in resource-
rich settings. The European Collaborative Study (ECS) enrols HIV-positive women during
pregnancy and prospectively follows their infants (European Collaborative Study, 2001). An
analysis of ECS data from nine European countries was conducted to investigate the
frequency and predictors of having a live birth reported during 1986-2003. Overall, 5.6%
(218/3911) of women had more than one live birth (37 of whom had three or more). The time to
subsequent birth decreased over time; during the latest period (2000-2003) 14% of women had
a subsequent delivery within two years of their first. Factors predictive of repeat live births in
adjusted analyses included black African ethnicity (OR compared with white women: 2.45, 95%
CI: 1.75-3.43) and younger age (OR for women aged >30 years vs. <25 years: 0.54, 95% CI:
0.37-0.80). In analyses restricted to the cART era there was no difference in terms of ART
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receipt in the index pregnancies of those who experienced subsequent pregnancies and those
who did not. Maternal health, as indicated by CD4 count, was not associated with the
probability of having a repeat birth (Agangi et al, 2005). There are, however, several
methodological limitations of this study. The ECS only includes live births, and thus the
probability or rate of repeat pregnancies overall could not be estimated. It is also a consented
cohort and some women may choose not to participate. Furthermore, the ECS operates in
selected sites within each country and does not therefore have national coverage; women who
present with a subsequent pregnancy at a non-participating centre would not have their repeat
birth incorporated into the dataset. The number of women experiencing a repeat pregnancy, or
indeed live birth, will thus be underestimated. Finally, the analysis was limited by the small
sample size and has limited generalisability to the contemporary population of HIV-positive
women in Europe due to the time period covered. Since this study no detailed analyses of
sequential pregnancies (or births) among diagnosed women in a European setting have been
published.
The US Women and Infants Transmission Study (WITS) is an ongoing prospective cohort
study of HIV-positive pregnant women. An analysis of data from six sites in the US and Puerto
Rico during 1989-2004 revealed that 22% (492/2246) of women had more than one pregnancy
reported. A range of socio-demographic and clinical factors were identified as being associated
with repeat pregnancy including being younger, healthier (and, linked with this, not being on
ART), having fewer previous live births, and a lower educational attainment, though these were
unadjusted analyses (Bryant et al, 2007). Unlike the European study, there was no association
between ethnicity and repeat pregnancy in the US study by Bryant et al, perhaps reflecting
broader differences in the characteristics of ethnic minority groups in Europe and the US
(Newell et al, 2007). For example, black African HIV-positive women in Europe are
predominantly migrants which is not the case in the US (Nesheim et al, 2013). An advantage of
this study over the earlier European study was that all pregnancies, rather than only live births,
were included. However, WITS shares the major limitation of the ECS for investigating the
occurrence of repeat pregnancies (or births) in that it is not a national study. Although the
authors state that most women are re-enrolled in subsequent pregnancies, since women may
move to a different geographical location between pregnancies under-ascertainment of their
repeat pregnancies is a possibility.
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Summary
Prior to the work carried out for this PhD, no national level analyses on the frequency, time
trends or predictors of repeat pregnancies in the UK and Ireland had been performed, and no
European study had estimated the rate of repeat pregnancies among diagnosed women.
Indeed, international data were sparse, and the few previous studies that had been conducted
were outdated (conducted on data collected up to the early to mid-2000’s), with the previous
European study, in particular, having been limited by the relatively small number of repeat
deliveries as well as some important methodological weaknesses.
2.3 Women’s engagement with antenatal care
The optimal management of HIV in pregnancy is reliant on women booking for antenatal care
in good time, regardless of whether they have diagnosed or undiagnosed HIV. Booking thus
presents a crucial step in the care pathway. The importance of booking for antenatal care early
in pregnancy, irrespective of HIV status, as well as the additional importance for women living
with HIV, is outlined here. Socio-demographic risk factors for late booking are reviewed among
the general UK population (in recognition of international variations in healthcare systems and
antenatal care pathways), and then among HIV-positive women specifically, also drawing on
the literature from other resource-rich settings owing to a paucity of UK studies.
Importance of timely booking for antenatal care
UK guidelines recommend that pregnant women should book for antenatal care by 10-13
weeks gestation (National Institute for Health and Clinical Excellence, 2008; Royal College of
Obstetricians and Gynaecologists, 2008). This enables the timely offer of screening for
infections including HIV and other STIs, conditions such as sickle cell disease, as well as fetal
anomalies and Downs Syndrome (National Institute for Health and Clinical Excellence, 2008)13.
It also allows adequate time for pregnant women to make informed decisions regarding their
care. For HIV-positive women a sexual health assessment is also recommended (Taylor et al,
2012), particularly for those newly diagnosed, since genital tract infections could potentially
influence the risk of MTCT (King et al, 2013). After a woman has booked for care, her
pregnancy ‘risk status’ can be assessed (Cantwell et al, 2011), enabling early intervention and
appropriate management of both pre-existing and pregnancy-related conditions such as
diabetes and pre-eclampsia. Women’s obstetric histories can also be reviewed and taken into
13 Also see NHS antenatal and newborn screening timeline: http://cpd.screening.nhs.uk/timeline (Accessed
January 2014).
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consideration in the management of their current pregnancy. Poor engagement with antenatal
care, as indicated by late or never booking and/or poor attendance for appointments, has been
associated with adverse maternal and perinatal outcomes in the general population (Blondel et
al, 1993; Blondel et al, 1998; Raatikainen et al, 2007; Tucker et al, 2010). The 2011
Confidential Enquiry into Maternal Deaths in the UK noted a high rate of late booking among
women who died (Cantwell et al, 2011), though causality cannot be presumed.
For women living with HIV, early booking is of additional importance to ensure that they receive
the HIV-specific care they require in a timely manner including assessment of their clinical
status and initiation of ART. Early booking for antenatal care is of increasing importance for the
optimal management of HIV in pregnancy in light of the move towards earlier initiation of
antenatal ART, as described in Chapter 1, Section 1.2.4. Indeed, a UK audit found late booking
to be a key reason for women receiving insufficient antenatal ART (Modestini et al, 2013).
Inadequate antenatal care has also been reported to be a risk factor for non-receipt of
antenatal ART in the US (Abatemarco et al, 2008; Wilson et al, 2004), and an increased risk for
the vertical transmission of HIV (Peters et al, 2003; Warszawski et al, 2008).
Antenatal care booking among the general UK population
National Health Service (NHS) maternity statistics for England show that during 2009-2010,
37% of women booked at 13 gestational weeks or later (Health and Social Care Information
Centre, 2010). Several studies have explored the reasons for late booking in the UK general
population though definitions of ‘late booking’ vary. A national survey of women’s experience of
maternity care in England, involving a random sample of over 5000 women receiving care
during 2010, reported that parous women booked later than nulliparous women (with 59% and
66% respectively having booked by 10 completed weeks) (Redshaw et al, 2010). An
association between higher parity and later booking was also reported by two retrospective
London-based studies one of which classified late booking as ≥13 weeks (Cresswell et al,
2013), and the other as >18 weeks (Baker et al, 2012). Both studies adjusted for confounding
factors and reported that although there was no significant difference in timing of booking
between nulliparous women and those with only one previous birth, women with a higher
number of previous births (two or more in the study by Creswell et al, and four or more in the
Baker et al study) were at significantly increased risk. Both were reasonably large studies
consisting of 20,135 women and 5629 women respectively. The national survey by Redshaw et
al did not report on maternal age in relation to antenatal booking but the two London-based
studies, as well as an earlier study which analysed data from nine UK maternity units, all
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reported that younger women were more likely to book late (Baker et al, 2012; Cresswell et al,
2013; Kupek et al, 2002).
With regard to socio-cultural factors, not being in a relationship (Redshaw et al, 2010; Rowe et
al, 2008) and having unstable accommodation (Cresswell et al, 2013), the latter a possible
marker of social marginalisation, have been associated with later booking. However, there was
no significant association with an area-level deprivation measure in the study by Redshaw et
al, nor in a study of social and ethnic variations in antenatal care usage, though the latter was a
postal survey subject to selection bias (for example, only 5% of those responding to the survey
had booked late) (Rowe et al, 2008). Meanwhile, being born outside the UK and/or being of
non-white ethnicity has been quite consistently reported as a risk factor for late booking
(Cresswell et al, 2013; Kupek et al, 2002; Redshaw et al, 2010; Rowe et al, 2008), particularly
noteworthy given that most HIV-positive women in the UK are black African. In the national
survey, women belonging to black and minority ethnic groups who were born outside the UK
had an adjusted OR for booking by 10 weeks of 0.59 (95% CI: 0.48-0.72) compared with white
UK born women (Redshaw et al, 2010). Linked to this, an inability to speak English has been
identified as a risk for late booking (Cresswell et al, 2013). A recently published systematic
review of the international literature on antenatal care usage among migrants and their
descendants living in the Western world identified a lack of knowledge about the healthcare
system and language difficulties as the most important barriers to accessing antenatal care,
other barriers included cultural factors e.g. religious practices, as well as practical concerns
e.g. lack of transport and childcare (Boerleider et al, 2013). However, the review excluded
certain groups such as undocumented migrants, refugees and asylum seekers who may
potentially face even greater difficulties accessing healthcare (Rechel et al, 2013).
Engagement with antenatal care among HIV-positive women
There is a paucity of published data from Europe, including the UK, on the engagement of HIV-
positive women with antenatal care. A small study in one London centre reported that HIV-
positive women tended to book later than the general clinic population (a median of 16
gestational weeks compared with 11 weeks) (Parisaei et al, 2007). The limited data that has
been published on factors associated with antenatal care engagement among HIV-positive
women originates largely from the US. These data are only briefly considered here as it may
be difficult to translate to the UK situation, not only due to differences between the UK and US
populations of HIV-positive women (Newell et al, 2007), but also because of the inherent
differences in healthcare systems. For example, the UK healthcare system is funded through
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general taxation and provides universal access14. Meanwhile, in the US healthcare is provided
largely by the private sector which may favour those who can afford good healthcare, leaving
the poor with limited access15. Despite this, the US studies identified similar risk factors to
those noted among the general UK population, with both higher parity and being single
(Abatemarco et al, 2008) being risk factors for receiving limited antenatal care (defined as less
than five visits). Additionally, drug use was negatively associated with antenatal care
engagement (Abatemarco et al, 2008; Peters et al, 2003; Turner et al, 1995). Women of black
ethnicity experienced poorer antenatal care usage (Abatemarco et al, 2008; Peters et al,
2003), a finding also reported in an analysis of data from the French Perinatal Cohort with 14%
of black Africans and 10% of white women initiating antenatal care during the third trimester
(p<0.001), though the association was attenuated after adjusting for late HIV diagnosis
(Jasseron et al, 2008)16.
Summary
Timely booking for antenatal care is a vital step in the care pathway for the optimal
management of HIV during pregnancy, as well as being important for a healthy pregnancy, yet
there is a notable lack of literature on HIV-positive women’s engagement with care. The
population sub-groups that emerge as being at risk of poorer engagement, for example,
migrant women, suggest that many HIV-positive women may be at heightened risk of late
booking as compared with the general population. Furthermore, being parous, particularly
having had several previous births, has been quite consistently identified as a significant risk
factor for poorer engagement both in the UK general population, and among HIV-positive
women in other settings. This suggests that diagnosed women experiencing repeat
pregnancies may be a group at potentially heightened risk.
14 Although primary care (i.e. access to a GP) is available to everyone, secondary care may be chargeable for
some population groups (see: http://www.nhs.uk/NHSEngland/AboutNHSservices/uk-visitors/Pages/accessing-
nhs-services.aspx, Accessed September 2014).
15 For further information on differences between the UK and US healthcare systems see:
http://news.bbc.co.uk/1/hi/health/8201711.stm, Accessed September 2014.
16 An association between black African ethnicity and later booking has also been recently reported in an
analysis of the NSHPC data by Tariq et al (2012). The work was conducted concurrently to the analyses
presented in this thesis and is discussed further in Chapter 5 in relation to analyses on antenatal care booking.
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2.4 Engagement with HIV care, and the health and management of women
in the context of pregnancy and beyond
Figure 2.1 provides a simplified overview of the ‘loop’ of care for diagnosed women
experiencing repeat pregnancies, linking together the various elements discussed in this
section (as well as antenatal booking, as discussed in the previous section). Specific details of
UK recommendations regarding timing of ART initiation and indications for treatment were
provided in Chapter 1 (Sections 1.1.5 and 1.2.4) and have been omitted from the figure for
clarity.
Figure 2.1 Simplified loop of care for women experiencing repeat pregnancies
*For women not already on ART
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After providing a brief overview of the potential impact of pregnancy on HIV disease, the
literature on the following aspects of women’s health and management are reviewed: i) timely
initiation of antenatal ART, ii) potential discontinuation of antenatal ART after delivery when
received for PMTCT only (which may impact on maternal health in future pregnancies), iii)
retention in HIV care after pregnancy (thus facilitating the timely ART initiation outside
pregnancy, and completing the ‘loop’).
Influence of pregnancy on HIV disease progression
Since the process of pregnancy itself is associated with physiological alterations e.g.
suppression of immune function (Kuhnert et al, 1998), it has the potential to alter the course of
HIV disease, or modify the impact of treatment on disease progression. Although an early
review of the literature tentatively concluded that pregnancy may slightly increase the risk of
HIV disease progression (French et al, 1998), the expanding evidence-base in the ART era
points towards no significantly increased risk (Heffron et al, 2014; MacCarthy et al, 2009;
Saada et al, 2000; van Benthem et al, 2002; Westreich et al, 2013). There are, however, some
contrasting findings. In one US observational cohort pregnancy was associated with a
significantly decreased risk of disease progression (Tai et al, 2007), though this could perhaps
partly be explained by healthier women becoming pregnant (Le Moing et al, 2008).
Furthermore, some important methodological limitations of the study have been noted
(Westreich et al, 2008). However, a French cohort study of women conceiving on ART found
that CD4 counts were stable with no increase after delivery, as may have been expected (Le
Moing et al, 2008). A detailed assessment of the evidence-base is beyond the scope of this
review. Of note with regard to repeat pregnancies, a US study specifically compared disease
trajectories among women with a single pregnancy and those with two pregnancies, and
reported that having more than one pregnancy did not result in any adverse consequences in
terms of CD4 count and viral load (Minkoff et al, 2003).
Timing of antenatal ART initiation
Women presenting in pregnancy and not yet in receipt of ART will comprise those who require
ART for their own health (CD4 <350 cells/µl and/or symptomatic) (Williams et al, 2012), and
those with higher CD4 counts who need ART for PMTCT only. A number of studies have
explored reasons for non-uptake, or delayed initiation of antenatal ART. Late HIV diagnosis
(Bailey et al, 2011; von Linstow et al, 2010), illicit drug use (Abatemarco et al, 2008; Bailey et
al, 2011; Orloff et al, 2001), being asymptomatic and/or less immunosuppressed (Abatemarco
et al, 2008; Bailey et al, 2011; Orloff et al, 2001) and being single (Bailey et al, 2011) have all
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been found to be important risk factors. With regard to ethnicity, the findings appear to differ
according to setting with no association between ethnicity and uptake of antenatal ART in
Western Europe (Bailey et al, 2011), but women of black ethnicity had a decreased odds of
ART receipt in the US (Abatemarco et al, 2008). This may reflect differences in the populations
studied (Newell et al, 2007), the time periods (the US study having been conducted during the
late 1990s), as well as potential differences between the US and Europe in terms of disparities
in access to healthcare according to ethnic group. Some women may also choose to decline
ART (Mayaux et al, 2003; Modestini et al, 2013; von Linstow et al, 2010).
Discontinuation of ART after pregnancy
Pregnant women who do not require treatment for their own health may receive short-course
ART, stopped after delivery (Panel on Treatment of HIV-Infected Pregnant Women and
Prevention of Perinatal Transmission, 2012; Taylor et al, 2012). Current policy for HIV
treatment outside the context of pregnancy is that once initiated, patients should remain on
ART for life (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2013; Williams et
al, 2012; World Health Organization, 2013). This is in light of some important randomised trials
that have raised concerns about the impact of HIV treatment interruptions (investigated as a
potential strategy to optimise lifelong HIV treatment). The Strategies for Management of
Antiretroviral Therapy (SMART) Study, the largest to date, reported that among people with
CD4 counts of >350 cells/µl, those randomised to episodic rather than continuous treatment
experienced a significantly increased risk of opportunistic disease and death (El-Sadr et al,
2006). Similar findings were reported from the Trivacan trial which reported a 2.5-fold higher
risk of severe morbidity among those on CD4 guided treatment interruption (Danel et al, 2006).
Both trials were consequently halted early, and call into question the risks, in terms of maternal
health, of short-course ART for PMTCT. Pregnant women are the only population group
recommended to take short-course therapy. This is because, for those with no indication for
treatment themselves, the purpose of antenatal ART is for the prevention of vertical
transmission of HIV. As discussed in Chapter 1, Section 1.1.5, the risk-benefit ratio of initiating
lifelong ART in adults with high CD4 counts (e.g. >350 cells/µl) is uncertain.
Several studies have explored disease progression after the discontinuation of antenatal ART.
A cohort study in Brazil which followed up women presenting with a CD4 count of >300 cells/µl
and receiving short-course ART during pregnancy, reported that CD4 counts fell to <300
cells/µl in a mean of 3.5 years after delivery (Palacios et al, 2009), though the study was
relatively small consisting of only 75 women. In a multi-country African study 28% of women
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with an initial CD4 count of ≥400 cells/µl had declined to <350 cells/µl at 24 months post-
partum (Ekouevi et al, 2012), while follow-up data from a randomised trial in Botswana found
that among women with CD4 counts ≥200 cells/µl discontinuing ART after the breastfeeding 
period, 15% of women (n=84) re-initiated cART for their own health (except in one woman who
initiated ART for PMTCT in a subsequent pregnancy) at a median of 12 months post-partum
(Shapiro et al, 2013). Meanwhile, a study in Haiti revealed that women with a delivery CD4
count of 350-499 cells/µl experienced decline to 350 cells/µl in an average of 19 months
(compared with 71 months among those with delivery counts of ≥500 cells/µl) (Coria et al,
2012). Indeed, some other studies on this topic have highlighted that women’s starting CD4
count is important for subsequent disease progression. For example, an analysis of trial data
(investigating an extended nevirapine regimen for infants to prevent HIV transmission via
breastfeeding in four African countries) found that during one year post-partum follow-up of the
mothers, 37% of those with a delivery CD4 count of 400-549 cells/µl had dropped to <350
cells/µl compared with just 7% of those with a delivery CD4 count of >550 cells/µl. Based on
these findings the authors suggest that continuation of ART after delivery may be advisable
only for those women with lower delivery CD4 counts (in this case <550 cells/µl) (Watts et al,
2013). In the multi-country African study by Ekouevi et al, when women were grouped into
those with enrolment CD4 counts of 400-499 cells/µl and those with counts of ≥500 cells/µl, 
46% and 19% respectively had declined to <350 cells/µl by 24 months (Ekouevi et al, 2012).
Other studies have compared levels of disease progression in women who continue vs.
discontinue ART post-partum. A retrospective cohort study in one US state followed 158
women (49 who continued, and 109 who discontinued ART post-partum) for a median of 33
months; opportunistic infections occurred in two (4%) women who continued ART and 10 (9%)
who discontinued (p=0.26), and there were two deaths, both among discontinuers who
developed opportunistic infections. However, this was a small study and the results were likely
influenced by the fact that there were some important differences between those who
continued vs. discontinued ART with greater parity, the absence of a partner, and having no
indication for treatment all being independently associated with ART discontinuation (Onen et
al, 2008). Among women enrolled in the US WITS with a CD4 count of >350 cells/µl, a
comparison of those who chose to stop and those continuing ART post-partum found no
significant difference in either clinical or immunological disease progression between groups
although the study was relatively short with a 12 month follow-up period (Watts et al, 2009). Of
course these observational data are subject to bias and confounding that cannot always be
completely adjusted for in the analyses. The Kesho Bora trial, a multi-centre African study
designed to assess the effectiveness of ART during pregnancy, randomised 824 women to
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receive either triple therapy continued throughout the breastfeeding period or zidovudine plus
sdNVP with no post-partum ART. Women continuing ART after delivery had a significantly
lower risk of disease progression (a combined endpoint of death, WHO clinical stage 4
disease, or CD4 <200/µl) during the post-partum period indicating a potential benefit, in terms
of maternal health, of the continuation of ART post-partum in this African setting17 (Kesho Bora
Study Group, 2012). Such randomised trial data can provide strong, high-quality evidence for
associations because confounding and selection bias should be minimal and standardised
procedures can be applied. On the other hand, trial data might have limited generalisability
since the characteristics of participants may differ from those of the broader population of
interest, and trials tend not to be carried out under ‘real life’ conditions.
In 2012 the WHO introduced ‘Option B+’ whereby pregnant women initiate lifelong ART
irrespective of their CD4 count (World Health Organization, 2012, 2013). The benefits of such
an approach have been cited as enabling the simplification of PMTCT programmes, potential
health benefits from the earlier initiation of lifelong ART, MTCT prevention in future
pregnancies, reducing the risk of HIV transmission to sexual partners, and avoiding stopping
and starting of ART (World Health Organization, 2012). In resource-rich settings this
recommendation needs to be considered in the context of changing guidelines towards earlier
initiation of ART among the general HIV-positive population, with some now recommending
treatment for all, irrespective of CD4 count (Panel on Antiretroviral Guidelines for Adults and
Adolescents, 2013; Thompson et al, 2012). It should, however, be noted that as discussed in
Chapter 1, the evidence-base on the optimal timing of ART initiation is inconclusive (Sabin et
al, 2013). Current UK guidelines do allow for the continuation of antenatal ART in women who
have not yet reached the treatment threshold, but have a CD4 count of 350-500 cells/µl and
wish to continue therapy (Taylor et al, 2012). The potential benefits and risks of the Option B+
strategy are wide-ranging, and the evidence-base is lacking, as highlighted in a recent review
(Ahmed et al, 2013). Further research is required, not only internationally, but also with regard
to the applicability of such an approach to resource-rich settings.
Retention in HIV care after pregnancy
Irrespective of whether ART is continued or discontinued after delivery, ensuring that women
remain engaged in HIV care after their pregnancy ends is key to their optimal health and
17 A key aim of the analysis was to assess whether triple ART taken during pregnancy and breastfeeding was
associated with an increased risk of disease progression after discontinuation, as compared with antenatal
zidovudine plus sdNVP (which was not expected to impact on the course of HIV disease). In this regard there
was no significant difference in disease progression between the two groups 18 months after ART was
stopped.
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management. HIV-related services encompass a broad spectrum of care for people living with
HIV including regular monitoring of CD4 counts to enable the timely initiation of ART,
monitoring of treatment side effects and sub-optimal response to therapy, adherence support,
regular sexual health assessments, and monitoring of general physical and psychological
health thus enabling appropriate referrals (Asboe et al, 2012; Fakoya et al, 2008). For women
of childbearing age, and their partners, attendance at HIV services also provides the
opportunity for advice on contraception, as well as pre-conception counselling (Fakoya et al,
2008).
In a study of loss to follow-up from HIV care in England, Wales and Northern Ireland during
1998-2007, following attendance for care in a given year, 10% of diagnosed adults did not
attend during the subsequent calendar year, and cumulatively nearly two-fifths of those
attending during 1998-2006 were lost to follow-up by the end of 2007 (Rice et al, 2011). The
study revealed that being female and of childbearing age were both associated with an
increased risk of loss to follow-up (Rice et al, 2011). Furthermore, there is a body of
international evidence to suggest that post-partum women are at particular risk of loss to
follow-up (Clouse et al, 2013; Lemly et al, 2007; Myer et al, 2012; Rana et al, 2010; Wang et al,
2011), as well as poorer adherence to ART, as highlighted in a large, international systematic
review (Nachega et al, 2012). For example, in a French study of HIV care attendance over a 24
month period after giving birth, although the proportion with no attendance (11%) was very
similar to the 10% one year loss to follow-up rate documented by Rice et al, attendance was
reported to be irregular (less than four visits during the 24 month follow-up) in a further 14% of
women. This meant that only 75% of these post-partum women attended care regularly (Lemly
et al, 2007). Meanwhile data from the US found that only 37% of women attended the
recommended number of HIV care visits during the year after delivery (Rana et al, 2010).
Again, the differing healthcare systems and standards of HIV care in the UK and the US should
be borne in mind here. In the UK, of all adults attending HIV care during 2011, 95% were
retained in care the following year (Aghaizu et al, 2013). The comparable figure for the US was
much lower at around 50% (Centers for Disease Control and Prevention, 2011). Childcare
responsibilities are a potential barrier to regular care attendance (Boehme et al, 2014), and
have also been linked to poorer adherence to ART in post-partum women (Merenstein et al,
2009; Merenstein et al, 2008; Turner et al, 2000). Psychological factors such as post-partum
depression may also play a role (Nachega et al, 2012). Since the NSHPC does not collect
information on the HIV-related care of women after delivery, it is not possible to explore the
level of lost to follow-up after pregnancy among diagnosed women in the UK using this data
source alone.
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Summary
There are gaps in knowledge regarding the optimal management of diagnosed women of
childbearing age. In particular, that many diagnosed women may have more than one
pregnancy raises the question as to whether lifelong ART (WHO Option B+) should be initiated
in all pregnant women, rather than short-term antenatal ART for PMTCT, discontinued after
delivery, as per current UK recommendations for women not needing treatment. The evidence-
base for such an approach is currently lacking.
2.5 Impact of short-course antenatal ART on subsequent response to
therapy
As discussed in Chapter 1, short-course ART has been an extremely effective cornerstone of
PMTCT interventions. However, aside from the potential detrimental impact of short-course
ART on women’s health in the short or longer-term, there is concern that the discontinuation of
therapy after delivery may limit future therapy options, either in subsequent pregnancies, or
when HIV treatment is later required for women’s own health.
Development of drug resistance following exposure to single dose nevirapine (sdNVP) for
PMTCT
Until 2006 sdNVP was recommended by the WHO for the prevention of vertical transmission in
resource-limited settings due to its relative effectiveness (reducing the risk of MTCT by around
40-50% (Guay et al, 1999; Jackson et al, 2003)), simplicity and low cost (World Health
Organization, 2004, 2006). There is, however, a substantial and growing evidence-base
demonstrating high levels of resistance mutations following sdNVP exposure, including those
which confer cross-resistance to other NNRTIs (Cunningham et al, 2002; Eshleman et al,
2001; Jourdain et al, 2004; Lockman et al, 2010; Wind-Rotolo et al, 2009). In a systematic
review and meta-analysis the pooled estimate of the prevalence of nevirapine resistance in
women exposed to sdNVP, with or without other antenatal ART, was 35.7% (95% CI: 23.0-
50.6) at 4-8 weeks post-partum (Arrive et al, 2007). Even when women receive nevirapine in
combination with other drugs, due to its long half-life ‘functional monotherapy’ may result if
drug stoppages are not staggered (Mackie et al, 2004). By providing a ‘tail’ of other drugs while
nevirapine levels decline, the risk of resistance mutations can be lowered as highlighted in a
recent review (Paredes et al, 2013). sdNVP continues to be used in many resource-limited
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settings (UNAIDS, 2011a), and there will be many women with a history of exposure to this
regimen in pregnancy.
Subsequent response to NNRTI-based therapy following exposure to sdNVP
NNRTI resistance mutations may be archived in the latent viral reservoir (Wind-Rotolo et al,
2009) and can therefore potentially hamper subsequent response to NNRTI-based therapy.
Studies from resource-limited settings have reported that women with sdNVP exposure may be
at increased risk of virological failure when they subsequently initiate nevirapine (or other
NNRTI)-containing regimes (Paredes et al, 2013). In a Thai trial, 1844 women who received
antenatal zidovudine were randomised to either receive sdNVP or placebo at delivery. Among
269 women who subsequently initiated nevirapine-containing cART regimens post-partum,
virological suppression after six months was less frequent among those exposed to sdNVP
(49% vs. 68%, p=0.03) (Jourdain et al, 2004). The Optimal Combination Therapy after
Nevirapine Exposure (OCTANE) study, conducted in seven African countries, demonstrated
that among women previously exposed to sdNVP, 8% of those on ritonavir-boosted lopinavir-
containing regimens experienced virological failure or death versus 26% of those on a
nevirapine-containing regimen (p=0.001) (Lockman et al, 2010). Data on women receiving
NNRTI-based ART (either nevirapine- or efavirenz-containing) in Zambia were also consistent
with an increased risk of virological failure in the six months after sdNVP exposure (compared
with those without prior sdNVP), though the adjusted HR was not significant (1.6, 95% CI: 0.9–
2.7) (Chi et al, 2007). All three were large-scale, high-quality studies and the findings have
important, far-reaching implications for PMTCT interventions in resource-limited settings.
However, several studies have demonstrated that the risks of subsequent virological failure
may decline with a longer interval between sdNVP and subsequent treatment, which fits with
the concept of fading resistance over time (Eshleman et al, 2001). Two studies (an
observational study nested within the Mashi randomised trial in which women receiving
antenatal zidovudine were randomised to receive either sdNVP or placebo, and a multi-country
study with no randomisation) reported inferior virological responses when NNTRI-based
regimens were commenced within six or twelve months of sdNVP exposure but not when the
interval was greater than this (Lockman et al, 2007) and (Stringer et al, 2010) respectively.
Since there was no randomisation in the latter study there may have been some systematic
differences between those who received sdNVP and those who did not, though women were
matched according to health status to help address this. Meanwhile, a South African
observational study showed no evidence of poorer virological suppression when NNRTI-based
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therapy was initiated 18-36 months after sdNVP but documented that presence of the K103N
mutation was strongly associated with virological failure (Coovadia et al, 2009).
Development of drug resistance following exposure to short-course cART for PMTCT
Some studies have evaluated the emergence of resistance resulting from receipt of cART for
PMTCT, though most were relatively small-scale. Selected studies are detailed in Table 2.1. In
general, these studies point towards the development of quite significant levels of NNRTI
resistance mutations in women exposed to nevirapine-containing regimens, but tend to report
much lower levels of resistance following exposure to PIs. For example, resistance mutations
were identified in 13% of women in the Irish analysis by Lyons et al, all of whom received a
nevirapine-containing regimen (Lyons et al, 2005b). Similar levels of resistance mutations were
subsequently reported in a small, single site study from the US; four of 21 (19%) women with
exposure to ART in a previous pregnancy (three of whom had received nevirapine) developed
resistance (Overton et al, 2005). Notably high levels of NNRTI resistance mutations were
detected in another US study in which two of eight women (25%) receiving nevirapine
developed an NNRTI resistance mutation. However, the study highlights that the estimated
prevalence of resistance mutations differs depending on the specific mutations tested for, and
also the resistance testing methodology employed (Paredes et al, 2010).
Meanwhile, no PI resistance mutations were detected in the US study by Overton et al and
rates were very low (1%) in the study by Paredes et al. In the small German study restricted to
women who had received PI-based cART the authors concluded that there were no clinically
significant resistance mutations (Gingelmaier et al, 2010). Likewise, in the Mma Bana study in
Botswana (a trial of ART-naive women randomised to either triple NRTI or PI-based regimens
for PMTCT) no clinically significant mutations were detected among 54 samples genotyped
one month after the discontinuation of ART (Souda et al, 2013). However, high levels of
resistance to nelfinavir were reported in the small sub-study of women enrolled in a
randomised trial (Ellis et al, 2011).
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Table 2.1 Selected studies investigating development of drug resistance following exposure to short-course cART for PMTCT
Study
reference Setting n*
Type of cART
regimen
Duration of cART
received
Timing of post-
partum
resistance
testing
Frequency of
resistance
mutations
Notes/ additional
details
(Lyons et al,
2005b)
Ireland 39 NNRTI (nevirapine)-
based in 29 (74%)
and PI (nelfinavir)-
based in 10 (26%)
Median: 70 days Median of 42
days post-partum
7 resistance
mutations in 5
(13%) women
All mutations were in
women who were
ART-naive and
received nevirapine
(Overton et
al, 2005)
US 21 Nevirapine-based in
13 (62%)
Not reported Conducted when
women
presented with a
subsequent
pregnancy
19% (4/21
women)
3 of the 4 mutations
were in women
exposed to
nevirapine. No PI
resistance mutations
were detected
(Pilotto et al,
2009)
Brazil 139 NNRTI-based (22%)
or PI-based (78%)
Median: 84 days Not reported 14% overall Conference abstract
(limited data
available)
(Paredes et
al, 2010)
US and
Puerto
Rico
114 82% received cART
(NNRTI (nevirapine)-
based in 8 women
and PI (nelfinavir)-
based in 87). 18%
received dual
therapy
Mean: 68 days for
NNRTI-based
cART and 110
days for PI-based
Median of 70
days post-partum
Overall, 49
women (43%)
had at least 1
resistance
mutation
Mutations were
detected in 25%**
(2/8) of those who
received nevirapine,
and 1% of those
who received PI-
based cART
Continued overleaf
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*Number of participants with post-partum resistance testing results
**Based on the K103N mutation (the proportion was 12.5% for the Y188C mutation)
Table 2.1 Continued: Selected studies investigating development of drug resistance following exposure to short-course cART for
PMTCT
Study
reference Setting n*
Type of cART
regimen
Duration of cART
received
Timing of post-
partum
resistance
testing
Frequency of
resistance
mutations
Notes/ additional
details
(Gingelmaier
et al, 2010)
Germany 36 All PI-based Median: 59 days Median of 44
days post-partum
None The authors state
that there were no
"clinically significant"
mutations
(Souda et al,
2013)
Botswana 54 NRTI-based in 29
(69%) and PI-based
in 25 (58%)
Median: 266 days One month after
cART
discontinuation (7
months post-
partum)
None The authors state
there were no
"clinically significant"
mutations - only
mutations present
among ART-naive
adults in Botswana)
(Ellis et al,
2011)
US 16 Half were
randomised to
nelfinavir and half to
nevirapine-based
therapy
Mean: 88 days
before delivery
plus 236 days after
(nelfinavir), and
125 days before
plus 372 days after
(nevirapine)
Median of 88
days after ART
discontinuation
Detected in
75% of those
who received
nelfinavir and
50% of those
who received
nevirapine
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Response to antenatal ART among women with exposure to short-course cART
There are relatively few data on the subsequent response to antenatal ART among women
with prior exposure to short-course cART for PMTCT. In a small Irish study during 1998-
2005 the authors reported no increased risk of MTCT in repeat compared with index
pregnancies, and a higher proportion of women achieved virological control in their repeat
pregnancies (Lyons et al, 2005a). However, this was an initial descriptive analysis, and the
type of ART received in women’s current and previous pregnancies was not detailed. The
most relevant study on this topic is an analysis of the French Perinatal Cohort that included
869 ART-naive women and 247 who had previously received ART for PMTCT during a
previous pregnancy (various regimens, 52% had received cART and this was largely PI-
based). The multivariable analysis was restricted to women receiving PI-based cART in
their current pregnancy and revealed that previous exposure to cART was not associated
with detectable viral load at delivery (adjusted OR (aOR): 0.60, 95% CI: 0.33-1.10). The
association between previous cART and MTCT was not, however, explored (Briand et al,
2011).
Conversely, in a US study, pre-pregnancy cART exposure (based on self-report and not
limited to use for PMTCT) was found to be a significant risk factor for detectable viral load
at delivery in unadjusted analyses (Katz et al, 2010). However, as the analysis was not
restricted to women who had received previous short-course cART during a pregnancy, the
results are less relevant to the question as to whether short-course ART for PMTCT
hampers subsequent response to therapy. For example, some of the women will have
previously initiated cART for their own health and stopped for some reason, possibly an
unscheduled stoppage. The multivariable analyses were conducted separately on cART-
naive and cART-experienced women so adjusted comparisons between the two groups
could not be drawn. Furthermore, information on the type of cART received previously was
not provided, which may be important in light of the resistance studies suggesting that the
risks may be largely confined to those with previous NNRTI exposure.
Meanwhile, a study in three US centres provided inconclusive results. The authors
assessed the time to virological suppression during pregnancy, defined as either <400
copies/ml or <1000 copies/ml, among 62 ART-experienced women (not necessarily during
a previous pregnancy) and 76 ART-naive women. Most (79%) received a PI-based regimen
and the proportion achieving virological suppression (<400 copies/ml) during pregnancy
was similar in the two groups: 92% in ART-experienced and 93% in ART naive (p=0.82),
although the median time to viral suppression was longer in the ART-experienced group
(27 days (IQR: 18.5–54.3) vs. 25 days (IQR: 16-34), p=0.02). A similar pattern was
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observed when the <1000 copies/ml virological failure cut-off was used. However, the
associations did not hold in adjusted analyses (Aziz et al, 2013). It should be borne in mind
that all these are observational studies and some demographic and clinical differences
between women with prior exposure to short-course cART and ART-naive women were
noted. Though some of these differences could be adjusted for in the analyses,
unmeasured or residual confounding may remain.
Summary
In the UK and Ireland, as in many resource-rich settings, the majority of women receive
cART for PMTCT, with most now recommended to receive PI-based cART (Taylor et al,
2012). While inferior virological responses to ART have been documented in women with
prior exposure to sdNVP, little is known about the impact of short-course cART for PMTCT
on response to cART in subsequent pregnancies. This information is important not only to
ensure women are managed effectively in their current pregnancy, but also to inform the
evidence-base on the potential benefits and risks of discontinuing ART after delivery.
2.6 Adverse perinatal outcomes among HIV-positive women
With an increasing proportion of women conceiving on treatment, more fetuses are being
exposed to ART throughout the gestational period. Adverse perinatal outcomes are thus a
high priority for pregnancy-related HIV research. When considering the risk of adverse
perinatal outcomes among diagnosed women one needs to keep in mind that in addition to
the biologic, obstetric, demographic and behavioural factors that influence risks among the
general population, the role of HIV disease and ART also require consideration. This
section provides a brief overview of the frequency of selected adverse perinatal outcomes
(namely preterm birth, low birthweight, congenital abnormalities and stillbirths) among
diagnosed women, and then explores some key risk factors for adverse outcomes, with an
emphasis on those of relevance to women experiencing repeat pregnancies. The narrative
then focuses on preterm delivery as an outcome of particular interest in view of the growing
but conflicting evidence-base on the risk of preterm delivery among diagnosed women,
particularly in relation to antenatal cART exposure.
Brief overview of the occurrence of adverse perinatal outcomes (see Box 2.2)
Preterm delivery, defined as <37 gestational weeks (Steer, 2005), affects around 7% of
pregnancies in England and Wales (Office for National Statistics, 2011a), and 6% across
Europe (Beck et al, 2010). Rates in the US are even higher at 12-13% (Goldenberg et al,
2008). Infants born preterm are at increased risk of mortality as well as a range of
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neurological and developmental conditions that continue into adulthood (Riley et al, 2008;
Saigal et al, 2008). In England and Wales the overall infant mortality rate in 2009 was 4.4
per 1000 live births but 27.5 per 1000 among those born at 24-36 weeks gestation (Office
for National Statistics, 2011a). A number of studies have reported higher rates of preterm
delivery among HIV-positive women than the general population, or in some cases an HIV-
negative control group (Boer et al, 2007; European Collaborative Study and Swiss Mother
and Child HIV Cohort Study, 2000; Lopez et al, 2012; Rudin et al, 2011; Sibiude et al,
2012; Townsend et al, 2007), with both HIV infection itself, as well as ART received during
pregnancy, appearing to play a role. The risk among HIV-positive women receiving
antenatal cART is a particularly active area of research, as will be discussed.
With any drug received during pregnancy the potential risk to the fetus needs careful
consideration. Internationally, the ongoing safety of ART in pregnancy, in terms of
teratogenic effects, is monitored through the Antiretroviral Pregnancy Registry (APR). This
passive surveillance scheme, introduced in 1989, is designed to detect any major
teratogenic effects of antiretrovirals to which women are exposed during pregnancy. Data
on potential teratogenic effects of antenatal ART from the APR and other studies are
largely reassuring, rates of congenital abnormalities among infants with in utero exposure
being consistent with those in the general population (Antiretroviral Pregnancy Registry
Steering Committee, 2013; Gibb et al, 2012; Townsend et al, 2009; Watts et al, 2007).
There have been concerns around first trimester exposure to ART, efavirenz in particular,
which originated from animal studies (Nightingale, 1998), and some clinical case reports
(De Santis et al, 2002; Fundaro et al, 2002). However, a recent systematic review and the
APR have both found no evidence of an increased risk of overall birth defects associated
with first trimester efavirenz exposure (Antiretroviral Pregnancy Registry Steering
Committee, 2013; Ford et al, 2011). Current UK guidelines recommend that efavirenz may
be prescribed during pregnancy, and may be continued throughout pregnancy in women
conceiving on it (Taylor et al, 2012). The frequency of congenital abnormalities in infants
born to diagnosed women reported to the NSHPC during 1990-2007 was 2.8% overall
(including major and minor abnormalities), consistent with rates in the general population
(around 2%) – see Box 2.2. There was no significant increase in risk for infants exposed to
ART, or by timing of ART exposure (2.8% in unexposed infants, 3.1% in those with first
trimester exposure, and 2.7% following second or third trimester exposure, p=0.69)
(Townsend et al, 2009).
Low birthweight (defined by the WHO as <2.5kg), which is of course correlated with
gestational age at delivery, is a risk for neonatal morbidity and mortality (Malin et al, 2014).
Earlier NSHPC analyses reported that around 14% of infants were of low birthweight
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(Townsend et al, 2008b) compared with around 6% in the general population (Moser et al,
2008). Meanwhile, around 1 in 200 pregnancies in the UK results in a stillbirth (Centre for
Maternal and Child Enquiries, 2011; Smith et al, 2007). Among births to diagnosed women
reported to the NSHPC the rate of stillbirths was notably higher at 11 per 1000 births
overall during 1990-2006 (Townsend et al, 2008b), and has been documented to be higher
in women on cART (12.7 per 1000) compared with those on mono or dual therapy (5.7 per
1000) (Townsend et al, 2007). It is thus clear that HIV-positive women may be at potentially
increased risk of some adverse perinatal outcomes as compared with the general
population (see Box 2.2, but note that data are not directly comparable), the reasons for
which are likely to be multifactorial including socio-demographic differences as well as the
potential impact of HIV and antenatal exposure to ART.
Box 2.2 Overview of the risk of selected adverse outcomes in HIV-positive women
compared with the general population, UK and Ireland*
Outcome
Risk in HIV-positive
women
Risk in the general population
All women Black African women
Pre-term
delivery (<37
gestational
weeks)
14.2% during 1990-
2006 (Townsend et al,
2008b)
7.0% in 2009 (Office
for National
Statistics, 2011a)
7.7% in 2009 (Office for
National Statistics, 2011a)
Congenital
abnormalities
2.8% of births during
1990-2007 (Townsend
et al, 2009)
2.2% of births during
2011** (Springett et
al, 2013)
Comparable data not
available
Low
birthweight
(<2.5 kg)
14.1% among
deliveries during 1990-
2006 (Townsend et al,
2008b)
6.1% among
singleton live births
in 2005 (Moser et al,
2008)
7.4% among singleton live
births in 2005 (Moser et
al, 2008)
Stillbirth 1.1% of deliveries
during 1990-2006
(Townsend et al,
2008b)
0.5% of deliveries in
2009 (Centre for
Maternal and Child
Enquiries, 2011)
0.9% of deliveries among
black women (not black
African women
specifically) in 2009
(Centre for Maternal and
Child Enquiries, 2011)
*Estimates of the frequency of adverse outcomes among HIV-positive women are based on analyses of
NSHPC data for the UK and Ireland. Estimates for the general population are based either on data for the
UK (stillbirths) or for England and Wales only (preterm delivery, congenital abnormalities, low birthweight).
**Prevalence is the number of cases of congenital abnormality (live births, stillbirths, late miscarriages and
terminations of pregnancy for fetal abnormality) as a proportion of the total number of live and stillbirths.
Data is for more recent years are likely to be incomplete (e.g. the prevalence was 2.6% in 2007) (Springett
et al, 2013).
Note: Data are intended to provide a broad, national-level picture of the frequency of the selected adverse
outcomes. Data for HIV-positive women and the general population are not directly comparable due to
differing methodologies, definitions and time periods for which data are available.
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Factors influencing perinatal outcomes
This section provides background on some key risk factors for adverse perinatal outcomes
that are of particular relevance to women experiencing repeat pregnancies. It does not aim
to elucidate reasons for the differing rates of adverse outcomes among HIV-positive women
as compared with the general population but rather draw on available data from both in
order to identify potential risk factors.
Parity itself has been associated with perinatal outcomes among the general population,
though the direction of the association differs depending on the outcome of interest.
Women who are parous appear to have lower risks of stillbirth; in a large systematic review
and meta-analysis nulliparous women had a 42% increased odds of stillbirth compared with
parous women (Flenady et al, 2011). Parous women also have a lower risk of having low
birthweight or small for gestational age infants with a pooled odds ratio for low birthweight
among nulliparous compared with parous women of 1.41, 95% CI: 1.26-1.58 based on a
meta-analysis of 41 studies (Shah, 2010), though the analyses were unadjusted for
confounding factors. The risk of congenital abnormalities according to parity is complex,
varying by type of abnormality (Duong et al, 2012). Finally, in the aforementioned meta-
analysis by Shah et al there was no association between parity and the probability of
preterm delivery (OR comparing nulliparous to parous women: 1.13, 95% CI: 0.96-1.34).
Elucidating the relationship between parity and adverse outcomes is, however,
complicated, likely encompassing both biological and psychosocial influences. For
example, the higher rate of adverse outcomes documented among nulliparous women may
in part be explained by higher risk women being less likely to have subsequent pregnancies
(Miranda et al, 2011).
In Western settings substantial proportions of pregnancies to diagnosed women are
occurring in those of older age (Aebi-Popp et al, 2010; Brown et al, 2012; Liuzzi et al, 2013;
Townsend et al, 2008b), and of course women will be older at their repeat pregnancies. In
the general population, advanced maternal age is a well-documented obstetric risk factor
and has been linked with an increased risk of a range of adverse outcomes. Some
examples are provided in Box 2.3. Older women are also at increased risk of pregnancy
complications such as pre-eclampsia and gestational diabetes (Jacobsson et al, 2004).
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Box 2.3 Examples of studies reporting an association between advanced maternal age
and an increased risk of adverse perinatal outcomes
Outcome Study reference
Stillbirth (Flenady et al, 2011; Fretts, 2010; Huang et al, 2008;
Nybo Andersen et al, 2000; Smith et al, 2007)
Miscarriage/fetal death (Fretts et al, 1995; Jacobsson et al, 2004; Nybo
Andersen et al, 2000)
Ectopic pregnancy (Nybo Andersen et al, 2000)
Low birthweight (Aldous et al, 1993; Cleary-Goldman et al, 2005;
Nabukera et al, 2008)
Preterm delivery (Aldous et al, 1993; Astolfi et al, 1999; Cleary-
Goldman et al, 2005; Jacobsson et al, 2004; Nabukera
et al, 2008)
Congenital abnormalities (Cleary-Goldman et al, 2005)
HIV-positive women of older ages may also face additional risks such as poorer health due
to more advanced HIV disease, and more complex treatment histories. Furthermore, HIV
may cause premature ageing, even among those with well controlled infection (Capeau,
2011). Therefore, the risks of childbearing at older ages may potentially be even more
pronounced in HIV-positive women. There are limited studies examining the association
between maternal age and perinatal outcomes among diagnosed women, but some
evidence of an increased risk of preterm delivery in older women is apparent. A Dutch
cohort study of 143 women delivering under a policy of vaginal delivery reported that
women aged ≥35 years had a five-fold increased risk of preterm delivery compared with 
those aged ≤25 years although this was not significant after adjusting for parity, CD4 count, 
first trimester cART use and mode of delivery (Boer et al, 2007). Meanwhile, an analysis of
data from the Swiss Mother and Child HIV Cohort Study for 2003-2008 revealed a
statistically significant increased odds of a combined ‘pregnancy complications’ variable
(mainly pre-term delivery) per one year increase in maternal age (aOR: 1.06, 95% CI: 1.01-
1.12), after adjusting for confounders including co-infections, body mass index, smoking,
and alcohol or drug use (Aebi-Popp et al, 2010). A recent Italian analysis of national
observational data on over 1500 pregnancies found that miscarriage, preterm delivery and
low birthweight were more common among women aged ≥35 years, though only 
miscarriage remained significantly associated in the multivariable analyses (Liuzzi et al,
2013). The lack of an association in the adjusted analyses of both Boer et al and Liuzzi et
al may reflect the important role of confounding factors that are potentially correlated with
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age such as maternal health. HIV-positive women in poorer health have been documented
to be at increased risk of preterm delivery (Aebi-Popp et al, 2010; Schulte et al, 2007;
Sibiude et al, 2012; Thorne et al, 2004; Townsend et al, 2007; Townsend et al, 2010a; van
der Merwe et al, 2011).
There is some debate regarding the optimal inter-pregnancy interval in the general
population (World Health Organization, 2005). Short, as well as very long, intervals have
been identified as a risk for adverse infant and maternal outcomes in both resource-limited
and resource–rich settings, as reported in two large meta-analyses (Conde-Agudelo et al,
2006; Wendt et al, 2012). The adjusted pooled estimates produced in the meta-analysis
exploring the influence of short inter-pregnancy intervals by Wendt et al revealed a
significant association between an interval of less than six months and preterm birth (aOR:
1.41, 95% CI: 1.20-1.65), low birthweight (aOR: 1.44, 95% CI: 1.30-1.61), stillbirth (aOR:
1.35, 95% CI: 1.07-1.71) and early neonatal death (aOR: 1.29, 95% CI: 1.02-1.64). The
associations with preterm delivery and low birthweight were also significant among the
group with an inter-pregnancy interval of six to 11 months. The earlier meta-analysis by
Conde-Agudelo et al also reported significant associations between intervals of less than
six months and preterm delivery, low birthweight and, additionally, small for gestational
age. Long intervals (of more than 59 months) were also significantly associated with all
three outcomes. Reflecting these risks, the WHO recommends that following a live birth
couples should wait at least 24 months before trying to conceive again (World Health
Organization, 2005). Inter-pregnancy intervals, and the associated probability of adverse
pregnancy outcomes, have not been explored among diagnosed women at the national
level in the UK and Ireland.
Factors associated with preterm delivery
This review now focuses on preterm delivery. Multiple pathways, which are incompletely
understood, are believed to lead to the onset of preterm labour including inflammation,
infection, placental abruption and maternal-fetal stress (Goldenberg et al, 2008; Short et al,
2014). Preterm deliveries may occur spontaneously, or may be delivered early, either by
induction of labour or caesarean section, for reasons such as obstetric or fetal
complications. These are termed ‘iatrogenic’ or ‘indicated’ preterm deliveries. Goldenberg
et al estimate that in the general population around 30–35% of preterm births are indicated,
and the remaining 65-70% are spontaneous, composed of 40–45% following spontaneous
preterm labour, and 25–30% following preterm premature rupture of membranes
(Goldenberg et al, 2008). Though spontaneous preterm delivery is more common, some
recent studies have suggested that iatrogenic preterm delivery may be of particular concern
for HIV-positive women (Lopez et al, 2012; Sibiude et al, 2012). Aside from the potential
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risk factors for preterm delivery already discussed in the context of adverse perinatal
outcomes more generally (parity, advanced maternal age and inter-pregnancy intervals),
other risk factors among the general population include obstetric history (e.g. history of
preterm delivery), maternal factors (e.g. lower socio-economic status, black ethnicity),
pregnancy characteristics (e.g. multiple pregnancy, poorer maternal nutritional and health
status), pregnancy complications (e.g. pre-eclampsia), stress and smoking (Goldenberg et
al, 2008; Slattery et al, 2002). Similar predictors, and additionally illicit drug use, have been
reported among HIV-positive women as outlined in a recent comprehensive review on HIV
and preterm delivery (Short et al, 2014).
Antenatal cART use and the risk of preterm delivery
In 1998 Swiss data raised concerns about the high rates (33%) of preterm delivery among
a small group (n=37) of women receiving cART (Lorenzi et al, 1998). This was followed by
a larger analysis of data from 10 European countries which found that compared with
women who did not receive antenatal ART those who received either PI-based cART or
non-PI-based cART during pregnancy had 2.60 (95% CI: 1.43-4.75) and 1.82 (95% CI:
1.13-2.92) times the odds of delivering preterm respectively, including adjustment for
maternal CD4 count (European Collaborative Study and Swiss Mother and Child HIV
Cohort Study, 2000). Since then antenatal cART use has been linked with an increased risk
of preterm delivery in a number of other European studies (Boer et al, 2007; Grosch-
Woerner et al, 2008; Lopez et al, 2012; Ravizza et al, 2007; Rudin et al, 2011; Thorne et al,
2004). In the UK and Ireland specifically, women receiving cART had 1.5 (95% CI: 1.19-
1.93) times the odds of delivering preterm compared with those on mono or dual therapy
(Townsend et al, 2007). An increased risk has also been reported in a more recent single-
centre UK study (Short et al, 2013). These observational European data have been
supported by findings from the Mma Bana randomised controlled trial (Powis et al, 2011),
as well as observational data (van der Merwe et al, 2011) from African settings, though the
Kesho Bora trial reported no increased risk (de Vincenzi, 2011). Conversely, some US-
based studies have failed to demonstrate an overall association between ART exposure
and preterm delivery (Dola et al, 2011; Patel et al, 2010; Tuomala et al, 2002; Tuomala et
al, 2005), although a pooled analysis of data from the UK and Ireland, Europe, and the US
did find a significant 1.5 increased odds of preterm delivery with cART as compared with
dual therapy (Townsend et al, 2010a).
Evidence is emerging that both type and timing of ART are important with respect to
preterm delivery risk. Several studies have explored the effect of the type of ART received,
many revealing an association among women receiving PI-based cART specifically, or that
the association was strongest among this group. A meta-analysis published in 2007 found
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no overall association between cART and preterm delivery but did report a pooled OR for
preterm delivery of 1.35, 95% CI: 1.08–1.70 among those receiving PI-based regimens
compared with other (non-PI) combination regimens (Kourtis et al, 2007). The growing
evidence-base, including data from the US, continues to link PI-based cART in particular
with an increased risk of preterm delivery (Cotter et al, 2006; Grosch-Woerner et al, 2008;
Ravizza et al, 2007; Schulte et al, 2007). Furthermore, a recent French study implicated
ritonavir boosted PI-based cART specifically (Sibiude et al, 2012), though it is not clear
whether this is due to the main PI received (lopinavir), the ritonavir booster, or the
effectiveness of the boosted regimen. These observational data have also been supported
by an analysis of data from the Mma Bana trial in Botswana in which women were
randomised to receive either PI- or NNRTI-based cART. Those in the PI group had a two-
fold increased odds of preterm delivery compared with those who received NNRTI-based
cART (Powis et al, 2011).
Meanwhile, a number of studies have reported an increased risk of preterm delivery in
women who conceived on ART or had first trimester exposure. For example, the
ECS/Swiss cohort study found that women on cART from prior to conception had over
twice the odds of delivering preterm compared with those initiating it during the third
trimester (OR: 2.17, 95% CI: 1.03-4.58) (European Collaborative Study and Swiss Mother
and Child HIV Cohort Study, 2000). Similarly, in a subsequent analysis of European data
for 2000-2004, compared with those receiving mono or dual therapy there was a
particularly high odds of preterm delivery among those who were on cART from prior to
pregnancy (OR: 2.05, 95% CI: 1.43-2.95) (Thorne et al, 2004). A recent US study reported
that women exposed to PI-based cART during the first trimester had a preterm delivery
odds of 1.55 (95% CI: 1.16-2.07) compared with those who had no first trimester ART
exposure (Watts et al, 2013). A Brazilian study found that women receiving cART from prior
to conception had a five-fold increased odds of preterm delivery compared with those
starting during pregnancy, although the analysis was not adjusted for CD4 count (Machado
et al, 2009). Finally, in the previously mentioned French Perinatal Cohort analysis the
adjusted odds of preterm delivery among those conceiving on cART (any type) was 1.31
(95% CI: 1.11-1.55) compared with those starting during pregnancy (Sibiude et al, 2012).
When considering these findings it should be borne in mind that women already on
treatment at conception may represent those in poorer health, which as has been
mentioned, may in itself may be a risk for preterm delivery thus creating confounding by
indication. Although most studies adjusted for maternal CD4 count some residual
confounding may remain. Indeed, the evidence-base is inconclusive. An analysis of the
NSHPC data by Townsend et al found no significant difference in risk among those
initiating cART at <13 vs. ≥13 weeks (Townsend et al, 2007). Swiss cohort data also
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showed no significant difference in preterm delivery risk between those starting cART
before rather than during pregnancy (Rudin et al, 2011). Meanwhile, a single centre UK
study reported a five-fold higher odds of preterm delivery among those initiating cART
during pregnancy (Short et al, 2013), with similar findings documented in a Spanish cohort
(Lopez et al, 2012), though the risk appears to vary depending on timing of initiation during
pregnancy. It has been suggested that an increased risk associated with cART initiation
during pregnancy may be due to immune reconstitution, whereby an increase in CD4 count
following ART initiation results in an increased inflammatory response to opportunistic
infections (Short et al, 2013; Short et al, 2014).
This is an area of ongoing research continuing to yield inconclusive results, in particular
with regard to the influence of the timing of ART initiation on preterm delivery risk. The
reasons for these disparate findings are a matter of discussion and debate but likely include
heterogeneity in the populations studied, variations in study designs, bias by indication for
treatment, and confounding (Kourtis et al, 2011; Short et al, 2014; Thorne et al, 2012;
Watts et al, 2012). The evidence for a link between PI-based cART and preterm delivery is
of concern since this is the recommended regimen for short-course antenatal ART in the
UK (Taylor et al, 2012). Meanwhile, the possible higher risk in women conceiving on ART is
worrying in light of the increasing proportion of women conceiving on ART, as documented
in Chapter 1. Furthermore, these data are pertinent to both the WHO option of lifelong ART
for pregnant women (Option B+) (World Health Organization, 2013), which would further
increase the number of women conceiving (any subsequent pregnancies) on therapy, and
international guidelines which are shifting towards recommending the earlier initiation
treatment among people living with HIV (Sabin et al, 2013).
Summary
HIV-positive women may be at increased risk of adverse pregnancy outcomes. Although it
appears that being parous per se may provide some protective effect, women experiencing
repeat pregnancies have other risk factors such as increased maternal age (as compared
with index pregnancies), the fact that they will have been living with HIV for longer, and are
potentially more likely to conceive (their subsequent pregnancies) on ART. Indeed, there is
a need for more data on perinatal outcomes, preterm delivery in particular, among
pregnancies to diagnosed women in the contemporary context of widespread cART use
and an increasing proportion of women conceiving on treatment.
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2.7 Obstetric management of sequential pregnancies
Caesarean section deliveries among HIV-positive women
Elective caesarean section has been widely used for PMTCT in resource-rich settings since
the 1990’s (Boer et al, 2010; Briand et al, 2013; Dominguez et al, 2003; Livingston et al,
2010; Mark et al, 2012; Townsend et al, 2008b). Since 2005, UK guidelines have allowed
for the option of a planned vaginal delivery in women on cART with an undetectable viral
load at 36 weeks (de Ruiter et al, 2008; Hawkins et al, 2005), with the most recent
guideline specifically recommending a vaginal delivery in these women (Taylor et al, 2012).
Guidelines for many other European countries now also allow for vaginal deliveries in
women on suppressive therapy (Aebi-Popp et al, 2013b). Data reported to the NSHPC
revealed that during 1999-2004 around 80% of deliveries were by caesarean section
(composed of 60% elective and 20% emergency), with a subsequent decline to 60% (35%
elective plus 25% emergency) in 2010-2012 (NSHPC, unpublished data18). Declines were
also reported in a recent analysis of data from 10 European countries with elective
caesarean sections accounting for 65% of deliveries before the change in guidelines and
27% afterwards (Aebi-Popp et al, 2013a). Despite these declines, as is clear from Figure
2.2, there is a large pool of diagnosed women in the UK and Ireland who have previously
delivered by caesarean section. During 1999-2012 there were a total of 9870 caesarean
section deliveries, accounting for 69% of all births. Furthermore, as evidenced here, and
highlighted in the recent European analysis by Abei-Popp et al, many women are
continuing to deliver by this route.
UK guidelines for the general obstetric population allow for vaginal birth after caesarean
(VBAC) in women with no contraindications19, with the decision made jointly between the
woman and obstetrician (Royal College of Obstetricians and Gynaecologists, 2007).
However, guidelines for the management of HIV in pregnancy offer few recommendations
in this regard (Taylor et al, 2012).
18 Data extracted from the NSHPC database, based on reports received by end of September 2013.
19 One such contraindication relates to the number of previous caesarean sections; repeat caesarean
section is recommended for women with a history of three or more caesarean sections (Royal College of
Obstetricians and Gynaecologists, 2007).
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Figure 2.2 Trends in mode of delivery among HIV-positive women in the UK and Ireland,
1999-2012
*Incomplete data due to reporting delays
Source: NSHPC, unpublished data (reported by end September 2013).
Risks associated with caesarean section deliveries
Caesarean section is a major operation, and is not without risks and potential
complications. Caesarean section deliveries have been associated with some adverse
post-natal outcomes including surgical site infection, a longer recovery period, and an
increased risk of hysterectomy caused by postpartum haemorrhage (Bernstein, 2005;
Goer, 2001; National Institute for Health and Clinical Excellence, 2011). Furthermore, a
number of studies have reported that the risk of complications following caesarean section
deliveries may be higher among HIV-positive women than HIV-negative controls (Calvert et
al, 2013b; Fiore et al, 2004; Grubert et al, 2002; Maiques-Montesinos et al, 1999)20.
However, others have found no difference (European Mode of Delivery Collaboration,
1999; Panburana et al, 2003). Maternal health may be important here. For example, in the
study by Semprini et al women who were severely immunosuppressed were found to be at
higher risk than healthier HIV-positive women (Semprini et al, 1995), and Maiques-
Montesinos et al reported a lower risk of complications in women with CD4 >500 cells/µl
20 Of note, the systematic review by Calvert et al and the study by Fiore et al both reported higher rates of
post-delivery complications in HIV-positive women irrespective of mode of delivery.
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compared with those with lower CD4 counts (Maiques-Montesinos et al, 1999). An
increased risk among those with more advanced disease was also noted in a Cochrane
review of caesarean section for PMTCT (Read et al, 2005). A recent analysis of diagnosed
women enrolled in the French Perinatal Cohort reported post-partum complications
(occurring immediately after delivery) in 6.5% of women delivering by caesarean section,
either elective or emergency, compared with 2.9% among those delivering vaginally
(p<0.01), with infection and haemorrhage being the most frequent. Complications, as well
as prolonged hospitalisation, were more common among women with low CD4 counts both
overall, and for all modes of delivery (Briand et al, 2013). Furthermore, women who have
experienced a previous caesarean section may be at increased risk of a range of
complications and adverse outcomes in subsequent pregnancies. These include abnormal
placentation, scar dehiscence, uterine rupture, hysterectomy and stillbirth, as well as
perinatal morbidity and mortality (Gilliam, 2006; Goer, 2001; O'Neill et al, 2013; Silver,
2012; Smith et al, 2003). A systematic review of 11 studies in the general obstetric
population found that the rate of a range of adverse outcomes including hysterectomy,
blood transfusions, surgical injury and placenta previa increased with the number of
caesarean sections (Marshall et al, 2011). Whether or not HIV-positive women are at
increased risk of complications compared with the general population, the risk of potential
post-operative complications following caesarean section delivery cannot be overlooked.
These risks should inform the mode of delivery decision-making process, particularly if
there is not a strong indication for a caesarean section e.g. maternal preference in those
with undetectable viral loads.
Risks of repeat caesarean section vs. vaginal birth after caesarean section (VBAC)
Several systematic reviews and meta-analyses have been conducted to assess the
evidence around the risks of VBAC compared with repeat caesarean section. However, the
evidence to date is inconclusive, perhaps reflecting the wide range of outcomes that require
consideration, many of which are rare. In a large systematic review published in 2010,
pooled data provided no evidence of a significantly increased risk of hysterectomy,
haemorrhage, or blood transfusions in women delivering by VBAC compared with repeat
caesarean section, but there was an increased risk of uterine rupture (0.47% vs. 0.03%
respectively, p<0.001) and perinatal mortality (0.13% vs. 0.05%, p=0.002). Meanwhile,
maternal mortality was higher in those delivering by repeat caesarean section (0.013% vs.
0.004%, p=0.027) (Guise et al, 2010). It should be noted that there was some
heterogeneity in the findings of the studies in the review, as well as variations in the
definitions and classifications used. Furthermore, all studies reported on the actual rather
than intended mode of delivery, and there were no randomised trials eligible for conclusion.
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The authors concluded that adverse outcomes were rare following both VBAC and repeat
caesarean section, and that VBAC is a reasonable option for most women.
In light of the limitations of the available data highlighted in the review by Guise et al, a
recently published Cochrane review sought to identify randomised trial data, published
subsequent to the review, assessing the benefits and harms of VBAC vs. planned repeat
caesarean section (Dodd et al, 2013). Only one study assessing clinical outcomes was
identified - a trial nested in a prospective cohort study, although only 1% of women actually
agreed to be randomised with others assigned mode of delivery according to their
preference. The risk of serious adverse infant outcomes (a composite measure) was lower
in the repeat elective caesarean section group (0.9% vs. 2.4%, p=0.011), as were serious
adverse outcomes for the mother (3.1% vs. 4.5%, though this was not statistically
significant: p=0.08) (Crowther et al, 2012). Despite randomisation to mode of delivery being
largely unfeasible, an advantage of the study was that women were analysed according to
planned, rather than actual, mode of delivery.
With regard to uterine rupture specifically, a major potential risk of VBAC, a national UK-
based case-control study has been conducted which included all 159 women who had
experienced a uterine rupture during a 13 month study period (2009-2010), and 448 control
women with a previous caesarean section delivery, regardless of current mode of delivery.
Although uterine rupture was rare (0.2 per 1000 maternities overall), among those with a
previous caesarean section, the rate was higher in women planning a vaginal delivery (2.1
per 1000) than in those planning a repeat caesarean section (0.3 per 1000) (Fitzpatrick et
al, 2012). Similarly, a large national study of 18,794 births registered in Norway to women
who had previously delivered by caesarean section found the risk of uterine rupture to be
significantly higher in women having a subsequent spontaneous (OR: 6.65, 95% CI: 2.4-
18.6) or induced (12.60, 95% CI: 4.4-36.4) trial of labour rather than a repeat caesarean,
though again the absolute risks were low (5 per 1000 overall) (Al-Zirqi et al, 2010). The
results of these two large studies are consistent with those of the review by Guise et al.
Summary
A large proportion of births to diagnosed women in the UK and Ireland have been delivered
by caesarean section. Many of these women may, under current guidelines, be eligible for
a vaginal delivery in subsequent pregnancies. Little is known about how HIV-positive
women experiencing repeat pregnancies are being managed obstetrically in the UK and
Ireland. The risks and benefits of vaginal delivery after previous caesarean section(s) are
uncertain among the general population and have been little explored among women living
with HIV.
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2.8 Rationale for this PhD
The aim of this thesis is to investigate the epidemiology of sequential pregnancies among
HIV-positive women in the UK and Ireland, and to explore the health, therapeutic and
obstetric management, and pregnancy outcomes of women experiencing them.
There are now a large number of pregnancies to HIV-positive women in the UK and
Ireland, with over 1500 currently reported each year. An increasing number of these
women will have experienced a previous pregnancy for which they received HIV-related
care, and may have further pregnancies. An understanding of the epidemiology of repeat
pregnancies is required to inform appropriate management strategies and service
provision. However, the few studies that have been conducted on this topic had some
important methodological limitations, were conducted some years ago, and included
relatively small numbers of pregnancies thus limiting their generalisability to the
contemporary population. The NSHPC is a well-established, active, national surveillance
system providing an ideal dataset with which to examine, on a large and national scale, the
epidemiology of repeat pregnancies among diagnosed women. This thesis examines
patterns of repeat pregnancies among HIV-positive women in the UK and Ireland,
estimates the rate of these pregnancies, and investigates the demographic and clinical
characteristics of women experiencing them (Chapter 4).
In the contemporary context of widespread cART use and PMTCT interventions, diagnosed
women are potentially presenting in pregnancy with increasingly complex treatment and
management histories, as well as the possibility of future pregnancies. Chapter 5 explores
several inter-related issues regarding women’s engagement with HIV and pregnancy-
related care, and the health and management of women experiencing sequential
pregnancies. Timely booking for antenatal care and initiation of antenatal ART, are
fundamental to ensure both maternal and infant health, and are thus explored here,
including assessment of predictors of late booking and ART initiation, in order to identify
potential inequalities in access to or uptake of care. Meanwhile, that many diagnosed
women may have more than one pregnancy raises the question of whether lifelong ART
should be initiated in all pregnant women, rather than short-term antenatal ART for PMTCT,
discontinued after delivery. This issue is explored by investigating the immunological status
and virological outcomes of a sub-group of women who were not on ART at conception of
their repeat pregnancy. Finally, women’s good engagement with HIV care is crucial to
maintain their optimal health, and the literature suggests that women may be at heightened
risk of loss to follow-up from HIV care after pregnancy. This has been little explored in the
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UK and Ireland and is therefore investigated the last part of Chapter 5 using NSHPC data
matched with the Survey of Prevalent HIV Infections Diagnosed (SOPHID).
For women not yet requiring treatment for their own health, short-course antenatal ART has
been the cornerstone of PMTCT interventions. However, there is a lack of data on the
impact of previous short-course cART for PMTCT on response to cART in subsequent
pregnancies. This information is important not only to ensure women are managed
effectively in their current pregnancy, but also to inform clinical decisions around the
potential future benefits and risks of discontinuing ART after delivery. Here, the risk of
detectable viral load at delivery, and of MTCT, in women who experienced short-course
cART for PMTCT in a previous pregnancy, is investigated (Chapter 6).
HIV-positive women are a complex group to manage obstetrically for a variety of reasons
that may be compounded in sequential pregnancies. For example, at their repeat
pregnancies women will be older, a well-documented risk factor for adverse pregnancy
outcomes in the general population, and will have been living with HIV for longer. As has
been highlighted, current rates of vertical transmission in the UK and Ireland are very low,
bringing other pregnancy and perinatal outcomes to the forefront. There is a need for more
data on the perinatal outcomes of pregnancies to diagnosed women in the contemporary
context. In particular, preterm delivery has become an outcome of concern in relation to
antenatal exposure to cART. Chapter 7 examines the frequency of adverse pregnancy and
perinatal outcomes (stillbirth, miscarriage, preterm delivery, low birthweight and congenital
abnormalities), and investigates whether women experiencing repeat pregnancies are at
increased risk of these. Risk factors for preterm delivery are explored among those
experiencing repeat pregnancies. Data on repeat pregnancies enables the exploration of
the influence of factors such as previous preterm delivery and inter-pregnancy interval on
preterm delivery risk, which are often not assessed or accounted for in studies of preterm
delivery among HIV-positive women.
Finally, over two-thirds of women reported to the NSHPC during the last decade or so
delivered by caesarean section, many of whom may, under the current guidelines, be
eligible for a vaginal delivery in subsequent pregnancies (if they are on suppressive therapy
and have no obstetric contraindications). The risks and benefits of vaginal delivery after
previous caesarean section(s) are, however, uncertain, and there is an absence of specific
recommendations for the management of HIV-positive women in this regard. It has not
been assessed, at the national level, how women with a history of caesarean section are
being obstetrically managed. The second part of Chapter 7 explores mode of delivery
among diagnosed women with repeat births, including temporal trends and patterns within
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women (VBAC, for example), and assesses the frequency of adverse outcomes likely
related to the mode of delivery.
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2.9 Aim and objectives
The overarching aim of this thesis is to investigate the epidemiology of repeat pregnancies
among diagnosed HIV-positive women in the UK and Ireland. The objectives are to:
1. Estimate the rate of repeat pregnancies, document temporal trends, and model
birth-spacing intervals
2. Characterise the group of women experiencing repeat pregnancies and identify
factors associated with having more than one pregnancy as a diagnosed woman
3. Investigate engagement with HIV and pregnancy-related care, and the health and
management of women experiencing sequential pregnancies. Specifically to:
a) Describe timing of antenatal booking for repeat compared with index
pregnancies, investigate factors associated with late booking, and
explore delays from booking to initiation of HIV-related antenatal care
b) Investigate immunological status, timing of ART initiation, and
virological outcomes among repeat pregnancies in women not on ART
at conception
c) Assess the completeness of matching of the NSHPC dataset with
SOPHID, and use the matched data to explore attendance for HIV care
after pregnancy
4. Investigate the probability of detectable viral load at delivery and MTCT in women
who experienced short-course cART for PMTCT in a previous pregnancy
5. Explore the probability of adverse pregnancy and perinatal outcomes (stillbirth,
miscarriage, preterm delivery, low birthweight and congenital abnormalities) among
women’s repeat pregnancies, and investigate risk factors for preterm delivery in this
group
6. Describe mode of delivery for women’s repeat births, explore patterns within
women, and document serious adverse outcomes that may be related to mode of
delivery
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Chapter 3 Data sources and methods
3.1 National Study of HIV in Pregnancy and Childhood (NSHPC)
The UK and Ireland’s NSHPC is based at the University College London (UCL) Institute of
Child Health (ICH). The study comprises two active confidential reporting schemes: an
obstetric and a paediatric scheme. Together these aim to capture all pregnancies to HIV-
positive pregnant women living in the UK or Ireland, all infants born to HIV-positive women,
and all children living with HIV infection21. A schematic representation of the structure of the
NSHPC data collection systems is provided in Figure 3.1 and the standardised data
collection forms are provided in Appendix III.
3.1.1 Obstetric scheme
The obstetric scheme began in 1989. The system is administered under the auspices of the
Royal College of Obstetricians and Gynaecologists (RCOG). All (currently 228) maternity
units in the UK and Ireland have a named respondent, an obstetrician originally but now
often a specialist midwife or other specialist as appropriate to that unit, who is responsible
for notifying all pregnancies in HIV-positive women, regardless of timing of diagnosis
(before or during pregnancy) to the NSHPC. This is an active scheme. Respondents are
requested to return a reporting card quarterly indicating the number of cases seen during
the previous quarter, including null returns. All pregnancies should be reported, including
those that have ended in a termination or miscarriage. Demographic and clinical
information on each reported pregnancy is then obtained from respondents using a
standardised notification form. For pregnancies expected to continue to term, a pregnancy
outcome form is sent to the respondent close to the expected date of delivery. New
pregnancy reports are linked to previous reports for the same woman based on maternal
date of birth together with the geographic location of the report and other relevant
information such as country of birth and timing of HIV diagnosis, and in more recent years,
NHS number. All stages of the reporting process are closely monitored by the NSHPC
team at ICH with non-response at any stage of the process followed up in order to ensure
high reporting rates.
21 The NSHPC also receives a small number of reports from the Channel Islands which are included in the
analyses presented in this thesis.
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3.1.2 Paediatric scheme
Paediatric cases of HIV and children born to HIV-positive mothers are mainly notified
through the British Paediatric Surveillance Unit (BPSU) of the Royal College of Paediatrics
and Child Health (RCPCH). The paediatric reporting scheme began in 1986 (reporting of
AIDS diagnoses only), and was extended to include HIV-exposed and HIV-positive children
when the obstetric scheme began in 1989. The BPSU routinely sends a monthly ‘orange
card’ to all consultant paediatricians in the UK and Ireland registered with the RCPCH. The
card contains a list of rare diseases and conditions in childhood, which includes paediatric
HIV/AIDS, as well as children born to HIV-positive women. Paediatricians are asked to
return the card indicating whether or not they have seen a child with any of the listed
conditions during the past month. The BPSU notifies the NSHPC of any paediatric cases of
HIV/AIDS or exposed infants, and the paediatrician is then requested to complete an
NSHPC paediatric notification form. Paediatric units seeing large numbers of HIV-exposed
children report cases directly to the NSHPC. Following the initial report a follow-up form is
sent in order to obtain the HIV status of exposed children. As per the obstetric reporting,
this is an active scheme with monitoring and follow-up of non-response at all stages.
Obstetric and paediatric reports are linked based on dates of birth, geographic location of
the report, NHS number and other demographic information. Infants born to HIV-positive
mothers should be independently reported through both the obstetric and paediatric
schemes. HIV-positive children born abroad and those born to women who remained
undiagnosed during pregnancy will only be reported through the paediatric scheme.
However, the majority of exposed infants (born in the UK or Ireland) were reported through
both schemes (>90% for births during 2000-2010). Finally, a very small number of reports
of HIV in children come from laboratories via Public Health England (PHE), formerly the
Health Protection Agency (HPA), though these contain minimal information. Such reports
are checked against children already in the NSHPC database to try to avoid duplicates.
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Figure 3.1 NSHPC reporting structure
Source: (Tariq, 2013), with permission.
77
3.1.3 Data items
All data are collected using standardised data collection forms (Appendix III). Forms are
periodically reviewed and new variables may be added. The scheme is anonymous, no
names or addresses, aside from residential postcodes excluding the last digit, are
collected. Some data items are collected through both schemes while others are collected
through just one as is appropriate22.
Women are assigned a unique NSHPC study number. Demographic information collected
includes women’s date of birth, ethnic origin, country of birth and date of arrival into the UK
or Ireland if born abroad, and previous reproductive history; live births, stillbirths,
terminations and miscarriages. Information on probable source of maternal HIV infection is
requested, including whether it was likely acquired in either the UK or Ireland or abroad
(and if abroad which country), and the likely source of exposure (heterosexual, injecting
drug use, vertical transmission or other). Timing of diagnosis includes date of first positive
HIV test, whether the woman was diagnosed prior to or during the current pregnancy,
where she was diagnosed (antenatal, GUM clinic or elsewhere), and whether there is any
evidence of seroconversion during this pregnancy. Pregnancy details include booking date,
expected date of delivery and/or date of last menstrual period, whether the pregnancy is
continuing to term (and if so, whether the planned mode of delivery is vaginal or caesarean
section), and whether the pregnancy has already ended in a miscarriage or termination
(and if so, the date or gestational weeks). Information on ART, including whether the
woman was on treatment at conception, and whether she received antiretrovirals in
pregnancy, together with drugs received and timing of antenatal ART (whether or not the
woman conceived on ART and ART start dates) is requested. Maternal clinical status
comprises whether the woman has ever had CDC Stage C disease (AIDS), whether she
has had HIV/AIDS symptoms during the pregnancy and concurrent infections. The earliest
antenatal CD4 count and viral load measurement are also collected.
The obstetric outcome form includes the date of delivery, pregnancy outcome, gestational
age, planned and actual mode of delivery, whether membranes ruptured prior to delivery
and, if so, the duration of rupture. Information on pregnancy complications such as pre-
eclampsia and gestational diabetes is also sought. Details of ante-partum and intra-partum
ART, as well as any other non-HIV drugs such as tuberculosis treatment or methadone
taken during pregnancy are requested. Maternal clinical status (HIV/AIDS symptoms) at
delivery, together with CD4 count and viral load closest to delivery are also collected.
22 Furthermore, some questions appear on both notification and outcome forms as a means of helping
ensure completeness of key data items and to update data reported on the notification form (e.g. in
relation to drugs received during pregnancy which may have not yet been initiated at the time the
notification form was completed, or may have changed during the course of pregnancy).
78
Information on the infant includes birthweight, the presence of perinatal infections and
congenital abnormalities, as well as details of post-partum prophylaxis.
Independently, the paediatric notification form requests information on the child’s
demographic details, their likely source of infection (including mother’s demographic and
HIV exposure details for those infants likely exposed to maternal HIV), perinatal details
including mode of delivery, ART received by the mother and/or infant, the presence of any
congenital abnormalities, whether or not the child was breastfed, initial infection status and
clinical details. A paediatric follow-up form to establish the infant’s HIV status is
subsequently sent to the relevant paediatric respondent.
3.1.4 Data management, checking and cleaning
The data are held and managed in a Microsoft Access database (version 2003 for the data
analysed in this thesis) (Microsoft Corp., Redmond, Washington, USA). All new reports are
checked against the current dataset to identify duplicates. Pregnancies from the same
woman are linked, as are obstetric and paediatric reports pertaining to the same live birth.
Routine checks and cleaning are conducted on the NSHPC dataset during data entry and
also through a series of Access queries performed quarterly by the NSHPC team which
help identify inconsistencies and unlikely values. Where appropriate, these are checked
with the relevant NSHPC respondent and corrected. At the end of each calendar quarter a
set of standard queries is run to extract paediatric and obstetric data for analysis from the
main dataset. The outputs of these queries are then compiled into a single analysis dataset
via R (R Development Core Team), with the analysis dataset subsequently imported into
Stata (Stata Corporation, College Station, Texas, USA) where further routine data checks
are carried out23. To ensure the quality of the data prior to the analyses presented in this
thesis, additional range checks were carried out on the variables of interest within the Stata
dataset to make sure that no variables were coded outside the expected range, and cross
tabulations were used to check consistency between variables. Where inconsistencies or
errors were identified corrections were made as appropriate e.g. by referring back to the
original hard copy of the report, or in some cases where there was no appropriate
alternative, recoding them as missing. Through the generation of a new ‘conception date’
variable (see Section 3.1.5 below), and the cross-checking dates of conception, expected
dates of delivery and pregnancy outcomes for subsequent pregnancies in the same woman
it was possible to detect a small number (<10) of duplicate reports not previously identified
through the standard data cleaning procedures.
23 These checks are supplementary to the routine quarterly data checks carried out within the Access
database.
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The NSHPC Stata dataset is structured as one row per pregnancy, with a unique identifier
for each pregnancy and also for each woman, thus pregnancies for the same woman can
be identified. In order to analyse repeat pregnancies in the NSHPC dataset the inbuilt _n
and _N variables for creating group identifiers were utilised (_n assigning a consecutive
number to each pregnancy occurring within the same woman, and _N indicating the total
number of pregnancies per woman).
3.1.5 Definitions and categorisation of variables
Definitions and categorisation of key variables utilised throughout this thesis are outlined
here. Specific groupings appropriate to each analysis, as well as the definitions of variables
that pertain to a single analysis only, are specified in the relevant chapter.
Repeat pregnancies
A woman’s first reported, or ‘index’ pregnancy (the terms are used interchangeably
throughout this thesis), refers to their first pregnancy as a diagnosed woman, whether their
HIV diagnosis was made prior to that pregnancy, for example in a GUM clinic, or through
antenatal screening. It is important to note that a proportion of women will already be
parous at the time of their first pregnancy reported to the NSHPC. Therefore, women’s first
reported pregnancy is not necessarily their first ever pregnancy. ‘Repeat’, ‘sequential’ or
‘subsequent’ pregnancies (terms are used interchangeably throughout this thesis) refer to
second and subsequent pregnancies since HIV diagnosis, reported to the NSHPC. The
way the variable was constructed, the inclusion criteria, and whether analyses were
conducted at the woman level or the pregnancy level, differ according to the specific
analyses being carried out. For example, some analyses include all repeat (second and
subsequent pregnancies), others only second reported pregnancies, and others the last
reported pregnancy according the question being addressed. The study population used for
individual analyses is therefore clearly defined within each chapter.
Maternal demographic characteristics
Maternal age at conception (used in Chapter 4) was defined as women’s age at the start of
their pregnancy (last menstrual period), derived using women’s date of birth and the
estimated date of conception. Maternal age at delivery (used in Chapters 5, 6 and 7) was
derived using women’s date of birth and the date of delivery (for live and stillbirths) or end
of pregnancy for other outcomes.
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Parity was defined as the number of live and stillbirths (of gestational age ≥24 weeks) 
(Royal College of Obstetricians and Gynaecologists). Up to 2001 only information on
previous live births was requested; previous stillbirths are thus only included for women
with a pregnancy reported from 2002 onwards. Women were classified as nulliparous if
they were reported to have had no previous live or stillbirths at the time of their first
pregnancy reported to the NSHPC, and parous if they had one or more previous live or
stillbirths.
For data collection purposes ethnic group is defined as white, black African, black
Caribbean, black other, Asian/Indian Subcontinent, Asian other/Oriental and other/mixed.
Maternal ethnic group was subsequently categorised as white, black African and other.
World region of birth was largely grouped as UK or Ireland, sub-Saharan Africa and
Elsewhere. For some analyses (Chapter 4) the following more detailed breakdown was
used: UK or Ireland, Europe, Eastern Africa, Middle Africa, Western Africa, Southern Africa,
Africa (unspecified) and Elsewhere. The division of sub-Saharan Africa into regions was
based on the United Nations definitions (United Nations, 2010).
Likely source of maternal HIV infection was categorised as either ‘injecting drug use’ or
‘other’, representing two quite distinct populations of women. The injecting drug use group
consists of women with a history of injecting drug use. The latter group comprises largely
women with a likely heterosexual route of acquisition and/or those originating from a high
HIV prevalence area of the world. There is substantial overlap between these two groups,
and this, combined with changes in the way information has been collected over time,
means that it was not appropriate to attempt to distinguish between them. The small groups
of women with other exposure risks, for example, transfusion-associated infection, and
young women who themselves acquired HIV vertically were also included in the ‘other’ risk
group.
Estimated date of conception and gestational age
Date of conception was estimated by taking 280 days (40 weeks) away from the expected
date of delivery for all pregnancies24 which is a widely used estimation of the average
duration of pregnancy (American College of Obstetricians and Gynecologists, 2013).
24 For the purposes of calculating date of conception, if only a paediatric report had been received for the
pregnancy (the paediatric form does not collect the expected date of delivery), date of conception was
approximated as the date of delivery minus gestational age, if gestational age was missing (~1% of all
reports) this was inputted as 280 days. This imputed variable was used solely for purpose of estimating
date of conception.
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The first, second and third trimesters of pregnancy were defined as 1-12 completed
gestational weeks, 13-26 weeks  and ≥27 weeks respectively. Pregnancies resulting in a 
live or stillbirth delivered at <37 gestational weeks were classified as being preterm.
Timing of antenatal booking
Gestation at antenatal booking was estimated by calculating the number of days from
estimated date of conception to reported date of booking for antenatal care. Details of the
categorisation of this variable are provided in the relevant chapter (Chapter 5).
Maternal clinical and immunological characteristics
Information on presence of maternal HIV/AIDS symptoms included those occurring at any
time during pregnancy; based on this, women were coded as either symptomatic or
asymptomatic during pregnancy. The NSHPC requests two antenatal CD4 count and viral
load measurements (earliest and last during pregnancy). These variables are therefore
pregnancy-specific e.g. the variable ‘earliest CD4 count’ refers to the earliest antenatal
measurement during the pregnancy of interest. Earliest measurements were restricted to
those taken during pregnancy, including those up to 14 days prior to the estimated date of
conception to allow for potential inaccuracies in estimated conception date. For some
analyses measurements were further restricted to those taken prior to (and up to 14 days
after) antenatal ART initiation. CD4 counts were grouped as: <200, 200-349, 350-499 and
≥500 cells/µl. A binary grouping of <350 and ≥350 cells/µl was also used because 
guidelines recommend that CD4 count <350 cells/µl be used as the threshold for initiation
of ART (Gazzard et al, 2008; Williams et al, 2012). Viral load measurements defined as
‘closest to delivery’ were restricted to those taken within 28 days prior to and seven days
after delivery25. An undetectable viral load was defined as <50 copies/ml. The detectability
limit of assays has changed over time. Where viral load was analysed as a continuous
variable those reported as being below a certain detection limit (e.g. ‘<200 copies/ml’) were
recoded as the mid-point thus the example given was recoded as 100 copies/ml
(Townsend et al, 2008a). This continuous variable was used for descriptive analyses only;
for most analyses viral load was treated either as a binary variable (detectable and
undetectable), or occasionally as a categorical variable classified as <50, 50-999, 1000-
9999 and ≥10,000 copies/ml.  
Antiretroviral therapy
Type of ART received during pregnancy was broadly classified as mono/dual therapy or
cART (defined as any combination of three or more antiretrovirals). For some analyses
25 See Section 3.4 for information on the imputation of viral loads missing within this restricted time period.
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cART was further classified as PI-based (either ritonavir boosted or unboosted), NNRTI-
based, PI- and NNRTI-based (triple class therapy) and NRTI only. With regards to the
timing of ART initiation, pregnancies were grouped according to whether they were
conceived on ART or not. Where ART was started antenatally the start date is collected
through the obstetric scheme only. For some analyses timing (e.g. trimester or gestational
week) of start of antenatal ART was used, while for others duration of antenatal ART
received (i.e. ART start date to date of delivery) was utilised, as appropriate.
Mode of delivery and pregnancy outcomes
Deliveries were classified as vaginal (planned or unplanned), elective caesarean section
(pre-planned and conducted before the onset of labour or the rupture of membranes), or
emergency caesarean section (conducted after rupture of membranes or onset of labour).
Information on whether vaginal deliveries were planned or unplanned has been collected
since 2002, with planned mode requested for all pregnancies since 2007.
Pregnancy outcomes were categorised as live births, stillbirths (deaths occurring from 24
weeks onwards), miscarriages (fetal deaths occurring before 24 weeks gestation) (Royal
College of Obstetricians and Gynaecologists, 2013), or terminations. At any given point in
time a proportion of pregnancies will be continuing to term. For others, the woman may be
reported to have gone abroad during pregnancy, or to have died. In some cases the
outcome had simply not been reported (i.e. no obstetric outcome form or paediatric form
had been returned). Finally, a small number of live births subsequently result in a neonatal
death, defined as deaths occurring during the first 28 days of life (Perinatal Institute, 2011).
Infant HIV status
Infants were categorised as being ‘presumed HIV-positive’ if they had a positive PCR test
at over one month of age. A confirmed diagnosis was based on a subsequent positive PCR
test on infants aged over three months, or a positive antibody test at >18 months of age.
Infants were ‘presumed HIV-negative’ if they had a negative initial PCR. They were
confirmed as being negative based on a repeat negative PCR test, or a negative antibody
test. Because it is rare that later tests do not confirm the initial results no distinction was
made between infants with a ‘presumed’ or ‘confirmed’ diagnosis in the analyses
(Townsend et al, 2008a).
3.1.6 Datasets for analysis
Two extracts of the NSHPC dataset were used in this thesis. The first included pregnancies
conceived between January 1990 and December 2009, and reported by the end of
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December 2010 (analysed in Chapter 4). The second included pregnancies ending
between January 1990 and December 2010, reported by the end of June 201126 (analysed
in Chapters 5, 6 and 7). The same exclusion criteria were applied to both datasets (see
Figures 3.2 and 3.3), but exclusions based on ‘pregnancy year’ were made according to the
year of conception for the first dataset since the analyses of this dataset were concerned
with the occurrence (conception) of pregnancies. For the second dataset, ‘pregnancy year’
was based on the year of delivery, or expected year of delivery for pregnancies ending in
outcomes other than a live or stillbirth.
The following standard exclusions were made to the datasets prior to all analyses
presented in this thesis (see Figures 3.2 and 3.3). Further exclusion criteria required for
specific analyses are detailed in the relevant chapters.
 Paediatric reports where the child’s source of HIV exposure was not vertical (for
example, haemophiliacs exposed to infected blood products)
 Pregnancies for which only a laboratory report was received since these contain
very minimal demographic and clinical information. Aside from this limitation, it was
also difficult to confirm that they are not duplicates of reports received through the
obstetric and/or paediatric scheme
 Pregnancies reported retrospectively – these are historical reports largely from prior
to the initiation of the NSHPC
 Pregnancies (or children born to) women who had not been diagnosed prior to
delivery. Although the NSHPC receives some reports (largely through the paediatric
scheme) that relate to such pregnancies, these women would not have been able
to receive any HIV-specific care during pregnancy and are not explored in this
thesis
 Children who were born abroad and subsequently came to the UK (unless the
mother was also reported to the NSHPC i.e. she was in the UK or Ireland at some
point during pregnancy)
26 To ensure the final year of data in each extract was as complete as possible pregnancies occurring
post-2009 were excluded from the first extract, and those delivered post-2010 excluded from the second
extract. Such pregnancies were largely ongoing at the time of analysis thus data were incomplete.
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 The second and third born infants of multiple pregnancies - their information was
retained and could be referred to as required, but due to the structure of the data
this was necessary to avoid each infant being counted as a separate pregnancy
Temporal trends in sequential pregnancies, presented in Chapter 4, were assessed using
all years of data (i.e. from 1990 onwards). However, subsequent analyses were restricted
to the year 2000 onwards to ensure that findings were reflective of the more recent
epidemiological situation (i.e. widespread antenatal HIV testing, availability of cART and
low MTCT rates) (Public Health England, 2013a; Townsend et al, 2014). The epidemiology
of HIV among pregnant women in the UK and Ireland has also changed significantly since
the early years of the epidemic (Townsend et al, 2014; Townsend et al, 2008b). The period
from 2000 onwards covers the majority of pregnancies reported to the NSHPC (almost 90%
of pregnancies occurred during 2000-2009, based on data presented in Chapter 4). Some
analyses were conducted on further restricted time periods as described in the relevant
chapters.
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Figure 3.2 NSHPC study population, pregnancies occurring during 1990-2009
*Unless the woman was also reported to the NSHPC (i.e. she was in the UK or Ireland during pregnancy)
**Thus two/three births are counted as one pregnancy only
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Figure 3.3 NSHPC study population, pregnancies ending during 1990-2010
*Unless the woman was also reported to the NSHPC (i.e. she was in the UK or Ireland during pregnancy)
**Thus two/three births are counted as one pregnancy only
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3.2 Survey of Prevalent HIV Infections Diagnosed (SOPHID)
SOPHID is a cross-sectional survey of all HIV-positive people attending for HIV-related
care at NHS sites in England, Wales and Northern Ireland. During the period of data
collection pertaining to the analyses presented in this thesis the survey was run by the HPA
(now PHE), with Scottish data collected separately by Health Protection Scotland. The
survey ran twice a year in London and annually outside London. In each survey, providers
of HIV treatment or care collated a list of all individuals who had attended for HIV-related
care. Anonymised epidemiological and demographic data collected on each patient were
provided to PHE where the data was collated, de-duplicated and cleaned. Data collected
included demographic information (e.g. sex, age and ethnicity) and clinical details such as
CD4 count and treatment status (Public Health England, 2013c). These data enable annual
estimates of all people attending care in each calendar year to be produced. Since
individuals are allocated a unique SOPHID personal identifier, which remains constant, it is
possible to trace HIV-care attendance for individuals, or population sub-groups over time.
Information on deaths was routinely incorporated into SOPHID by matching with the HIV
and AIDS New Diagnoses and Deaths (HANDD) database. HANDD, also run by PHE,
collates information on all new HIV diagnoses, AIDS and death reports from clinicians and
laboratories in England, Wales and Northern Ireland (Scottish data are collected separately
by Health Protection Scotland). The HANDD dataset is also linked to the Office for National
Statistics deaths register (Public Health England, 2013b).
SOPHID data were used to investigate the retention of women in HIV care following
delivery and pertain to Chapter 5 only. Further details, including procedures used to link the
NSHPC and SOPHID datasets are therefore detailed in that chapter.
3.3 Ethical approval and governance
The NSHPC has been approved by the London Multi-Centre Research Ethics Committee
approval (MREC/04/2/009). This work was a secondary analysis of routinely collected
surveillance data for which individual patient consent was not required27. SOPHID is
exempt from ethical approval as it fulfils a surveillance purpose. The HPA was registered
under the Data Protection Act 1998 to handle data for diagnostic, public health and other
purposes, and is registered under Section 251 of the Health and Social Care Act 2001.
27 Further details of NSHPC ethical approval and governance are available here:
http://www.ucl.ac.uk/nshpc/ethics (Accessed March 2014).
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During the period of SOPHID data collection presented in this thesis (data to 2010), the
HPA had approval from the Patient Information Advisory Group to handle data for purposes
that include surveillance and the control of disease, even where specific patient consent
has not been given.
3.4 Missing data
As has been described, in the process of NSHPC data collection, and the cleaning and
preparation of the dataset for analysis, the amount of missing data was minimised as far as
possible. As with any surveillance study, some missing data are inevitable. This was dealt
with by examining the extent of missing data on key outcome and exposure variables, and
assessing whether this was likely to significantly bias the findings, by comparing the
characteristics of those with and without missing data, as appropriate to each analysis
(these data are presented within each relevant chapter). Other potential options for dealing
with missing data include methods such as multiple imputation which involves generating a
number of different imputed datasets, based on the distribution of the available data, the
results of which are then combined (Rubin, 1987; Sterne et al, 2009). The application of
such an approach to dealing with missing data in the NSHPC dataset was assessed. It
was, however, deemed largely inappropriate, and was therefore not utilised. The main
reasons for this are as follows: i) the NSHPC dataset has a complex structure, consisting
of pregnancies with some women potentially having more than one pregnancy reported,
therefore some variables would need to remain constant across pregnancies in the same
woman e.g. maternal ethnic group, while others are pregnancy-specific e.g. antenatal CD4
count measurements, ii) the dataset consists of a range of variable types including
continuous variables which are mainly non-normally distributed, iii) multiple imputation
relies on the assumption that data are missing at random (Sterne et al, 2009). While for
some NSHPC variables this could be a reasonable assumption e.g. the respondent may
have simply missed the question, for many this assumption is unlikely to hold e.g. maternal
demographic and clinical details may be less likely to be reported for women who present
late in pregnancy or only at delivery, and are also more likely to have been collected for
women with more than one pregnancy reported, iv) finally, of course the outcome variable
of interest cannot be imputed, and the NSHPC dataset contains a number of potential
outcomes of interest.
One key outcome variable with substantial missing data was viral load at delivery. This was
missing for around 45% of deliveries during 2000-2010 (based on data presented in
Chapter 6). That many of these women had an earlier undetectable viral load reported
earlier in the pregnancy is a potential reason in itself for a later (undetectable) viral load not
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to have been reported. Since the majority of women in the UK and Ireland receive ART
during pregnancy (Townsend et al, 2014), with most receiving cART, it is reasonable to
assume that most of those with an undetectable viral load earlier in that pregnancy will
remain undetectable at delivery. The method devised to address this is outlined here since
it pertains to several analyses presented in this thesis. Essentially, if delivery viral load (as
measured during the 28 days before and up to seven days after delivery) was missing but
the woman’s last available viral load measurement at any time during that pregnancy was
undetectable, delivery viral load was imputed as undetectable. Supporting this approach,
an analysis of data from the US WITS study demonstrated that 87% of women with an
initial undetectable viral load remained undetectable at delivery (Katz et al, 2010).
Furthermore, among women in the NSHPC (during 2000-2010) for whom both an ‘earliest’
and ‘closest to delivery’ viral load was reported only 8% with an initially undetectable viral
load were reported to be detectable at the time of delivery. Where the imputed variable was
used as the main outcome variable, sensitivity analyses were conducted based on the
original non-imputed variable, to confirm that imputation did not significantly alter the
findings or the conclusions drawn.
3.5 Statistical analyses
Data were analysed using Stata versions 11.0-12.1 (Stata Corp., College Station, Texas,
USA). Where names of commands in the Stata language are provided these appear in
courier font.
Descriptive analyses and tests of significance
Proportions were calculated among cases with known information on the variable of
interest, and were compared using the 2 or Fisher’s exact test (if the size of any cells was
less than five), with trends in proportions assessed using the 2 test for trend (Kirkwood et
al, 2003). A Bonferroni correction for multiple comparisons was used were applicable
(Bland et al, 1995). For non-normally distributed variables medians were compared using
the Wilcoxon-Mann-Whitney test (‘ranksum’) (Kirkwood et al, 2003; Mann, 1947) and
trends in medians using Cuzick's non-parametric test for trend across ordered groups
(‘nptrend’) which is an extension of the Wilcoxon-Mann-Whitney test (Cuzick, 1985).
Statistical tests were considered significant if the p-value was <0.05, unless otherwise
stated.
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Construction of multivariable models
The general approach to multivariable model construction is provided here, in the context of
a logistic regression analysis (a methodology which was used for a number of analyses of
binary outcome variables presented in this thesis28). The same approach was applied to
analyses conducted using other statistical methods, namely Cox proportional hazards and
ordinal logistic regression modelling. Further details of specific analyses are provided in the
relevant chapters.
Univariable analyses were carried out to obtain crude ORs with 95% CIs. Corresponding p-
values were obtained using the Wald test for binary variables and the likelihood ratio (LR)
test for categorical variables. Multivariable models were developed using a forward-fitting
approach. For analyses examining the association between a defined exposure and
outcome, potential confounders were identified in bivariate analyses; if adjusting for a
variable changed the crude OR by at least 10%, and the variable was not believed to be on
the causal pathway, it was considered a potential confounder. Each potential confounder
was then added to the model starting with the one for which there was the strongest
evidence of confounding (based on the results of the bivariable analysis). Variables were
kept in the model if they improved the fit (based on extent of change in the crude OR, and
the p-value from the LR test comparing the model including the variable to the model
excluding it). Once the model had been built, other variables that were not identified as
potential confounders in the bivariable analysis were added to the model to see if they
improved the fit. If not, they were removed.
Meanwhile, for risk factor analyses, conducted to identify all relevant factors independently
associated with a defined outcome, variables significantly associated with the outcome in
the univariable analysis were included in the multivariable model. Remaining variables that
were significantly associated with the outcome at the more conservative p<0.1 level were
then added to the model in turn; goodness-of-fit was assessed using LR tests.
Selection of the baseline group for categorical variables
For categorical variables the most appropriate baseline group was selected, generally the
lowest value of the variable (e.g. earliest time period), but the decision took into account
what was most logical and relevant in terms of interpreting the analyses, the size of each
group (avoiding the use of very small groups as the baseline where possible), and the
desirability of ensuring consistency between analyses as far as was reasonable.
28 For common (often cited as >10%) outcomes, the odds ratio does not provide a close approximate of
the risk ratio (as it does for rare outcomes) (Bland et al, 2000; McNutt et al, 2003). However, it remains a
valid measure of association.
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Adjustment for clustering
For some analyses, women with repeat pregnancies contributed more than one pregnancy
to the dataset, which may therefore be described as being clustered at the woman level. If
these clustered observations (pregnancies) are treated as being independent, as is the
case with standard statistical approaches, the resulting standard errors are likely to be
biased and will be too narrow due to intracluster correlation (i.e. pregnancies in the same
woman are likely be more similar to each other than pregnancies in different women).
Clustering was adjusted for using robust standard errors. This method adjusts the standard
errors (and thus the 95% confidence intervals) based on the variability within the data
rather than variability determined by a statistical model, without altering the point estimate,
and is appropriate where the number of clusters is large ≥30 (Kirkwood et al, 2003). This
adjustment was applied using the ‘cluster’ option in Stata (Rogers, 1993). Since the LR
test does not take account of clustering, in analyses conducted using robust standard
errors the Wald test was used in place of the LR test (Kirkwood et al, 2003). For analyses
which included only one pregnancy per woman, for example, those restricted to second
reported pregnancies, no adjustment for clustering was required.
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3.6 Role of the researcher
During the course of this PhD research I was based within the NSHPC team at the UCL
Institute of Child Health. The NSHPC dataset has not previously been analysed in the
context of exploring repeat pregnancies to diagnosed women (most prior NSHPC analyses
have been carried out at either the pregnancy or woman level only). I therefore generated
new identifiers for pregnancies within the same woman and established appropriate
analytic methods for data of this form. I cleaned and prepared the NSHPC datasets prior to
analysis, including making appropriate exclusions, and the generation of new variables as
required. The NSHPC and SOPHID datasets have not been previously been matched. I
liaised with colleagues at PHE (where matching was conducted) regarding the matching
procedures, and was responsible for integrating the matched dataset into the main NSHPC
Stata dataset, making the appropriate exclusions, and preparing this matched dataset for
analysis29. I designed and conducted all analyses presented in this thesis.
29 Preparation of the matched dataset was carried out in collaboration with my colleague Shema Tariq.
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Chapter 4 Incidence, patterns and predictors of repeat
pregnancies
Alongside the year-on-year increase in the overall number of pregnancies to HIV-positive
women in the UK and Ireland has been an increase in the proportion occurring in previously
diagnosed women. Though this is due in part to increasing uptake of HIV testing in a range
of settings, a substantial proportion are in women who were diagnosed antenatally during a
previous pregnancy. However, little is known about the incidence, temporal trends or
predictors of repeat pregnancies among diagnosed women in the UK and Ireland, or indeed
internationally. Reliable national data on the number and rate of repeat pregnancies is
important to inform HIV and reproductive health service provision. The objectives of this
chapter are firstly to estimate the rate of repeat pregnancies in HIV-positive women in the
UK and Ireland during 1990-2009, document temporal trends, and explore birth-spacing
intervals (Objective 1), and then to characterise the group of women with repeat
pregnancies and identify factors associated with having a sequential pregnancy during
2000-2010 (Objective 2).
4.1 Incidence and patterns of repeat pregnancies
4.1.1 Methods
Dataset
The following analyses were conducted on pregnancies that occurred during 1990-2009,
and were reported by the end of December 2010. For this reason data for 2009 are
incomplete. However, the proportion of repeat pregnancies and characteristics of women
reported were considered to be representative of the full year. Reported pregnancies were
included in the analysis regardless of outcome: live births, stillbirths, terminations,
miscarriages (including ectopic pregnancies), and those that were ongoing or had unknown
outcomes (e.g. because the woman had gone abroad during pregnancy). Analyses were
conducted on women’s pregnancies reported to the NSHPC, rather than exploring their
total reproductive histories in depth30. However, it should be noted that a proportion of
women are already parous at the time of their first pregnancy reported to the NSHPC.
30 Information requested by the NSHPC on women’s reproductive histories prior to their HIV diagnosis is
limited simply to the number of previous births they have had. No other details, such as the dates of these
previous births, are collected.
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Rate calculations
The rate of repeat pregnancies was estimated per 100 woman-years. For calculation of the
rate of all repeat pregnancies (i.e. second, third, fourth etc), the numerator was the number
of all repeat pregnancies reported. The denominator ‘time at risk of repeat pregnancies’
was defined as the sum of the time from the end of women’s first reported pregnancy to the
end of the study period (31st December 2009), the end of their reproductive life which was
defined as turning age 50, or their date of death (if reported to have died), whichever
occurred first. Women were not ‘at risk’ of becoming pregnant and therefore did not
contribute to the denominator, whilst pregnant. There is no consensus definition regarding
the age at which a woman reaches the end of her childbearing years. Turning either age 45
or age 50 are commonly used definitions and since there are a number of pregnancies
reported to the NSHPC among women aged 45 years and over (n=126 during 1990-2009),
a cut-off of turning age 50 was deemed most appropriate. Figure 4.1 provides an example
of the reproductive history of a woman in the NSHPC dataset. This woman had three
repeat pregnancies and contributed a total of 5.75 years at risk of repeat pregnancy.
For calculation of the rate of second pregnancies only (i.e. excluding third and subsequent
pregnancies), the numerator consisted of second pregnancies, and time at risk ended at
the start of the second pregnancy, the end of the study period, the end of women’s
reproductive life, or date of death – whichever occurred first. Figure 4.2 provides an
example of a woman who had a second pregnancy, and contributed a total of 2.75 years at
risk.
The rate of second pregnancies during each calendar year was estimated (the numerator
was the number of second pregnancies occurring in a given calendar year). Trends in the
rate of repeat pregnancies were assessed fitting Poisson regression models.
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Figure 4.1 Time at risk of repeat pregnancies – an example
Figure 4.2 Time at risk of a second pregnancy – an example
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Kaplan–Meier analyses
To further explore the pattern of repeat pregnancies, Kaplan–Meier analyses were used to
estimate the probability of having a second pregnancy among all women in the NSHPC (i.e.
all women with one pregnancy already reported to the study). As for analyses of the rate of
second pregnancies, time at risk started at the end of women’s first pregnancy, and women
were censored at the end of the study period, or their date of death – whichever occurred
first. The Kaplan–Meier approach assumes that censoring is non-informative (i.e. that it is
independent of the event of interest) (Bland et al, 1998). To ensure that this assumption
was met, women were not censored at the end of their reproductive lives31. The
proportional hazards assumption was checked by comparing the Kaplan–Meier plots with
the predicted plots by time period (Therneau et al, 2000).
The probability of having a second pregnancy according to the time period in which
women’s first reported pregnancy occurred was also explored. For this analysis women
were censored at four years after the end of their first pregnancy, rather than the end of the
study period, since women who had their first pregnancy during the most recent time period
(2005-2009) could not contribute more than four years at risk. Differences between time
periods were assessed using the log rank test for trend.
Estimating birth spacing intervals
Birth spacing intervals were estimated among women with more than one pregnancy
reported. There are various methods for estimating birth spacing intervals. Two of the WHO
methods were used. Firstly, birth-to-birth intervals were estimated among live births only,
defined as the time in years between the dates of delivery of women’s first and second live
births, and between each subsequent live birth. Secondly, birth-to-pregnancy intervals –
defined as the time in years between the date of delivery of a live birth and the start of the
subsequent pregnancy, irrespective of the outcome (World Health Organization, 2005).
Figure 4.3 illustrates these two different methods. Using the first method, the woman
depicted has a 3.75 year interval between her first and second live birth, while using the
second method, the same woman has a 1.5 year interval between her first live birth and the
start of her subsequent pregnancy.
31 Since reaching the end of reproductive life is associated with the probability of experiencing the outcome
of interest (pregnancy), right censoring women in this way would constitute ‘informative censoring’. In
practical terms it made very little difference to the results whether or not women were censored at the end
of their reproductive lives.
97
Figure 4.3 Birth spacing interval definitions
Source: Based on definitions provided by: (World Health Organization, 2005).
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4.1.2 Study population
There were a total of 14,096 pregnancies during 1990-2009. Of the 13,355 pregnancies
with a recorded outcome, 11,915 (89.2%) resulted in a live birth, 121 (0.9%) in a stillbirth,
1317 (9.9%) in either a miscarriage or termination, and for two (0.01%) the woman was
reported to have died. Of those remaining, 146 were continuing to term, 183 women had
gone abroad, and for 412 the outcome was not reported. Of the 12,036 live and stillbirths,
there were 11,818 singletons, 214 sets of twins and four sets of triplets.
The number of pregnancies reported to the NSHPC between 1990 and 2009, according to
year of conception, increased dramatically (by 1546%) from 89 to 1465 (p<0.001) (Figure
4.4). The number of pregnancies was below 200 each year until 1997 and then rapidly
increased. Since 2006 the number of pregnancies reported each year has been relatively
stable with a slightly lower number in 2009 most likely due to reporting delay.
Figure 4.4 Number of pregnancies by year, 1990-2009
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Table 4.1 describes some key maternal characteristics for all pregnancies reported during
1990-2009, overall and by time period. Almost 90% of all pregnancies reported occurred
during 2000-2009. The median age of women at conception of their pregnancy was 29.8
years (IQR: 26.0-33.8). Over three quarters of pregnancies were to black African women,
and just under a third were in nulliparous women. To briefly summarise key changes over
time, average maternal age increased (p<0.001), and the proportion of pregnancies
occurring in white women declined (p<0.001) with a corresponding increase the proportion
occurring in black African women (p<0.001). In line with this, the proportion of pregnancies
to women who were born in the UK or Ireland declined (p<0.001), while an increasing
proportion of pregnancies occurred in women from Western and Southern Africa in
particular (both p<0.001). The proportion in women with a history of injecting drug use
declined substantially. There was an increase in the proportion of pregnancies occurring in
nulliparous women between 1990-1994 and 2000-2004, with some decline in 2005-2009.
As discussed in Chapter 1, the demographics of the population of HIV-positive women in
the UK and Ireland have changed dramatically over the last two decades, and the changes
documented in Table 4.1 largely reflect this. However, some diagnosed HIV-positive
women will experience more than one pregnancy, and it may be hypothesised that some of
the observed changes could be partly explained by this.
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Table 4.1 Maternal characteristics for pregnancies reported to the NSHPC, overall and by time period, 1990-2009
Characteristic TOTAL
Time period*
p-value**1990-1994 1995-1999 2000-2004 2005-2009
n (%) n (%) n (%) n (%) n (%)
Total 14096 484 1022 4985 7605 -
Age at conception, yrs (n=14,010)
Median (IQR) 29.8 (26.0-33.8) 27.1 (24.2-29.9) 28.9 (25.6-32.4) 29.0 (25.4-32.9) 30.7 (26.8-34.6) <0.001
Ethnic group (n=13,963)
White 2124 (15.2) 212 (49.2) 274 (26.9) 648 (13.1) 990 (13.1) <0.001
Black African 10748 (77.0) 206 (47.8) 684 (67.1) 3913 (79.1) 5945 (78.6) <0.001
Other 1091 (7.8) 13 (3.0) 62 (6.1) 389 (7.9) 627 (8.3) <0.001
World region of origin (n=13,749)
UK/Ireland 2035 (14.8) 146 (47.1) 253 (25.0) 683 (13.9) 953 (12.8) <0.001
Europe 427 (3.1) 14 (4.0) 43 (4.3) 116 (2.4) 254 (3.4) 0.76
Eastern Africa 5957 (43.3) 145 (41.4) 422 (41.7) 2111 (42.8) 3279 (44.0) 0.07
Middle Africa 1064 (7.7) 21 (6.0) 78 (7.7) 421 (8.5) 544 (7.3) 0.37
Western Africa 2335 (17.0) 9 (2.6) 129 (12.8) 857 (17.4) 1340 (18.0) <0.001
Southern Africa 1018 (7.4) 2 (0.6) 32 (3.2) 397 (8.1) 587 (7.9) <0.001
Africa (unspecified) 160 (1.2) 4 (1.1) 13 (1.3) 56 (1.1) 87 (1.2) 0.93
Elsewhere 753 (5.5) 9 (2.6) 42 (4.2) 288 (5.8) 414 (5.6) 0.05
HIV risk factor (n=13,274)
Other*** 12743 (96.0) 323 (68.7) 886 (89.2) 4620 (96.8) 6914 (98.2) <0.001
Injecting drug use 531 (4.0) 147 (31.3) 107 (10.8) 153 (3.2) 124 (1.8) <0.001
Parity (n=12,365)
Nulliparous 3913 (31.7) 22 (13.6) 225 (24.0) 1529 (35.3) 2137 (30.8) 0.04
1 4523 (36.6) 64 (39.5) 379 (40.5) 1528 (35.2) 2552 (36.8) 0.44
2 2404 (19.4) 42 (25.9) 179 (19.1) 788 (18.2) 1395 (20.1) 0.33
≥3 1525 (12.3) 34 (21.0) 153 (16.4) 493 (11.4) 845 (12.2) 0.003
Continued overleaf
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Table 4.1 Continued: Maternal characteristics for pregnancies reported to the NSHPC, overall and by time period, 1990-2009
Characteristic TOTAL
Time period*
p-value**1990-1994 1995-1999 2000-2004 2005-2009
n (%) n (%) n (%) n (%) n (%)
Timing of HIV diagnosis (n=13,969)
Before this pregnancy 8223 (58.9) 335 (72.5) 596 (58.8) 2194 (44.2) 5098 (67.7) <0.001
During this pregnancy 5746 (41.1) 127 (27.5) 417 (41.2) 2765 (55.8) 2437 (32.3) <0.001
*Based on year of conception
**p-values for trends over time comparing each category with all others combined with a Bonferroni correction to take account of multiple comparisons
***Other comprises largely those originating from a high HIV prevalence area and/or with heterosexual exposure to HIV
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4.1.3 Number and proportion of repeat pregnancies
The 14,096 reported pregnancies occurred among 10,568 diagnosed HIV-positive women,
totalling 3528 repeat pregnancies in all. There were 2737 (25.9%) women who experienced
repeat pregnancies (2117 women had two pregnancies, 475 had three and 145 had four or
more). The maximum number of pregnancies was six (three women each had six
pregnancies). Of the 3528 repeat pregnancies an outcome was recorded for 3404. Of
these, 3013 (88.5%) resulted in a live birth, 30 (0.9%) in a stillbirth, 360 (10.6%) in either a
miscarriage or termination, and for one (0.03%) the woman was reported to have died. Of
the remaining 124 pregnancies, 38 were continuing to term, for 22 the woman had gone
abroad, and for 64 the outcome was not reported.
Both the number and proportion of repeat pregnancies (i.e. pregnancies to women who
already had at least one pregnancy reported) increased. The proportion increased between
1990 and 1994 with some levelling off during the remainder of the 1990’s. During the next
decade the proportion increased substantially from 14.9% (87/585) in 2000 to 38.6%
(565/1465) in 2009 (p<0.001). In 2009, 28.2% of all pregnancies were second pregnancies,
7.4% were third, and 2.9% were fourth or subsequent (Figure 4.5).
Figure 4.5 Proportion of first and subsequent pregnancies by year, 1990-2009
103
4.1.4 Rate of repeat pregnancies
The analysis of the rate of repeat pregnancies included 9916 women (652 were excluded
because their first pregnancy was ongoing thus they did not contribute any time at risk).
There were a total of 52,676 woman-years at risk and 3528 repeat (second, third, fourth
etc) pregnancies. The median time at risk was 4.6 years. The overall rate of repeat
pregnancies was 6.7 (95% CI: 6.5-6.9) per 100 woman-years (i.e. among 100 women
followed for one year it would be anticipated that seven would become pregnant).
For the analysis of second pregnancies, the number of women was the same (9916) and
the 2737 second pregnancies were included. The total duration of time at risk was 40,760
woman-years. The median time at risk was 3.2 years. The overall rate of second
pregnancies was also 6.7 (95% CI: 6.5-7.0) per 100 woman-years. Subsequent analyses
focus on second pregnancies.
The rate of second pregnancies was 7.0 per 100 woman-years during 1990-1994, 6.1
during 1995-1999, 7.3 during 2000-2004 and 6.5 during 2005-2009 (Table 4.2).
Table 4.2 Number and rate of second pregnancies by time period, 1990-2009
Time period Number of secondpregnancies
Woman-years
at risk
Rate (95% CI) per
100 woman-years
1990-1994 54 766 7.0 (5.4-9.2)
1995-1999 159 2590 6.1 (5.3-7.2)
2000-2004 726 9920 7.3 (6.8-7.9)
2005-2009 1798 27,484 6.5 (6.2-6.9)
When trends in the rate of second pregnancies were examined by single calendar year
(Figure 4.6), the rate was stable overall (p=0.167). There was, however, some increase
between 1995 and 1999, after which the rate stabilised with some decline in the most
recent years. This will likely be due to the large number of women having a first pregnancy
during the most recent years who have had little time to go on and have a second
pregnancy. The wider confidence intervals in the earlier years of the study reflect the
relatively small number of pregnancies during that period.
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Figure 4.6 Rate of second pregnancies per 100 woman years, by year, 1992-2009
*For clarity this figure excludes data for 1990 and 1991 due to the very small number of second
pregnancies in each of those years (<10)
Note: Lower and upper confidence limits are denoted by the dashed lines.
4.1.5 Probability of repeat pregnancies
In the initial Kaplan–Meier analysis an estimated 25% of women had a second pregnancy
after 3.2 years of follow-up, and an estimated 50% of women had a second pregnancy after
20 years of follow-up (Figure 4.7). As can be seen in the figure, most women who
experienced a repeat pregnancy did so within 10 years of their first; over 40% of women
were an estimated to have had a second pregnancy after 10 years of follow-up.
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Figure 4.7 Cumulative probability of having a second pregnancy during 1990-2009
Note: Probability is represented by the dark blue line and the 95% CIs by the lines above and below.
Kaplan–Meier analysis of time to second pregnancy showed differences in the probability of
having a second pregnancy according to the time period in which women’s first pregnancy
occurred (log rank test: p=0.06) (Figure 4.8). Women having their first pregnancy during the
earliest time period (1990-1994) were least likely to have a second pregnancy while those
whose first pregnancy occurred during 1995-1999 were most likely to, and to do so more
quickly. The probability of second pregnancies was very similar among women whose first
pregnancy occurred during the periods 2000-2004 and 2005-2009.
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Figure 4.8 Cumulative probability of second pregnancy by time period of first reported
pregnancy
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4.1.6 Birth spacing intervals
The median birth-to-birth interval among live births during 1990-2009 was 2.7 years (IQR:
1.7-4.1) between first and second deliveries, with a range of 0.7 years (257 days) to 18.6
years. However, very few women had an interval of more than 10 years (Figure 4.9) Very
short intervals occurred in a few women who conceived quickly after their first delivery,
some of whom delivered their second infant preterm (hence the very short gap). The
interval between second and third deliveries was 2.3 years (IQR: 1.5-3.9), it was also 2.3
years (1.5-3.7) between third and fourth deliveries (Figure 4.10). The pattern was similar
when live birth-to-pregnancy intervals were examined; the median interval between first live
birth and the subsequent pregnancy was 1.9 years (IQR: 1.0-3.3). The interval between the
second live birth and subsequent pregnancy was 1.6 years (IQR: 0.7-3.0), as was the
interval between the third live birth and subsequent pregnancy (1.6 years (IQR: 0.7-3.0)
(Figure 4.11). When the analyses were restricted to women whose first birth occurred
during 2000 or later, the findings were similar; the median birth-to-birth interval between
first and second delivery was 2.6 years (IQR: 1.7-3.9), and the birth-to-pregnancy interval
was 1.8 years (IQR: 0.9-3.1).
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Figure 4.9 Interval between first and second live birth (birth-to-birth interval)
Figure 4.10 Quartiles of birth-to-birth intervals
Note: Squares represent the median interval and lines represent the first and third quartiles.
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Figure 4.11 Quartiles of birth-to-pregnancy intervals
Note: Squares represent the median interval and lines represent the first and third quartiles.
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4.2 Predictors of repeat pregnancies
4.2.1 Methods
Dataset
The following analyses were restricted to women whose first pregnancy occurred during
2000-2009 to ensure that findings were reflective of the more recent epidemiological
situation. Reported pregnancies were included in the analysis regardless of pregnancy
outcome. Only the first born of twin and triplet pregnancies were included in the analyses,
with one exception in the analyses addressing stillbirth and neonatal death (see below).
Since not all women were at risk of a subsequent pregnancy during the study period, for
the comparisons of characteristics of women with repeat pregnancies and those with a
single pregnancy only, the following women were excluded: i) those whose first reported
pregnancy ended on or after 31st December 2009, and ii) those who were reported to have
died during their first pregnancy. As for the first part of this chapter, women were not
censored at the end of their reproductive life to ensure that the assumption of non-
informative censoring was met (Bland et al, 1998) since reaching the end of reproductive
life is clearly associated with the probability of becoming pregnant.
For analyses investigating the occurrence of a stillbirth or neonatal death in women’s first
pregnancy as a predictor of repeat pregnancy, the dataset was restricted to women whose
first pregnancy ended in either a stillbirth/neonatal death or a live birth (as the comparison
group). One first born twin (a stillbirth) was excluded from this specific analysis because the
second twin was a live birth. There were no other twin or triplet pregnancies with discordant
outcomes. The analysis of having an HIV-positive infant in first pregnancy as a predictor of
repeat pregnancy was restricted to live births with known information on infant HIV status.
Kaplan–Meier analyses
Kaplan–Meier analyses were used to explore the probability of repeat pregnancies and
time to repeat pregnancies according to demographic, clinical and immunological
characteristics, and previous adverse pregnancy outcomes. Differences between groups
were assessed with the log rank test or the log rank test for trend for ordered categorical
variables. The y-axes of Kaplan–Meier graphs examining differences between groups are
truncated at 0.6 for clarity.
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Cox proportional hazards modelling
Demographic, clinical and immunological characteristics associated with having a second
pregnancy during 2000-2009 were explored in separate risk factor analyses. For the
analysis of clinical and immunological factors associated with repeat pregnancies two
variables were used: earliest CD4 count and HIV/AIDS symptoms during first reported
pregnancy.
For risk factor analyses univariable and multivariable analyses were conducted using Cox
proportional hazards models to calculate crude and adjusted hazard ratios (HR and aHR
respectively). Multivariable models were built using a forward-fitting approach as described
in Chapter 3, Section 3.5. Year of first pregnancy was included in the multivariable models
a priori to take account of changes, for example in the management of women, over the
study period. The proportional hazards assumption (i.e. that the HR is constant over time)
was assessed by examining log-log plots to ensure plots for the different strata of a given
variable, adjusted for all other variables included in the model, were approximately parallel.
The model’s Schoenfeld residuals were also analysed, both for each covariate and globally
(Therneau et al, 2000). The association between adverse pregnancy outcomes in women’
first reported pregnancy and the probability of repeat pregnancy were also analysed fitting
Cox proportional hazards models.
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4.2.2 Study population
The analysis of women whose first pregnancy occurred during 2000-2009 excluded 651
women with a single pregnancy who were not ‘at risk’ of having a repeat pregnancy during
the study period because their first pregnancy was ongoing (no women were reported to
have died during their first pregnancy). A total of 11,426 pregnancies among 8661 women
(2238 (25.8%) of whom had repeat pregnancies) were thus included in the subsequent
analyses. Of these, 1798 had two pregnancies, 364 had three, 65 women had four, and 11
women had five. Of all 11,426 pregnancies an outcome was recorded for 10,858 (95.0%) of
which 9826 (90.5%) resulted in a live birth, 100 (0.9%) in a stillbirth, and 932 (8.6%) in a
miscarriage or termination. Outcome was not known for 568 pregnancies, including 36
continuing to term and 167 where the woman had gone abroad before delivery.
To briefly characterise the study population, the median age of women at conception of
their first pregnancy was 29.4 years (IQR: 25.6-33.4) and 56.7% of women were parous
(58.6% among women from sub-Saharan Africa and 48.3% among those born in the UK or
Ireland). The majority of women (87.2%, n=7402) were born abroad, and 78.8% (n=6773)
were of black African ethnicity. Nearly all (97.7%, n=7873) had acquired HIV through a non-
injecting drug use route (largely composed of those with heterosexual exposure and/or
originating from a high HIV prevalence area of the world).
4.2.3 Demographic predictors
The demographic characteristics of women with and without repeat pregnancies are
compared in Table 4.3. Women with repeat pregnancies were more likely to have had their
first pregnancy earlier in the study period. They were also younger (at their first pregnancy)
than those with a single pregnancy, and a significantly higher proportion originated from the
UK or Ireland (14.1% vs. 12.3%). Half of the women with repeat pregnancies were
nulliparous at time of their first reported pregnancy, a significantly higher proportion than
among those with a single pregnancy.
Information on key demographic variables was generally well reported: maternal date of
birth (from which age at first pregnancy is derived) was missing for 43 (0.5%) women,
ethnicity for 70 (0.8%), world region of origin for 173 (2.0%), likely route of HIV acquisition
for 601 (6.9%), and parity for 1009 (11.7%). Table 4.4 compares the characteristics of
women who had missing information on one or more of the key demographic variables
(n=1577) and those with complete information. Women with missing information on any
demographic variable were younger, more likely to be white, born in the UK or Ireland, and
less likely to have repeat pregnancies than those with complete information.
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Table 4.3 Comparison of the demographic characteristics of women with a single
pregnancy and those with repeat pregnancies
Characteristic
Number of women
with a single
pregnancy (%)
Number of
women
with repeat
pregnancies (%)
p-value
Total 6423 (100) 2238 (100) -
Year of conception* (n=8661)
2000-2002 1254 (19.5) 815 (36.4) <0.001
2003-2005 2208 (34.4) 912 (40.8)
2006-2009 2961 (46.1) 511 (22.8)
Age at conception, yrs* (n=8618)
<25 1206 (18.9) 654 (29.3) <0.001
25-29 2014 (31.6) 815 (36.5)
30-34 1898 (29.7) 571 (25.5)
≥35 1264 (19.8) 196 (8.8)
Ethnic group (n=8591)
White 819 (12.9) 287 (12.8) 0.590
Black African 5019 (79.0) 1754 (78.4)
Other 515 (8.1) 197 (8.8)
World region of origin (n=8488)
UK/Ireland 771 (12.3) 315 (14.1) <0.001
Europe 209 (3.3) 52 (2.3)
Eastern Africa 2878 (46.0) 895 (40.0)
Middle Africa 396 (6.3) 217 (9.7)
Western Africa 954 (15.3) 458 (20.5)
Southern Africa 576 (9.2) 161 (7.2)
Africa (unspecified) 105 (1.7) 10 (0.5)
Elsewhere 362 (5.8) 129 (5.8)
HIV risk factor (n=8060)
Injecting drug use 138 (2.4) 49 (2.3) 0.793
Other** 5742 (97.7) 2131 (97.8)
Parity* (n=7652)
Nulliparous 2326 (40.7) 987 (50.9) <0.001
1 2921 (33.6) 596 (30.7)
2 916 (16.0) 244 (12.6)
≥3 547 (9.6) 115 (5.9)
*At first reported pregnancy
**Other comprises largely those originating from a high HIV prevalence area and/or with heterosexual
exposure to HIV
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Table 4.4 Comparison of women with complete information on key demographic
variables and those with missing information (on one or more variable)
Characteristic
Number of women
with complete
information (%)
Number of women
with missing
information (%)
p-value
Total 7084 (100) 1577 (100) -
Age at conception, yrs* (n=8618)
<25 1480 (20.9) 380 (24.8) 0.002
25-29 2318 (32.7) 511 (33.3)
30-34 2074 (29.3) 395 (25.8)
≥35 1212 (17.1) 248 (16.2)
Ethnic group (n=8591)
White 802 (11.3) 304 (20.2) <0.001
Black African 5702 (80.5) 1071 (71.1)
Other 580 (8.2) 132 (8.8)
World region of origin (n=8488)
UK/Ireland 791 (11.2) 295 (21.0) <0.001
Europe 205 (2.9) 56 (4.0)
Eastern Africa 3268 (46.1) 505 (36.0)
Middle Africa 511 (7.2) 102 (7.3)
Western Africa 1202 (17.0) 210 (15.0)
Southern Africa 608 (8.6) 129 (9.2)
Africa (unspecified) 78 (1.1) 37 (2.6)
Elsewhere 421 (5.9) 70 (5.0)
HIV risk factor (n=8060)
Injecting drug use 1158 (2.2) 29 (3.0) 0.149
Other** 6926 (97.8) 947 (97.0)
Parity* (n=7652)
Nulliparous 3065 (43.3) 248 (43.7) 0.778
1 2340 (33.0) 177 (31.2)
2 1070 (15.1) 90 (15.8)
≥3 609 (8.6) 53 (9.3)
Timing of HIV diagnosis (n=8587)*
Before pregnancy 2986 (42.3) 629 (41.3) 0.487
During pregnancy 4078 (57.7) 894 (58.7)
Repeat pregnancy (n=8661)
Yes 1893 (26.7) 345 (21.9) <0.001
No 5191 (73.3) 1232 (78.1)
*At first reported pregnancy
**Other comprises largely those originating from a high HIV prevalence area and/or with heterosexual
exposure to HIV
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In the time to event Kaplan–Meier analysis there were a total of 29,306 woman-years at
risk. The median time at risk was 2.9 years. Figure 4.12 shows the Kaplan–Meier curve of
the probability of second pregnancy; at 10 years of follow-up 40% of women had a second
pregnancy. The 25% survival time was 3.3 years (i.e. after 3.3 years of follow-up an
estimated 25% of women would have had a second pregnancy). The subsequent three
graphs show Kaplan–Meier curves stratified by the key demographic characteristics that
were found to be associated with having a repeat pregnancy in the descriptive analyses.
Figure 4.12 Cumulative probability of having a second pregnancy by time since first
pregnancy, 2000-2009
Note: Probability is represented by the dark blue line and the 95% CIs by the lines above and below.
Figure 4.13 shows both a strong association and a clear pattern between maternal age at
first pregnancy and repeat pregnancy (log rank test for trend: p<0.001). Women aged <25
years at their first pregnancy were most likely to have a second pregnancy, with over 50%
having one by 10 years of follow-up. During the first year of follow-up the estimated
probability of having a second pregnancy was around 10% among all age groups (except
those aged ≥35 years) but subsequently diverged. Women aged ≥35 years at the time of 
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their first pregnancy took longest to conceive their second pregnancy, and had the lowest
probability of having one. After approximately six years of follow-up there were no further
second pregnancies among this group of women.
Figure 4.13 Cumulative probability of having a second pregnancy by age group at first
pregnancy
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Figure 4.14 shows a clear trend between women’s parity at their first pregnancy (i.e. the
number of births women had experienced prior to their first pregnancy reported to the
NSHPC) and the probability of having a second pregnancy (log rank test for trend:
p<0.001). Women who were nulliparous at their first reported pregnancy were most likely to
have a second pregnancy, with over 45% having one by the end of follow-up. The
probability of second pregnancy was inversely associated with women’s parity at first
reported pregnancy.
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Figure 4.14 Cumulative probability of having a second pregnancy by parity at first
pregnancy
Figure 4.15 shows that the probability of repeat pregnancy varies by maternal world region
of origin (log rank test: p<0.001). Women from Middle and Western Africa, followed by
those born in the UK or Ireland were most likely to have a second pregnancy and to do so
more quickly. The number of women from the rest of Europe was relatively small.
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Figure 4.15 Cumulative probability of having a second pregnancy by world region of
origin
Table 4.5 shows the results of univariable and multivariable Cox proportional hazards
analysis of demographic factors associated with having a second pregnancy. As seen in
the preceding Kaplan–Meier analyses, the univariable Cox proportional hazards analysis
showed that older women and parous women were less likely to have a repeat pregnancy.
There were also variations by maternal world region of origin. The final multivariable model
included maternal region of origin, year of pregnancy, maternal age and parity at first
pregnancy, with 7525 women included. There was no association between the year in
which women’s first pregnancy occurred and the probability of repeat pregnancy in this
model. The probability of a repeat pregnancy declined with increasing age at first
pregnancy (p<0.001), and women who were parous at first reported pregnancy were less
likely to conceive again. Compared with women born in the UK or Ireland, those from the
rest of Europe, Eastern Africa, Southern Africa and Africa (unspecified) were less likely to
have a repeat pregnancy, while women from Middle Africa and Western Africa were more
likely to. The global Therneau-Grambsch test32 for the final model was significant
suggesting that the assumption of proportional hazards may not be met. Inspection of the
individual Schoenfeld residuals for each variable in the model indicated that maternal age
group and parity were the variables contributing to this non-proportionality. However, the
32 The Therneau and Grambsch test was run in Stata using the estat phtest command.
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global test for proportionality might be over sensitive to small deviations from the
proportional hazards assumption. This means that observing a significant value of the test
statistic often makes no difference to the overall conclusions and estimates, particularly
with large datasets (Therneau et al, 2000). Examination of the log-log plots (i.e. the plot of
the probability of having a second pregnancy against time since first pregnancy on log-log
scale) revealed that the lines were reasonably parallel, satisfying the proportional hazards
assumption to an acceptable degree. Plots stratified by maternal age group and parity
together with a brief description and interpretation of these are provided in Appendix IV.
The model was therefore accepted in its current form33.
33 An alternative, where there is only one exposure of interest is to present stratified analyses. However, as
this was a risk factor analysis with several exposure variables, stratification was not appropriate and would
result in an overly complex and difficult to interpret model.
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Table 4.5 Univariable and multivariable analyses of demographic characteristics
associated with having a second pregnancy
n (%)**
Univariable analyses Multivariable analysis
(n=7525)
HR (95% CI) p-value aHR (95% CI) p-value
Year of conception*
Change per year - 1.00 (0.98-1.02) 0.929 1.02 (1.00-1.04) 0.134
Age at conception, yrs*
<25 1860 (35.2) 1 <0.001 1 <0.001
25-29 2829 (28.8) 0.82 (0.74-0.90) 0.86 (0.77-0.97)
30-34 2469 (23.1) 0.68 (0.61-0.76) 0.73 (0.64-0.83)
≥35  196 (13.4) 0.40 (0.34-0.47) 0.44 (0.37-0.53)
World region of origin
UK/Ireland 1086 (29.0) 1 <0.001 1 <0.001
Europe 261 (19.9) 0.69 (0.51-0.92) 0.73 (0.54-0.98)
Eastern Africa 3773 (23.7) 0.76 (0.67-0.86) 0.83 (0.72-0.95)
Middle Africa 613 (35.4) 1.18 (0.99-1.40) 1.29 (1.07-1.55)
Western Africa 1412 (32.4) 1.13 (0.98-1.31) 1.16 (1.00-1.36)
Southern Africa 737 (21.9) 0.68 (0.56-0.82) 0.62 (0.51-0.77)
Africa (unspecified) 115 (8.7) 0.24 (0.13-0.46) 0.24 (0.11-0.51)
Elsewhere 491 (26.3) 0.80 (0.65-0.98) 0.85 (0.69-1.06)
Parity*
Nulliparous 3313 (30.0) 1 <0.001 1 <0.001
1 2517 (23.7) 0.75 (0.68-0.83) 0.83 (0.75-0.93)
2 1160 (21.0) 0.65 (0.56-0.75) 0.79 (0.68-0.91)
≥3 115 (17.4) 0.50 (0.41-0.60) 0.65 (0.53-0.80)
*At first reported pregnancy
**n is the total of number women, and the proportion of those women who had repeat pregnancies is
shown in brackets
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4.2.4 Clinical and immunological predictors
The clinical and immunological characteristics (at first reported pregnancy) of women with
and without a repeat pregnancy are compared in Table 4.6. Women with a repeat
pregnancy were less likely to have been diagnosed prior to their first pregnancy. There was
no significant difference between the two groups with respect to reported HIV/AIDS
symptoms. Neither was there any significant different in earliest antenatal CD4 counts;
around 45% in both groups had CD4 counts <350 cells/μl in their first pregnancy, with a 
median count of 370 cells/µl in both groups (and IQRs of 250-520 cells/µl in those with a
repeat pregnancy and 250-520 cells/µl in those with a single pregnancy reported, p=0.642).
However, some treatment differences were apparent with a lower proportion of women with
repeat pregnancies conceiving their first pregnancy on treatment (among those diagnosed
before pregnancy), and a higher proportion having not received antenatal ART in their first
pregnancy. That 7.3% of those in the repeat pregnancy group did not receive antenatal
ART is concerning, although it should be noted that only 3.8% (81/2130) of women did not
receive ART during their second pregnancy.
Information on earliest CD4 count was missing for 1488 (17.2%) women and information on
the presence of HIV/AIDS symptoms at any time during pregnancy for 1131 (13.1%)
women. In total 1831 (21.1%) women were missing information on either of these variables.
Women with missing information were younger, more likely to be white, to be from the UK
or Ireland, or from Middle, Western or Southern Africa, to have an injecting drug use-
associated mode of HIV acquisition, and to have been diagnosed during pregnancy. They
were less likely to have a repeat pregnancy compared with those who had complete
information (Table 4.7).
121
Table 4.6 Comparison of clinical and immunological characteristics of women with a
single pregnancy and those with repeat pregnancies
Characteristic
Number of women
with a single
pregnancy (%)
Number of women
with repeat
pregnancies (%)
p-
value
Earliest CD4 count, cells/μl* (n=7173)
≥500 1529 (28.9) 532 (28.3) 0.953
350-499 1398 (26.4) 493 (26.3)
200-349 1568 (29.6) 562 (29.9)
<200 800 (15.1) 291 (15.5)
HIV/AIDS symptoms* (n=7530)
No 5358 (97.2) 1957 (97.1) 0.822
Yes 156 (2.8) 59 (2.9)
Timing of HIV diagnosis* (n=8337)
Prior to first reported pregnancy 2760 (43.4) 855 (38.4) <0.001
During first reported pregnancy 3599 (56.6) 1373 (61.6)
Antenatal ART* **(n=3473)
From before conception 1320 (49.6) 374 (46.0) 0.031
Started during pregnancy 1202 (45.2) 381 (46.8)
None 137 (5.2) 59 (7.3)
*At first reported pregnancy
**Among women diagnosed prior to their first reported pregnancy only
122
Table 4.7 Comparison of women with complete information on key clinical and
immunological factors (CD4 count or HIV/AIDS symptoms) and those with missing
information on these variables
Characteristic
Number of women
with complete
information (%)
Number of women
with missing
information (%)
p-value
Age at conception, yrs* (n=8618)
<25 1378 (21.1) 482 (23.2) 0.021
25-29 2127 (32.5) 702 (33.8)
30-34 1924 (29.4) 545 (26.3)
≥35 1113 (17.0) 347 (16.7)
Ethnic group (n=8591)
White 853 (12.5) 253 (14.3) <0.001
Black African 5364 (78.6) 1409 (79.7)
Other 606 (8.9) 106 (6.0)
World region of origin (n=8488)
UK/Ireland 838 (12.4) 248 (14.4) <0.001
Europe 213 (3.2) 48 (2.8)
Eastern Africa 3143 (46.5) 630 (36.5)
Middle Africa 473 (7.0) 140 (8.1)
Western Africa 1076 (15.9) 336 (19.5)
Southern Africa 536 (7.9) 201 (11.7)
Africa (unspecified) 67 (1.0) 48 (2.8)
Elsewhere 417 (6.2) 74 (4.3)
HIV risk factor (n=8060)
Injecting drug use 131 (2.0) 56 (3.6) <0.001
Other** 6392 (98.0) 1481 (96.4)
Timing of HIV diagnosis* (n=8587)
Before pregnancy 2922 (42.8) 693 (39.3) 0.008
During pregnancy 3902 (57.2) 1070 (60.7)
Repeat pregnancy (n=8661)
Yes 1823 (26.7) 415 (22.7) <0.001
No 5007 (73.3) 1416 (77.3)
*At first reported pregnancy
**Other comprises largely those originating from a high HIV prevalence area and/or with heterosexual
exposure to HIV
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The Kaplan–Meier analysis showed no association between earliest antenatal CD4 count in
first pregnancy and the probability of repeat pregnancy (log rank test for trend: p=0.665)
(Figure 4.16). There was also no association between having HIV/AIDS symptoms at any
time during first pregnancy and the probability of repeat pregnancy (log rank test: p=0.658)
(Figure 4.17).
Figure 4.16 Cumulative probability of having a second pregnancy by earliest CD4 count
(cells/μl) during first pregnancy
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Figure 4.17 Cumulative probability of having a second pregnancy according to presence
of HIV/AIDS symptoms during first pregnancy
Cox proportional hazards modelling showed no univariable association between maternal
health and the probability of repeat pregnancy (Table 4.8)34. There remained no association
between CD4 count and repeat pregnancy (p=0.619) after adjusting for the demographic
variables that had previously been shown to be associated with the probability of repeat
pregnancy (year (adjusted for a priori), maternal age and parity at first pregnancy, and
maternal region of origin). Similarly, there remained no association between having
HIV/AIDS symptoms at first pregnancy and the probability of repeat pregnancy (p=0.895)
after adjustment for the demographic variables (data not shown).
34 The findings were very similar, with no evidence of an association, if the earliest antenatal CD4 count
measurements were restricted to those taken prior to ART initiation (overall p-value for the association
between CD4 count and probability of repeat pregnancy based on the univariable Cox proportional
hazards model: p=0.772).
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Table 4.8 Univariable analyses of clinical and immunological factors associated with
having a second pregnancy
n (%)**
Univariable analyses
HR (95% CI) p-value
Earliest CD4 count, cells/μl* 
≥500 2061 (25.8) 1 0.860
350-499 1891 (26.1) 1.04 (0.92-1.18)
200-349 2130 (26.4) 1.05 (0.93-1.18)
<200 1091 (26.7) 1.02 (0.88-1.17)
HIV/AIDS symptoms*
No 7315 (26.8) 1 0.657
Yes 215 (27.4) 0.94 (0.73-1.22)
*At first reported pregnancy
**n is the total of number women, and the proportion of those women who had repeat pregnancies is
shown in brackets
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4.2.5 Previous adverse pregnancy outcomes
The analysis of stillbirth or neonatal death in first pregnancy as a predictor of repeat
pregnancy included 7496 women (1970 of whom had a second pregnancy) with a total of
25,496 woman-years of follow-up. The analysis investigating whether having an HIV-
positive infant in first pregnancy was a predictor of repeat pregnancy included 6471 women
with 22,969 years of follow-up.
Table 4.9 describes the association between adverse outcomes in women’s first pregnancy
and their probability of having a second pregnancy. Women whose first pregnancy ended in
either stillbirth or neonatal death were significantly more likely to have a second pregnancy
than those ending in a live birth. The interval between having a first birth which resulted in
either a stillbirth or neonatal death and conceiving again was just 0.67 years (IQR: 0.26-
1.23)35. There was no evidence of an association between MTCT having occurred the first
pregnancy and the probability of having further pregnancies, although the number of
transmissions that occurred may have been too small to detect such an association.
Table 4.9 Comparison of the outcomes of first pregnancies among women with a single
pregnancy and those with repeat pregnancies
Outcome of first reported
pregnancy
Number of women
with a single
pregnancy (%)
Number of women
with repeat
pregnancies (%)
p-
value
Stillbirth or neonatal death (n=7496)
Yes 57 (1.0) 48 (2.4) <0.001
No* 5469 (99.0) 1922 (97.6)
HIV-positive infant (n=6471)
Yes 54 (1.2) 22 (1.2) 0.777
No 4637 (98.9) 1758 (98.8)
*Live birth
35 As compared with a live birth-to-pregnancy interval of 1.8 years (IQR: 0.9-3.1) as documented in the first
part of this chapter.
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That women whose first pregnancy ended in a stillbirth or neonatal death were more likely
to have a repeat pregnancy, and to do so more quickly than those whose first pregnancy
ended in a live birth (log rank test: p<0.001), can be seen clearly in the Kaplan–Meier
analysis (Figure 4.18). For example, after two years of follow-up an estimated 43% of
women who had previously experienced a stillbirth or neonatal death had become pregnant
again compared with 16% of those with a prior live birth.
Figure 4.18 Cumulative probability of having a second pregnancy according to the
outcome of women’s first reported pregnancy
Using Cox proportional hazards modelling the crude HR for the association between
stillbirth or neonatal death in first pregnancy and the probability of repeat pregnancy was
2.2 (95% CI: 1.66-2.94), p<0.001. There was no evidence of significant confounding of this
association by year of first pregnancy, maternal age, maternal world region of origin, or
parity in the bivariable analyses, and the association remained when a multivariable model
was constructed adjusting for the aforementioned demographic variables (aOR: 2.37, 95%
CI: 1.76-3.20, p<0.001).
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In the Kaplan–Meier analysis of the association between HIV status of women’s first infant
and the probability of further pregnancy, there was no association (log rank test: p=0.604)
(Figure 4.19). This figure should, however, be interpreted with some caution due to the
small number of vertical transmissions (n=22); the seemingly large increase in the
probability of repeat pregnancy among these women at around nine years of follow-up
represents the occurrence of just one repeat pregnancy.
The crude HR for the association between having an HIV-positive infant in first pregnancy
and the probability of repeat pregnancy was 0.89 (95% CI: 0.59-1.36), p=0.604. There was
no evidence of significant confounding of this association by year of first pregnancy,
maternal age, maternal world region of origin, or parity in the bivariable analyses, and there
remained no evidence of an association when a multivariable model was constructed
(adjusting for the aforementioned demographic variables); aOR: 0.98, 95% CI: 0.63-1.50,
p=0.916).
Figure 4.19 Cumulative probability of having a second pregnancy according to HIV status
of fist infant
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4.3 Discussion
Frequency of pregnancies and trends over time
There has been a significant increase in the number of pregnancies among diagnosed
women in the UK and Ireland over the last two decades (though the annual number of
pregnancies reported to the NSHPC has plateaued at around 1500 per year since 2006),
with a growing proportion accounted for by repeat pregnancies (39% in 2009). This
increase largely reflects changing migration patterns, with increases in migration from sub-
Saharan Africa36 where HIV prevalence is high (UNAIDS, 2013), together with the
introduction of routine antenatal screening for HIV in the late 1990’s (Townsend et al,
2006). However, reproductive decision-making and fertility which, as discussed in Chapter
2, Section 2.2, are likely to be influenced by a wide range of biological, social and cultural
factors, have also played a role. It is pertinent that women who had their first pregnancy
during 1995-1999 were most likely to have a second pregnancy, and to do so most quickly,
possibly reflecting the advent of cART which had a significant impact on the quality of life
and life expectancy of people living with HIV (Gange et al, 2002; May et al, 2011b;
Nakagawa et al, 2012; Samji et al, 2013; van Sighem et al, 2010). There may well have
been an accumulation of women of child-bearing age who had either avoided starting a
family, or were unable to conceive due to poor health in the pre-cART era. Improvements in
women’s health, together with reductions in MTCT risk (Duong et al, 1999; Townsend et al,
2008a), may have had both biological and psychological effects on women’s fertility (Blair
et al, 2004; Sharma et al, 2007). This pool of women may thus have been quick to initiate
and complete their childbearing after the introduction of cART. This overall increase in
pregnancies will have resulted in an accumulation of diagnosed HIV-positive women who
have already had a pregnancy and are therefore ‘at risk’ of further (repeat) pregnancies.
The aim of the analyses presented in this chapter was to estimate the incidence of repeat
pregnancies occurring in diagnosed HIV-positive women in the UK and Ireland. This may
not, however, accurately reflect women’s full reproductive history since becoming infected
with HIV. Women’s first pregnancy reported to the NSHPC is, for the purposes of this
thesis, classified as their first pregnancy as a diagnosed woman (whether her diagnosis
was made before or during that pregnancy). Since uptake of antenatal HIV testing is high in
the UK (>95%) (Public Health England, 2013a), as is reporting of pregnancies to the
36 An analysis of the 2001 UK Census data, conducted by the Institute for Public Policy Research and
Sheffield University Social and Spatial Inequalities Research Group is available on the BBC News website
(http://news.bbc.co.uk/1/shared/spl/hi/uk/05/born_abroad/html/overview.stm). Additionally, 2011 Census
data are available here: Estimated Overseas born Population resident in the UK tab 1.3 (both websites
Accessed October 2013).
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NSHPC, very few diagnosed women will have had a pregnancy in the UK or Ireland that
was not reported to the study. In addition, during the study period, a large proportion of
women (around 60%) were not aware of their HIV status until antenatal screening during
their first reported pregnancy. However, the majority of HIV-positive pregnant women in the
UK and Ireland originate from abroad. A substantial proportion of migrants are likely to
have been infected with HIV prior to arriving in the UK or Ireland (Rice et al, 2012), many of
whom will be part way through their childbearing when they arrive (for example, 59% of
women from sub-Saharan Africa were parous at their first reported pregnancy). Although it
is therefore reasonable to assume that some women will have experienced a pregnancy as
an HIV-positive woman prior to their arrival into the UK or Ireland, the vast majority
originate from sub-Saharan Africa where availability of HIV testing is often low. Data
compiled through Demographic and Health Surveys and AIDS Indicator Surveys in 29
African countries during 2003-2011 revealed that on average, 71% of women had never
been tested for HIV (Staveteig et al, 2013), thus many of these women will have remained
undiagnosed prior to arrival. Although the NSHPC collects information on women’s overall
parity, irrespective of their HIV status at the time of any previous pregnancies, neither the
date of any previous unreported pregnancy nor whether the woman had diagnosed HIV at
the time is available.
Meanwhile, women may return to their country of origin or move elsewhere outside the UK
and Ireland, either temporarily or permanently, at some stage during their reproductive
lives; any further pregnancies that they then have would not be eligible to be reported to the
NSHPC37. In these analyses only 1% of women were documented to have ‘gone abroad’
during pregnancy, but others may travel after their pregnancy ends and this information
would not be captured though the NSHPC. Some of those who do travel home may of
course subsequently return to the UK or Ireland; among women with a first pregnancy
during 2000-2009 who were reported to have gone abroad during that pregnancy, 5%
(8/152) had a subsequent pregnancy reported to the NSHPC. In a cross-sectional survey of
African migrants living in London, 46% of women had visited their home country in the last
five years (Fenton et al, 2001). Though all those participating in the study by Fenton et al
had subsequently returned to the UK, this data demonstrates that many migrants from sub-
Saharan Africa are able to visit their country of origin, a proportion of whom may remain
there.
It is probable that some women who experience an early termination or miscarriage will not
be reported to the NSHPC as they did not access antenatal care (an issue which is
explored in more detail in Chapter 7). Therefore, such pregnancies are likely to be under-
37 Assuming they do not return to the UK or Ireland during their subsequent pregnancy.
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ascertained through the NSHPC which would result in an under-estimation of the number
and rate of pregnancies, and an over-estimation of pregnancy spacing intervals. However,
other ongoing studies of HIV in pregnancy, for example, the ECS only collect information
on pregnancies ending in a live birth (Thorne et al, 2005). A further issue is that the
probability of repeat pregnancy among women whose first pregnancy occurred towards the
end of the study period may be an underestimation due to lack of time for a subsequent
pregnancy, as well as delays in the reporting of pregnancies. The rate of repeat
pregnancies was 6.5 per 100 woman years during 2005-2009, lower than the rate of 7.3
per 100 woman years during 2000-2004. One might expect the true rate for the latest
period to be similar to that for the preceding period.
This was the first European study to estimate the rate of repeat pregnancies among
diagnosed HIV-positive women, and there is no study with which to make a direct
comparison of the rate. Previous studies from the US and Europe have provided estimates
of the overall pregnancy rate among HIV-positive women; a rate of 5.5 (95% CI: 5.2-5.8)
per 100 woman-years in the US during 1992-2001 was estimated using data from the Adult
and Adolescent Spectrum of Disease Project (Blair et al, 2004), while slightly higher rates
have been reported among women enrolled in the US Women’s Interagency HIV Study; 7.4
per 100 woman-years during 1994-2002 (Massad et al, 2004), and 6.8 (95% CI: 6.1-7.5)
per 100 woman-years in more recent years (2002-2009) (Linas et al, 2011). Similar rates,
6.0-8.2 per 100 woman-years (depending on time since HIV diagnosis), have been
reported from Europe (van Benthem et al, 2000). The rate of repeat pregnancies reported
here (6.7, 95% CI: 6.5-6.9) per 100 woman-years is thus consistent with the range
observed in similar settings. A recent UK study, published subsequent to this work,
conducted on an extract of the NSHPC dataset linked with women enrolled in the UK
Collaborative HIV Cohort (UK CHIC) study38, reported a pregnancy incidence of 3.5% (95%
CI: 2.7-4.3) in 2000 and 4.7% (95% CI: 4.1-5.3) in 2009 among women attending care in 13
HIV Centres (Huntington et al, 2013). Again, these are overall pregnancy rates (i.e.
including first pregnancies to diagnosed women) so are not directly comparable with repeat
pregnancy rates presented in this chapter. Furthermore, as UK CHIC is not a national
cohort, only 23% of HIV-positive women with a pregnancy in the UK were matched with UK
CHIC (Huntington et al, 2012).
Birth spacing
The birth-to-birth interval of 2.6 years between first and second live births during 2000-2009
is in line with the interval among the general UK population (2.9 years in 2008). It is not
38 The UK Collaborative HIV Cohort (UK CHIC) study collects clinical data on diagnosed HIV-positive
people attending a sample of large HIV Clinics. The study does not collect information on pregnancy
(Huntington et al, 2012; UK Collaborative HIV Cohort Steering Committee, 2004).
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surprising that they are not exactly the same since the demographics of the population of
HIV-positive women are very different to those of the general UK population. A much larger
proportion of women reported to the NSHPC are black African (>75%) compared with the
proportion of black Africans in the general population (approximately 1.5%)39 (Office for
National Statistics, 2011b). The earlier European study of repeat pregnancies reported a
longer interval of 3.5 years between live births (Agangi et al, 2005). This could be due to
cultural factors and/or policies that influence the advice given to women by healthcare
professionals, as well as the availability of, and attitudes towards, contraception.
Differences in population structures may also contribute e.g. the proportion of women of
black African ethnicity was much lower (19%) in the study by Agangi et al.
Demographic predictors of repeat pregnancies
Aside from variations in the probability of repeat pregnancies by time period, Cox
proportional hazards modelling demonstrated that younger age at first pregnancy was
associated with an increased probability of further pregnancies. This is both logical and
consistent with other studies of repeat pregnancies among diagnosed women in similar
settings (Agangi et al, 2005; Blair et al, 2004; Bryant et al, 2007). Studies of the overall
pregnancy rate among diagnosed women have also found younger age to be a predictor of
pregnancy (Blair et al, 2004; Huntington et al, 2013; Linas et al, 2011; Massad et al, 2004),
and of childbearing desires and intentions (Berhan et al, 2013). Women who were parous
at their first reported pregnancy were less likely to conceive again, and the probability
declined with increasing number of previous births at first (HIV-positive) pregnancy. An
association between fewer previous births and an increased probability of repeat
pregnancy was also observed in the US (Bryant et al, 2007). In the previous European
study, restricted to live births only, although a similar trend was observed, the finding was
non-significant (Agangi et al, 2005). Since the NSHPC does not collect information on the
number of living children, this could not be explored as a predictor of pregnancy, nor
adjusted for in the analyses. Some of the parous women in the study may have children
that are no longer living, thus potentially increasing their childbearing desires (see Chapter
2, Section 2.2).
The lower probability of repeat pregnancies among women born elsewhere in Europe
compared with those born in the UK or Ireland may reflect the low fertility rates in some
European countries (Billari et al, 2004). European women could also potentially be more
likely, than those born in Africa for example, to move between the UK or Ireland and their
home country during their reproductive lives. Any subsequent pregnancies that they
experienced would hence not be reported to the NSHPC. There were marked variations in
39 Based on the 2009 mid-year population estimates for England and Wales stratified by ethnic group.
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the probability of repeat pregnancy among women from different regions of sub-Saharan
Africa even after adjusting for maternal age, parity and year of first pregnancy; the
probability was higher among those from Middle and Western Africa though the latter was
borderline significant, and lower among those from Eastern and Southern Africa. This
pattern is likely to reflect a complex range of cultural, behavioural and migratory factors
such as fertility patterns in women’s countries of origin, the demographics of women who
migrate from different regions, and cultural beliefs and attitudes regarding HIV and
childbearing. For example, in many African countries, and indeed elsewhere, HIV
unfortunately remains a significant source of stigma (Grossman et al, 2013; Rankin et al,
2005). However, in some cultures the stigma of not having children can be greater than the
stigma of being HIV-positive since child bearing is often a central component of social
status and identity for both men and women (Ibisomi et al, 2014; Nabukera et al, 2008;
Nattabi et al, 2009). These stigmas can thus influence the fertility of HIV-positive people in
various ways. For example, in South Africa it has been documented that it is socially
unacceptable for people who had disclosed their HIV status to have more children (Cooper
et al, 2007). On the other hand, HIV-positive women have reported that in order to avoid
stigmatisation by the community they continued to have children to conceal their HIV status
(Aka-Dago-Akribi et al, 1999; Cooper et al, 2007), to be seen as leading ‘normal’ lives
(Smith et al, 2010). Such influences, the direction in which they act, and their strength, may
differ by African region/country. Similarly, there are variations in fertility across Africa; for
example, the average number of children per woman is 5.7 in Nigeria (National Population
Commission (NPC) [Nigeria] and ICF Macro, 2009), compared with 2.1 in South Africa
(Department of Health/ Medical Research Council/ OrcMacro, 2007). Such differences may
be borne out in women’s fertility patterns after arrival into the UK and Ireland.
Clinical predictors of repeat pregnancies
Women with repeat pregnancies were less likely to have been diagnosed prior to their first
pregnancy, which may reflect the fact that these women were more likely to have their first
pregnancy earlier in the study period when HIV testing was less widespread (British HIV
Association et al, 2008). Maternal health, indicated by CD4 count and presence of
HIV/AIDS symptoms at first pregnancy, was not associated with the probability of repeat
pregnancy. In interpreting this finding it should be borne in mind that a woman’s health
status could change considerably between her first pregnancy and the time that she
conceives again, for example, if she initiates treatment for her own health during the
intervening period. Some treatment differences were, however, apparent. Among women
diagnosed prior to their first reported pregnancy, those who went on to have a repeat
pregnancy were less likely to have conceived their first pregnancy whilst on ART. However,
given that there was no association between CD4 count and repeat pregnancy (and this
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remained the case when women’s earliest antenatal CD4 measurements were restricted to
those taken prior to ART initiation), this difference may reflect issues such as access to
treatment rather than women’s health status. Furthermore, both this finding, and the fact
that a higher proportion of women who went on to have a repeat pregnancy did not receive
ART in their index pregnancy (7% compared with 5%), are likely, in part at least, due to
changes in treatment policies and practice over time. Over a third (36%) of index
pregnancies to those who subsequently experienced a repeat pregnancy occurred during
the earliest time period (2000-2002) compared with 19% of those to women with a single
pregnancy reported. The overall proportion of women in the NSHPC conceiving on
treatment has increased over time, while the proportion not receiving antenatal ART has
declined considerably (Townsend et al, 2014; Townsend et al, 2008b). It is reassuring that
there were fewer (3.8%) women who did not receive ART during their second pregnancy,
tying in with the temporal change in antenatal ART uptake.
Data from the US has shown that healthier women, indicated by higher CD4 percentages
and lower viral loads, were more likely to have repeat pregnancies (Bryant et al, 2007;
Minkoff et al, 2003), with a 10% increased probability of repeat pregnancy per 10%
increase in CD4 percentage reported by Bryant et al during 1989-2004. Meanwhile, no
association was observed in Europe (Agangi et al, 2005). The two US studies both used
data from the US WITS so one would expect their findings to concur. In these studies CD4
measurements were taken post-partum (after women’s first pregnancy), whereas in the
analyses presented here the earliest CD4 measurement in women’s first pregnancies were
used. The US studies also measured CD4 percentages, rather than counts. The recent
analysis of linked NSHPC and UK CHIC data reported that compared with women who had
CD4 counts of 200-350 cells/µl, those with CD4 <200 cells/µl had a significantly lower
overall pregnancy rate (not only repeat pregnancies) (adjusted relative rate: 0.65, 95% CI:
0.55-0.77), though CD4 measurements were the earliest taken during the year in which
women became pregnant (Huntington et al, 2013).
Previous adverse pregnancy outcomes and the probability of repeat pregnancy
Data from the general population indicates that women who have experienced a previous
adverse pregnancy outcome such as a stillbirth frequently become pregnant again, with
around 50% of women conceiving again within 12 months (Hughes et al, 1999; Lee et al,
2013). Among HIV-positive women specifically, studies in African settings have reported
increased pregnancy desire and intentions among those who have experienced adverse
pregnancy outcomes (Moyo et al, 2004; Smee et al, 2011). In the present analyses, the
increased probability and rapidity of repeat pregnancy among women whose first
pregnancy resulted in a stillbirth or neonatal death was marked. The birth-to-pregnancy
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interval among this group of women was just 0.67 years (eight months). Similarly short
intervals among women who have experienced a stillbirth have been documented
previously in the general population (Hughes et al, 1999). There was, however, little
evidence for an association between vertical transmission of HIV occurring in the first
pregnancy and having a repeat pregnancy. Although this could be due to a lack of power to
detect an association, other studies from the UK and the US also found no association
between having an HIV-positive infant and the desire for further children (Cliffe, 2005;
Sowell et al, 2002). If having an HIV-positive child does influence the desire for further
children its impact may be complex. For example, women may not want to risk having
further children for fear of transmitting HIV again; alternatively they may be more likely to
desire further, possibly HIV-negative, children. Any potential association may also have
changed over time; prior to the introduction of DNA PCR methods for HIV diagnosis in
children (Dunn et al, 1995), diagnosing a child took around 18 months40 thus a woman
could have become pregnant again before knowing whether or not her first child was HIV-
positive.
Limitations
Though the NSHPC provides an excellent data source for estimating the incidence of
repeat pregnancies (the strengths of the system in this regard are discussed further in
Chapter 8), some limitations require consideration. The study collects little information on
social factors such as socio-economic status, relationship status or level of education,
which could be important predictors of repeat pregnancy. Also, information on
contraceptive use is not available, and the system does not collect information on whether
or not pregnancies were planned. Studies among HIV-positive women in Europe and
Canada have reported that around half of pregnancies were unplanned (Fiore et al, 2008;
Loutfy et al, 2011). Meanwhile, data from the third National Survey of Sexual Attitudes and
Lifestyles (Natsal-3) in Britain revealed that 16% of pregnancies to all women aged 16-44
years were unplanned with a further 29% being classified as ambivalent (Wellings et al,
2013). As noted in Chapter 2, defining a pregnancy as ‘planned’ vs. ‘unplanned’ or
‘unintended’ or ‘unwanted’ is not clear cut, and the terms may be interpreted differently by
different people (Barrett et al, 2002; Fischer et al, 1999). It is feasible that where the
distinction can be made, the characteristics of women experiencing ‘planned’ pregnancies
may be quite different to those experiencing ‘unplanned’ pregnancies. For example, the
Natsal-3 survey reported that characteristics such as young age, smoking, drug use, and
40 The delay is necessary with antibody detection methods to ensure that the presence of an infant’s own
antibodies can be distinguished from passively transferred maternal antibodies. Current UK guidelines do,
however, still recommend that all children born to HIV-positive mothers have a confirmatory antibody test
at 18 months in order to detect any late transmissions via breastfeeding (Taylor et al, 2012).
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lower educational level were strongly associated with the risk of having an unplanned
pregnancy (Wellings et al, 2013).
With regards to missing data, there were some differences between individuals missing key
demographic variables and those with complete data. It was therefore not appropriate to
entirely exclude cases with missing data from the analyses. Any bias that would be
introduced by excluding these cases was minimised by only excluding them where
necessary (i.e. from the bivariable and multivariable analyses as appropriate). Women with
missing demographic and/or clinical and immunological information were younger, much
more likely to be white and to be born in the UK or Ireland. It is possible that this may
represent a sub-group of women who are less engaged with HIV services and antenatal
care. That repeat pregnancies were less frequent in those with missing information will
largely reflect the fact that for women who have experienced repeat pregnancies there will
have been more than one opportunity for the NSHPC to collect demographic information on
the woman. Self-reported information is subject to recall bias (Coughlin, 1990). Most
variables explored as predictors of repeat pregnancy in these analyses were not self-
reported. However, in many cases parity (at first reported pregnancy) will be self-reported
(to the care provider who subsequently reported data to the NSHPC), and could therefore
be reported differentially. For example, women who have experienced the loss of a child, or
who have left children in their country of origin, may be less likely to report these children
when asked about their childbearing history (United Nations Statistics Division, 2013).
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4.4 Key findings
 The annual number of pregnancies among HIV-positive women in the UK and
Ireland has increased dramatically since the NSHPC began (from 89 pregnancies
in 1990 to 1465 in 2009, p<0.001)
 During 1990-2009, 14,096 pregnancies were reported in 10,568 diagnosed HIV-
positive women; 2737 (25.9%) women had repeat pregnancies (2117 women had
two pregnancies, 475 had three and 145 had four or more)
 The proportion of pregnancies that were repeat increased substantially over time
(p<0.001), reaching 38.6% (565/1465) in 2009
 The overall rate of repeat pregnancies was 6.7 (95% CI: 6.5-6.9) per 100 woman-
years during 1990-2009
 The median birth-to-birth interval between first and second deliveries was 2.7 years
(IQR: 1.7-4.1) and the birth-to-pregnancy interval was 1.9 years (IQR: 1.0-3.3)
 There were a total of 11,426 pregnancies among 8661 women whose first
pregnancy occurred during 2000-2009, 2238 (25.8%) of whom had repeat
pregnancies
 Cox proportional hazards modelling of predictors of repeat pregnancy revealed that
during 2000-2009:
o The probability of having a repeat pregnancy declined significantly with
increasing age at first pregnancy
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o Women who were parous at their first reported pregnancy since HIV
diagnosis were less likely to conceive again, and the probability declined
with increasing number of previous births at first pregnancy
o Compared with women born in the UK or Ireland, those from the rest of
Europe, Eastern Africa, Southern Africa and Africa (unspecified) were less
likely to have a repeat pregnancy, while women from Middle Africa and
Western Africa were more likely to
 In this study population, few women had HIV/AIDS symptoms during their index
pregnancy and the overall median CD4 count was 370 cells/µl. Maternal health
status during first pregnancy (CD4 count and presence of HIV/AIDS symptoms)
was not associated with the probability of repeat pregnancy
 Women whose first pregnancy ended in a stillbirth or neonatal death were more
likely to have a repeat pregnancy, and did much more rapidly than those whose
initial pregnancy resulted in a live birth
 There was no evidence of an association between having a previously had an HIV-
positive infant and the probability of having a second pregnancy though numbers
were small, with MTCT rates of <1.5%
 These findings highlight that diagnosed women experiencing repeat pregnancies
are a substantial and growing group; it is important that the epidemiology of repeat
pregnancies in this population is thoroughly understood
139
Chapter 5 Engagement with care, and the health and
management of women experiencing
sequential pregnancies
This chapter investigates engagement with HIV and pregnancy-related care, and the health
and management of women experiencing sequential pregnancies (Objective 3). It aims to
inform the optimal management of HIV-positive women of childbearing age in the context of
current and potential future pregnancies, as well as identifying variations in access to or
uptake of care.
5.1 Timing of presentation for antenatal care
Booking for antenatal care in good time not only helps ensure a healthy pregnancy but, for
women living with HIV, it is also important in order to enable timely PMTCT interventions.
There is a paucity of literature on HIV-positive women’s engagement with antenatal care,
as highlighted in Chapter 2, Section 2.3. The objective of this first part of the chapter is to
describe timing of antenatal booking for repeat pregnancies compared with index
pregnancies, explore factors associated with late booking among the repeat pregnancies,
and delays from booking to initiation of HIV-related antenatal care (Objective 3a).
5.1.1 Methods
Dataset
These analyses were based on NSHPC pregnancies delivered during 2008-2010 as
antenatal booking data were not collected by the NSHPC prior to 2008. The main group for
analysis consisted of pregnancies ending in a live or stillbirth to diagnosed HIV-positive
women who had already had a previous birth reported to the NSHPC (irrespective of when
their first delivery occurred). A comparison group consisting of first reported live and
stillbirths was also utilised in initial descriptive analyses (Figure 5.1).
Women who had had a previous pregnancy with an outcome other than a live or stillbirth,
e.g. miscarriage or termination, were excluded since the aim was to explore booking
among women who had experienced a previous complete pregnancy. Women with a
previous birth would have experienced the various aspects of general and HIV-specific
management and care that completing a pregnancy entails including booking for antenatal
care, antenatal HIV testing (if appropriate), laboratory monitoring of HIV disease and
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complications, receiving or being offered ART, and caregiving to other children. Those with
outcomes other than a live or stillbirth in their subsequent pregnancy were excluded since
women experiencing outcomes such as termination of pregnancy or miscarriage may not
have had sufficient time to book for antenatal care before the pregnancy ended, and the
group who did so would be biased towards women who booked for care early. If a woman
had more than two births reported to the NSHPC only her last was included in the
‘subsequent pregnancy’ group. There were, however, some women appearing in the full
dataset (n=3825) more than once, for example, having had a first pregnancy in 2008 and a
second in 2010.
Figure 5.1 Study population flow chart – antenatal care booking analyses
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Classifications and definitions
Timing of antenatal booking was categorised as follows: <13 completed weeks gestation,
13-17 weeks, 18-23 weeks, ≥24 weeks. The <13 weeks cut-off was based on UK
recommendations that women should book by around 10-13 gestational weeks (National
Institute for Health and Clinical Excellence, 2008; Royal College of Obstetricians and
Gynaecologists, 2008). Booking after 13 completed weeks was thus considered ‘late’.
However, in order to further explore late booking, this group was divided into three
categories. A ≥24 weeks group was chosen based on the 2008 BHIVA guideline which 
recommended ART initiation by 20-28 weeks (de Ruiter et al, 2008), and the current
guideline recommending starting by 24 weeks (Taylor et al, 2012). The remaining group
(13-23 weeks) was split at 17 weeks as a pragmatic cut-off. Earliest antenatal CD4 counts
were restricted to those prior to ART initiation. As a high proportion of women had no
delivery viral load reported (with 28 days before and up to seven days after delivery), an
imputed variable was also used as described in Chapter 3 (if viral load in the last 28 days of
pregnancy was missing but an undetectable viral load was last reported earlier in that
pregnancy, delivery viral load was imputed as undetectable).
Statistical analyses
Univariable and multivariable ordinal logistic regression models were fitted to analyse
factors associated with timing of booking for antenatal care in women’s subsequent
pregnancies. Ordinal logistic regression allows modelling of outcomes with more than two
naturally ordered categories (Dupont, 2009). It was used to explore the four antenatal
booking groups in a more appropriate way than simply dichotomising the outcome variable.
The Brant test was used to check that the proportional odds assumption that underlies
ordinal logistic regression was not violated (i.e. that the log odds between successive
outcome categories can be expressed as parallel lines) (Brant, 1990). This means, for
example, that the change in log-odds for the lowest (<13 weeks) category compared with
the remaining three groups combined is equal to that for the highest (≥24 weeks) group 
compared with all three lower groups combined. Therefore, only one model is required to
describe the relationships between each outcome group vs. the other three groups
combined (UCLA: Statistical Consulting Group).
Regression analyses were restricted to women’s last reported pregnancy during 2008-
2010, and did not include first reported pregnancies, thus each woman only contributed one
pregnancy to the dataset. It was therefore not necessary to use statistical methods to
adjust for clustering of pregnancies within women. Although first pregnancies were included
as a comparison group in some of the initial descriptive analyses there were only 85
women who contributed both a first and subsequent pregnancy to the dataset. Ordinal
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logistic regression models are fitted using a likelihood-based method thus models were
constructed using the same procedures as for a standard risk factor analysis logistic
regression model (as described in Chapter 3, Section 3.5).
5.1.2 Study population
The study population consisted of 3825 deliveries during 2008-2010. There were 1275
subsequent deliveries (1266 live and 9 stillbirths) to women who already had at least one
birth reported to the NSHPC; 1002 were second deliveries, 236 third, 33 fourth, and four
were fifth deliveries. There were 1255 singleton and 20 twin pregnancies in the subsequent
pregnancy group. Meanwhile, the comparison group of first reported births during 2008-
2010 consisted of 2550 deliveries; 2529 live births and 21 stillbirths. There were 2487
singleton pregnancies and 63 sets of twins.
The characteristics of the first and subsequent pregnancy groups are compared in Table
5.1. Subsequent pregnancies were less likely to have occurred earlier in the study period
(p<0.001), more likely to be in women aged ≥35 years (p<0.001), more likely to have been
reported in London or Ireland (p<0.001), and the women experiencing them were more
likely to be on ART at conception (p<0.001). There was little difference in maternal HIV risk
factor (p=0.702). Subsequent pregnancies were slightly, though not significantly, more
likely to be in women from sub-Saharan Africa (p=0.093), and less likely to be twin or triplet
pregnancies (p=0.071).
Information on antenatal booking date was reported for just under three quarters of all
pregnancies (73.9%, 2827/3825), and this proportion was similar among the subsequent
(74.8%, 953/1275) and first pregnancy groups (73.5%, 1874/2550) (p=0.405). Compared
with women for whom date of antenatal booking was reported to the NSHPC, those with
missing booking date were more likely to be reported earlier in the study period; over half
(53.8%) of those with missing information were reported in 2008 compared with 26.9% of
those with known information (p<0.001), less likely to have been reported in London
(26.0% vs. 42.9%, p<0.001), and less likely to have conceived on ART (33.5% vs. 40.7%).
There were no significant differences in maternal age (p=0.403), HIV risk factor (p=0.211),
world region of origin (p=0.426), parity (p=0.119), or whether the woman was diagnosed
prior to or during (her first reported) pregnancy (p=0.295).
143
Table 5.1 Antenatal care booking analyses – characteristics of first and subsequent
pregnancies
Characteristic
First
pregnancies
Subsequent
pregnancies p-value
n % n %
Parity* (n=3504)
Nulliparous 1007 43.1 0 0.0 -
1 780 33.4 533 44.3
2 376 16.1 413 34.3
≥3 137 7.4 258 21.4
Year of delivery (n=3825)
2008 939 36.8 359 28.2 <0.001
2009 841 33.0 474 37.2
2010 770 30.2 442 34.7
Age at delivery, yrs (n=3811)
<25 354 14.0 102 8.0 <0.001
25-34 1507 59.4 771 60.5
≥35 675 26.6 402 31.5
HIV risk factor (n=3496)
Other** 2221 98.7 1228 98.6 0.702
Injecting drug use 29 1.3 18 1.4
World region of origin (n=3759)
UK/Ireland 344 13.8 163 12.8 0.093
Sub-Saharan Africa 1898 76.4 1010 79.3
Elsewhere 243 9.8 101 7.9
Pregnancy type (n=3825)
Singleton 2487 97.5 1255 98.4 0.071
Twin/triplet 63 2.5 20 1.6
Conception interval, yrs*** (n=1275)
<2 - - 366 28.7 -
2-3 - - 498 39.1
4-5 - - 263 20.6
≥6 - - 148 11.6
Reporting region (n=3816)
London 925 36.4 543 42.6 <0.001
Elsewhere in England 1282 50.4 530 41.6
Wales, Scotland, N Ireland 175 6.9 54 4.2
Ireland 160 6.3 147 11.5
Earliest CD4 count, cells/µl (n=3239)
≥500 649 29.8 400 37.6 <0.001
350-499 598 27.5 326 30.7
200-349 627 28.8 253 23.8
<200 302 13.9 84 7.9
Continued overleaf
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Table 5.1 Continued: Antenatal care booking analyses – characteristics of first and
subsequent pregnancies
Characteristic
First
pregnancies
Subsequent
pregnancies p-value
n % n %
On ART at conception (n=3577)
No 1652 68.1 526 45.7 <0.001
Yes 775 31.9 624 54.3
Timing of HIV diagnosis (n=2526)
Before first reported pregnancy 1481 58.6 - - -
During first reported pregnancy 1045 41.4 - -
*Number of previous live or stillbirths irrespective of whether woman had diagnosed HIV at the time of
these previous pregnancies
**Other comprises largely those originating from a high HIV prevalence area and/or with heterosexual
exposure to HIV
***Interval between conception date of current pregnancy and previous pregnancy reported to the NSHPC
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5.1.3 Timing of antenatal booking
The median gestational age at antenatal booking was 13.0 weeks (IQR: 10.6-17.0) overall,
thus half of women (50.1%, 1416/2827) booked at 13 completed weeks gestation or later.
The medians were similar among the first and subsequent pregnancy groups: 12.9 weeks
(IQR: 10.5-17.4) vs. 13.0 weeks (IQR: 10.6-16.4) respectively (p=0.268), and the
corresponding proportions booking at ≥13 weeks were 49.8% and 50.7% (p=0.653). When
the first pregnancies were restricted to those in nulliparous women the median was 12.6
weeks (IQR: 10.3-17.0) and there remained no statistically significant difference in timing of
booking between the first and repeat pregnancies (p=0.673). Figures 5.2 and 5.3 show the
distribution of gestational weeks at antenatal booking among the first and subsequent
pregnancy groups respectively. Both have a right-skewed distribution. The number of
women booking after 28 completed weeks gestation is relatively low in both groups, though
there is a tail of women booking late, and right up to the time of delivery. When the group of
first pregnancies was split into those in women who were diagnosed with HIV prior to and
during pregnancy the medians were 12.3 weeks (IQR: 10.1-15.6) and 14.3 weeks (IQR:
11.1-20.1) respectively (p<0.001).
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Figure 5.2 Distribution of gestational weeks at antenatal booking among first reported
pregnancies
Figure 5.3 Distribution of gestational weeks at antenatal booking among subsequent
pregnancies
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Among the subsequent pregnancy group, the majority of women booked before 24
completed weeks; 49.3% before 13 weeks, 32.0% between 13 and 17 weeks, 11.9% at 18-
23 weeks, and the remaining 6.8% at 24 weeks or later. The proportion booking before 13
completed weeks increased from 38.5% in 2008 to 59.7% in 2010.
With little evidence of any overall difference in the proportion of women booking late (≥13 
weeks) in first compared with subsequent pregnancies, further analyses focused on
subsequent pregnancies in order to identify factors associated with late booking in this
group specifically. This also enabled risk factors that were only available for the subsequent
pregnancy group to be included in the analyses e.g. inter-pregnancy conception interval.
There were 85 women with more than one pregnancy during 2008-2010 who had
information available on timing of antenatal booking (i.e. both their first and last reported
pregnancies occurred during the three year study period). Table 5.2 explores patterns in
timing of antenatal booking in first and subsequent pregnancies among this small sub-
population of women. Among the 40 women who booked at <13 weeks for their
subsequent pregnancy, over half (52.5%) had also booked at <13 weeks for their previous
pregnancy, although 10.0% had booked for their first pregnancy very late (≥24 weeks). 
Looking at the table the other way around, of the 22 women who booked at ≥18 weeks for 
their first pregnancy, over three quarters (77.3%) booked before 18 weeks for their
subsequent pregnancy (with 40.9% having booked before 13 weeks). There were only four
women who booked at ≥24 weeks in their subsequent pregnancy, all of whom had booked 
at 13-17 weeks in their first. Due to the relatively small number of women with more than
one pregnancy during 2008-2010, these findings should be interpreted with some caution.
It was also therefore not appropriate to consider timing of booking at previous pregnancy in
the analyses of factors associated with timing of booking in women’s repeat pregnancies.
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Table 5.2 Patterns in timing of booking for antenatal care in women’s first and subsequent pregnancies
Timing of antenatal
booking for
subsequent
pregnancy
Timing of antenatal booking for first reported pregnancy
<13 wks 13-17 wks 18-24 wks ≥24 wks Total 
n % n % n % n % n %
<13 wks 21 52.5 10 25.0 5 12.5 4 10.0 40 100
13-17 wks 15 50.0 7 23.3 6 20.0 2 6.7 30 100
18-24 wks 3 27.3 3 27.3 5 45.5 0 0.0 11 100
≥24 wks 0 0.0 4 100.0 0 0.0 0 0.0 4 100
Total 39 45.9 24 28.2 16 18.8 6 7.1 85 100
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5.1.4 Factors associated with late booking for antenatal care
Table 5.3 shows the characteristics of women in the subsequent pregnancy group
according to timing of antenatal booking (n=953). There were variations in timing of
booking according to year of delivery (p<0.001), conception interval (p=0.003), region of
reporting (p<0.001) and whether or not the woman was on ART at conception (p<0.001), as
well as some weaker evidence of a difference by parity (p=0.065). Specifically, women
delivering earlier in the study period were more likely to book later (33.8% of those booking
at ≥24 weeks were delivered in 2008 compared with 17.0% of those booking at <13 
weeks). Women with a very short inter-pregnancy conception interval also booked later
(46.2% of those booking at ≥24 weeks had an interval of <2 years compared with 24.3% of 
those booking at <13 weeks), as did those who were not on ART at conception (accounting
for 60.9% of those booking at ≥24 weeks vs. 37.3% of those booking at <13 weeks). The
relationship between region of reporting and timing of booking appears a little more
complex with both early and very late bookers being more common in London. Finally,
women with ≥3 previous births (irrespective of whether they had diagnosed HIV at the time 
of these previous births) were more likely to book very late (accounting for 33.9% of women
booking at ≥24 weeks and 18.7% of those booking at <13 weeks).  
Although overall there were no significant differences in timing of booking according to
maternal age (p=0.604), world region of origin (p=0.115), HIV risk factor (p=0.954), or
earliest antenatal CD4 count in that pregnancy (p=0.246), some patterns are apparent.
Women booking late tended to be older (38.5% of those booking at ≥24 weeks were aged 
≥35 years compared with 30.6% of those booking at <13 weeks), which may well be 
associated with the fact that women of higher parity (who were more likely to book later)
may be older. The late booking women were somewhat more likely to originate from sub-
Saharan Africa (89.2% of very late bookers (≥24 weeks) compared with 78.3% of early 
bookers). Finally, of some concern, 15.9% of the very late bookers had a CD4 count of
<200 cells/µl though numbers were small (n=10).
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Table 5.3 Characteristics of women according to timing of antenatal booking for subsequent pregnancies
Characteristic
Gestation at booking for antenatal care
p-
value<13 wks 13-17 wks 18-23 wks  ≥24 wks 
n % n % n % n %
Parity (n=923)*
1 212 46.6 121 41.0 44 40.7 24 36.9 0.065
2 158 34.7 96 32.5 40 37.0 19 29.2
≥3 85 18.7 78 26.4 24 22.2 22 33.9
Year of delivery (n=953)
2008 80 17.0 73 23.9 33 29.2 22 33.8 <0.001
2009 178 37.9 131 43.0 49 43.4 32 49.2
2010 212 45.1 101 33.1 31 27.4 11 16.9
Age at delivery, yrs (n=953)
<25 42 8.9 22 7.2 13 11.5 3 4.6 0.604
25-34 284 60.4 185 60.7 64 56.6 37 56.9
≥35 144 30.6 98 32.1 36 31.9 25 38.5
World region of origin (n=953)
UK/Ireland 59 12.6 41 13.4 12 10.6 5 7.7 0.115
Sub-Saharan Africa 368 78.3 240 78.7 98 86.7 58 89.2
Elsewhere 43 9.1 24 7.9 3 2.7 2 3.1
HIV risk factor (n=935)
Other** 453 98.5 295 98.3 110 99.1 63 98.4 0.954
Injecting drug use 7 1.5 5 1.7 1 0.9 1 1.6
Continued overleaf
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Table 5.3 Continued: Characteristics of women according to timing of antenatal booking for subsequent pregnancies
Characteristic
Gestation at booking for antenatal care
p-
value<13 wks 13-17 wks 18-23 wks ≥24 wks
n % n % n % n %
Conception interval, yrs*** (n=953)
<2 114 24.3 93 30.5 27 23.9 30 46.2 0.003
2-3 197 41.9 120 39.3 53 46.9 15 23.1
4-5 96 20.4 58 19.0 26 23.0 9 13.8
≥6 63 13.4 34 11.1 7 6.2 11 16.9
Reporting region (n=952)
London 253 53.8 123 40.5 40 35.4 32 49.2 <0.001
Elsewhere in England 163 34.7 124 40.8 38 33.6 23 35.4
Wales, Scotland, N Ireland 17 3.6 18 5.9 5 4.4 0 0.0
Ireland 37 7.9 39 12.8 30 26.5 10 15.4
Earliest CD4 count, cells/µl (n=870)
≥500 169 39.4 100 35.8 37 37.4 25 39.7 0.246
350-499 128 29.8 96 34.4 28 28.3 16 25.4
200-349 106 24.7 61 21.9 24 24.2 12 19.0
<200 26 6.1 22 7.9 10 10.1 10 15.9
On ART at conception (n=938)
No 172 37.3 150 49.5 59 53.6 39 60.9 <0.001
Yes 289 62.7 153 50.5 51 46.4 25 39.1
*Number of previous live or stillbirths irrespective of whether woman had diagnosed HIV at the time of these previous pregnancies
**Other comprises largely those originating from a high HIV prevalence area and/or with heterosexual exposure to HIV
***Interval between conception date of current pregnancy and previous pregnancy reported to the NSHPC
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The results of the univariable ordinal logistic regression analyses (Table 5.4) showed that
the following variables were significantly associated with timing of booking for antenatal
care: parity (p=0.016), year of delivery (p<0.001), world region of origin (p=0.040) and
region of pregnancy report (p<0.001). There was weak evidence of an association between
timing of booking and inter-pregnancy conception interval (p=0.074), and also earliest
antenatal CD4 count (p=0.091). Meanwhile, there was very little evidence of an association
with maternal age (p=0.620) or maternal HIV risk factor (p=0.858). After including all
variables that were significant in the univariable analyses in the multivariable model, there
was reasonable evidence that adding conception interval and earliest antenatal CD4 count
each improved the fit of the model (LR test: p=0.117 and p=0.055 respectively). There was
little support for the inclusion of either maternal age (LR test: p=0.386) or HIV risk factor
(LR test: p=0.140).
Table 5.4 shows the results of the multivariable ordinal logistic regressions. The result from
the Brant test was not significant (p=0.282) confirming that the proportional odds
assumption for the ordinal logistic regression model was met. The multivariable model
demonstrated that higher parity (≥3), earlier year of delivery, being reported in England 
(excluding London) or Ireland, and not being on ART at conception were independently
associated with later booking for antenatal care. In the multivariable model the association
between a very short conception interval (<2 years) and later booking was attenuated and
no longer significant at the p<0.05 level, however, the pattern remained. This may be due
to the reduction in power in the multivariable model (there were 849 observations in the
final model whereas 953 women had information available on conception interval). There
was also some (non-significant) suggestion that women from sub-Saharan Africa were
more likely than those born in the UK or Ireland to book late (aOR: 1.36, 95% CI: 0.90-
2.04), and that women with the lowest CD4 counts were more likely to book later (aOR:
1.56, 95% CI: 0.93-2.60 among those with <200 cells/µl compared with women with ≥500 
cells/µl).
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Table 5.4 Univariable and multivariable analyses of factors associated with later booking
for antenatal care among subsequent pregnancies
Univariable analyses Multivariable analysis(n=849)
OR 95% CI
p-
value aOR 95% CI
p-
value
Parity*
1 1 0.016 1 0.023
2 1.11 (0.84-1.47) 0.99 (0.73-1.35)
≥3 1.57 (1.15-2.15) 1.54 (1.10-2.17)
Year of delivery
2008 1 <0.001 1 <0.001
2009 0.74 (0.54-1.01) 0.75 (0.53-1.06)
2010 0.41 (0.29-0.56) 0.44 (0.30-0.63)
Age at delivery, yrs
<25 1 0.620
25-34 1.06 (0.68-1.66)
≥35 1.19 (0.74-1.90)
World region of origin
UK/Ireland 1 0.040 1 0.104
Sub-Saharan Africa 1.19 (0.83-1.72) 1.36 (0.90-2.04)
Elsewhere 0.67 (0.38-1.18) 0.86 (0.46-1.63)
Maternal HIV risk factor
Other** 1 0.858
Injecting drug use 0.91 (0.34-2.46)
Conception interval, yrs***
<2 1 0.074 1 0.178
2-3 0.71 (0.53-0.96) 0.72 (0.52-0.99)
4-5 0.73 (0.52-1.04) 0.71 (0.48-1.04)
≥6 0.64 (0.42-0.98) 0.75 (0.47-1.20)
Reporting region
London 1 <0.001 1 <0.001
Elsewhere in England 1.36 (1.04-1.78) 1.47 (1.10-1.97)
Wales, Scotland, N Ireland 1.36 (0.76-2.44) 1.31 (0.67-2.56)
Ireland 2.70 (1.85-3.94) 2.50 (1.65-3.77)
Earliest CD4 count, cells/µl
≥500 1 0.091 1 0.067
350-499 1.05 (0.78-1.42) 0.87 (0.63-1.20)
200-349 0.94 (0.67-1.31) 0.77 (0.54-1.10)
<200 1.80 (1.10-2.94) 1.56 (0.93-2.60)
On ART at conception
No 1 <0.001 1 <0.001
Yes 0.55 (0.43-0.70) 0.59 (0.46-0.78)
*Number of previous live or stillbirths irrespective of whether woman had diagnosed HIV at the time
**Other comprises largely those originating from a high HIV prevalence area and/or with heterosexual
exposure to HIV
***Interval between conception date of current and previous pregnancy reported to the NSHPC
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5.1.5 Time lag between antenatal booking and laboratory testing
Among the 870 subsequent pregnancies with information available, the median time lag
from antenatal booking to date of first laboratory test (e.g. CD4 count, viral load) during that
pregnancy was zero weeks (i.e. the blood sample was taken on the same day as antenatal
booking) (IQR: -3.1 to 4.9 weeks). As shown in Figure 5.4, there is thus a large spike at
zero weeks. Since this analysis included subsequent pregnancies only, all women had
been diagnosed with HIV before the pregnancy under consideration, and around half had
had their laboratory test prior to their antenatal care booking appointment. However, 29.8%
(259/870) did not have an HIV-related laboratory test until four or more weeks after
booking, accounting for 58.7% (259/441) of those women whose laboratory test was
carried out after they booked for care. Among the sub-group of women who were not on
ART at conception and had their first laboratory test after their date of booking (n=216), the
median lag between booking and laboratory test was 4.2 weeks (IQR: 1.7-9.4).
Figure 5.4 Time lag from date of antenatal booking to first laboratory test during that
pregnancy, among subsequent pregnancies
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A plot of the time lag between antenatal booking and first laboratory test against gestational
weeks at booking (restricted to women whose first laboratory test was carried after their
date of booking) is provided in Figure 5.5. This shows that although many were carried out
close to the time of booking there were substantial delays for some women. Women
booking late in pregnancy would be expected to have laboratory testing carried out as soon
as possible, yet delays were apparent even among some women booking at ≥18 weeks as 
can be seen in the figure. For example, of the 162 women booking at ≥18 weeks for whom 
date of first laboratory test was known (and was after the date of booking) the median lag to
laboratory test of 8.2 weeks (IQR: 6.9-14.3) and 19 had a delay of more than five weeks.
Figure 5.5 Time lag from antenatal booking to first laboratory test during that pregnancy
by gestation at booking, among subsequent pregnancies
Notes:
The line of equality (dashed line) represents the border for admissible points on the scatter plot assuming
a 40 week pregnancy gestation. For example, a woman booking at 10 gestational weeks is unlikely to
have a time lag of more than 30 weeks from booking to laboratory test.
Analyses restricted to those with a first laboratory test after date of antenatal booking.
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5.1.6 Time lag between antenatal booking and ART initiation
Analyses were conducted on 358 pregnancies in women who were not on treatment at
conception and started ART after booking (46 of the available 404 pregnancies were
excluded because the woman had already started ART by the time of booking, or did no
antenatal ART was received). The median time lag between antenatal booking and start of
ART was 8.7 weeks (IQR: 4.6-12.6 weeks) overall. There was no evidence that this lag
changed during the three year study period; 8.3 weeks (IQR: 5.1-12.7) in 2008 and 8.6
weeks (IQR: 3.8-12.4) in 2010, p=0.980). The distribution is shown in Figure 5.6, with
reasonably uniform numbers starting ART over the period of 1-15 weeks after booking, and
relatively few (though some, n=40), not starting until 15 weeks after booking. When this
association was examined separately for women with an earliest antenatal CD4 count of
<350 cells/µl and those with a count of ≥350 cells/µl, the medians were 7.1 weeks (IQR: 
3.3-10.4) and 10.0 weeks (IQR: 5.7-13.6) respectively (p<0.001).
Figure 5.6 Time lag from antenatal booking to ART initiation, among subsequent
pregnancies
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Figure 5.7 shows that the time lag between antenatal booking and start of ART declined
with increasing gestational weeks at booking. There were however, 130 women who had a
delay of more than 10 weeks, nine of whom had a lag of more than 20 weeks. Of the 121
women with a lag of between 10 and 20 weeks, 30.4% had a detectable viral load at
delivery and one infant was known to have acquired HIV. Almost one quarter (28/118) had
an earliest antenatal CD4 count of <350 cells/µl, five of which were <200 cells/µl.
Meanwhile, of the nine women with a lag greater than 20 weeks, viral load close to delivery
was reported for eight, three of which were detectable. There were no HIV-positive infants
although information was missing for two women, one with a detectable viral load and one
whose viral load was undetectable. Six women had an earliest antenatal CD4 count of
≥500 cells/µl, but two had counts <350 cells/µl (one of which was <200 cells/µl), and CD4 
count was not reported for the one remaining woman.
A restricted analysis was carried out to explore the time lag between antenatal booking and
ART by gestational weeks at booking among 110 women with an earliest antenatal CD4
count of <350 cells/µl (Figure 5.8). These women should be initiated on ART promptly for
their own health (de Ruiter et al, 2008; Taylor et al, 2012). Quite substantial delays were
apparent among some women, for example, as can be seen, 30 women had a lag of
greater than 10 weeks, five of whom had not booked for antenatal care until ≥13 weeks. 
These delays are of particular concern for the health of these women, as well as for MTCT
risks.
A more detailed adjusted analysis of demographic, clinical and immunological factors
associated with timing of ART initiation are presented in the second part of this chapter,
enabling the analyses to be conducted on the larger dataset of subsequent pregnancies
during 2000-2010 rather than the sub-group of pregnancies with information available on
timing of antenatal booking.
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Figure 5.7 Association between gestation at antenatal booking and time lag from booking
to ART initiation, among subsequent pregnancies
Note: The line of equality (dashed line) represents the border for admissible points on the scatter plot
assuming a 40 week pregnancy gestation. For example, a woman booking at 10 gestational weeks is
unlikely to have a time lag of more than 30 weeks from booking to starting ART.
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Figure 5.8 Association between gestation at antenatal booking and time lag from booking
to ART initiation among subsequent pregnancies to women with an earliest antenatal
CD4 count of <350 cells/µl
Note: The line of equality (dashed line) represents the border for admissible points on the scatter plot
assuming a 40 week pregnancy gestation. For example, a woman booking at 10 gestational weeks is
unlikely to have a time lag of more than 30 weeks from booking to starting ART.
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5.2 Immunological status, timing of antenatal ART, and virological
outcomes among women not on ART at conception
HIV-positive pregnant women not requiring treatment for their own health are
recommended to take short-course ART to prevent vertical transmission (de Ruiter et al,
2008; Taylor et al, 2012). Although this is a highly effective prevention measure (Townsend
et al, 2014), increased morbidity and mortality among people randomised to CD4 count
guided HIV treatment interruptions have been reported in non-pregnant populations (Danel
et al, 2006; El-Sadr et al, 2006), which may have implications for optimal management of
HIV in childbearing women. Current WHO guidelines provide the option of lifelong ART for
pregnant women irrespective of health status (Option B+) (World Health Organization,
2013)41. To help address the question of whether it would be beneficial to initiate lifelong
ART in all pregnant women, the immunological status and virological outcomes of second
pregnancies to women not on ART at conception are investigated here. Timing of antenatal
ART initiation is also explored among this group of women (Objective 3b).
5.2.1 Methods
Dataset
The main study population included second pregnancies reported during 2000-2010 to
women whose first reported pregnancy occurred from 2000 onwards and who were not on
ART at conception of their second pregnancy (Figure 5.9). Further subsequent pregnancies
(i.e. third, fourth etc) were not included as few women were not on treatment by such time
and these pregnancies are likely to represent a very specific, small, sub-population. For
analyses exploring maternal viral load at delivery a comparison group consisting of second
pregnancies (resulting in a live or stillbirth) to women who conceived their second
pregnancy on ART was used. These analyses were restricted to pregnancies in which the
woman received ART during pregnancy as the aim was to compare the risk of detectable
viral load at delivery in women who conceived on treatment with those starting ART during
pregnancy.
41 The WHO states that the advantages of Option B+ are “further simplification of regimen and service
delivery and harmonization with ART programmes, protection against mother-to-child transmission in
future pregnancies, a continuing prevention benefit against sexual transmission to serodiscordant partners,
and avoiding stopping and starting of ARV drugs”.
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Figure 5.9 Study population flow chart – second pregnancies according to women’s ART
status at conception
Classifications and definitions
CD4 counts were the earliest reported measurements in the relevant pregnancy.
Measurements were restricted those taken prior to ART initiation (except where CD4 count
was included as a covariate in the analyses of detectable viral load at delivery). An
immunological indication for treatment was defined as a CD4 count of <350 cells/µl
(Williams et al, 2012). Delivery viral load measurements taken prior to or within the first
seven days after ART initiation were excluded except those taken within seven days of
delivery, since the probability of achieving an undetectable viral load within this short period
of time is likely to be low (Patel et al, 2007). The imputed viral load variable described in
Chapter 3, Section 3.4, was utilised (i.e. if viral load in the last 28 days of pregnancy was
missing but an undetectable viral load was last reported earlier in that pregnancy, delivery
viral load was imputed as undetectable). As a sensitivity analysis the multivariable analyses
were re-run using the original non-imputed variable.
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Statistical analyses
Analyses of factors associated with having a CD4 count of <350 cells/µl were conducted
using standard risk factor analysis logistic regression methods as described in Chapter 3,
Section 3.5. As only second pregnancies were included in the analyses, each woman only
contributed one pregnancy to the dataset thus no adjustment for clustering of pregnancies
within women was required.
Kaplan–Meier analysis was used to graphically describe the time to ART initiation.
Analyses of factors associated with the time to antenatal ART initiation were conducted
using Cox proportional hazards modelling. These analyses were restricted to pregnancies
resulting in a live or stillbirth since initiation of antenatal ART is unlikely in pregnancies
resulting in other outcomes (e.g. a termination). Even where treatment is required for the
woman’s own health, information on ART start dates are tend to be poorly reported to the
NSHPC if the pregnancy has not resulted in a birth. Crude and adjusted HRs were
estimated. The proportional hazards assumption (i.e. that the HR is constant over time,
with constant differences over strata) was assessed by examining log-log plots to ensure
plots for the different strata of a given variable, adjusted for all other variables included
in the model, were approximately parallel. The model’s Schoenfeld residuals were also
analysed, both for each covariate and globally (Therneau et al, 2000).
Logistic regression models were fitted to analyse the association between timing of ART
initiation and the risk of detectable viral load at delivery. As above, no adjustment for
clustering at the woman level was required.
5.2.2 Study population
The main study population consisted of 1177 second pregnancies to women who were not
on treatment at conception, 1063 of which resulted in a live or stillbirth. Among the 1177
pregnancies, 76.0% were in women from sub-Saharan Africa, and the median maternal
age at delivery (or end of pregnancy for outcomes other than a live or stillbirth) was 30.3
years (IQR: 26.9-34.0). Most pregnancies (74.1%) occurred during the more recent (2006-
2010) time period, with 43.4% occurring during 2008-2010, and only 4.1% during 2000-
2002. The median interval between conception of women’s first and second pregnancies
was 2.3 years (IQR: 2.2-2.5).
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5.2.3 Immunological status
Earliest antenatal CD4 count was available for 71.2% (838/1177) of pregnancies, this was
measured at a median of 15.0 gestational weeks (IQR: 9.6-20.6). When pregnancies with
missing information on CD4 count were compared with those with known CD4 count, they
were more likely to have occurred during the earlier time periods (p<0.001). There was,
however, little difference in median maternal age (30.0 years, IQR: 26.7-33.3 vs. 30.4
years, IQR: 27.0-34.2, p=0.133), the proportion originating from sub-Saharan Africa (79.4%
vs. 74.6%, p=0.082), with a history of injecting drug use (4.0% vs. 2.2%, p=0.10), or with a
short (<2 year) inter-pregnancy conception interval (43.7% vs. 39.4%, p=0.153).
The median earliest antenatal CD4 count was 390 cells/µl (IQR: 271-534, range: 20-
164442) (Figure 5.10). Forty-one percent (340/838) of women had immunological indication
for treatment a quarter (n=85) of whom were severely immunosuppressed (<200 cells/µl),
representing 10.1% of all 838 women. The remaining approximately 60% of women, who
were not yet requiring treatment, were composed of 29.2% (n=245) with CD4 counts of
350-499 cells/µl and 30.2% (n=253) with ≥500 cells/µl. The findings did not change when 
the analysis was restricted to the most recent time period (2008-2010), 39.8% (160/402) of
women had an indication for treatment with 10.0% (40/402) being severely
immunosuppressed43. The distribution of CD4 counts that were <350 cells/µl are shown in
more detail in Figure 5.11. The cluster of women with CD4 counts <100 cells/µl are a group
of particular concern requiring rapid initiation of ART. Some of the large spikes, for
example, at around 200 cells/µl, are likely due to rounded values being reported to the
NSHPC.
42 The small number of high CD4 count measurements (>1200 cells/µl, including the outlier at 1644
cells/µl) were double-checked on the original report submitted to the NSHPC, and cross-checked with the
CD4 counts reported for the women’s previous pregnancies which were found to be similarly high
suggesting that the high values were not due to data entry errors. Although high, these values are
approximately within the range of possible CD4 count values (http://namlife.org/cms1254931.aspx,
Accessed December 2013), and were therefore retained in the dataset.
43 Since 2008 UK guidelines have recommended that people living with HIV initiate treatment before their
CD4 count falls below 350 cells/µl (Gazzard et al, 2008; Williams et al, 2012). Prior to this treatment
initiation was recommended at CD4 counts of 200-350 cells/µl (Gazzard, 2005; Pozniak et al, 2003).
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Figure 5.10 Distribution of earliest antenatal CD4 counts among women not on ART at
conception
Figure 5.11 Distribution of earliest antenatal CD4 counts among women with a CD4 count
<350 cells/µl who were not on ART at conception
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Of those women with an immunological indication for treatment at their second pregnancy,
44.3% (93/210) had had an earliest antenatal CD4 count of ≥350 cells/µl at their first. 
Looking at this the other way around, 25.9% (93/359) of women with CD4 count of ≥350 
cells/µl at their first pregnancy had declined to CD4 <350 cells/µl at their second. These
findings demonstrate that HIV disease can progress quite markedly between a woman’s
first and subsequent pregnancy and should be considered when recommending whether
women remain on lifelong ART after their first pregnancy ends. Of the 359 women with
CD4 count of ≥350 cells/µl at their first pregnancy, 169 had 350-499 cells/µl of whom 
40.2% (n=68) had declined to <350 cells/µl at their second pregnancy, compared with
13.2% (n=25) of those starting with CD4 ≥500 cells/µl. Also noteworthy is that of the 340 
women with an earliest antenatal CD4 count of <350 cells/µl in their second pregnancy,
55.7% (117/210) had also had an indication for treatment at the time of their first reported
pregnancy (CD4 <350 cells/µl) and yet were not on ART at conception of their subsequent
pregnancy. This may at least in part be due to disengagement from HIV care between
pregnancies. The third part of this chapter explores women’s attendance for HIV care after
pregnancy.
5.2.4 Factors associated with an immunological indication for treatment among
women not on ART at conception
Table 5.5 shows factors associated with presenting with a CD4 count of <350 cells/µl at
second pregnancy. Firstly, the influences of women’s demographic and clinical
characteristics at the time of their second pregnancy were explored. The most important
factor was the inter-pregnancy conception interval; compared with women who had a very
short conception interval (<2 years) those with longer intervals tended to be more likely to
have an earliest antenatal CD4 count of <350 cells/µl (p=0.054) though this was only
significant at the p<0.05 level for the group with an interval of 4-5 years. There was also
some weaker evidence that women who were diagnosed with HIV during (rather than prior
to) their first reported pregnancy were less likely to have a CD4 count of <350 cells/µl (OR:
0.79, 95% CI: 0.58-1.07). Although a slightly higher proportion of those from sub-Saharan
Africa compared with women born in the UK or Ireland had a CD4 count of <350 cells/µl at
their second pregnancy (42.1% vs. 35.5%) the difference was not significant (OR: 1.32,
95% CI: 0.90-1.94). Similarly, women aged ≥35 years had a higher risk compared with 
those aged <25 years (46.4% vs. 38.8%) but this was not significant (OR: 1.37, 95% CI:
0.85-2.20). There was no difference according to time period (p=0.879).
Secondly, key clinical and immunological characteristics at women’s preceding pregnancy
(i.e. first reported) were explored (also shown in Table 5.5). Women with lower earliest
antenatal CD4 counts during their first pregnancy were, not surprisingly, more likely to have
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an earliest antenatal CD4 count of <350 cells/µl at their second pregnancy (p<0.001). This
association held when last CD4 count measurements taken during their first pregnancy
were examined (also p<0.001). It should be noted that while earliest antenatal CD4 counts
were restricted to those taken prior to ART initiation, no such restriction was applied to the
last antenatal CD4 count measurements thus the majority of women would have been on
ART at the time of their last antenatal CD4 count. When the proportion of women with a
CD4 count <350 cells/µl at their second pregnancy was compared among those who had
missing information on CD4 count during their first pregnancy and those with a known CD4
count there was little difference (40.8% vs. 40.6% based on earliest CD4 count in first
pregnancy, and 42.9% vs. 40.0% based on last CD4 count in first pregnancy, data not
shown in Table 5.5). In relation to the duration of ART received during their first pregnancy,
women who received less than two weeks ART were more likely than those who received
12-40 weeks ART to present with a CD4 count of <350 cells/µl at their second pregnancy
(OR: 2.58, 95% CI: 1.09-6.08), as were women who did not receive ART during their first
pregnancy (OR: 2.13, 95% CI: 1.36-3.33).
The multivariable model included latest CD4 count in first reported pregnancy and
conception interval only. Earliest CD4 count and duration of ART received during first
pregnancy were excluded due to co-linearity. For example, latest antenatal CD4 counts will
be highly dependent on duration of ART received, and also influenced by earliest antenatal
CD4 count. Meanwhile, there was no evidence from the LR test that adding maternal age
group (p=0.818), world region of origin (p=0.382), HIV risk factor (p=0.312), time period
(p=0.935), or timing of HIV diagnosis (p=0.234) improved the fit of the model. It is thus clear
that the key predictors of women having a CD4 count of <350 cells/µl at their second
pregnancy were having a lower CD4 count in their first pregnancy and having a longer
inter-pregnancy conception interval.
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Table 5.5 Univariable and multivariable analyses of factors associated with having a CD4
count of <350 cells/µl at second pregnancy among women not on ART at conception
CD4 count <350
cells/µl/
Total (%)
Univariable analyses Multivariable analysis(n=606)
OR 95% CI
p-
value aOR 95% CI
p-
value
Age at delivery, yrs
<25 51/131 (38.9) 1 0.155
25-34 211/541 (39.0) 1.00 (0.68-1.48)
≥35 78/165 (47.3) 1.41 (0.88-2.24)
World region of origin
UK/Ireland 49/138 (35.5) 1 0.292
Sub-Saharan Africa 263/624 (42.1) 1.32 (0.90-1.94)
Elsewhere 28/75 (37.3) 1.08 (0.60-1.94)
HIV risk factor
Other* 328/804 (40.8) 1 0.213
Injecting drug use 10/18 (55.6) 1.81 (0.71-4.65)
Time period of delivery**
2000-2002 10/23 (43.5) 1.20 (0.51-2.84)
2003-2005 65/164 (39.6) 1.03 (0.69-1.53)
2006-2008 160/382 (41.9) 1.13 (0.82-1.55)
2009-2010 105/269 (39.0) 1 0.879
Timing of HIV diagnosis
Before first reported pregnancy 109/244 (44.7) 1 0.125
During first reported pregnancy 230/591 (38.9) 0.79 (0.58-1.07)
Conception interval, yrs***
<2 123/330 (37.3) 1 0.054 1 0.003
2-3 137/344 (39.8) 1.11 (0.82-1.52) 1.52 (0.98-2.35)
4-5 63/122 (51.6) 1.80 (1.18-2.73) 3.16 (1.71-5.84)
≥6 17/42 (40.5) 1.14 (0.59-2.20) 2.23 (0.90-5.55)
Earliest CD4 count, cells/µl†
≥500 25/190 (13.2) 1 <0.001
350-499 68/169 (40.2) 4.44 (2.64-7.48)
200-349 96/132 (72.7) 17.60 (9.96-31.09)
<200 21/28 (75.0) 19.80 (7.63-51.36)
Last CD4 count, cells/µl†
≥500 54/318 (17.0) 1 <0.001 1 <0.001
350-499 88/190 (46.3) 4.22 (2.80-6.35) 4.73 (3.04-7.34)
200-349 109/138 (79.0) 18.38 (11.11-30.40) 24.50 (13.91-43.16)
<200 16/22 (72.7) 13.04 (4.88-34.84) 13.23 (4.44-39.47)
Duration of ART, wks***
<2 15/24 (62.5) 2.58 (1.09-6.08)
2-12 100/305 (32.8) 0.75 (0.54-1.05)
13-40 119/303 (39.3) 1 <0.001
Unknown duration 25/60 (41.7) 1.10 (0.63-1.94)
None received 62/107 (57.9) 2.13 (1.36-3.33)
*Other comprises largely those originating from a high HIV prevalence area and/or with heterosexual
exposure to HIV
**Expected year of delivery for outcomes other than a live or stillbirth
***Interval from conception of first pregnancy to conception of second pregnancy
†During first reported pregnancy
168
Overall, 4.7% (45/951) of women had HIV/AIDS symptoms during their second pregnancy,
of whom most (81.1%, 36/44) were asymptomatic at the time of their first reported
pregnancy. As per the definition of the study population, none of these symptomatic women
had commenced ART for their own health in the interval between their first and second
pregnancies. Or if they had, they discontinued treatment at some point prior to conception
of their second pregnancy, which is of concern.
5.2.5 Timing of antenatal ART initiation
Of the 1063 women who had a live or stillbirth and did not conceive on treatment, 97.2%
(1028/1058) were reported to have received antenatal ART during their second pregnancy,
with information on date of ART initiation available for 1002. Figure 5.12 shows the
distribution of gestational weeks at ART initiation. ART commenced at a median gestation
of 23.7 weeks (IQR: 20.4-27.0); 24.1 weeks (IQR: 21.6-27.5) among those with CD4 ≥350 
cells/µl and 22.7 weeks (IQR: 18.6-26.0) among those with CD4 <350 cells/µl. The cluster
of values at around 14 weeks links in with the median time of booking for antenatal care
being 13 weeks; those requiring ART for their own health should start ART without delay. It
also ties in with some women waiting until the start of their second trimester to commence
ART. Meanwhile, the second cluster at around 24 weeks reflects the approximate gestation
for ART initiation as per UK recommendations (de Ruiter et al, 2008; Hawkins et al, 2005).
The majority (70.2%) started during the second trimester, 4.4% during the first trimester,
while the remaining quarter did not start ART until their third trimester. Among women
starting during the first trimester this ranged from week one onwards. Of course women
starting ART in the first few weeks after conception are unlikely to have been aware of their
pregnancy and would have simply started ART as part of their routine non-pregnancy
related HIV care. Of the 256 women who did not start ART until the third trimester of their
pregnancy, seven received less than two weeks of ART prior to delivery. Of those seven
women, six were of black African ethnicity (all born abroad) and one was white; six
received cART and one received dual therapy; one had CDC stage C disease (AIDS) at
delivery while the rest were asymptomatic. One had an infant who was known to have
acquired HIV (delivered vaginally at 38 weeks).
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Figure 5.12 Timing of antenatal ART initiation
In line with shifting UK recommendations for the earlier initiation of ART during pregnancy,
there was a significant decrease in the median gestational age at ART initiation over time
(test for trend: p<0.001) (Table 5.6).
Table 5.6 Median gestation at antenatal ART initiation, by time period
Time period* n Gestation, wks IQR, wks p-value**
2000-2002 34 25.6 23.4-29.5
<0.0012003-2005 252 26.0 22.4-28.5
2006-2008 246 23.7 20.9-26.5
2009-2010 293 21.5 18.6-24.5
*Based on year of delivery
**Test for trend
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When timing of ART initiation was explored according to earliest antenatal CD4 count,
among all CD4 groups the majority of women started ART during the second trimester
(Figure 5.13). The proportion starting ART during the first trimester was small in all CD4
groups but did increase with decreasing CD4 count. Of those with a CD4 count of <200
cells/µl, 83.1% had started ART by the end of the second trimester compared with 68.5% of
those with a CD4 count of ≥500 cells/µl. However, it is of note that even among the lowest 
CD4 count group (<200 cells/µl) 16.9% of women did not start ART until the third trimester.
As mentioned, disengagement from HIV care after pregnancy is explored in the third part of
this chapter.
Figure 5.13 Timing of antenatal ART initiation according to earliest antenatal CD4 count
Note: Number of pregnancies shown above bars.
171
Women with higher earliest pre-ART antenatal viral loads were more likely to have initiated
ART by the end of the second trimester than those with lower viral loads (Figure 5.14).
However, 18.3% of those in the highest viral load group (≥10,00 copies/ml) did not start 
ART until the third trimester. The 63 women with undetectable earliest antenatal viral loads
in their second pregnancy will likely be a combination of those who had been on ART prior
to pregnancy, and perhaps stopped when they decided to conceive or discovered they
were pregnant (e.g. to avoid taking ART during the first trimester of pregnancy), those who
already had a low viral load at conception that rapidly declined to undetectable after ART
initiation44, and elite controllers45. Information on ART taken outside of pregnancy is not
collected by the NSHPC.
Figure 5.14 Timing of antenatal ART initiation according to earliest antenatal viral load
Note: Number of pregnancies shown above bars.
44 Pre-ART measurements included those taken up to 14 days after ART initiation (though most women
would have their viral load and CD4 count assessed prior to ART initiation).
45 A small proportion of people living with HIV are able to maintain a low viral load in the absence of ART
(Lambotte et al, 2005).
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5.2.6 Factors associated with timing of antenatal ART initiation
A time-to-event analysis was conducted to explore factors independently associated with
the timing of antenatal ART. The analysis was based on 1032 of the total 1063 live and
stillbirths: 1002 with information available on timing of ART initiation (as described in
Section 5.2.5 above), and 30 in women who did not receive ART and were thus censored
at their date of delivery. The remaining 31 women were excluded from the analyses as they
either had missing information of antenatal ART receipt (n=5) or did receive antenatal ART
but the start date was missing (n=26). The 50% survival time was 23.7 weeks; i.e. after
23.7 weeks of follow-up an estimated 50% of women had initiated ART (as documented in
the earlier descriptive analyses) (Figure 5.15).
Figure 5.15 Cumulative probability of initiating antenatal ART by gestational week
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Note: Probability is represented by the dark blue line and the 95% CIs by the lines above and below.
In the Cox model a HR of less than one indicates a longer time from conception to start of
antenatal ART compared with the baseline group for that variable. The univariable Cox
proportional hazards models (Table 5.7) showed that the following factors were associated
with timing of ART initiation: world region of origin (p=0.015), time period (p<0.001), region
of report (p<0.001), earliest antenatal CD4 count (p=0.005) and viral load (p<0.001).
Specifically, women originating from sub-Saharan Africa had a slightly longer time from
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conception to start of ART, though this was not significantly different to those born in the
UK or Ireland (HR: 0.89, 95% CI: 0.75-1.05). In line with changing guidelines towards
earlier antenatal ART initiation, ART started earlier in the later years. Women in Ireland had
a significantly longer time to ART than those reported in London (HR: 0.80, 95% CI: 0.65-
0.97), while those in Wales, Scotland or Northern Ireland had a shorter time (HR: 1.95,
95% CI: 1.41-2.71). As would be expected, both lower CD4 counts and higher viral loads
were associated with a shorter time to ART. Women with a history of injecting drug use
showed a longer time to ART initiation though this was not significant, possibly due to small
numbers in this group. There was no significant evidence that timing of ART initiation varied
according to maternal age (p=0.502).
All variables that were significantly associated with timing of ART initiation in the univariable
analysis were included in the initial multivariable model (world region of origin, time period,
region of report, earliest antenatal CD4 count and viral load). Adding maternal age did not
further improve the fit (LR test: p=0.400) and it was therefore dropped. Although decisions
regarding when to start ART in the non-pregnant HIV-positive population are based mainly
on CD4 counts (or other clinical indicators) (Williams et al, 2012), in pregnant women timing
will depend more heavily on both viral load (the main aim of ART during pregnancy being to
achieve an undetectable viral load by the time of delivery), and CD4 counts. It therefore
makes sense to investigate the influence of both CD4 count and viral load in the model
despite potential co-linearity. There was also reasonable evidence for including both
variables in the model: LR test p=0.128 for including CD4 count after accounting for viral
load, and p=0.013 for including viral load after accounting for CD4 count.
In the final multivariable model (Table 5.7) women with a high viral load (≥10,000 
copies/ml) or low CD4 count (<200 cells/µl) started ART significantly earlier than those with
lower viral load or higher CD4 counts respectively, while women from sub-Saharan Africa
started later than those from the UK or Ireland. There remained a strong trend of earlier
ART initiation over time period (p<0.001). However, there was no longer a significant
association between region of report and time to ART initiation (p=0.315).
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Table 5.7 Univariable and multivariable analyses of time to antenatal ART initiation
n Univariable analyses
Multivariable analysis
(n=714)
HR* 95% CI p-value aHR* 95% CI p-value
Age at delivery, yrs
<25 163 1 0.502
25-34 686 1.10 (0.92-1.31)
≥35 182 1.12 (0.91-1.39)
World region of origin
UK/Ireland 162 1 0.015 1 0.029
Sub-Saharan Africa 788 0.89 (0.75-1.05) 0.78 (0.63-0.97)
Elsewhere 81 1.23 (0.94-1.61) 0.99 (0.73-1.35)
HIV risk factor
Other** 981 1 0.214
Injecting drug use 28 0.78 (0.52-1.16)
Time period of delivery
2000-2002 40 1 <0.001 1 <0.001
2003-2005 259 1.43 (1.00-2.04) 1.01 (0.61-1.66)
2006-2008 433 2.03 (1.43-2.88) 1.52 (0.94-2.45)
2009-2010 300 2.74 (1.92-3.92) 2.26 (1.38-3.68)
Reporting region
London 482 1 <0.001 1 0.315
Elsewhere in England 385 1.19 (1.04-1.36) 1.05 (0.89-1.23)
Wales, Scotland, N Ireland 39 1.95 (1.41-2.71) 1.39 (0.91-2.13)
Ireland 125 0.80 (0.65-0.97) 0.88 (0.67-1.16)
Continued overleaf
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Table 5.7 Continued: Univariable and multivariable analyses of time to antenatal ART initiation
n Univariable analyses
Multivariable analysis
(n=714)
HR* 95% CI p-value aHR* 95% CI p-value
Earliest CD4 count, cells/µl***
≥500 224 1 0.005 1 0.128
350-499 221 1.11 (0.92-1.34) 1.08 (0.88-1.32)
200-349 233 1.25 (1.04-1.51) 1.21 (0.98-1.48)
<200 72 1.59 (1.22-2.08) 1.35 (1.01-1.80)
Earliest viral load, copies/ml***
<50 64 1 <0.001 1 0.013
50-999 133 1.00 (0.74-1.35) 1.14 (0.83-1.58)
1000-9999 255 1.34 (1.02-1.77) 1.31 (0.97-1.78)
≥10,000 297 1.55 (1.18-2.03) 1.52 (1.12-2.08)
*HR of <1 indicates a longer time to ART initiation
**Other comprises largely those originating from a high HIV prevalence area and/or with heterosexual exposure to HIV
***Restricted to measurements taken prior to ART initiation
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The global Therneau-Grambsch statistic46 for the final model was significant suggesting
that the assumption of proportional hazards may not be met. Inspection of the individual
Schoenfeld residuals for each variable in the model indicated that time period and earliest
antenatal CD4 count were the variables contributing to this non-proportionality. As
discussed in Chapter 4, the global test for proportionality might be over sensitive to small
deviations from the proportional hazards assumption. This means that observing significant
value of the test statistic often makes no difference to the overall conclusions and
estimates, particularly with large datasets (Therneau et al, 2000). Examination of the log-
log plots (i.e. the plot of the probability of not initiating ART against time to treatment
initiation in log-log scale) revealed the lines to be reasonably parallel in line with satisfying
the proportional hazards assumption to an acceptable degree. Plots stratified by time
period and by CD4 count and a brief description and interpretation of these are provided in
Appendix V.
Sensitivity analyses
In light of the significant changes in timing of ART initiation over the study period, and the
possible non-proportionality of time period in the main model, a sub-analysis was
conducted in which the multivariable model was re-run restricted to 341 pregnancies during
2008-2010 (Table 5.8). This cut-off was chosen to represent the most recent time period
and also because 2008 was the year of the last BHIVA guideline published during the study
period. This three-year period was thus homogeneous with respect to UK guidelines for the
management of HIV in pregnant women. The findings were similar to those of the main
model, and the only variable with some evidence of non-proportionality was CD4 count.
Even within this short time period there was a clear trend of shorter time to ART initiation by
year. Women from sub-Saharan Africa had a longer time to ART initiation than white
women. Although the difference was no longer significant at the p<0.05 level, this was likely
due to a reduction in power as the point estimate (aOR 0.78) was unchanged. There
remained a trend towards a shorter time to ART in women with lower CD4 counts and with
high viral loads. In fact, the influence of CD4 count was even stronger, likely due to
changing guidelines for the management of adults living with HIV towards initiation of ART
at higher CD4 counts. The 2008 guideline recommended ART initiation in all those with
CD4 counts of <350 cells/µl (Gazzard et al, 2008). Meanwhile, ART initiation was
significantly quicker in the rest of England compared with London. Although the direction of
association was observed in the full model (2000-2010) it was non-significant.
46 The Therneau and Grambsch test was run in Stata using the estat phtest command.
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Table 5.8 Multivariable analysis of time to ART initiation, restricted to 2008-2010
n
Multivariable analysis
(n=341)
aHR* 95% CI p-value
World region of origin
UK/Ireland 51 1 0.136
Sub-Saharan Africa 255 0.78 (0.57-1.09)
Elsewhere 35 1.08 (0.69-1.69)
Year of delivery
2008 113 1 <0.001
2009 127 1.01 (0.77-1.32)
2010 101 1.68 (1.26-2.23)
Reporting region
London 141 1 0.011
Elsewhere in England 155 1.45 (1.14-1.85)
Wales, Scotland, N Ireland 17 1.71 (0.99-2.96)
Ireland 28 1.05 (0.69-1.61)
Earliest CD4 count, cells/µl**
≥500 106 1 0.002
350-499 102 0.96 (0.72-1.29)
200-349 102 1.49 (1.10-2.01)
<200 31 1.71 (1.10-2.65)
Earliest viral load, copies/ml**
<50 26 1 0.057
50-999 50 1.74 (1.06-2.87)
1000-9999 121 1.45 (0.92-2.27)
≥10,000 144 1.73 (1.10-2.72)
*HR of <1 indicates a longer time to ART initiation
**Restricted to measurements taken prior to ART initiation
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5.2.7 Virological outcomes
For this part of the analysis, alongside the 1063 live and stillbirths to women not on ART at
conception, a comparison group consisting of 914 second pregnancies resulting in a birth
to women who conceived on treatment was used. The characteristics of the two groups are
compared in Table 5.9. Compared with women conceiving on treatment, women not on
ART at conception of their second pregnancy were younger, more likely to have delivered
during an earlier time period, to be reported in Ireland, and more likely to have received a
PI-based cART regimen during pregnancy. There was no significant difference in maternal
health status between the two groups (p=0.162). Of the women who were not on ART at
conception but received antenatal ART, most (70.1%) received more than 12 weeks of
ART, 29.2% received 2-12 weeks and the remaining 0.7% received less than two weeks.
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Table 5.9 Characteristics of second pregnancies ending in a live or stillbirth according to
whether the woman was on ART at conception
Characteristic
Women not on ART at
conception (n=1063)
Women on ART at
conception (n=914) p-value
n % n %
Age at delivery, yrs (n=1976)
<25 168 15.8 61 6.7 <0.001
25-34 706 66.5 544 59.5
≥35 188 17.7 309 33.8
World region of origin (n=1976)
UK/Ireland 169 15.9 114 12.5 0.082
Sub-Saharan Africa 812 76.5 733 80.2
Elsewhere 81 7.6 67 7.3
HIV risk factor (n=1929)
Other* 1009 97.2 875 98.2 0.148
Injecting drug use 29 2.8 16 1.8
Time period of delivery (n=1977)
2000-2002 43 4.0 33 3.6 <0.001
2003-2005 262 24.6 165 18.1
2006-2008 452 42.5 371 40.6
2009-2010 306 28.8 345 37.7
Reporting region (n=1976)
London 489 46.0 448 49.0 0.016
Elsewhere in England 400 37.7 355 38.8
Wales, Scotland, N Ireland 40 3.8 37 4.0
Ireland 133 12.5 74 8.1
Type of antenatal ART (n=1942)
Mono/dual 98 9.5 6 0.7 <0.001
cART - PI-based 738 71.8 401 43.9
cART - NNRTI-based 156 15.2 438 47.9
cART - PI and NNRTI 23 2.2 56 6.1
cART - NRTI only 13 1.3 13 1.4
Earliest CD4 count, cells/µl** (n=1790)
≥500 302 31.6 285 34.2 0.162
350-499 278 29.0 262 31.5
200-349 285 29.8 221 26.5
<200 92 9.6 65 7.8
*Other comprises largely those originating from a high HIV prevalence area and/or with heterosexual
exposure to HIV
**Not restricted to measurements taken prior to ART initiation
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Among women not on ART at conception, 30 were reported to have not received ART
during pregnancy. Of these, information on viral load at delivery was only reported for five;
one of which was undetectable and four were detectable. Three women with detectable
HIV RNA had particularly high viral load (all >17,000 copies/ml). Further analyses exploring
viral suppression by delivery were restricted to the 1942 pregnancies in which the woman
received ART during pregnancy; 1028 in women not on ART at conception (but were
known to have received antenatal ART) and 914 in women conceiving on treatment. Viral
load at delivery was reported for 57.1% of all pregnancies, and was available for a similar
proportion of women in the two groups (59.6% and 54.2% respectively). Imputation of
missing viral load as undetectable if there was an undetectable viral load earlier during the
pregnancy increased available data to 86.8% of all pregnancies; 81.7% among those not
on ART at conception and 92.6% among those who were.
Overall 16.2% (273/1686) of women’s second pregnancies ending in a live or stillbirth had
a detectable viral load at delivery, although among these the actual value was reasonably
low (median: 188 copies/ml, IQR: 90-590, range: 51-412,000). The proportion of women
with detectable viral load at delivery was 26.2% (220/840) in women starting ART in
pregnancy compared with 6.3% (53/846) in women who conceived their second pregnancy
on ART. Among those starting ART during pregnancy the risk of detectable viral load
increased the later ART was started; from 15.8% (6/38) among those starting in the first
trimester to 35.7% (71/199) among those not starting until the third trimester (Figure 5.16).
The risk of MTCT in women not on ART at conception was 0.91% (8/878) compared with
0.27% (2/740) among those who were (p=0.121). No further analyses were conducted on
this outcome due to the small number of vertical transmissions.
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Figure 5.16 Timing of ART initiation and risk of detectable viral load at delivery
For the univariable and multivariable analyses of factors associated with detectable
maternal viral load at delivery it was not appropriate to consider duration of antenatal ART
since all women conceiving on ART will have received ≥12 weeks of ART. Similarly, 
earliest viral load was not considered since the vast majority of women who were on ART
at conception had an undetectable viral load, which is simply a product of already being on
treatment.
In the univariable analyses, factors associated with having a detectable viral load at
delivery of second pregnancy were: not being on ART at conception, delivering during an
earlier time period, being reported in London (or elsewhere in England), receiving mono or
dual ART compared with PI-based cART (while those receiving NNRTI-based cART had a
lower odds), lower earliest antenatal CD4 count, and younger maternal age. There was
little evidence of a difference according to world region of origin (although women born
abroad did have a slightly increased odds) and no difference according to HIV risk factor
(Table 5.10).
In the multivariable analysis, compared with women conceiving on treatment, those not on
ART at conception (but who received it during pregnancy) had a 4.3-fold increased odds of
detectable viral load at delivery after adjusting for time period, place of report, type of ART
received, and earliest CD4 count (Table 5.10). The following factors also remained
associated with a detectable viral load at delivery in the final multivariable model: delivering
during an earlier time period, receiving mono or dual therapy (while those receiving NNRTI-
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based cART had a lower risk compared with the baseline PI-based cART group), and
having a lower CD4 count. The odds were lower among those reported in Ireland, and
higher (though not significantly so) among those reported in England (outside London)
compared with those reported in London. There was little evidence the fit of the model was
improved by the addition of maternal age (LR test p=0.519), world region of origin (LR test
p=0.472), or HIV risk factor (LR test p=0.301).
Sensitivity analyses
Several sensitivity analyses were conducted on the main multivariable model to assess the
robustness of the findings. When the main multivariable model (as shown in Table 5.10)
was re-run using the non-imputed viral load variable the aOR was similar though slightly
lower at 3.85, 95% CI: 2.65-5.59, p<0.001 (n=1048), compared with aOR: 4.34, 95% CI:
3.03-6.20 obtained from the main model (n=1590). Next, to check whether the observed
association was driven by the small group of ‘high risk’ women who received a very short
(<14 days) duration of ART (n=7), the main model (based on the imputed viral load
variable) was re-run excluding this sub-group of pregnancies. The findings were very
similar to those of the model fitted to the full dataset (aOR: 4.31, 95% CI: 3.01-6.18,
p<0.001).
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Table 5.10 Univariable and multivariable analyses of the association between timing of ART and detectable viral load at delivery
Detectable/Total
(%)
Univariable analyses Multivariable analysis (n=1590)
OR 95% CI p-value aOR 95% CI p-value
Timing of ART
After conception 220/840 (26.2) 5.31 (3.86-7.30) 4.34 (3.03-6.20)
Prior to conception 53/846 (6.3) 1 <0.001 1 <0.001
Age at delivery, yrs
<25 33/184 (17.9) 1 0.046
25-34 183/1049 (17.4) 0.97 (0.64-1.46)
≥35 57/452 (12.6) 0.66 (0.41-1.05)
World region of origin
UK/Ireland 30/234 (12.8) 1 0.288
Sub-Saharan Africa 218/1317 (16.6) 1.35 (0.90-2.03)
Elsewhere 24/134 (17.9) 1.48 (0.83-2.66)
HIV risk factor
Other* 260/1612 (16.1) 1 0.499
Injecting drug use 7/34 (20.6) 1.35 (0.58-3.13)
Time period of delivery
2000-2002 12/47 (25.5) 2.34 (1.16-4.70) 3.32 (1.38-8.00)
2003-2005 76/338 (22.5) 1.98 (1.39-2.81) 1.90 (1.24-2.90)
2006-2008 110/715 (15.4) 1.24 (0.90-1.70) 1.05 (0.74-1.49)
2009-2010 75/586 (12.8) 1 <0.001 1 0.002
Reporting region
London 141/830 (17.0) 1 0.001 1 <0.001
Elsewhere in England 116/647 (17.9) 1.07 (0.81-1.40) 1.34 (0.98-1.83)
Wales, Scotland, N Ireland 3/63 (4.8) 0.24 (0.08-0.79) 0.31 (0.09-1.06)
Ireland 13/145 (9.0) 0.48 (0.26-0.88) 0.42 (0.22-0.80)
Continued overleaf
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Table 5.10 Continued: Univariable and multivariable analyses of the association between timing of ART and detectable viral load at delivery
Detectable/Total
(%)
Univariable analyses Multivariable analysis (n=1590)
OR 95% CI p-value OR 95% CI p-value
Type of antenatal ART
Mono/dual 33/71 (46.5) 3.96 (2.42-6.50) 2.89 (1.65-5.06)
cART - PI-based** 177/985 (18.0) 1 <0.001 1 <0.001
cART - NNRTI-based 45/536 (8.4) 0.41 (0.29-0.58) 0.48 (0.32-0.74)
cART - Other*** 18/94 (19.1) 1.13 (0.66-1.91) 1.16 (0.62-2.18)
Earliest CD4 count, cells/µl†
≥500 60/534 (11.2) 1 <0.001 1 <0.001
350-499 82/486 (16.9) 1.60 (1.12-2.29) 1.94 (1.31-2.87)
200-349 77/442 (17.4) 1.67 (1.16-2.40) 2.00 (1.34-2.97)
<200 38/128 (29.7) 3.34 (2.10-5.31) 4.50 (2.69-7.51)
*Other comprises largely those originating from a high HIV prevalence area and/or with heterosexual exposure to HIV
**Of the 985 women who received PI-based cART it was ritonavir boosted in 89.4% (n=881)
***Includes NNRTI and PI, and NRTI only – groups combined due to small numbers
†Not restricted to measurements taken prior to ART initiation
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5.3 Attendance for HIV care after pregnancy
Current UK guidelines on the routine monitoring of people living with HIV recommend
between two and four visits to HIV services per year (Asboe et al, 2012). Pregnancy
provides an opportunity to engage women in long-term HIV care. Retention in HIV care
after pregnancy ends is important for the continuation of HIV treatment in women requiring
ART for their own health, and the monitoring of those discontinuing ART after delivery so
that treatment can be initiated when indicated. For those not already on ART, it may also
facilitate early initiation for PMTCT in any subsequent pregnancies. The NSHPC only
collects information on women during their pregnancy and the immediate post-partum
period, so it is not possible to investigate attendance for HIV care after pregnancy using
NSHPC data alone. Therefore, to obtain this information the NSHPC dataset was linked
with SOPHID data for England, Wales and Northern Ireland. SOPHID is described in
Chapter 3, Section 3.2. This final part of the chapter assesses the completeness of
matching of the NSHPC dataset with the SOPHID dataset, describes representativeness of
the women in the matched dataset, and uses the matched data to explore attendance for
HIV care after pregnancy (Objective 3c).
5.3.1 Methods
Matching procedure
An extract of the NSHPC dataset consisting of women reported to the obstetric reporting
scheme who were known to have been pregnant during 2000-2010 was provided to the
HPA (PHE since April 2013). The dataset included various demographic and clinical
identifiers on which to match the dataset with SOPHID, including postcode minus the last
letter (full postcode is not collected by the NSHPC). Women who attend care during their
pregnancy should be independently reported to both the NSHPC and SOPHID.
Data linkage procedures were carried out by the HIV and STI Department of the HPA47.
Matching was conducted on a range of identifiers collected by both the NSHPC and
SOPHID. Initial matches were identified using date of birth (and female sex), and a
hierarchical matching procedure was then applied utilising full/part postcode, country of
birth and clinical information as detailed in the matching algorithm (provided in Appendix
VI). Where potential duplicates were identified, for example, one NSHPC record matching
to more than one SOPHID record, these were excluded if it was not possible to manually
47 Matching was conducted by Cuong Chau.
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assign a best match. Women who were reported to the NSHPC as having gone abroad
during pregnancy were excluded based on the assumption that the majority of these
women do not subsequently return to the UK48. SOPHID does not cover Ireland, and data
from Scotland (pregnancies reported to the NSHPC and HIV care attendances in Scotland
reported to SOPHID) were excluded because prior to 2008 Scottish reports to SOPHID for
the same person were not reliably linked over time. The analyses were thus based on
pregnancies reported in England, Wales and Northern Ireland.
The analyses presented here were restricted to women with one or more pregnancies
during 2000-2009 whose first pregnancy reported to the NSHPC occurred from 2000
onwards. The 2009 cut-off was applied in order that there was a minimum of one calendar
year of follow-up (opportunity to be reported to SOPHID) for each pregnancy reported to
the NSHPC.
Definitions
Women present in the NSHPC dataset were coded as being ‘matched’ with SOPHID if they
appeared in the SOPHID dataset at any point during 2000-2009. Since women attending
care during pregnancy should be reported to both the NSHPC and SOPHID, it should be
possible to match them (dependent on the availability and accurate recording of variables
used to match on), even if they never attended care outside of pregnancy. However, some
women in the NSHPC may not be matched to SOPHID because they never attended HIV
care, for example, a woman who received no HIV-related antenatal care during pregnancy
and presented to hospital in labour. The coding of these women as ‘not matched’ and
subsequently estimating the proportion that were lost to follow-up only among those that
were matched may lead to an under-estimation of loss to follow-up. Therefore, a sensitivity
analysis was also carried out in which women who were not matched were, instead of
being excluded from the analyses, coded as being lost to follow-up (a worst-case scenario).
However, there are also other reasons for non-matches such as a lack of information or
incorrect information on the identifiers used for matching. For example, if women move and
change their postcode this may result in a non-match.
Attendance for HIV care during the calendar year following delivery was coded as a binary
(‘yes’ or ‘no’) variable. Women in the NSHPC who were successfully matched with SOPHID
were coded as attending care during the calendar year following delivery if they had an
attendance for HIV care reported to SOPHID (during the relevant calendar year). For
example, a woman delivering at any point during 2006 would be coded as attending HIV
48 In Chapter 4 it was noted that among women with a first pregnancy during 2000-2009 who were
reported to have gone abroad during that pregnancy, 5% had a subsequent pregnancy reported to the
NSHPC.
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care during the subsequent calendar year if she was had at least one SOPHID HIV care
attendance reported at any time during 2007.
5.3.2 Study population
The NSHPC dataset for matching consisted of 7253 women with a total of 9338
pregnancies ending during 2000-2009 (based on date of birth or expected date of delivery
for outcomes other than live or stillbirths). At their first reported pregnancy the median age
of women in the dataset was 30.3 years (IQR: 26.6-34.3), 78.9% originated from sub-
Saharan Africa, and 42.2% were diagnosed with HIV prior to pregnancy.
5.3.3 Completeness of matching of the NSHPC and SOPHID
Of the 7253 women in the NSHPC dataset, 6218 (85.7%) were matched with a woman in
SOPHID. Looking at this at the pregnancy, rather than the woman level, of the 9338
pregnancies in the NSHPC dataset, 8224 (88.1%) were matched with a woman in SOPHID.
5.3.4 Characteristics of matched and unmatched women
The demographic characteristics of the 7253 women in the NSHPC dataset according to
whether they had been matched to a SOPHID record are shown in Table 5.11. A
significantly larger proportion of matched than unmatched women had more than one
pregnancy reported to the NSHPC (26.3% vs. 6.9%, p<0.001). This is likely because each
pregnancy a woman has reported to the NSHPC provides an additional opportunity for the
demographic information which was utilised in the matching process to have been
collected. Since attending for antenatal HIV care should also be recorded as an attendance
for HIV care in SOPHID it provides an additional opportunity for her information to be
collected by SOPHID too. There was also an association between matching and time
period (p=0.026); matched women were less likely to have delivered their first pregnancy
early in the study period (17.1% of matched women had their first pregnancy during 2000-
2002 vs. 20.3% of unmatched women) and also later in the study period (10.8% vs. 12.1%
respectively during 2009-2010). A smaller proportion of matched than unmatched women
had a history of injecting drug use (1.3% vs. 3.1%, p<0.001). There were differences
according to reporting region of women’s first pregnancy (p<0.001) with a larger proportion
of unmatched women being reported in London (49.5% vs. 42.0%), and maternal age
(p=0.041) with a smaller proportion of matched than unmatched women being aged ≥35 
years (21.0% vs. 24.1%). There was little difference according to world region of origin
(p=0.416).
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Information on the majority of the demographic variables provided in Table 5.11 was
missing for ≤2% of women. Therefore, missingness of general demographic information 
(not necessarily variables specifically matched on) is unlikely to be strongly associated with
the probability of matching.
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Table 5.11 Demographic characteristics of women reported to the NSHPC according to
whether they were matched to SOPHID
Characteristic Matched Unmatched p-valuen % n %
Number of pregnancies reported* (n=7253)
1 4583 73.7 964 93.1 <0.001
>1 1635 26.3 71 6.9
Time period of delivery** (n=7253)
2000-2002 1062 17.1 210 20.3 0.026
2003-2005 2128 34.2 338 32.7
2006-2008 2357 37.9 362 35.0
2009-2010 671 10.8 125 12.1
Age at delivery, yrs (n=7248)
<25 1060 17.1 182 17.6 0.041
25-34 3854 62.0 601 58.2
≥35 1302 21.0 249 24.1
World region of origin (n=7154)
UK/Ireland 735 11.9 105 10.5 0.416
Sub-Saharan Africa 4846 78.7 800 80.3
Elsewhere 577 9.4 91 9.1
HIV risk factor (n=6890)
Other*** 5845 98.7 941 96.9 <0.001
Injecting drug use 74 1.3 30 3.1
Reporting region (n=6407)
London 2773 49.5 340 42.0 <0.001
Elsewhere in England 2733 48.8 440 54.4
Wales and N Ireland 92 1.6 29 3.6
*Includes only pregnancies reported to the NSHPC (i.e. to diagnosed HIV-positive women)
**Expected year of delivery for outcomes other than a live or stillbirth
***Other comprises largely those originating from a high HIV prevalence area and/or with heterosexual
exposure to HIV
190
5.3.5 Attendance for HIV care after pregnancy
Overall, among the 8224 NSHPC pregnancies that had been matched to SOPHID, 12.2%
(1005/8216) of the women did not access HIV care during the calendar year after delivery,
after excluding eight women who, based on the matched data, were identified as having
died during the same year, or the calendar year after, their pregnancy ended49. Five of the
eight women had HIV, AIDS or an AIDS-defining illness (e.g. Kaposi's sarcoma) listed as a
cause of death (up to four causes of death are documented), three of whom died within 42
days of the date of delivery50. Other causes of death included septicaemia (in two women,
both of whom also had AIDS reported as a cause of death), bronchopneumonia and liver
failure.
Some women will become pregnant again during the calendar year after delivery and will
be coded in the matched dataset as attending care and being pregnant. However, we
cannot be sure whether they are simply attending HIV-related antenatal care or whether
they would have attended HIV care regardless of their subsequent pregnancy. Meanwhile,
if all unmatched pregnancies (n=1114) were, instead of being excluded from the analyses,
coded as being lost to follow-up (i.e. the assumption being that they could not be matched
because they had never attended HIV care either before, during or after pregnancy and
were therefore not present in the SOPHID dataset), the proportion not attending care was
22.7% (2119/9338) – the worst case scenario. All subsequent analyses are based on the
initial estimate of the proportion of pregnancies for which the woman did not attend HIV
care during the year after delivery (12.2%).
The proportion of women not attending care during the year after delivery decreased over
the study period; from 15.5% among women whose pregnancy ended in 2001 to 10.3%
among those whose pregnancy ended in 2009 (test for trend 2000-2009: p<0.001) (Figure
5.17). The low proportion among women whose pregnancy ended in 2000 may be a
spurious result as there were relatively few pregnancies in this year compared with the later
years and the number of women not attending care the following year was also small
(n=20).
49 Although a further seven women died during the calendar year following delivery, all of these women did
attend care that year so it was not appropriate to exclude them.
50 The WHO defines a maternal death as “the death of a woman while pregnant or within 42 days of
termination of pregnancy, irrespective of the duration and site of the pregnancy, from any cause related to
or aggravated by the pregnancy or its management but not from accidental or incidental causes” (see:
http://www.who.int/healthinfo/statistics/indmaternalmortality/en/, Accessed September 2014).
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Figure 5.17 Proportion of women who did not attend HIV care during the calendar year
after pregnancy, by year, 2000-2009
The proportion of women not attending care during the year after their pregnancy ended
was 12.5% (777/6210) after first reported pregnancies, and 11.4% (228/2006) after
subsequent pregnancies (i.e. including all second, third etc pregnancies) (p=0.173). When
only women’s last reported pregnancies (among those with more than one pregnancy
reported) were examined the proportion was 12.2% (199/1635) in comparison with the
aforementioned 12.5% among first pregnancies (p=0.710).
When the potential impact of parity per se (regardless of whether the woman had
diagnosed HIV at the time of any previous births) was examined, 12.5% of nulliparous
women did not attend care the year following delivery, and the proportion was 12.0%
among those with one previous birth, 11.7% among those with two and 11.8% among
those with three or more previous births (test for trend: p=0.451).
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5.4 Discussion
Engagement with antenatal care
Entering the antenatal care pathway early in pregnancy is crucial to enable effective
interventions for PMTCT, as well as helping to ensure a healthy pregnancy. Among women
experiencing a repeat pregnancy, the median gestational age at antenatal booking was 13
weeks. In the present analyses half of women booked at ≥13 weeks. It thus appears that 
HIV-positive women may be at risk of booking later than the general population in which
37% booked at ≥13 weeks (data for 2009-2010) (Health and Social Care Information 
Centre, 2010), although a clear trend towards earlier booking over time was apparent
among women in the NSHPC. The potential later booking among women living with HIV
likely reflects the socio-demographic characteristics of this population. A large proportion of
HIV-positive women live in London (43% of those presenting with a sequential pregnancy in
this analysis), and in an earlier London-based study HIV-positive women booked later than
a general population (Parisaei et al, 2007). In the present analyses, although women in
London tended to book earlier based on the multivariable analyses, the descriptive
analyses revealed a more complex pattern with both early and very late bookers being
more common in London.
Other important factors may include socio-economic status and maternal ethnicity or region
of origin. Being born outside the UK and/or being of non-white ethnicity has been quite
consistently reported as a risk factor for later booking (Cresswell et al, 2013; Kupek et al,
2002; Redshaw et al, 2010; Rowe et al, 2008). Although being of lower socio-economic
status has not been clearly linked with later booking in the few studies that have examined
this among the general UK population (Redshaw et al, 2010; Rowe et al, 2008), its potential
role should not be overlooked. It was not possible to assess the influence of socio-
economic status here because this information is not collected by the NSHPC, although
being born abroad, which is collected by the NSHPC, does form a component of socio-
economic status. The majority of HIV-positive women in the NSHPC originate from sub-
Saharan Africa and may, even at their repeat pregnancies, book later for reasons such as
language barriers or concerns about their immigration status. Migrants, particularly groups
such as asylum seekers and undocumented migrants, may have transient lifestyles which
could lead to disengagement from care (Dartnall et al, 2005), and some may return to their
home country in between pregnancies. Furthermore, disparities in antenatal care usage
may be influenced by variations in health literacy51. Poorer health literacy has been
51 There is no universally accepted definition of health literacy. It is defined by the US Centres for Disease
Control as “The capacity to obtain, process, and understand basic health information and services to make
appropriate health decisions”. See: http://www.cdc.gov/healthliteracy/ (Accessed January 2014).
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associated with lower levels of health care service utilisation, and a range of adverse health
outcomes (Berkman et al, 2011). Although in the current analysis women from sub-
Saharan Africa were not significantly more likely to book late compared with women born in
the UK or Ireland, the direction of the association was compatible with this (aOR: 1.36, 95%
CI: 0.90-2.04). A separate analysis of the NSHPC data focusing on the association
between ethnicity and late presentation to antenatal care revealed that African ethnicity
was a significant predictor of late booking among women diagnosed with HIV prior to that
pregnancy (aOR: 1.80, 95% CI: 1.14-2.82) compared with white women (Tariq et al, 2012).
The non-significant association in the present analysis may be a combination of the
different grouping of the outcome variable (a binary <13 weeks vs. ≥13 weeks was used in 
the analysis by Tariq et al rather than the four categories used here), together with the
present analysis being restricted to women who had already experienced a pregnancy
since their diagnosis. Though the analysis by Tariq et al was restricted to women with a
prior HIV diagnosis, only a portion (~40%) of these will have had a previous pregnancy,
with some diagnosed in other settings (Byrne et al, 2013).
A higher number of previous births was correlated with later booking. Similar findings have
been observed in the general UK population (Baker et al, 2012; Cresswell et al, 2013;
Redshaw et al, 2010), and also among HIV-positive women in the US (Abatemarco et al,
2008), as discussed in Chapter 2, Section 2.3. The reason for this is not entirely clear but
may reflect a combination of factors such as women feeling less anxious about subsequent
pregnancies, combined with being busy looking after their other children. It was, however,
reassuring that over three quarters of those who booked at ≥18 weeks for their first 
pregnancy booked before 18 weeks for their subsequent pregnancy (and 40% had booked
before 13 weeks). That women not on ART at conception booked significantly later than
those conceiving on treatment is of concern since timely booking and prompt referral to HIV
services for prescription of ART is needed for this group. Higher levels of loss to follow-up
from HIV care have been reported among people not receiving treatment (Gerver et al,
2010); disengagement from services may thus be important among this group. This
assertion is further supported by the finding in the present analyses that 16% of very late
bookers (≥24 weeks) had a CD4 count of <200 cells/µl. It is also noteworthy that 7% of 
women didn’t book until ≥24 weeks, with those from sub-Saharan Africa at disproportionate 
risk. Booking this late may leave insufficient time for antenatal ART to be initiated early
enough to reduce viral load to undetectable levels prior to delivery, as well as meaning that
women may miss out on other aspects of routine antenatal care.
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Timing of antenatal ART initiation
The timing of antenatal ART initiation among women’s subsequent pregnancies since their
HIV diagnosis was investigated in two parts of this chapter. Delays from antenatal booking
to initiation of ART during 2008-2010 were explored in the first part. Meanwhile, predictors
of timing of antenatal ART initiation (regardless of antenatal care booking) during 2000-
2010 were investigated in the second part52. When considering the timing of antenatal ART
initiation it should be remembered that women not conceiving on ART may include those
who need ART for their own health, and those with higher CD4 counts who require ART for
PMTCT only.
In the main analysis (2000-2010) the vast majority of women received ART prior to delivery
with only 3% receiving none. This is within the range reported across Europe (Bailey et al,
2011; Keiser et al, 2008; von Linstow et al, 2010). Among those not conceiving on
treatment, antenatal ART was commenced at a median of 23.7 gestational weeks; this
declined over time reflecting evolving practice towards earlier initiation of ART in pregnancy
(de Ruiter et al, 2008; Hawkins et al, 2005; Taylor et al, 2012). However, almost a quarter
of women did not start ART until the third trimester. Delays in both laboratory assessment
and ART initiation were further explored among sequential pregnancies in women who had
booked for antenatal care, and were thus known to have at least some engagement with
services. The median time lag from antenatal booking to first laboratory test during that
pregnancy was zero weeks (i.e. blood sample was taken on the same day as booking), with
half of women having their earliest antenatal laboratory test prior to the date of booking
(presumably in many cases these were routine monitoring tests since all women were
previously diagnosed). This prompt laboratory assessment in the bulk of women is
reassuring. However, delays were noted, with 30% of women having a delay of four or
more weeks suggesting that this is an area of practice that needs improving. It is possible
that some of the delays in laboratory testing may be explained by tests being conducted in
other parts of the healthcare system, not captured by the NSHPC. For example, if a woman
has a routine laboratory assessment in the few weeks before she becomes pregnant, this
would not necessarily be reported to the NSHPC (which only requests the results of tests
conducted during pregnancy) but may influence the decision about when to conduct
baseline laboratory testing in pregnancy (with testing potentially being deemed as less
urgent in women with a recently documented undetectable viral load, for example).
Delays from antenatal booking to ART initiation were apparent (8.7 weeks overall). Such
delays may have consequences on pregnancy outcomes. For example, nearly a third of
52 Thus enabling analyses to be conducted on all (second) pregnancies to women not on ART at
conception rather than restricted to the sub-group for whom timing of antenatal care booking was
available.
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women who experienced a delay of 10-20 weeks between booking and starting ART had
detectable viral load at delivery, and there was one vertical transmission among this group.
Among women with CD4 counts <350 cells/µl who had not initiated ART prior to booking,
there was an average lag of seven weeks from booking (the point at which, on average,
women’s first antenatal CD4 count measurements were taken) to ART initiation. Women
with an immunological indication for treatment are recommended to initiate ART as soon as
possible, though this may be deferred until the start of the second trimester (de Ruiter et al,
2008; Taylor et al, 2012).
It is not clear to what extent delays in ART initiation are health system or provider-related,
structural (e.g. the socio-economic environment of HIV-positive women), or related to
women’s individual circumstances, beliefs and choices. The analysis of antenatal ART
initiation among all second pregnancies indicated that timing of treatment initiation was
largely influenced by women’s viral loads and CD4 counts as one would expect. Several
non-clinical predictors also emerged in these analyses. There was evidence that women
from sub-Saharan Africa were more likely to start ART later in pregnancy. Variations in
uptake of antenatal ART among women reported to the NSHPC according to African region
of origin have been documented, with those from Western Africa being at greatest risk of
non-receipt of antenatal ART (Tariq, 2013). It is difficult to draw conclusions about the
potentially increased risk of delays in ART initiation among women with a history of
injecting drug use due to small numbers which may have limited power to detect an
association, but this observation does tie in with data from Europe and the US (Abatemarco
et al, 2008; Bailey et al, 2011; Orloff et al, 2001). Meanwhile, in the analysis restricted to
2008-2010 there was evidence of later ART initiation in London though this could reflect
more complex case loads in London rather than differences in practice.
Women’s motivations for taking antenatal ART require some consideration here. The main
aim of ART during pregnancy is to reduce the risk of vertical transmission, as well as
having health benefits for women with low CD4 counts. A qualitative study of African HIV-
positive women’s engagement with HIV care in the UK revealed that women are strongly
motivated to take ART for the health of their babies (Tariq, 2013). Meanwhile, in interviews
conducted with pregnant women in Australia, even those who had reservations about
taking ART for their own health were prepared to adhere to therapy during pregnancy for
the sake of their babies (McDonald et al, 2011). However, some women do have concerns
and reservations about taking ART during pregnancy (McDonald et al, 2011; Tariq, 2013).
An audit of women in the NSHPC who received either no antenatal ART or a short duration
reported that, among women diagnosed prior to conception, declining treatment was the
most common reason (11/15, 73%) (Modestini et al, 2013). This has also been shown to be
an important reason for non-receipt of antenatal ART elsewhere. In the French Perinatal
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Cohort, although the overall proportion of women who did not receive antenatal ART was
low (4%), a third of these had declined ART (Mayaux et al, 2003), and in Denmark two of
the seven women who did not receive ART had declined it (von Linstow et al, 2010). These
data are not only of relevance to the 3% of women who received no antenatal ART in their
second pregnancy, but may also be pertinent to some of the delays noted. For example,
some women may delay ART initiation for fear of causing harm to their unborn baby.
Women’s experience of ART in previous pregnancies may also have an influence – those
who have had negative experiences such as drug side-effects or adverse pregnancy
outcomes may have concerns that these will re-occur. Finally, it should be remembered
that some HIV-positive women have very difficult personal and social circumstances with
issues around housing, immigration status and intimate partner violence (Anderson, 2008;
Dhairyawan et al, 2013; Tariq, 2013) to name but a few, potentially leading to delays in
receiving the pregnancy-related HIV care that they require, even for those experiencing
sequential pregnancies.
Maternal health among those not on ART at conception
The analyses revealed that two-fifths of women not on ART at conception had an
immunological indication for treatment. In itself, this finding suggests that there may have
been potential health benefits for these women of remaining on (lifelong) ART after their
first pregnancy ended. With regards to the management of these women, guidelines in
place during the study period stated that diagnosed adults with CD4 counts of <350 cells/µl
were eligible for treatment (Gazzard, 2005; Gazzard et al, 2008), with the pre-2008
guidelines allowing for individualised decisions for patients with CD4 counts of 200-350
cells/µl. However, 10% of women in this analysis had advanced disease (CD4 count of
<200 cells/µl) and should therefore have been on treatment irrespective of time period. It is
also of note that the proportion of women with an indication for treatment was little altered
when data were restricted to 2008-2010. Delays in HIV treatment outside the context of
pregnancy have been reported in the UK. For example, data from UK CHIC showed that
during 1997-2003, a third of adults diagnosed with CD4 counts of >500 cells//µl did not start
ART until their CD4 count had fallen to <200 cells/µl (Stohr et al, 2007), contrary to national
guidelines. A more recent analysis of the same dataset revealed that although the majority
(>90%) of people with low CD4 counts do receive treatment (a finding also supported by
national level data (Delpech et al, 2013)), there was an approximate three month lag from
having a low (<350 cells/µl) CD4 count measurement to ART initiation (Kober et al, 2012).
Late diagnosis has been identified as a key reason for people starting treatment at low CD4
counts more generally (47% of people in the UK and Ireland were diagnosed late in 2012
(Aghaizu et al, 2013), though of course this would not apply to a population of previously
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diagnosed women presenting with repeat pregnancies. In US and UK settings socio-
demographic factors that have been associated with non-receipt of ART among people
requiring treatment include injecting drug use (Cohen et al, 2004; Fleishman et al, 2012;
Gebo et al, 2005; Kober et al, 2012) and younger age (Fleishman et al, 2012; Gebo et al,
2005; Kober et al, 2012). Some studies have also found female gender to be a risk factor
(Fleishman et al, 2012; Gebo et al, 2005), though this was not the case in two UK studies
(Elford et al, 2008b; Kober et al, 2012). In the US individuals of black ethnicity were at
increased risk of not receiving ART (Fleishman et al, 2012; Gebo et al, 2005), but in the UK
this does not appear to apply. One study reported that only those for whom ethnicity was
unknown were at increased risk (Kober et al, 2012), while Elford et al reported no
differences by ethnicity (Elford et al, 2008b).
In the current analyses there were no clear demographic predictors of having an indication
for treatment among women not on ART at conception of their subsequent pregnancy. It is
not entirely clear whether this is due to a lack of power, simply reflects equality in access to
care, or the greater homogeneity of the population of HIV-positive pregnant women
compared with the broader population of people living with HIV. However, social
marginalisation may also be relevant here. Although information on women’s social
situation and psychological status is not collected by the NSHPC, an audit of perinatal
transmissions in England revealed psychosocial issues to be important (National Study of
HIV in Pregnancy and Childhood et al, 2007). Indicators of marginalisation such as
homelessness, a lack of social support and mental health issues have been linked with
delayed access to HIV care (Aidala et al, 2004; Maisels et al, 2001; Tegger et al, 2008).
Meanwhile, that women with a longer conception interval between their pregnancies were
more likely to present with a low CD4 count at their second pregnancy will partly reflect the
natural course of HIV disease (characterised by declining CD4 counts over time) but also
suggests a potential lack of consistent engagement with care in between pregnancies.
Although all women in the present study have had a prior pregnancy and most likely
therefore had at least some level of engagement with HIV care, it cannot be assumed that
all will engage well with HIV services after their pregnancy ends. Good engagement with
HIV care is no doubt fundamental to the timely initiation of ART.
Attendance for HIV care after pregnancy and HIV treatment initiation
That a significant proportion of women not on ART at conception of their second pregnancy
had an indication for treatment raises the question as to women’s engagement with routine
HIV care after their pregnancy ends. In order to help address this, the NSHPC was, for the
first time, matched with the SOPHID dataset of people attending HIV care in England,
Wales and Northern Ireland. The proportion of women in the NSHPC dataset for 2000-2009
198
who were successfully matched was high (86%), demonstrating the feasibility of this
methodology, particularly among women with more than one pregnancy reported. Most
women, 88%, attended HIV care during the calendar year following pregnancy (12% were
classed as lost to follow-up), similar to the findings of a French study in which 11% of
women were lost to follow-up post-partum (Lemly et al, 2007). The proportion is also
consistent with that reported in a SOPHID analysis of diagnosed adults attending care
during 1998-2007 in which 10% did not access care during the following year (Rice et al,
2011).
That only 12% of women did not attend HIV care after their pregnancy ended suggests that
a lack of engagement with HIV services following pregnancy may not be the main, or
certainly not the only, reason for women presenting with low CD4 counts (and not being on
treatment) in their subsequent pregnancy. The reasons for CD4 counts falling to low levels
before treatment begins (or never starting treatment) among those already diagnosed may
include missed appointments or inconsistent care (Dombrowski et al, 2013; Wolbers et al,
2008) and patients declining treatment (Horne et al, 2007; Maisels et al, 2001). In the UK
study by Horne et al, 28% of patients initially declined the offer to start treatment (Horne et
al, 2007). People’s motives for being unwilling to initiate ART are likely to be wide-ranging
and complex, encompassing social, behavioural and psychological factors, interlaced with
their beliefs about, and understanding of, both HIV and ART. In a South African study
‘feeling healthy’ was cited by over a third of those who did not wish to initiate ART (Katz et
al, 2011). Perceived necessity of treatment has also been associated with uptake of ART in
the UK (Horne et al, 2007) and other Western settings (Gold et al, 2001; Maisels et al,
2001). Fear of side effects emerges as another salient explanation in the published
literature (Bassetti et al, 1999; Gold et al, 2000; Gold et al, 2001; Horne et al, 2007; Katz et
al, 2011; Kremer et al, 2004; Maisels et al, 2001; Misener et al, 1998). Other factors include
concerns around disclosure of HIV status (Katz et al, 2011), and concepts around
embarking on, and adhering to, complex lifelong treatment regimens and the perceived
impact of this on people’s lives (Bassetti et al, 1999; Gold et al, 2001; Horne et al, 2007;
Maisels et al, 2001). In some cases clinicians may make a decision to delay treatment, for
example, where they have serious concerns regarding a patient’s likely level of adherence
(Bassetti et al, 1999; Bogart et al, 2000). Of note to the UK setting specifically, during the
period studied undocumented migrants were charged for their ART which may well have
put some off trying to access treatment. Since 2012, in England treatment has been
provided free regardless of migration status (Department of Health, 2012).
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Reasons for loss to follow-up from HIV care
Reasons for non-attendance for HIV care after pregnancy are likely to be multifactorial.
Emigration is an important consideration. A recent UK audit reported that one quarter of
people living with HIV who appeared not to be in care were no longer in resident in the UK
(Clay, 2013), while a case note review in a London clinic revealed that for over half of those
lost to follow-up there was some indication that they may have left the UK, either voluntarily
or involuntarily (Gerver et al, 2010). However, this information is not routinely collected by
SOPHID. Deaths are likely to have been under-estimated since this information is
incorporated into SOPHID via matching with the HIV and AIDS New Diagnoses Database;
as with any such procedure there will be some under-matching. Eight women were
reported to have died during the calendar year that their pregnancy ended or the year after.
In the context of the total number of pregnancies this number in itself is relatively small, and
Gerver et al reported that in a London clinic only 2% of those lost to follow-up were known
to have died (Gerver et al, 2010). Therefore, death is unlikely to be a significant reason for
non-matches. However, further investigation into the specific circumstances of these
deaths may help inform strategies or policies to help prevent future deaths among HIV-
positive women. In sub-Saharan Africa, HIV is a major contributor to maternal mortality with
HIV-positive pregnant and post-natal women being an estimated eight times more likely to
die compared with HIV-negative women (Calvert et al, 2013a; Zaba et al, 2013). Exploring
the contribution of HIV to maternal mortality in the UK is an important area for investigation.
The most recent report of the Confidential Enquiries into Maternal Deaths in the United
Kingdom documented 11 deaths for which HIV was the cause of death (out of 817 deaths
overall) during 2000-2008 (Cantwell et al, 2011).
Disengagement from care may be intentional or unintentional (Ware et al, 2013), and in
relation to HIV care, may involve issues such as stigma and fear of disclosure as well as
practical difficulties e.g. transportation (Boehme et al, 2014; Coleman et al, 2007;
Horstmann et al, 2010). In childbearing women, psychological factors such as post-partum
depression may be relevant (Nachega et al, 2012). A small UK study reported depression
in 21% (n=62) of HIV-positive post-partum women (Loftus et al, 2014). Also of relevance to
this population group, childcare responsibilities53 may be a barrier to regular HIV care
attendance (Boehme et al, 2014), and have also been linked to poorer adherence to ART in
post-partum women (Merenstein et al, 2009; Merenstein et al, 2008; Turner et al, 2000).
53 The majority of pregnancies reported to the NSHPC result in a live birth (>90% during 2000-2009, based
on data presented in Chapter 4, Section 4.2).
200
Disease progression following pregnancy
It was not feasible to assess detailed trajectories of women’s HIV disease progression over
time using the NSHPC dataset, since only measurements taken during pregnancy are
requested. It is, however, salient that a quarter of women with a CD4 count of ≥350 cells/µl 
at their first pregnancy had fallen below the treatment threshold by their second pregnancy,
particularly as second pregnancies occurred relatively soon, on average 2.3 years after the
first. Significant levels of disease progression after the discontinuation of antenatal ART in
post-partum women have also been reported elsewhere (Coria et al, 2012; Ekouevi et al,
2012; Watts et al, 2013), as detailed in Chapter 2, Section 2.4. Not surprisingly, initial CD4
count is important – in the present analysis 40% of women with a CD4 count of 350-499
cells/µl at their first pregnancy had declined to <350 cells/µl by their second, compared with
13% of those with initial CD4 counts of ≥500 cells/µl. More data are needed on differences 
in disease progression in women who continue and discontinue ART post-partum (among
those not yet requiring treatment for their own health). The ongoing Promoting Maternal
and Infant Survival Everywhere (PROMISE) Study, a trial in which women are randomised
to either continue or stop ART post-partum with follow-up to compare morbidity and
mortality among the two groups (International Maternal Pediatric Adolescent AIDS Clinical
Trials Group, 2009) is due for completion in 2016 and should provide an important
contribution to the evidence-base.
With regards to disease progression among untreated HIV-positive people more generally,
the largest study to date was based on data from Concerted Action on Seroconversion to
AIDS and Death in Europe (CASCADE), a collaboration of 25 European HIV cohorts
involving over 18,000 individuals with reliable information on the date of seroconversion.
The median time from HIV seroconversion to CD4 count falling to <350 cell/µl was 4.18
years (95% CI: 4.09–4.28) with just over one quarter of people requiring treatment (at the
CD4 count <350 cell/µl threshold) within one year of seroconverting (Lodi et al, 2011). The
findings of all these aforementioned studies on HIV disease progression are clearly
pertinent to the question as to whether, with regards to maternal health, it may be beneficial
for all pregnant women to initiate lifelong ART.
Virological outcomes according to timing of ART initiation (before or during pregnancy)
That longer duration of antenatal ART decreases the risk of detectable viral load at
delivery, and hence MTCT, has been well documented in a wide range of settings
(Chibwesha et al, 2011; Denoeud-Ndam et al, 2013; Hoffman et al, 2010; Patel et al, 2007;
Rachas et al, 2013; Read et al, 2012; Warszawski et al, 2008), including a recent analysis
of the NSHPC data (Townsend et al, 2014). However, the analyses presented in the
second part of this chapter revealed that women starting ART antenatally had over four
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times the odds of a detectable viral load at delivery in their second pregnancy compared
with those conceiving on treatment, adjusting for confounders including CD4 count.
Although with appropriate interventions the risk of MTCT is now very low (Townsend et al,
2014), some transmissions do still occur, and the rate was three times higher among those
not on ART at conception in the present analyses. These findings suggest that in terms of
MTCT risk there appears to be a clear benefit of being on ART prior to conception, which
may avert in utero transmissions as well as those occurring around the time of delivery. A
lower risk of MTCT in women conceiving on treatment compared with those starting cART
during pregnancy has been reported from South Africa (0.7% vs. 5.7%, p=0.01) (Hoffman
et al, 2010).
Only 6% of women conceiving on ART had a detectable viral load at delivery indicating that
the vast majority are being well managed prior to and during pregnancy, and suggesting
high levels of adherence among this population. However, poor adherence, viral load ‘blips’
(transient increases in viral load levels) (Havlir et al, 2001), or treatment failure may be
contributing to the detectable levels in the remaining small proportion of women. Recent
data from Western Europe also documented very low rates (3%) of virological failure
(defined as >200 copies/ml after ≥24 weeks of ART) among women conceiving on 
treatment (Bailey et al, 2013).
Limitations
Information on timing of antenatal care booking was only available for 2008-2010,
precluding detailed analyses of patterns in the timing of booking for women’s previous and
subsequent pregnancies as only 85 had date of booking reported for more than one
pregnancy, though some informative descriptive analyses were possible. Furthermore,
booking date was missing for around a quarter of pregnancies, though this appeared to be
largely related to time period (as well as being more common in London centres), with
reporting improving significantly between 2008 and 2010. This likely reflects the fact that
this ‘new’ piece of information has only been collected by the NSHPC since 2008.
However, a proportion of those with missing booking date may be accounted for by women
who did not receive antenatal care (e.g. presented in labour). Such women may represent
a particularly high risk group requiring targeted interventions to help them engage with
services. As noted, assessments of variations in access to and uptake of care are limited
by the absence of information on some potentially important socio-demographic
characteristics of women. This broader limitation of the NSHPC is discussed further in
Chapter 8, including possible future work to help elucidate reasons for delays.
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Earliest antenatal CD4 count was missing for around 30% of pregnancies (Section 5.2).
Though this proportion is quite high, there was little difference in the characteristics of
pregnancies with and without missing CD4 counts suggesting that this is unlikely to have
substantially biased the findings. As mentioned, limited data are available on disease
trajectories as the NSHPC does not routinely collect clinical measurements on women
outside of their pregnancies and this precluded detailed follow-up of women’s health status
after pregnancy. Examination of changes in women’s CD4 counts between their first and
second pregnancies did, however, provide the opportunity to make some assessment of
the change in women’s immunological status between their first and second pregnancies
since their diagnosis. It should be borne in mind that immune function is lowered during
pregnancy (Kuhnert et al, 1998), thus women’s immunological status in pregnancy may not
be an accurate reflection of their ‘non-pregnant’ state of health.
Although a high proportion of women reported to the NSHPC were successfully matched to
a SOPHID record, there were some notable differences between women who were
matched and those who were not which could have biased the findings. Unmatched women
could represent a group particularly poorly engaged with services. These women may be
more likely to be lost to follow-up after pregnancy than matched women, thus resulting in
an over-estimation of women’s attendance for HIV care after pregnancy. The lack of data
on emigration which, as discussed, may be an important exploratory factor for non-
attendance after pregnancy, is an important limitation. Assuming, as seems likely, that a
proportion of those who do not attend care (whether or not matched) have left the country,
then the true rate of loss to follow-up among women in the UK and Ireland may be lower
than the estimated 12%. Furthermore, analyses of attendance for care after pregnancy only
examined the calendar year after delivery. It is recognised that a proportion of women not
attending HIV services during this single year will attend at some point in the future.
However, since women are recommended to attend care several times per year (Asboe et
al, 2012), non-attendance during one complete calendar year represents a good indicator
of at least some extent of loss to follow-up whether permanent or temporary. Meanwhile, a
proportion of those who did attend during the calendar year after delivery may be lost to
follow-up at some point in the future. Indeed, women’s motivation to attend care may be
heightened during the post-partum period.
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5.5 Key findings
Timing of antenatal booking
 Information on antenatal booking date was reported for 73.9% (n=2827) of all
pregnancies during 2008-2010. The proportion was similar for repeat (74.8%,
n=953) and first pregnancies (73.5%, n=1874)
 Median gestational age at antenatal booking among women presenting with a
repeat pregnancy was 13.0 weeks (IQR: 10.6-16.4), similar to that among first
reported pregnancies. At women’s repeat pregnancies, 49.3% booked at <13
weeks, 32.0% at 13-17 weeks, 11.9% at 18-23 weeks, and the remaining 6.8% at
≥24 weeks  
 Higher parity (≥3), earlier year of delivery, being reported in England (outside 
London) or Ireland, and not being on ART at conception were independently
associated with later booking for antenatal care
 Median time lag from booking to antenatal ART initiation among those not on ART
prior to pregnancy was 8.7 weeks (IQR: 4.6-12.6 weeks), and was significantly
shorter in women requiring ART for their own health (<350 cells/µl) than those
requiring it for PMTCT only (CD4 ≥350 cells/µl); 7.1 weeks (IQR: 3.3-10.4) vs. 10.0
weeks (IQR: 5.7-13.6) respectively (p<0.001)
Immunological status, timing of ART, and virological outcomes among women not on ART
at conception
 There were 1177 second pregnancies to women not on treatment at conception
during 2000-2010 (accounting for 53% of second pregnancies)
 Two-fifths had an immunological indication for ART (CD4 <350 cells/µl), of whom
nearly half had a CD4 count of  ≥350 cells/µl at their first pregnancy 
 3% of women did not receive antenatal ART and the remainder commenced
treatment at a median of 23.7 weeks, with a quarter not starting until their third
trimester
 In a multivariable analysis women with a high viral load or low CD4 count started
ART significantly earlier. There was a strong trend of earlier ART initiation over
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calendar time, while women from sub-Saharan Africa started later than those from
the UK or Ireland
 Compared with women conceiving on ART, those who initiated it during pregnancy
had over four times the odds of having a detectable viral load at delivery
Attendance for HIV care after pregnancy
 88% of 9338 pregnancies in the NSHPC dataset for England, Wales and Northern
Ireland during 2000-2009 were matched with a SOPHID record
 Based on the matched data, 12.2% of women did not access HIV care during the
calendar year after delivery
 The proportion of women not attending care during the calendar year after delivery
was similar for first reported and subsequent pregnancies
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Chapter 6 Influence of short-course antenatal cART on
response to therapy in subsequent
pregnancies
Many pregnant women not yet requiring treatment for their own health will receive short-
course ART for PMTCT (Taylor et al, 2012). As discussed in Chapter 2, Section 2.5, inferior
virological responses to NNRTI-based treatment have been well documented among
women with prior exposure to sdNVP. However, the influence of previous short-course
cART for PMTCT on response to therapy in subsequent pregnancies has been little
investigated. Such information will help inform clinical decision-making around the use of
short-course cART in pregnancy given the high probability of future pregnancies (as shown
in Chapter 4). Therefore, the objective of this chapter is to investigate the probability of
detectable viral load at delivery and MTCT in women who experienced short-course cART
for PMTCT in a previous pregnancy (Objective 4).
6.1 Methods
Dataset
Pregnancies to women whose first reported pregnancy occurred during 2000-2010 were
included in these analyses. The dataset included both index (first reported) and subsequent
(second) pregnancies in this group of women. Analyses were performed on the following
two groups: i) ‘ART-naive’ - consisting of pregnancies in women with no known ART use
prior to pregnancy (based on the fact that they were not on ART at conception of their first
reported pregnancy) which provided the baseline group, and ii) ‘previous short-term cART
for PMTCT’ (hereafter referred to as the ‘cART-experienced’ group) - consisting of
pregnancies in women who had received at least seven days of cART during their previous
(index) pregnancy, regardless of that pregnancy outcome, but were not on ART at the time
of conception of their subsequent pregnancy. The two analysis groups were constructed
independently and although some women will contribute their first reported pregnancy to
the ART-naive group and their subsequent pregnancy to the cART-experienced group,
others will only contribute one pregnancy to the dataset e.g. those women who only had
one pregnancy reported to the NSHPC can only possibly contribute a pregnancy to the
ART-naive group. Further eligibility criteria for both the analysis groups were that
pregnancy outcome was a live birth to a woman who did not conceive on treatment but
received antenatal cART (Figure 6.1). Pregnancies resulting in an outcome other than a
live birth (e.g. stillbirth, miscarriage) were excluded as information on infant HIV status is
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only obtained for live born infants. Pregnancies among women with exposure to mono or
dual therapy in a previous pregnancy, and in those who had taken short-course cART in
more than one previous pregnancy, were excluded to ensure the dataset for analysis was
as ‘clean’ and homogeneous as possible.
Figure 6.1 Study population inclusion criteria – influence of short-course antenatal cART
on response to therapy in subsequent pregnancies
ART-naive group cART-experienced group
Index pregnancy Second reported pregnancy
Live birth Live birth
Woman was not on ART at conception but
received cART (any duration) during that
pregnancy
Woman was not on ART at conception but
received cART (any duration) during that
pregnancy
Woman was not on ART at conception of her
first reported pregnancy but had received at
least seven days of cART during that
previous pregnancy
Definitions
Detectable viral load at delivery was analysed. Viral load measurements taken prior to, or
within the first seven days after cART initiation, were excluded, except those within seven
days of delivery54, since the probability of achieving an undetectable viral load within this
short period of time is likely to be low (Patel et al, 2007). As a high proportion of women
had no viral load data reported, an imputed variable was also constructed as described in
Chapter 3, Section 3.4 (if viral load within 28 days before and seven days after delivery was
missing but the last reported viral load measurement in that pregnancy was undetectable
then delivery viral load was imputed as undetectable). Multivariable analyses were also
carried out with the original non-imputed variable as sensitivity analyses.
54 Although it is possible that some women with a detectable viral load within the seven days after delivery
actually had an undetectable viral load at delivery (which was not reported to the NSHPC) and
discontinued cART at delivery resulting in an increase in their viral load to detectable levels, this is likely to
apply to few women. Of the 53 women with detectable viral loads measured during the seven days after
delivery, most (n=42) were taken within the first three days. Furthermore, not all women discontinue cART
after delivery.
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Statistical analyses
The proportion of pregnancies with viral load <50 copies/ml at delivery was compared
between the cART-experienced group and the ART-naive group. Logistic regression
models were fitted in univariable and multivariable analyses to investigate the probability of
detectable maternal viral load at delivery and MTCT in the cART-experienced group
compared with the ART-naive group. Robust standard errors were used to account for the
contribution some women made to both analysis groups (i.e. a pregnancy in the ART-naive
group and a subsequent pregnancy in the cART-experienced group) (Kirkwood et al, 2003).
This may lead to clustering of outcomes at the woman level (see Chapter 3, Section 3.5).
Time period of delivery was included in the models a priori to take account of changes over
time in the management of HIV in pregnancy. Further logistic regression models in which
type of cART (PI-based or NNRTI-based) was specified were constructed using the same
variables as were included in the overall model to ensure comparability. These further
models were constructed to examine in more detail the range of potential patterns of
antenatal ART use that women with sequential pregnancies may have experienced. PI-
based and NNRTI-based regimens were the main focus of these analyses, being the most
common. As will be shown, other regimens e.g. triple NRTI-based cART are relatively rare,
therefore the numbers eligible for inclusion in multivariable analyses would be small and
the findings of less relevance to the current clinical situation.
6.2 Probability of detectable viral load at delivery
6.2.1 Study population
The study population consisted of 5977 pregnancies; 5372 in ART-naive women, and 605
in women who had received at least seven days of cART for PMTCT during their previous
pregnancy55. Among the cART-experienced group, the median interval from the end of their
previous pregnancy to the start of their current pregnancy was 1.7 years (IQR: 0.9-2.7).
The median maternal age at delivery was 29.5 years (IQR: 25.9-33.3), and the age
distribution was similar in the cART-experienced and ART-naive groups; the majority of
women in both groups being aged 25-34 years (66.3% and 63.3% respectively) (Table 6.1).
Among the ART-naive group, 27.7% (1487/5365) of pregnancies were in women diagnosed
before pregnancy. The median duration of antenatal cART was 14.1 weeks (IQR: 10.7-
17.6) overall. The cART-experienced group was more likely to have received >12 weeks of
antenatal cART (74.8% vs. 62.3%), and more likely to deliver vaginally (33.5% vs. 28.5%).
55 If women who were missing information on cART duration during their previous pregnancy but had
achieved an undetectable viral load at delivery of that previous pregnancy were re-coded as having
received at least seven days of cART this only added one additional pregnancy to the cART-experienced
group so was deemed unnecessary.
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The proportion of preterm deliveries (<37 weeks gestation) was similar in the two groups
(10.9% and 12.9% respectively), as was the median earliest antenatal viral load
measurement (4600, IQR: 374-20,587 copies/ml and 4565, IQR: 479-22,000 copies/ml),
p=0.371.
Maternal immune function (earliest antenatal CD4 count in that pregnancy), was better in
the cART-experienced group (median: 400 cells/µl, IQR: 277-533) compared with the ART-
naive group (median: 348 cells/µl, IQR: 230-498). The cART-experienced group was more
likely to receive PI-based cART than the ART-naive group (80.9% vs. 65.1%), and a higher
proportion received a boosted PI (92.0% vs. 79.1%). NNRTI-based cART was received by
15.5% of the cART experienced group and 30.3% of the ART-naive group.
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Table 6.1 Demographic, clinical and obstetric characteristics of pregnancies in ART-
naive and cART-experienced women
Characteristic
Pregnancies to
ART-naive
women (n=5372)
Pregnancies to
cART-
experienced
women (n=605)
p-
value
n % n %
Age at delivery, yrs (n=5958)
<25 1094 20.4 102 16.9 0.114
25-34 3391 63.3 401 66.3
≥35 868 16.2 102 16.9
World region of origin (n=5922)
UK/Ireland 691 13.0 91 15.1 0.362
Sub-Saharan Africa 4110 77.3 456 75.5
Elsewhere 517 9.7 57 9.4
Time period of delivery (n=5977)
2000-2002 760 14.1 13 2.1 <0.001
2003-2005 1757 32.7 106 17.5
2006-2008 1951 36.3 287 47.4
2009-2010 904 16.8 199 32.9
Timing of antenatal booking* (n=1395)
First trimester 538 46.8 100 40.8 0.014
Second trimester 521 45.3 134 54.7
Third trimester 91 7.9 11 4.5
Earliest CD4 count, cells/µl (n=5261)
≥500 1169 24.9 174 30.9 <0.001
350-499 1172 24.9 170 30.2
200-349 1477 31.4 165 29.3
<200 880 18.7 54 9.6
Type of cART (n=5964)
PI-based 3490 65.1 487 80.9 <0.001
Of which were ritonavir-boosted 2759 79.1 448 92.0
Of which were unboosted 730 20.9 39 8.0
NNRTI-based 1626 30.3 93 15.5
PI and NNRTI 200 3.7 15 2.5
Of which were ritonavir-boosted 110 55.0 14 93.3
Of which were unboosted 90 45.0 1 6.7
NRTI only 46 0.9 7 1.2
cART duration, wks (n=5572)
<2 155 3.1 1 0.2 <0.001
2-12 1720 34.5 148 25.0
13-40 3105 62.3 443 74.8
Mode of delivery (n=5962)
Elective caesarean section 2895 48.6 286 47.4 0.006
Emergency caesarean section 1366 22.9 115 19.1
Vaginal 1701 28.5 202 33.5
Gestational age, wks (n=5935)
≥37  5171 87.1 539 89.1 0.128
<37 764 12.9 66 10.9
*Available from 2008
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There were changes over time in the type of cART that women received. NNRTI-based
regimens predominated during 2000-2003. There was then an increase in PI-based
regimens – initially these were mainly unboosted PIs but from 2005/06 ritonavir-boosted PI-
based cART became the most common regimen (Figure 6.2). Among those women
receiving NNRTI-based cART, almost all in both the cART-experienced and ART-naive
groups took regimens containing nevirapine (95.7% and 98.0% respectively).
Figure 6.2 Type of antenatal cART received, by year, 2000-2010
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6.2.2 Patterns of cART use among cART-experienced women
Among the 605 pregnancies in cART-experienced women, type of cART received in both
current and previous pregnancy was reported for 600 (Table 6.2). Overall, 58.8% (n=353)
of women received the same type of cART regimen in their current and previous
pregnancy. Looking at the patterns of cART use in a little more detail, in conjunction with
Table 6.2 there were 385 pregnancies in women who had received PI-based cART in a
previous pregnancy, and 194 in those with previous NNRTI-based cART exposure. Among
current pregnancies in which the woman received NNRTI-based cART (n=92), most
(82.6%) had also received NNRTI-based cART in their previous pregnancy (all of whom
had received a regimen containing nevirapine). Among those receiving PI-based cART in
their current pregnancy (n=487) almost three-quarters (74.1%) had received PI-based
cART in their previous pregnancy. Of women receiving boosted PI-based cART in their
current pregnancy, over half also received a boosted PI in their previous pregnancy, with
most others receiving either an NNRTI (21.0%) or an unboosted PI (18.5%). Among all 194
pregnancies in women with previous NNRTI-based cART exposure, over half received PI-
based cART in their current pregnancy (n=110, composed of n=94 boosted + n=16
unboosted).
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Table 6.2 Type of cART received in current and previous pregnancy among cART-experienced women
Type of cART in
current pregnancy
Type of cART in previous pregnancy
NRTI only NNRTI Unboosted PI Boosted PI PI & NNRTI Total
n % n % n % n % n % n %
NRTI only 2 28.6 0 0.0 1 14.3 2 28.6 2 28.6 7 100
NNRTI 1 1.1 76 82.6 11 12.0 4 4.4 0 0.0 92 100
Unboosted PI 0 0.0 16 41.0 18 46.2 3 7.7 2 5.1 39 100
Boosted PI 4 0.9 94 21.0 83 18.5 257 57.4 10 2.2 448 100
PI & NNRTI 0 0.0 8 57.1 0 0.0 6 42.9 0 0.0 14 100
Total 7 194 113 272 14 600
Note: The type of ART recommended by the British HIV Association varied over the study period (see Appendix II).
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6.2.3 Availability of data on viral load at delivery
Viral load at delivery was reported for 54.9% (3281/5977) of all pregnancies, and was
available for a greater proportion of the cART-experienced than ART-naive group (62.3%
vs. 54.1%, p<0.001). Imputation of missing viral load as undetectable if there was an
undetectable viral load earlier in that pregnancy increased available data to 74.7% for all
pregnancies (4462/5977): 85.1% (515/605) among cART-experienced and 73.5%
(3947/5372) among ART-naive. These differences reflect the declining frequency of
missing viral load over time, from 55.0% in 2000 to 14.1% in 2010 (p<0.001) based on the
imputed viral load variable, and from 65.9% to 38.4% (p<0.001) based on the non-imputed
variable (Figure 6.3).
Figure 6.3 Proportion of pregnancies with missing viral load (imputed and non-imputed
variable), by year, 2000-2010
Further analyses were conducted on the imputed viral load variable (with concurrent
sensitivity analyses to confirm that the models did not differ significantly from those
conducted using the non-imputed variable). Women with missing viral load were younger
(22.7% vs. 19.2% being aged <25 years p=0.003), more likely to have received less than
two weeks of antenatal cART (7.1% vs. 1.6%, p<0.001), and to have a low CD4 count
(<350 cells/µl) (56.2% vs. 47.3%, p<0.001). There was no difference in maternal world
region of origin (p=0.331) (Table 6.3).
0
10
20
30
40
50
60
70
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Pr
op
or
tio
n
(%
)
Year
Imputed variable
Non-imputed variable
214
Table 6.3 Key characteristics of women with and without information on viral load at
delivery (based on imputed viral load variable)
Characteristic
Women with
viral load at
delivery
Women missing
viral load at
delivery
p-
value
n % n %
Age at delivery, yrs (n=5958)
<25 856 19.2 340 22.7 0.003
25-34 2849 63.9 943 63.0
≥35 756 16.9 214 14.3
World region of origin (n=5922)
UK/Ireland 576 13.0 206 13.8 0.331
Sub-Saharan Africa 3413 77.0 1154 77.4
Elsewhere 442 10.0 131 8.8
cART duration, wks (n=5572)
<2 71 1.6 85 7.1 <0.001
2-12 1328 30.4 540 45.0
13-40 2973 68.0 575 47.9
Earliest CD4 count, cells/µl (n=5261)
≥500 1104 25.8 239 24.5 <0.001
350-499 1154 26.9 188 19.3
200-349 1303 30.4 339 34.8
<200 726 16.9 208 21.4
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6.2.4 Detectable viral load among ART-naive and cART-experienced women
Among those women with data on viral load at delivery, it was detectable for 26.0% of
deliveries, although among these the actual level was generally low (median: 192
copies/ml, IQR: 89-696), with only 7.4% at ≥10,000 copies/ml. The proportion of 
pregnancies in which the woman had a detectable viral load at delivery peaked at 40.2% in
2001 and then declined year-on-year to 23.1% in 2006, thereafter remaining stable (Figure
6.4).
Figure 6.4 Proportion of pregnancies with a detectable viral load at delivery, by year,
2000-2010
The probability of detectable viral load was 26.2% in the ART-naive and 24.3% in the
cART-experienced groups giving an unadjusted OR of 0.90 (95% CI: 0.73-1.11). Among
those with a detectable viral load, the median measurement was similar in the two groups
(ART-naive: 196 copies/ml, IQR: 89-703, and cART-experienced: 184, IQR: 88-510). In
univariable analyses, younger age, earlier time period, receiving less than two weeks of
cART, receiving a triple class regimen, and having a lower antenatal CD4 count were
significantly associated with detectable viral load. After adjusting for these factors there was
a slightly, but only weakly significant, increased odds of detectable viral load (aOR: 1.27,
95% CI: 1.01-1.60, p=0.043) associated with prior cART exposure in pregnancy (Table
6.4). When the analysis was repeated using the original (non-imputed) viral load variable,
the aOR was similar at 1.21 (95% CI: 0.95-1.54, p=0.127), with the lack of statistical
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significance most likely a result of loss of power in the model. Although a woman’s earliest
antenatal viral load may be associated with her viral load at the time of delivery, it was not
considered appropriate to adjust for earliest viral load in the multivariable models since
earlier undetectable viral loads were used to impute viral load at delivery where this was
missing. There was no difference in the median earliest viral load between the two analysis
groups (p=0.371). There is also substantial overlap between earliest viral load and viral
load at delivery since the vast majority of women with an undetectable earliest viral load will
remain undetectable at the time of delivery.
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Table 6.4 Univariable and multivariable analyses of the association between previous
antenatal cART and detectable viral load at delivery in a subsequent pregnancy
Detectable/
Total (%)
Univariable analyses Multivariable analysis(n=4208)
OR 95% CI p-value aOR 95% CI
p-
value
Group
ART-naive 1033/3947 (26.2) 1 0.342 1 0.043
Previous cART 125/515 (24.3) 0.90 (0.73-1.11) 1.27 (1.01-1.60)
Age at delivery, yrs
<25 255/856 (29.8) 1 0.016 1 0.009
25-34 719/2849 (25.2) 0.80 (0.67-0.94) 0.76 (0.63-0.92)
≥35 183/756 (24.2) 0.75 (0.60-0.94)   0.72 (0.57-0.93)   
World region of origin
UK/Ireland 140/576 (24.3) 1 0.640
Sub-Saharan Africa 889/3413 (26.0) 1.10 (0.89-1.36)
Elsewhere 118/442 (26.7) 1.13 (0.85-1.52)
Time period of delivery
2000-2002 144/391 (36.8) 1 <0.001 1
2003-2005 371/1338 (27.7) 0.66 (0.52-0.84) 0.61 (0.46-0.80) <0.001
2006-2008 433/1802 (24.0) 0.54 (0.43-0.69) 0.55 (0.41-0.74)
2009-2010 210/931 (22.6) 0.50 (0.39-0.65) 0.62 (0.45-0.86)
cART duration, wks
<2 62/71 (87.3) 1 <0.001 1 <0.001
2-12 555/1328 (41.8) 0.10 (0.05-0.21) 0.11 (0.06-0.23)
13-40 514/2973 (17.3) 0.03 (0.01-0.06) 0.03 (0.01-0.06)
Type of cART
PI 803/3134 (25.6) 1 <0.001 1 <0.001
NNRTI 282/1108 (25.5) 0.99 (0.85-1.16) 0.62 (0.50-0.76)
NRTI 6/44 (13.6) 0.46 (0.19-1.09) 0.48 (0.17-1.35)
PI & NNRTI 66/173 (38.2) 1.79 (1.30-2.46) 1.20 (0.82-1.74)
Earliest CD4 count, cells/µl
≥500 214/1104 (19.4) 1 <0.001 1 <0.001 
350-499 276/1154 (23.9) 1.31 (1.07-1.60) 1.50 (1.20-1.88)
200-349 353/1303 (27.1) 1.55 (1.27-1.88) 1.94 (1.56-2.41)
<200 253/726 (34.8) 2.22 (1.79-2.76) 3.40 (2.64-4.38)
Note: All pregnancy-specific characteristics relate to current pregnancy.
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All further models were adjusted for the same factors as the initial model (as shown in
Table 6.4) namely maternal age, time period, duration of cART, CD4 count and type of
cART received in current pregnancy. Firstly a logistic regression model was fitted including
type of cART previously received (Table 6.5). Only pregnancies in women who had prior
exposure to either PI- or NNRTI-based cART were included (excluding those who had
taken both PIs and NNTRIs). Comparing pregnancies in those who had previously received
a PI-based cART regimen with all ART-naive pregnancies, there was no difference in the
odds of detectable viral load (aOR: 1.08, 95% CI: 0.81-1.45, p=0.580). Meanwhile, among
pregnancies in women who had previously received an NNRTI-based cART regimen, there
was an increased odds of detectable viral load compared with the ART-naive group (aOR:
1.81, 95% CI: 1.25-2.63, p=0.002). Younger maternal age, earlier time period, receiving
less than two weeks of cART, type of cART, and lower antenatal CD4 count all remained
associated with a detectable viral load in the multivariable model. Receipt of an NNRTI-
based cART regimen in the current pregnancy was associated with a decreased odds of
detectable viral load compared with PI-based regimens, a difference which remained when
only boosted PI-based regimens were included (aOR: 0.52, 95% CI: 0.42-0.66, p<0.001).
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Table 6.5 Univariable and multivariable analyses of the association between type of
previous antenatal cART received and detectable viral load at delivery in a subsequent
pregnancy
Detectable/
Total (%)
Univariable analyses Multivariable analysis(n=4188)
OR 95% CI p-value* aOR 95% CI
p-
value*
Group
ART-naive 1033/3947 (26.2) 1 1
Previous PI cART 73/332 (22.0) 0.80 (0.61-1.04) 0.088 1.08 (0.81-1.45) 0.580
Previous NNRTI
cART 47/162 (29.0) 1.15 (0.82-1.63) 0.419 1.81 (1.25-2.63) 0.002
Age at delivery, yrs
<25 254/853 (29.8) 1 0.017 1 0.007
25-34 716/2836 (25.2) 0.80 (0.67-0.95) 0.76 (0.63-0.92)
≥35 182/751 (24.2) 0.75 (0.60-0.94)   0.72 (0.56-0.92)   
World region of origin
UK/Ireland 140/574 (24.4) 1 0.652
Sub-Saharan Africa 884/3396 (26.0) 1.09 (0.88-1.35)
Elsewhere 118/440 (26.8) 1.14 (0.85-1.52)
Time period of delivery
2000-2002 144/390 (36.9) 1 <0.001 1 <0.001
2003-2005 371/1336 (27.8) 0.66 (0.52-0.83) 0.60 (0.45-0.79)
2006-2008 429/1792 (23.9) 0.54 (0.43-0.68) 0.55 (0.41-0.73)
2009-2010 209/923 (22.6) 0.50 (0.39-0.65) 0.64 (0.46-0.88)
cART duration, wks
<2 62/71 (87.3) 1 <0.001 1 <0.001
2-12 554/1322 (41.9) 0.10 (0.05-0.21) 0.11 (0.06-0.23)
13-40 510/2958 (17.2) 0.03 (0.01-0.06) 0.03 (0.01-0.06)
Type of cART
PI 800/3120 (25.6) 1 0.002 1 <0.001
NNRTI 282/1106 (25.5) 0.99 (0.85-1.16) 0.60 (0.49-0.74)
NRTI 6/41 (14.6) 0.50 (0.21-1.19) 0.56 (0.20-1.57)
PI & NNRTI 65/172 (37.8) 1.76 (1.28-2.42) 1.17 (0.80-1.70)
Earliest CD4 count, cells/µl
≥500 214/1097 (19.5) 1 <0.001 1 <0.001 
350-499 275/1149 (23.9) 1.30 (1.06-1.59) 1.50 (1.20-1.87)
200-349 352/1297 (27.1) 1.54 (1.27-1.87) 1.95 (1.57-2.42)
<200 252/725 (34.8) 2.20 (1.77-2.73) 3.40 (2.64-4.38)
*Individual p-values provided for the exposure of interest
Note: All pregnancy-specific characteristics relate to current pregnancy.
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Further analyses were conducted to explore the association between type of previous
cART exposure and probability of detectable viral load. When the model was restricted to
pregnancies in women who received PI-based (boosted or unboosted) cART in their
current pregnancy (and the cART-experienced group included only pregnancies in women
who had received PI-based cART in both their previous and current pregnancy), there was
no increased probability of detectable viral load in the PI-experienced compared with the
ART-naive group (aOR: 1.09, 95% CI: 0.81-1.47, p=0.571) (Table 6.6).
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Table 6.6 Univariable and multivariable analyses of the association between previous PI-
based antenatal cART receipt and detectable viral load at delivery in a subsequent
pregnancy (among those who received PI-based cART in their current pregnancy)
Detectable/
Total (%)
Univariable analyses Multivariable analysis(n=2868)
OR 95% CI p-value aOR 95% CI
p-
value
Group
ART-naive 703/2717 (25.9) 1 0.114 1 0.571
Previous PI cART 68/311 (21.9) 0.80 (0.61-1.05) 1.09 (0.81-1.47)
Age at delivery, yrs
<25 183/596 (30.7) 1 0.005 1 0.002
25-34 462/1904 (24.3) 0.72 (0.59-0.89) 0.69 (0.55-0.86)
≥35 125/527 (23.7) 0.70 (0.54-0.92)   0.65 (0.49-0.87)   
World region of origin
UK/Ireland 100/412 (24.3) 1 0.338
Sub-Saharan Africa 573/2278 (25.2) 1.05 (0.82-1.35)
Elsewhere 89/309 (28.8) 1.26 (0.90-1.77)
Time period of delivery
2000-2002 33/78 (42.3) 1 <0.001 1 0.169
2003-2005 211/688 (30.7) 0.60 (0.37-0.97) 0.69 (0.41-1.15)
2006-2008 349/1465 (23.8) 0.43 (0.27-0.68) 0.60 (0.37-1.00)
2009-2010 178/797 (22.3) 0.39 (0.24-0.64) 0.69 (0.41-1.16)
cART duration, wks
<2 37/42 (88.1) 1 <0.001 1 <0.001
2-12 359/871 (41.2) 0.09 (0.04-0.24) 0.11 (0.05-0.29)
13-40 357/2056 (17.4) 0.03 (0.01-0.07) 0.03 (0.01-0.08)
Earliest CD4 count, cells/µl
≥500 161/853 (18.9) 1 <0.001 1 <0.001 
350-499 199/860 (23.1) 1.29 (1.02-1.64) 1.42 (1.10-1.84)
200-349 249/901 (27.6) 1.64 (1.31-2.06) 1.99 (1.55-2.54)
<200 128/309 (41.4) 3.04 (2.28-4.05) 3.97 (2.90-5.43)
Note: All pregnancy-specific characteristics relate to current pregnancy.
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When the model was restricted to pregnancies in women who received NNRTI-based cART
in their current pregnancy (and the cART-experienced group included only pregnancies in
women who had received NNRTI-based cART in both their previous and current
pregnancy), there was no increased probability of detectable viral load in the NNRTI-
experienced compared with the ART-naive group (aOR: 0.93, 95% CI: 0.47-1.83, p=0.828)
(Table 6.7).
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Table 6.7 Univariable and multivariable analyses of the association between previous
NNRTI-based antenatal cART receipt and detectable viral load at delivery in a subsequent
pregnancy (among those who received NNRTI-based cART in their current pregnancy)
Detectable/
Total (%)
Univariable analyses Multivariable analysis(n=1023)
OR 95% CI p-value aOR 95% CI
p-
value
Group
ART-naive 265/1031 (25.7) 1 0.367 1 0.828
Previous NNRTI
cART 13/63 (20.6) 0.75 (0.40-1.40) 0.93 (0.47-1.83)
Age at delivery, yrs
<25 51/203 (25.1) 1 0.499 1 0.861
25-34 192/730 (26.3) 1.06 (0.74-1.52) 0.99 (0.66-1.49)
≥35 35/161 (21.7) 0.83 (0.50-1.36)   0.86 (0.48-1.56)   
World region of origin
UK/Ireland 28/123 (22.8) 1 0.655
Sub-Saharan Africa 227/877 (25.9) 1.18 (0.75-1.87)
Elsewhere 21/92 (22.8) 1.00 (0.52-1.93)
Time period of delivery
2000-2002 103/283 (36.4) 1 <0.001 1 0.004
2003-2005 120/531 (22.6) 0.51 (0.37-0.70) 0.55 (0.38-0.80)
2006-2008 39/209 (18.7) 0.40 (0.26-0.62) 0.49 (0.29-0.82)
2009-2010 16/71 (22.5) 0.51 (0.28-0.93) 0.95 (0.48-1.88)
cART duration, wks
<2 16/18 (88.9) 1 <0.001 1 <0.001
2-12 163/374 (43.6) 0.10 (0.02-0.43) 0.09 (0.02-0.42)
13-40 91/673 (13.5) 0.02 (0.00-0.09) 0.02 (0.03-0.08)
Earliest CD4 count, cells/µl
≥500 38/174 (21.8) 1 0.484 1 0.003 
350-499 49/219 (22.4) 1.03 (0.63-1.68) 1.43 (0.82-2.48)
200-349 79/313 (25.2) 1.21 (0.78-1.88) 1.78 (1.05-3.01)
<200 92/340 (27.1) 1.33 (0.86-2.05) 2.63 (1.54-4.50)
Note: All pregnancy-specific characteristics relate to current pregnancy.
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However, in a final model which included women who received PI-based cART (boosted or
unboosted) in their current pregnancy and NNRTI-based cART in their previous pregnancy,
there was a significantly increased odds of detectable viral load in the NNRTI-experienced
compared with the ART-naive group (aOR: 2.12, 95% CI: 1.30-3.47, p=0.003) (Table 6.8).
This association remained when the analysis was restricted to the 2309 women who
received a boosted PI in their current pregnancy (2231 women in the ART-naive group
received a boosted PI and 78 cART-experienced women); aOR: 2.18, 95% CI: 1.28-3.74,
p=0.004 with 2183 observations in the multivariable model (details not shown as very
similar to Table 6.8).
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Table 6.8 Univariable and multivariable analyses of the association between previous
antenatal NNRTI-based cART receipt and detectable viral load at delivery in a subsequent
pregnancy (among those who received PI-based cART in their current pregnancy)
Detectable/
Total (%)
Univariable analyses Multivariable analysis(n=2659)
OR 95% CI p-value aOR 95% CI
p-
value
Group
ART-naive 703/2717 (25.9) 1 0.226 1 0.003
Previous NNRTI
cART 29/92 (31.5) 1.32 (0.84-2.06) 2.12 (1.30-3.47)
Age at delivery, yrs
<25 171/558 (30.6) 1 0.019 1 0.004
25-34 441/1753 (25.2) 0.76 (0.62-0.94) 0.71 (0.56-0.89)
≥35 119/497 (23.9) 0.71 (0.54-0.94)   0.65 (0.48-0.87)   
World region of origin
UK/Ireland 97/374 (25.9) 1 0.644
Sub-Saharan Africa 543/2110 (25.7) 0.99 (0.77-1.27)
Elsewhere 84/297 (28.3) 1.13 (0.80-1.59)
Time period of delivery
2000-2002 33/77 (42.9) 1 <0.001 1 0.323
2003-2005 210/697 (30.1) 0.57 (0.36-0.93) 0.65 (0.39-1.09)
2006-2008 342/1371 (24.9) 0.44 (0.28-0.71) 0.62 (0.38-1.03)
2009-2010 147/664 (22.1) 0.38 (0.23-0.62) 0.64 (0.38-1.08)
cART duration, wks
<2 36/41 (87.8) 1 <0.001 1 <0.001
2-12 341/823 (41.4) 0.10 (0.04-0.25) 0.12 0.05-0.30)
13-40 337/1889 (17.8) 0.03 (0.01-0.08) 0.03 (0.01-0.08)
Earliest CD4 count, cells/µl
≥500 155/783 (19.8) 1 <0.001 1 <0.001 
350-499 186/795 (23.4) 1.24 (0.97-1.57) 1.37 (1.06-1.78)
200-349 239/834 (28.7) 1.63 (1.29-2.05) 1.98 (1.54-2.55)
<200 120/299 (40.1) 2.72 (2.03-3.63) 3.55 (2.59-4.87)
Note: All pregnancy-specific characteristics relate to current pregnancy.
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6.3 Risk of MTCT
Information on infant HIV status was available for 87.8% of births (5248/5977). Missing HIV
status was more common in recent years due to delays in the reporting of this. However,
the proportion was similar for the ART-naive and cART-experienced groups (12.1% vs.
13.4% respectively, p=0.345). The overall risk of MTCT was 1.1% (60/5248, 95% CI: 0.9-
1.4). Of these 60 transmissions, 69.7% occurred in pregnancies among women who
received <13 weeks antenatal cART, and 86.5% were in women with a detectable viral load
at delivery (based on the imputed viral load variable). The risk was 1.2% (58/4724) among
the ART-naive, and 0.4% (2/542) among the cART-experienced groups (OR: 0.31, 95% CI:
0.08-1.27, p=0.103).
In univariable analyses, factors associated with an increased MTCT risk were preterm
delivery, earlier time period, shorter duration of antenatal cART, and emergency caesarean
section delivery (Table 6.9). The final model investigating the association between previous
cART exposure and MTCT included time period and duration of cART received; no other
explanatory variables were included as none significantly improved the fit of the model
(Wald test p-values: preterm delivery p=0.383, type of cART p=0.801, mode of delivery
p=0.215, CD4 count: p=0.188). Delivery viral load was not considered for inclusion in the
multivariable model since it is on the causal pathway. There remained no association
between previous cART for PMTCT and the probability of transmission in the final model
(aOR: 0.42, 95% CI: 0.10-1.78, p=0.241, Table 6.9). However, the number of transmissions
was low, precluding investigation according to type of cART previously received.
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Table 6.9 Univariable and multivariable analyses of the association between previous
antenatal cART and MTCT occurring in a subsequent pregnancy
HIV-positive
infants/Total
(%)
Univariable analyses Multivariable analysis(n=4867)
OR 95% CI p-value aOR 95% CI
p-
value
Group
ART-naive 58/4724 (1.2) 1 0.103 1 0.241
Previous HAART 2/524 (0.4) 0.31 (0.08-1.27) 0.42 (0.10-1.78)
Age at delivery, yrs
<25 13/1064 (1.2) 1 0.913
25-34 36/3330 (1.1) 0.88 (0.47-1.67)
≥35 10/837 (1.2) 0.98 (0.43-2.24)
World region of origin
UK/Ireland 7/700 (1.0) 1 0.429
Sub-Saharan Africa 50/4008 (1.3) 1.25 (0.56-2.77)
Elsewhere 3/496 (0.6) 0.60 (0.16-2.34)
Time period of delivery
2000-2002 16/714 (2.2) 1 0.039 1 0.184
2003-2005 18/1773 (1.0) 0.45 (0.23-0.88) 0.46 (0.23-0.93)
2006-2008 19/2043 (0.9) 0.41 (0.21-0.80) 0.58 (0.28-1.21)
2009-2010 7/718 (1.0) 0.43 (0.18-1.05) 0.69 (0.26-1.80)
cART duration, wks
<2 9/130 (6.9) 1 <0.001 1 <0.001
2-12 30/1689 (1.8) 0.24 (0.11-0.52) 0.25 (0.12-0.55)
13-40 17/3048 (0.6) 0.08 (0.03-0.17) 0.08 (0.03-0.19)
Type of cART
PI 35/3404 (1.0) 1 0.069
NNRTI 21/1586 (1.3) 1.29 (0.75-2.23)
NRTI 1/48 (2.1) 2.05 (0.27-15.29)
PI & NNRTI 3/198 (1.5) 1.48 (0.45-4.86)
Mode of delivery
Elective caesarean 26/2584 (1.0) 1 0.037
Emergency caesarean 22/1196 (1.8) 1.84 (1.04-3.27)
Vaginal 12/1454 (0.8) 0.82 (0.41-1.63)
Gestational age, wks
≥37  46/4543 (1.0) 1 0.035 
<37 13/664 (2.0) 1.95 (1.04-3.63)
Last CD4 count, cells/µl
≥500 12/1597 (0.8) 1 0.085 
350-499 10/1222 (0.8) 1.09 (0.47-2.53)
200-349 16/1250 (1.3) 1.71 (0.81-3.63)
<200 11/565 (2.0) 2.62 (1.15-5.97)
Note: All pregnancy-specific characteristics relate to current pregnancy.
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6.4 Discussion
ART prophylaxis for PMTCT needs to be effective in reducing viral load to undetectable
levels by the time of delivery, safe and well tolerated during pregnancy, and should not limit
future therapy options for the woman, or indeed any HIV-positive infants. Although
antenatal cART has shown to be highly effective in reducing viral loads to undetectable
levels, and consequently preventing MTCT (Townsend et al, 2014), few studies have
examined the effect of short-course therapy on response to ART in subsequent
pregnancies (see Chapter 2, Section 2.5). This chapter investigated whether previous
exposure to short-term cART for PMTCT was associated with the probability of detectable
viral load at delivery and/or the risk of MTCT in subsequent pregnancies.
Overall probability of detectable viral load at delivery
Overall, around a quarter of women had a detectable viral load at delivery (≥50 copies/ml). 
This is consistent with data from other European countries and the US. For example, the
proportion was 27% among women enrolled in the ECS during 1997-2004 (Patel et al,
2007) and 21% in the Swiss Mother and Child HIV Cohort Study during 2003-2008 (Aebi-
Popp et al, 2010). Meanwhile, 32% of women enrolled in the US WITS during 1998-2002
had a detectable delivery viral load, defined as >400 copies/ml (Katz et al, 2010). In these
studies, all or the vast majority of women received antenatal ART. Given that maternal viral
load is the pre-eminent risk factor for MTCT (see Chapter 1, Section 1.2.3), and that all
women included in the current analyses received antenatal cART, the finding that one in
four women did not achieve virological suppression by delivery is of concern. Receipt of a
sufficient duration of ART during pregnancy is key to the achievement of full viral
suppression by delivery and thus the avoidance of MTCT (Aziz et al, 2013; Thorne et al,
2005; Townsend et al, 2014; Tubiana et al, 2010), particularly among those with high
baseline viral loads (Read et al, 2012). Women included in the current analysis received on
average 14 weeks of cART. As has been mentioned, UK guidelines have brought forward
the recommended gestation by which women not requiring treatment for their own health
should start antenatal ART (Taylor et al, 2012), similar to WHO guidelines (World Health
Organization, 2013). This move is pertinent given the findings presented here. This allows
more time for women to achieve an undetectable viral load, particularly those with high
baseline levels. It should be borne in mind that, as shown in Chapter 5, compared with
women conceiving on ART, those who initiated it during pregnancy had over four times the
odds of having a detectable viral load at delivery.
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Aside from duration of antenatal ART, adherence is likely a key mediator of viral
suppression (Aziz et al, 2013; Weinberg et al, 2009). Though adherence tends to be better
in pregnant than post-partum women, levels are still frequently below those required to
achieve viral suppression. In a systematic review meta-analysis of the international
literature the pooled estimate showed that 24% of pregnant women had inadequate
adherence (<80% adherence) (Nachega et al, 2012). There is little data on adherence
among HIV-positive pregnant women in the UK specifically. A small study in one centre
reported that five of the 32 women eligible for inclusion were non-adherent (though the term
was not defined) during pregnancy (Kingston et al, 2007). Meanwhile, a review of 73
women in receipt of boosted lopinavir-based cART noted poor adherence in 14% of them
(Caswell et al, 2011). These data suggest that poor adherence may well be an important
contributor to the lack of viral suppression by delivery documented in a quarter of women in
the present analysis.
Type of cART received in current pregnancy and probability of detectable viral load at
delivery
The analyses presented here demonstrate that NNRTI-based cART appears more effective
than PI-based regimens in reducing viral load to undetectable levels during pregnancy56.
Almost all women receiving NNRTI-based cART took a nevirapine-containing regimen. The
evidence on the relative effectiveness of PIs and NNRTIs varies. A comprehensive review
and meta-analysis conducted by Chou et al in 2006 reported that in a direct meta-analysis
of ‘head-to-head’ trials comparing PI-based and NNRTI-based regimens found NNRTI-
based regimens to be more effective in viral suppression (OR 1.60, 95% CI: 1.31−1.96). By 
contrast, indirect comparisons drawn between studies showed NNRTIs to be less effective
than PIs. The authors suggest that indirect comparisons may be unreliable in the context of
HARRT due to the complex nature of the regimens used, variations between studies and
changes over time (Chou et al, 2006). A recent meta-analysis including four studies which
examined the effectiveness, in terms of viral suppression by 48 weeks, of nevirapine-based
cART compared with ritonavir-boosted PI regimens reported no significant difference (risk
ratio: 0.90; 95% CI: 0.77-1.06), and the findings of the four individual studies were
homogeneous in this respect (Kawalec et al, 2013). Among pregnant women specifically,
the evidence is also inconclusive. The ECS reported a shorter time to achieving
undetectable viral load among pregnant women starting nevirapine-based cART compared
with PI-based cART, adjusting for baseline viral load and other factors (Patel et al, 2007).
However, most women received nelfinavir which, as an unboosted PI, has been shown to
be inferior to ritonavir-boosted regimens (Walmsley et al, 2002). An analysis of the US
56 A finding also demonstrated in the analyses of the association between timing of ART initiation and the
risk of detectable viral load at delivery (Chapter 5), though neither analysis was specifically designed to
compare the effectiveness of NNTRI and PI based regimens per se.
230
WITS data for 1998-2005 reported no significant association between the type of ART
received and the risk of detectable viral load, though the numbers in each group were
relatively small (Katz et al, 2010). However, data from three US centres revealed that
pregnant women receiving NNTRI-based therapy achieved a viral load of <400 copies/ml
more rapidly than those receiving PIs (aHR: 2.48, IQR: 1.33–4.63) (Aziz et al, 2013).
Meanwhile, an analysis of data from five UK centres reported a shorter time to
undetectable viral load for PI compared with NNRTI-based regimens (nevirapine-based in
all but one woman) with a HR of 0.70 (95% CI: 0.52–0.94) (Read et al, 2012).
When comparing the findings of such studies it should be remembered that there are
variations between studies in the specific drugs used, the populations studied, and the
confounders adjusted for. Indications for treatment, which often cannot be accounted for,
may also have a significant impact. In the present analysis, two-thirds of PI regimens were
boosted and the increased risk of detectable virus among those receiving PIs remained
when comparing boosted PIs with NNRTI-based regimens. This could in part relate to the
fact that higher adherence may be required for PI-based regimens in order to achieve
virological suppression (Maggiolo et al, 2005), while less than 95% adherence to NNRTI-
based regimens can be sufficient (Bangsberg, 2006). Of course, the type, frequency and
severity with which side effects are experienced may impact on adherence. For example,
lopinavir/ritonavir (Kaletra®) is the most commonly used boosted PI in this population; of the
women in these analyses who received a boosted PI-based regimen, most (81%,
2605/3207) took Kaletra®. Though this is generally a well-tolerated drug, the most common
side-effects are those of a gastrointestinal nature including nausea and vomiting (Croxtall et
al, 2010) which may exacerbate common symptoms of pregnancy. Another relevant issue
is that nevirapine-based cART is only recommended for those with low CD4 counts (<250
cells/µl) (de Ruiter et al, 2008; Taylor et al, 2012) because of the potential risk of
hepatotoxicity in those with better functioning immune systems (Dieterich et al, 2004; Lyons
et al, 2006; Sanne et al, 2005). This may also introduce some confounding by indication
with regard to the type of ART received, because women with low CD4 counts may have
high baseline viral loads, which are associated with an increased time to viral suppression.
Furthermore, there is some evidence that higher CD4 counts may be independently
associated with a more rapid reduction in viral load after ART initiation (Aziz et al, 2013;
Read et al, 2012). In the present analyses this was taken into account by adjusting for CD4
counts in the multivariable models.
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Influence of previous short-course cART on the probability of detectable viral load at
delivery
Overall, there was weak evidence of an increased risk of detectable viral load at delivery
among the cART-experienced group in the multivariable analysis (aOR: 1.27, 95% CI: 1.01-
1.60). In the US, Katz et al reported an overall increased risk of detectable viral load at
delivery among cART-experienced women (37% among the cART experienced compared
with 24% among the cART-naive), though the cART-experienced group was not restricted
to those previously exposed solely for PMTCT (Katz et al, 2010). Meanwhile, no overall
difference was observed in an Irish study (Lyons et al, 2005a) (details of previous studies
on this topic are provided in Chapter 2, Section 2.5). However, when the association in the
present analysis was explored according to type of cART previously received an increased
risk was apparent only among women who had received NNRTI-based cART (aOR: 1.81,
95% CI: 1.25-2.63), and not among those with prior PI-based cART exposure (aOR: 1.08,
95% CI: 0.81-1.45).
The presence of resistance mutations, and an increased risk of subsequent virological
failure, has been documented in women exposed to ART for PMTCT, particularly
nevirapine-containing regimens (Arrive et al, 2007; Paredes et al, 2013). In the present
study, all women who received NNRTI-based cART in their previous pregnancy had taken
a regimen containing nevirapine. Resistance data is not collected by the NSHPC but the
fact that women with previous NNRTI-based cART exposure were at increased risk of not
achieving virological suppression compared with ART-naive women could reasonably be
considered to be due to the development of resistance to nevirapine. However,
interestingly, when the association was investigated further, it emerged that the increased
risk only applied to women who were exposed to NNTRI-based cART during their first
pregnancy and subsequently received PI-based regimens, but not those receiving repeat
NNRTI-based therapy. This may reflect differences in indication for the type of cART
received. Drug resistance testing is recommended for all women discontinuing ART after
delivery (Taylor et al, 2012), and type of ART given in any subsequent pregnancy should
depend on the results. Women receiving NNRTIs in more than one pregnancy may
therefore represent a group who were relatively straightforward to manage e.g. presented
early and had no adherence issues thus increasing their probability of achieving viral
suppression. Meanwhile, women who had adherence problems in their first pregnancy, or
were more complex cases to manage for a variety of social and behavioural reasons, may
have been more likely to be prescribed a PI in their subsequent pregnancy, particularly
since boosted PIs are now the regimen of choice for short-course antenatal ART in the UK
(Taylor et al, 2012). Furthermore, as mentioned, those starting nevirapine-based regimens
during pregnancy should have only been those with low CD4 counts who required
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treatment for their own health (de Ruiter et al, 2008; Hawkins et al, 2005; Taylor et al,
2012). It would therefore likely have been planned that they would continue treatment after
delivery. The women who did stop at some point after delivery may well have decided to do
so themselves rather than having a structured treatment interruption overseen by their
clinician. Again, this ties in with such women being initiated on PI-based regimens in their
subsequent pregnancies.
Meanwhile, that there was no increased risk of detectable viral load among women who
received PI-based cART in both their previous and current pregnancy is consistent with the
findings of the French Perinatal Cohort. The authors reported no evidence of an increased
risk of detectable viral load among women receiving antenatal PI-based cART who had
been exposed to cART (mostly, 93%, PI-based) for PMTCT during a previous pregnancy
(Briand et al, 2011). This is also consistent with the lack of genotypic resistance to PI-
based cART following short-course therapy for PMTCT observed in Germany (Gingelmaier
et al, 2010) and in the Mma Bana study in Botswana (Souda et al, 2013). However, some
studies have reported the development of PI resistance mutations, to nelfinavir in particular,
following the use of PI-based cART for PMTCT (see Chapter 2, Section 2.5).
There has been a significant shift towards the use of boosted PI-based regimens for
pregnant women in the UK and Ireland, and this regimen has predominated since 2005.
Since the majority of women are therefore now receiving boosted PI-based cART (85% of
the study population in 2010), these findings are reassuring in terms of potential future
pregnancies for women whose index pregnancy occurred in recent years. Meanwhile,
although the use of NNRTI-based cART declined significantly between 2000 and 2006, it
has been quite stable since then; in 2010 16% of women received this regimen (consistent
with the low proportion of women with severe immunosuppression). It is important that any
ART discontinuations among this group are structured as outlined in UK guidelines (Taylor
et al, 2012).
Influence of previous short-course cART on the risk of MTCT
The risk of vertical transmission was 1.2% among ART-naive women and 0.4% among
those with previous cART exposure. There was no association in the multivariable analysis
(p=0.241), though the number of transmissions was low and power was therefore limited.
Previous studies have not specifically assessed the association between prior exposure to
cART for PMTCT and MTCT in subsequent pregnancies, although Lyons et al reported no
increased risk of HIV transmission in repeat compared with index pregnancies (Lyons et al,
2005a). However, the study also had limited power. The lack of an association is consistent
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with there being little increased risk of detectable viral load overall, and the fact that even
where delivery viral load was detectable, levels were generally low.
Limitations
A limitation of the NSHPC data for these analyses is that only information on ART received
in relation to pregnancy is collected. Therefore it has been assumed that if a woman did not
conceive her first pregnancy on ART then she has not previously received cART (i.e. is
ART-naive). It is possible that some women may have previously received ART for their
own health and subsequently stopped. However, this is likely to only apply to a small
proportion of women and any such misclassification is likely non-differential so will only
have attenuated the associations between previous cART exposure and the outcomes.
Some women who were born abroad may also have been exposed to ART during previous
pregnancies prior to arriving in the UK or Ireland.
That no information was available on the presence of resistance mutations hinders the
interpretation of the findings. The lack of evidence of an increased risk of detectable viral
load at delivery among women who received either repeat NNRTI-based cART or repeat
PI-based cART suggests that resistance may not be a significant issue in this population.
However, this assertion would need to be verified by obtaining drug resistance profiles for
the women reported to the NSHPC. Indeed, as mentioned, women in whom resistance
mutations were detected may have consequently received a different drug combination
from the same class in their subsequent pregnancy. Some measure of women’s level of
adherence to ART during pregnancy would also aid interpretation of the findings.
Reported viral load close to delivery was missing for 45% of women, a potentially important
limitation. However, the use of an imputed variable increased available data thus providing
greater power to detect associations. Sensitivity analyses supported the use of the imputed
variable. It was not felt appropriate to adjust baseline viral load in these analyses
(notwithstanding that this is an important predictor of delivery viral load) because earlier
undetectable viral loads were used to impute viral load at delivery where this was
missing. Since baseline viral loads were not significantly different in the ART-naive and
cART-experienced groups (p=0.371) this was unlikely to have been an important
confounder overall.
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6.5 Key findings
 There were 5372 pregnancies in ART-naive women who started cART after
conception, and 605 in women who had received short-term cART in their previous
pregnancy
 cART was received for a median of 14.1 weeks (IQR: 10.7-17.6) and in around a
quarter of pregnancies there was a detectable viral load at delivery
 The risk of detectable viral load at delivery was 26.2% among ART-naive women
and 24.3% among the cART-experienced
 Overall, there was weak evidence of an increased risk of detectable viral load at
delivery in the cART-experienced group compared with the ART-naive group in
adjusted analyses (aOR: 1.27, 95% CI: 1.01-1.60)
 In stratified analyses an increased risk of detectable viral load at delivery was
apparent only among women who previously received NNRTI-based cART
(aOR:1.81, 95% CI: 1.25-2.63), and not among those with PI-based cART exposure
(aOR:1.08, 95% CI: 0.81-1.45)
 The risk of MTCT was 1.2% (58/4724) among the ART-naive, and 0.4% (2/542)
among the cART-experienced groups (OR: 0.31, 95% CI: 0.08-1.27, p=0.103)
 In multivariable analyses there was no association between previous cART for
PMTCT and the probability of MTCT (aOR: 0.42, 95% CI: 0.10-1.78, p=0.241)
though the number of transmissions was low with only two transmissions in the
cART experienced group
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Chapter 7 Adverse pregnancy and perinatal outcomes,
and mode of delivery
This chapter focuses largely on the perinatal period, firstly exploring adverse pregnancy
and perinatal outcomes in HIV-positive women’s sequential pregnancies, and then
investigating trends and patterns in mode of delivery.
7.1 Adverse pregnancy and perinatal outcomes
As discussed in Chapter 2, Section 2.6, there is evidence to suggest that HIV-positive
women may be at greater risk of adverse perinatal outcomes such as preterm delivery, low
birthweight and stillbirth compared with the general population. Furthermore, these women
may be at additional risk at their repeat pregnancies compared with index pregnancies. For
example, they will be older, have been living with HIV for longer, and may be more likely to
conceive on ART. The first part of this chapter explores the probability of adverse
pregnancy and perinatal outcomes (stillbirth, miscarriage, preterm delivery, low birthweight,
congenital abnormalities) among women’s repeat pregnancies. Risk factors for preterm
delivery are also investigated in this group (Objective 5). Utilising data on these repeat
pregnancies also enables the exploration of the influence of factors such as previous
preterm delivery and inter-pregnancy interval on preterm delivery risk, which are often not
assessed or accounted for in studies of preterm delivery among HIV-positive women.
7.1.1 Methods
Dataset
All repeat (second and subsequent) pregnancies during 2000-2010 to women whose first
reported pregnancy ended in 2000 or later were included. A comparison group of index
pregnancies reported during the same period was also utilised (Figure 7.1). Women’s
pregnancies were assigned a ‘pregnancy number’ (i.e. first, second, third, among all
reported pregnancies for each woman irrespective of outcome), even for analyses that
were subsequently restricted to live and stillbirths. Women classed as being of ‘older’ or
‘advanced’ maternal age were those aged ≥35 years at delivery (or end of pregnancy for 
outcomes other than a live or stillbirth), a commonly used cut-off (Brown et al, 2012;
Cleary-Goldman et al, 2005; Fretts et al, 1995; Liuzzi et al, 2013; Nabukera et al, 2008).
236
Figure 7.1 Study population flow chart – adverse pregnancy and perinatal outcomes
analyses
*Excludes pregnancies where the outcome was not reported to be either a live birth, stillbirth, miscarriage
(including ectopic pregnancy), or termination
Pregnancy outcomes
Descriptive analyses of pregnancy outcomes (live birth, stillbirth, miscarriage, termination)
included all repeat pregnancies with a known pregnancy outcome, and a comparison group
of first reported pregnancies with known outcomes. Definitions of pregnancy outcomes,
including stillbirth and miscarriage, are provided in Chapter 3, Section 3.1.5.
Preterm delivery
These analyses included pregnancies resulting in a live or stillbirth. Preterm delivery was
defined as a delivery at <37 gestational weeks. For some sub-analyses preterm was further
restricted to include only infants born at <35 weeks and at <32 weeks. ‘Previous preterm
delivery’ was coded as ‘yes’ if the woman had had one or more previous preterm deliveries
(<37 weeks) ever reported to the NSHPC. Information on whether any previous unreported
deliveries (e.g. those that occurred before the woman was diagnosed with HIV or prior to
her arrival into the UK or Ireland) were preterm is not collected by the NSHPC. Since UK
guidelines state that elective caesarean sections for PMTCT should be scheduled for 38-39
weeks (Taylor et al, 2012), elective caesarean sections carried out solely for PMTCT
should not influence the rate of preterm deliveries.
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Low birthweight
Birthweight has been collected through the NSHPC paediatric scheme since its inception,
and began to also be collected through the obstetric scheme in 2002. Low birthweight was
defined as <2.5kg, and very low birthweight as <1.5kg (World Health Organization, 2010b).
Birthweight z-scores57 by sex and gestational age were calculated for the study population
using the British 1990 growth reference population as the standard. This standard
population was created using the LMS method which uses three curves; the median (M),
coefficient of variation (S) and skewness (L) to summarise the changing distribution of a
measurement, in this case birthweight, by age (Cole et al, 1992). The software is freely
available including the reference population (Pan et al, 2012). A z-score of zero indicates
that the baby’s birthweight is the mean, for that gestation and gender, of the birthweight in
the British standard population. Infants with a negative z-score have a lower birthweight
than the standard population mean.
Congenital abnormalities
Abnormalities were categorised using WHO International Classification of Diseases (World
Health Organization, 2010b). The following abnormalities were classified as minor:
polydactyly, malformed ear, abnormalities of the feet, minor mouth abnormalities,
undescended testes, accessory nipple, spinal hairy patch, strawberry nevi, skin tag, and
subclinical sub-ependymal cysts, in line with previous analyses of the NSHPC dataset
(Townsend et al, 2009). For infants with more than one abnormality only the most major
was included in the analysis. Information is presented at the pregnancy, rather than infant,
level for consistency with other analyses in this chapter. For multiple pregnancies, an
abnormality was coded as being present if either twin was recorded as having an
abnormality.
Statistical analyses
The main aim of the analyses was to explore adverse outcomes, preterm delivery in
particular, among repeat pregnancies. Some important exposures of interest, such as birth-
to-pregnancy intervals and history of previous adverse outcomes, are only available for
repeat pregnancies. Therefore, although a comparison group of first reported pregnancies
was used for some descriptive analyses, detailed univariable and multivariable analyses
focused on repeat pregnancies. This was so that the associations between such exposures
and pregnancy outcomes could be fully explored. Logistic regression models were used to
identify demographic, clinical and immunological predictors of preterm delivery. Robust
57 These are standard deviation scores, which indicate the distance, in standard deviations, of an
individual’s birthweight from the mean birthweight of a specified reference population.
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standard errors were used to adjust for clustering since women may contribute more than
one repeat pregnancy to the dataset (Kirkwood et al, 2003) (see Chapter 3, Section 3.5).
It is well documented that women who have multiple pregnancies are at higher risk of
preterm delivery (Goldenberg et al, 2008; Steer, 2005). However, they were included here
as an exposure of interest because there is little current data on the magnitude of
increased risk of outcomes such as preterm delivery among multiple pregnancies in HIV-
positive women since they are often excluded from analyses from the outset (Lopez et al,
2012; Sibiude et al, 2012; Townsend et al, 2007). Where the time elapsed between
pregnancies was explored as an exposure, the birth-to-pregnancy rather than birth-to-birth
interval was used to avoid overestimation of the association between the birth interval and
adverse pregnancy outcomes. For example, if a second pregnancy results in a preterm
delivery, then the interval between the previous and current birth will be shorter than if the
second delivery had been at term (Conde-Agudelo et al, 2006; Shachar et al, 2013). The
birth-to-pregnancy interval was categorised as <6, 6-17, 18-35, 36-59, and ≥60 months. In 
the study population there was a right-skewed distribution of birth-to-pregnancy intervals
hence the smaller groupings for the more common, shorter intervals. The association
between the birth-to-pregnancy interval and adverse pregnancy outcomes is commonly
represented by a J-shaped curve (Conde-Agudelo et al, 2006). Therefore, one of the lowest
risk middle categories of birth-to-pregnancy interval (36-59 months) was used as the
baseline for univariable and multivariable analyses. Viral load at delivery was not
considered as a potential predictor of preterm delivery in these analyses due to the
potential for reverse causality (i.e. women delivering early may not have had the
opportunity to receive a sufficient duration of antenatal ART to reduce viral load to
undetectable levels) (Bailey et al, 2011).
7.1.2 Study population
These analyses included 3028 repeat pregnancies (97.0% of all repeat pregnancies – the
remaining 3% were those for which the outcome of the pregnancy was unknown e.g. the
pregnancy was continuing to term, or the woman had gone abroad). Of these, 2737
(90.4%) resulted in a live birth, 24 (0.8%) in a stillbirth, 199 (6.6%) a miscarriage, and 68
(2.2%) in a termination. Of the 2761 live and stillbirths, there were 2713 singletons and 48
sets of twins (all twin pregnancies resulted in a live birth). In addition to the repeat
pregnancies, there were 9195 index pregnancies with a known outcome including 8432 live
and stillbirths.
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7.1.3 Characteristics of first and repeat pregnancies
Table 7.1 shows the key characteristics of the first and repeat pregnancies. At their repeat
pregnancies, women were significantly older than in their index pregnancies (31.9 years,
IQR: 28.2-35.4 vs. 30.3 years, IQR: 26.5-34.3, p<0.001), and over a quarter (27.6%) were
aged ≥35 years, with 5.0% being aged ≥40 years. There was a significant secular increase 
in the proportion of pregnancies that were in women aged ≥35 years (e.g. from 15.9% in 
2003 to 33.9% in 2010, p<0.001). At their index pregnancy 42.7% of women were
nulliparous. Women were significantly more likely to conceive their repeat pregnancies
while on ART (48.8% vs. 21.9%, p<0.001), and less likely to be immunosuppressed (8.5%
had a CD4 <200 cells/µl compared with 15.7% at their first pregnancy, p<0.001). They were
also more likely to have suppressed viral load by the time of delivery in their repeat
pregnancies (83.5% vs. 73.7%, p<0.001). Of note, the proportion of repeat pregnancies
conceived on treatment increased significantly in more recent years (from 40.7% in 2005 to
61.5% in 2010, test for trend: p<0.001).
Information on the interval between the date of delivery of women’s previous live birth
(reported to the NSHPC) and the start of their subsequent pregnancy was available for
2561 repeat pregnancies. The median interval was 1.8 years (IQR: 0.9-3.1 years), 43.2%
were conceived in less than 18 months, and 10.7% in less than six months.
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Table 7.1 Adverse pregnancy and perinatal outcomes analyses - characteristics of
women in their first and subsequent pregnancies
Characteristic
First
pregnancies
Subsequent
pregnancies p-value
n % n %
Age at delivery, yrs (n=12,175)
<25 1602 17.5 314 10.4 <0.001
25-29 2793 30.5 796 26.3
30-34 2794 30.5 1081 35.7
35-39 1589 17.4 684 22.6
≥40 371 4.1 151 5.0
Ethnic group (n=12,049)
White 1205 13.4 429 14.2 0.585
Black African 6998 77.6 2368 78.2
Other 819 9.1 230 7.6
Time period of delivery* (n=12,223)
2000-2002 1549 16.8 102 3.4 <0.001
2003-2005 2883 31.4 622 20.5
2006-2008 3066 33.3 1224 40.4
2009-2010 1697 18.5 1080 35.7
HIV risk factor (n=11,517)
Other** 8349 97.6 2896 97.8 0.489
Injecting drug use 207 2.4 65 2.2
Pregnancy type (n=12,223)
Singleton 9039 98.3 2980 98.4 0.678
Twin/triplet 156 1.7 48 1.6
On ART at conception (n=11,562)
No 6909 78.1 1392 51.2 <0.001
Yes 1935 21.9 1326 48.8
Parity (n=8194)
Nulliparous 3496 42.7 - - -
Parous 4698 57.3 - -
Earliest CD4 count, cells/µl (n=9770)
≥500 2106 28.6 827 34.5 <0.001
350-499 1909 25.9 720 30.0
200-349 2202 29.9 648 27.0
<200 1154 15.7 204 8.5
Viral load at delivery, copies/ml (n=8619)***
<50 4664 73.3 1885 83.5 <0.001
≥50 1697 26.7 373 16.5
*Expected year of delivery for outcomes other than a live or stillbirth
**Other comprises largely those originating from a high HIV prevalence area and/or with heterosexual
exposure to HIV
***Based on the imputed viral load variable (see Chapter 3, Section 3.4)
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7.1.4 Pregnancy outcomes among first and repeat pregnancies
Table 7.2 shows pregnancy outcomes according to pregnancy number, including first
reported pregnancies as a comparison group. The live birth rate was very similar at around
90%, irrespective of pregnancy number, except for fifth and sixth births for which it was
much lower at 78.6%. The probability of stillbirth was 0.9% overall, and was slightly, but not
significantly, lower among repeat compared with first pregnancies (0.8% vs. 1.0%,
p=0.440), perhaps because miscarriages were more common among repeat pregnancies
(6.6% vs. 4.7%, p<0.001). However, this increased risk of reported miscarriage needs to be
interpreted with caution as ascertainment may be an issue. At their repeat pregnancies
women are, by definition, previously diagnosed and miscarriages among this group may be
more likely to be reported to the NSHPC, an issue which is discussed in more depth in the
discussion section of this chapter. The increased risk among repeat pregnancies remained
after adjusting for maternal age (p=0.002), but was attenuated (p=0.282) after adjusting for
the fact that women were more likely to be on ART at conception of their repeat pregnancy
(which could simply reflect the better reporting of miscarriages among women already on
ART at conception). The probability of reported miscarriage was particularly high for the
fourth pregnancies (8.9%) and fifth pregnancies (14.3%) (p=0.065 and p=0.092 respectively
when compared with first reported pregnancies), although the numbers were small. Only
one woman had a sixth pregnancy reported and this ended in a miscarriage. Terminations
were less common among repeat than first reported pregnancies (2.2% vs. 3.6%, p<0.001).
When the group for analysis was restricted to women who were known to be nulliparous at
the time of their first reported pregnancy, the live birth rate was slightly lower among the
repeat pregnancies (90.9% vs. 92.7%, p=0.042), there remained no significant difference in
the stillbirth rate (1.0% vs. 1.1%, p=0.605) and miscarriage remained more common among
the repeat pregnancies (5.7% vs. 4.0%, p=0.012). Women were still slightly less likely to
have termination at their repeat pregnancy although the difference was no longer significant
(2.2% vs. 2.5%, p=0.585).
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Table 7.2 Pregnancy outcomes according to pregnancy number
Outcome
Pregnancy Total among repeat
pregnancies1st 2nd 3rd 4th 5th 6th
n % n % n % n % n % n % n %
Live birth 8345 90.8 2175 90.3 470 91.4 81 90.0 11 78.6 0 0.0 2737 90.4
Stillbirth 87 1.0 22 0.9 2 0.4 0 0.0 0 0.0 0 0.0 24 0.8
Miscarriage* 434 4.7 155 6.4 33 6.4 8 8.9 2 14.3 1 100.0 199 6.6
Termination 329 3.6 57 2.4 9 1.8 1 1.1 1 7.1 0 0 68 2.2
Total 9195 100 2409 100 514 100 90 100 14 100 1 100 3028 100
*Includes ectopic pregnancies
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Focusing on the repeat pregnancy group, the 24 stillbirths occurred at a median gestational
age of 31.5 weeks (IQR: 29.0-38.0 weeks). One woman had two stillbirths reported. Those
aged ≥35 years appeared to be at slightly higher risk than younger women (1.0% vs. 0.8%)
though this was not statistically significant (p=0.784). There were also seven reported
neonatal deaths among the live born infants (a rate of 2.6 per 1000). Of these, five were
born very preterm (<32 weeks), one was 32-34 weeks, and the remaining infant was born
at term but had a major congenital abnormality.
Of the 199 miscarriages four were ectopic pregnancies. The median gestational age at
miscarriage was 12.0 weeks (IQR: 9.0-14.0 weeks). There were 20 late miscarriages (≥20 
completed weeks gestation). A total of 33 women had more than one miscarriage reported
(one woman had four, two women had three, and 30 women had two). Having a
miscarriage, rather than a live birth, was significantly more common among those aged ≥35 
years compared with those <35 years (10.2% (83/813) vs. 5.4% (115/2121), p<0.001), and
was particularly prevalent among those aged ≥40 years (13.9%).  
Among the 68 terminations the median gestational age was 10.0 weeks (IQR: 9.0-14.5).
There were four terminations carried out at 24 weeks, all had major congenital
abnormalities; two had severe chromosomal abnormalities, and the remaining two had
multiple abnormalities, the most significant being a cleft lip/palate in one and a digestive
abnormality in the other. There were no terminations carried out after 24 weeks.
Infant HIV status was reported for 84.3% of live births (2306/2737) in the repeat pregnancy
group; 13 infants (0.47%) were known to have acquired HIV. None of these women were
reported to have had more than one HIV-positive infant.
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7.1.5 Preterm delivery
Information on gestational age was available for 98.3% (2715/2761) of the repeat
pregnancies ending in a live or stillbirth. The median gestational age at delivery was 38
weeks (IQR: 37-39). The proportion of preterm deliveries (<37 weeks) was 13.1%
(355/2715), including 82 (3.0%) very preterm (<32 weeks). The proportion of singleton
repeat pregnancies that were preterm was 12.4%. Among those deliveries that were
preterm, the median gestational age was 34 weeks (IQR: 32-36). The risk of preterm
delivery was similar though slightly but not significantly (p=0.240) lower among repeat than
first reported pregnancies (1161/8311, 14.0%). The findings were similar if restricted to
women who were nulliparous at their first reported pregnancy (12.9% in repeat and 14.0%
in first pregnancies, p=0.280). Subsequent analyses are based on repeat pregnancies only.
As shown in Table 7.3, 40.8% of preterm deliveries were in women who had a history of
preterm delivery. Pregnancies in women belonging to the white ethnic group accounted for
18.9% of preterm deliveries but only 11.7% of term deliveries and, likely related to this,
women with a history of injecting drug use accounted for 4.6% of preterm deliveries and
only 1.9% of those that were at term. Not surprisingly, multiple pregnancies accounted for a
much larger proportion of preterm than term deliveries (6.8% vs. 1.0%). Women who were
severely immunosuppressed accounted for 12.2% of preterm and 5.2% of term deliveries
and, tying in with this, 5.3% of preterm deliveries were in symptomatic women compared
with 2.0% of those delivered at term.
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Table 7.3 Comparison of the characteristics of women with preterm and term deliveries
Characteristic Preterm Term p-valuen % n %
History of preterm delivery (n=2429)
No 173 59.2 1885 88.2 <0.001
Yes 119 40.8 252 11.8
Age at delivery, yrs (n=2714)
<25 39 11.0 245 10.4 0.576
25-29 97 27.3 620 26.3
30-34 120 33.8 871 36.9
35-39 78 22.0 522 22.1
≥40 21 5.9 101 4.3
Birth-to-pregnancy interval, mths* (n=2311)
<6 39 14.3 202 9.9 0.201
6-17 84 30.8 663 32.5
18-35 87 31.9 629 30.9
36-59 43 15.8 386 18.9
≥60 20 7.3 158 7.8
Ethnic group (n=2715)
White 67 18.9 276 11.7 0.001
Black African 263 74.1 1885 79.9
Other 25 7.0 199 8.4
Time period of delivery (n=2715)
2000-2002 14 3.9 73 3.1 0.214
2003-2005 84 23.7 459 19.4
2006-2008 138 38.9 975 41.3
2009-2010 119 33.5 853 36.1
HIV risk factor (n=2653)
Other** 332 95.4 2262 98.1 0.001
Injecting drug use 16 4.6 43 1.9
Pregnancy type (n=2715)
Singleton 331 93.2 2337 99.0 <0.001
Twin/triplet 24 6.8 23 1.0
HIV/AIDS symptoms (n=1950)
No 248 94.7 1655 98.0 0.001
Yes 14 5.3 33 2.0
On ART at conception (n=2488)
No 161 49.2 1137 52.6 0.254
Yes 166 50.8 1024 47.4
Earliest CD4 count, cells/µl (n=2342)
≥500 99 32.7 796 39.0 <0.001
350-499 82 27.1 650 31.9
200-349 85 28.1 487 23.9
<200 37 12.2 106 5.2
Type of ART (n=2654)
None 6 1.7 31 1.3 0.366
Mono/dual 14 4.0 118 5.1
cART - PI-based 202 58.2 1343 58.2
cART - NNRTI-based 99 28.5 696 30.2
cART - other*** 26 7.5 119 5.2
*Only includes pregnancies to women whose previous pregnancy resulted in a live birth
**Other comprises largely those originating from a high HIV prevalence area and/or with heterosexual
exposure to HIV
***Includes PI and NNRTI, NRTI only and unspecified
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In the univariable analyses (Table 7.4) a history of preterm delivery was strongly associated
with the preterm delivery in current pregnancy; the probability of preterm delivery was 8.4%
in those who had not had a previous preterm delivery reported, and 32.1% in those who
had, giving an unadjusted odds ratio for the association between previous preterm delivery
and subsequent preterm delivery of: 5.15, 95% CI: 3.90-6.79. Other factors associated with
preterm delivery were white ethnicity, multiple pregnancy, a history of injecting drug use,
maternal HIV/AIDS symptoms, and a low CD4 count. Although overall there was no
evidence of an association between birth-to-pregnancy interval and preterm delivery, those
with an interval of <6 months were at significantly increased risk compared with the
baseline group (with an interval of 36-59 months): OR: 1.73, 95% CI: 1.09-2.76. There was
little evidence of an association between preterm delivery and maternal age although there
was an indication of a higher odds among those aged ≥40 years (unadjusted OR compared 
with the 30-34 year age group: 1.51, 95% CI: 0.92-2.48). Time period of delivery was not
significantly associated with preterm delivery, and there was little evidence of an
association between being on ART at conception and preterm delivery (p=0.253). Antenatal
exposure to cART (compared with mono/dual therapy) has been previously linked with
preterm delivery in the UK, including previous analyses of the NSHPC data (Martin et al,
2007; Short et al, 2013; Townsend et al, 2007). In this analysis, although there was a trend
towards an increased probability among those on cART, this was not significant, likely due
to the fact that there were only 14 preterm deliveries in the mono/dual baseline group.
The multivariable model (Table 7.4) included previous preterm delivery, maternal ethnic
group, HIV risk factor, pregnancy type and antenatal CD4 count closest to delivery.
Although the presence of HIV/AIDS symptoms was associated with preterm delivery in the
univariable analysis, this variable was not included in the multivariable model since it is
correlated with CD4 count and was also missing for 28.2% of pregnancies. Previous
preterm delivery was strongly associated with preterm delivery in the multivariable model
(aOR: 5.60, 95% CI: 4.13-7.59). Compared with white women, black African women had a
lower odds of preterm delivery, as did those belonging to other ethnic groups. Multiple
pregnancies remained strongly associated with an increased probability of preterm delivery
(aOR: 9.63, 95% CI: 5.05-18.35), as did having a CD4 count of <200 cells//µl (aOR: 2.80,
95% CI: 1.72-4.55). After adjusting for the other variables in the model, the association
between having a history of injecting drug use and preterm delivery was attenuated, though
numbers were small. There was little evidence from the Wald test that any of the remaining
variables improved the fit of the model; time period (p=0.333), whether the woman was on
ART at conception (p=0.657), maternal age at delivery (p=0.398) or type of antenatal ART
received (p=0.621). There was also no evidence to include birth-to-pregnancy interval in
the model (p=0.854), and, if this variable was included in the multivariable model, there was
no longer any evidence that intervals of <6 months were associated with an increased risk
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of preterm delivery compared with intervals of 36-59 months (aOR: 1.25, 95% CI: 0.72-
2.18).
When the model was re-run with the outcome defined as preterm delivery at <35 completed
gestational weeks (rather than <37 weeks) but keeping all other variables constant
(including previous preterm delivery being defined as a previous delivery at <37 weeks), the
association between previous and subsequent preterm delivery was even stronger (aOR:
6.94, 95% CI: 4.73-10.19, p<0.001), and stronger still when the outcome was defined as
<32 weeks (aOR: 7.73, 95% CI: 4.40-13.58, p<0.001).
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Table 7.4 Univariable and multivariable analyses of factors associated with preterm delivery among repeat pregnancies
Preterm/Total (%) Univariable analyses Multivariable analysis (n=2057)OR 95% CI p-value aOR 95% CI p-value
History of preterm delivery
No 173/2058 (8.4) 1 <0.001 1 <0.001
Yes 119/371 (32.1) 5.15 (3.90-6.79) 5.60 (4.13-7.59)
Age at delivery, yrs
<25 39/284 (13.7) 1.16 (0.77-1.73)
25-29 97/717 (13.5) 1.14 (0.85-1.52)
30-34 120/991 (12.1) 1 0.579
35-39 78/600 (13.0) 1.08 (0.79-1.48)
≥40 21/122 (17.2) 1.51 (0.92-2.48)
Birth-to-pregnancy interval, mths*
<6 39/241 (16.2) 1.73 (1.09-2.76)
6-17 84/747 (11.2) 1.14 (0.77-1.67)
18-35 87/716 (12.2) 1.24 (0.85-1.82)
36-59 43/429 (10.0) 1 0.198
≥60 20/178 (11.2) 1.14 (0.65-1.99)
Ethnic group
White 67/343 (19.5) 1 0.002 1 <0.001
Black African 263/2148 (12.2) 0.57 (0.42-0.79) 0.46 (0.30-0.69)
Other 25/224 (11.2) 0.52 (0.31-0.85) 0.38 (0.20-0.71)
Time period of delivery
2000-2002 14/87 (16.1) 1 0.224
2003-2005 84/543 (15.5) 0.95 (0.52-1.75)
2006-2008 138/1113 (12.4) 0.74 (0.41-1.33)
2009-2010 119/972 (12.2) 0.73 (0.40-1.31)
Continued overleaf
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Table 7.4 Continued: Univariable and multivariable analyses of factors associated with preterm delivery among repeat pregnancies
Preterm/total (%) Univariable analyses Multivariable analysis (n=2057)OR 95% CI p-value aOR 95% CI p-value
HIV risk factor
Other** 332/2594 (12.8) 1 0.002 1 0.566
Injecting drug use 16/59 (27.1) 2.54 (1.41-4.55) 1.27 (0.56-2.86)
Pregnancy type
Singleton 331/2668 (12.4) 1 <0.001 1 <0.001
Twin/triplet 24/47 (51.1) 7.37 (4.11-13.20) 9.63 (5.05-18.35)
HIV/AIDS symptoms
No 248/1903 (13.0) 1 0.001
Yes 14/47 (29.8) 2.83 (1.50-5.34)
On ART at conception
No 161/1298 (12.4) 1 0.253
Yes 166/1190 (13.9) 1.14 (0.91-1.44)
Last antenatal CD4 count, cells/µl
≥500 99/895 (11.1) 1 <0.001 1 <0.001
350-499 82/732 (11.2) 1.01 (0.74-1.39) 1.07 (0.75-1.53)
200-349 85/572 (14.9) 1.40 (1.03-1.92) 1.34 (0.92-1.94)
<200 37/143 (25.9) 2.81 (1.83-4.31) 2.80 (1.72-4.55)
Type of ART
None 6/37 (16.2) 1.63 (0.59-4.54)
Mono/dual 14/132 (10.6) 1 0.765
cART - PI-based 202/1545 (13.1) 1.27 (0.71-2.25)
cART - NNRTI-based 99/795 (12.5) 1.20 (0.66-2.18)
cART - other*** 26/145 (17.9) 1.84 (0.91-3.72)
*Only includes pregnancies to women whose previous pregnancy resulted in a live birth
**Other comprises largely those originating from a high HIV prevalence area and/or with heterosexual exposure to HIV
***Includes PI and NNRTI, NRTI only and unspecified
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To assess the potential influence of missing data on the model, when women with missing
information on any of the variables included in the main multivariable model were
compared with those with complete information, they were at increased risk of preterm
delivery (17.2% (113/658) vs. 11.8% (242/2057), p<0.001). This difference remained even
when missing CD4 count was ignored (p<0.001), but was mainly due to missing information
on history of preterm delivery; the risk was 22.0% (63/286) in those with missing
information on history of preterm delivery compared with 12.0% (292/2429) with known
information (p<0.001).
Sensitivity analyses: Association between previous preterm delivery and subsequent
preterm delivery
Since multiple pregnancies were included in the model, if a woman’s previous preterm
delivery was a multiple pregnancy then the association between previous preterm delivery
and subsequent preterm delivery could potentially be underestimated (i.e. if the previous
preterm delivery was solely due to it being a multiple pregnancy). Therefore, as a sensitivity
analysis the model was re-run after excluding all multiple pregnancies (i.e. both current and
previous) (Table 7.5). The resulting aOR for the association between previous preterm
delivery and current preterm delivery was very similar (aOR: 5.79).
As outlined earlier in this chapter, repeat pregnancies were coded as such if the woman
had one or more previous pregnancies reported to the NSHPC. However, women may be
parous at the time of their first reported pregnancy, and some of these women may have
experienced a preterm delivery prior to their entry into the NSHPC. To explore this potential
source of misclassification the main model was re-run excluding all repeat pregnancies to
women who were parous at their first reported pregnancy. The strong association between
previous and subsequent preterm delivery remained (aOR: 4.39), although the aOR was
slightly lower (Table 7.5).
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Table 7.5 Sensitivity analyses of the association between previous and subsequent
preterm delivery
Restrictions to study population
Multivariable analysis*
n aOR 95% CI p-value
Singletons 2002 5.79 4.23-7.92 <0.001
Women nulliparous at their first
reported pregnancy 1198 4.39 2.90-6.64 <0.001
*Odds of preterm delivery among women with a previous preterm delivery compared with those without
(model adjusted for maternal ethnic group, HIV risk factor, multiple pregnancy, and last antenatal CD4
count)
Sub-analyses: Conceiving on ART as a predictor of preterm delivery
Several analyses presented in Chapter 5 of this thesis explored issues regarding the
potential benefits of the initiation of lifelong ART for all pregnant women. Related to this,
any associations between conceiving on ART and adverse pregnancy outcomes need to be
considered. Therefore, the association between conceiving on ART and the risk of preterm
delivery was explored in more detail (Table 7.6), particularly given that, although possible in
the present analyses, most previous studies on ART and preterm delivery have not
adjusted for previous preterm delivery (Boer et al, 2007; European Collaborative Study and
Swiss Mother and Child HIV Cohort Study, 2000; Grosch-Woerner et al, 2008; Lopez et al,
2012; Martin et al, 2007; Ravizza et al, 2007; Rudin et al, 2011; Short et al, 2013; Thorne et
al, 2004; Townsend et al, 2007). As was shown in Table 7.4, overall there was no
significant association between being on ART at conception and the probability of preterm
delivery. However, the analysis was based on all women thus the group who were not on
ART at conception will include some women who never received ART during pregnancy
(n=42). When the univariable analysis was restricted to women who received at least 14
days of ART (any type) during pregnancy the odds of preterm delivery among women on
ART at conception compared with those initiating ART during pregnancy was 1.19 (95% CI:
0.94-1.50) (Table 7.6). When the analysis group was further restricted to include only those
who received ≥14 days of PI-based cART during pregnancy, the association was stronger 
(OR: 1.36, 95% CI: 1.00-1.87). However, this association was nullified when the other
variables included in the main multivariable analysis (previous preterm delivery, ethnic
group, HIV risk factor, multiple pregnancy, and last antenatal CD4 count) were adjusted for
(aOR: 1.05, 95% CI: 0.70-1.57).
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Given current CD4 count thresholds of <350 cells/µl for initiation of lifelong ART (Taylor et
al, 2012), it is among women who present in pregnancy with a CD4 count of ≥350 cells/µl 
where the balance of risks and benefits of initiating lifelong ART (in terms of future
pregnancy outcomes) need careful consideration. When the probability of preterm delivery
in those conceiving on PI-based cART was compared with those not on ART at conception
but who received ≥14 days of PI-based antenatal cART, and restricted to those with a pre-
ART antenatal CD4 count of ≥350 cells/µl, the OR was 1.77 (95% CI: 1.23-2.54). Although 
the association became non-significant after adjusting for the other variables in the main
multivariable model (excluding CD4 count), the direction of the aOR was the same (1.37,
95% CI: 0.90-2.10).
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Table 7.6 Sub-analyses: conceiving on ART as a predictor of preterm delivery
Restrictions to study
population*
Univariable analyses 1*** Univariable analyses 2 ***† Multivariable analyses***
n OR 95% CI p-value n OR 95% CI
p-
value n aOR 95% CI
p-
value
Women who received ≥14 
days of antenatal ART (any
type) 2440 1.19 0.94-1.50 0.150 2039 1.04 0.79-1.36 0.778 2039 0.95 0.71-1.27 0.726
Women who received ≥14 
days of antenatal PI-based
cART 1434 1.36 1.00-1.87 0.053 1203 1.21 0.84-1.74 0.302 1203 1.05 0.70-1.57 0.810
Women who received ≥14 
days of antenatal PI-based
cART and had a pre-ART
CD4 count of ≥350 cells/µl** 1164 1.77 1.23-2.54 0.002 1030 1.73 1.20-2.49 0.003 1030 1.37†† 0.90-2.10 0.145
*Restrictions detailed in the table were applied to both women on ART at conception and those who were not (see ** below for the exception to this rule)
**Pre-ART CD4 counts for women on ART at conception are not routinely collected by the NSHPC. This specific restriction was therefore only applied to women not on ART at
conception
***Odds of preterm delivery among women on ART at conception compared with those starting ART during pregnancy. Multivariable model adjusted for previous preterm
delivery, ethnic group, HIV risk factor, multiple pregnancy, and last antenatal CD4 count
†Models restricted to those with complete information on all variables included in the multivariable model
††Not adjusted for CD4 count since the analyses were restricted to those with a CD4 count of ≥350 cell/µl 
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7.1.6 Low birthweight and small for gestational age
Analyses of low birthweight and small for gestational age were restricted to live born
infants. Among repeat pregnancies the median birthweight was 3.1kg (IQR: 2.8-3.4), and
12.6% (2232/2553) of infants were of low birthweight (<2.5kg), including 53 infants (2.1%)
of very low birthweight (<1.5kg). The median birthweight among repeat pregnancies was
significantly (p<0.001) higher compared with first reported pregnancies (3.0kg, IQR: 2.7-
3.4). In line with this, the proportion of low birthweight infants was significantly (p=0.009)
lower among the repeat pregnancies compared with first reported pregnancies (14.7%,
1099/7491). This difference remained when the analysis was restricted to infants born at
term: 5.0% (112/2230) among repeat pregnancies and 6.2% (404/6486) for first reported
pregnancies (p=0.037). When the analysis was restricted to women who were nulliparous
at their first reported pregnancy a similar pattern was observed; the proportion of low
birthweight infants was 13.5% among the repeat pregnancies and 15.4% among the first
reported (p=0.131). Similarly, mean z-scores of birthweight (accounting for gestational age
and gender) were higher among repeat than first reported pregnancies (-0.009 and -0.179
respectively, p<0.001), and a significant difference remained when the analysis was
restricted to infants born at term (-0.020 vs. -0.175, p<0.001).
7.1.7 Congenital abnormalities
Information on the presence of congenital abnormalities was reported for 96.7%
(2648/2737) of pregnancies resulting in a live birth and 83.3% (20/24) of those resulting in a
stillbirth. Overall, 2.9% (78/2668) of pregnancies resulted in the birth of an infant with an
abnormality; 2.8% (n=75) of live born infants and 15.0% (n=3) of stillborns. The probability
of abnormality among the repeat pregnancies was very similar to that among first reported
pregnancies (also 2.9%, 235/8159, p=0.908). There was also no significant difference if the
study population was restricted to women who were nulliparous at their first reported
pregnancy (p=0.943).
Among the repeat pregnancies there were 34 infants with minor abnormalities and 46 with
major abnormalities, the latter thus accounting for 57.5% of all 80 abnormalities reported.
The most common types of abnormalities were those affecting the limbs, the majority of
which were having extra digits (17/20), followed by heart and circulatory abnormalities
(n=15) all of which were considered major abnormalities (Table 7.7). Of the three stillborn
infants with an abnormality one had a heart defect, one had a bowel obstruction, and the
remaining infant had a chromosomal abnormality.
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The probability of having an infant with an abnormality was similar in women aged ≥35 
years and <35 years (2.7% (19/713) vs. 3.0% (1895/1954), p=0.630, but there was
evidence of an increased risk among those aged ≥40 years compared with <40 years 
(5.8% (7/120) vs. 2.8% (71/2547), p=0.053). There was no evidence to suggest that infants
born to women on ART at conception were at an increased risk of abnormalities compared
with those starting during pregnancy (2.7% vs. 3.0% respectively, p=0.615).
Table 7.7 Congenital abnormalities among live and stillbirths
Congenital
abnormality
Minor Major Total*
n %
Limbs 17 3 20 25.0
Heart & circulatory 0 15 15 18.8
Integument 9 0 9 11.3
Urinary 1 5 6 7.5
Musculoskeletal 0 6 6 7.5
Chromosomal 0 6 6 7.5
Genital organs 3 2 5 6.3
Digestive 0 3 3 3.8
Eye, ear, face, neck 2 0 2 2.5
Respiratory 1 1 2 2.5
Cleft palate/lip 0 2 2 2.5
Nervous system 0 1 1 1.3
Type not specified 0 1 1 1.3
Total 34 46 80 100
*Includes two second born twins (where the first born did not have an abnormality but the second born
twin did)
Among the 62 repeat pregnancies that ended in a termination at <24 completed gestational
weeks, two abnormalities were reported, both of which were major (one was anencephaly
and the other chromosomal). Abnormalities among the four terminations carried out at 24
gestational weeks (there were none later than this) were described earlier in this chapter in
relation to pregnancy outcomes (Section 7.1.4).
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7.2 Mode of delivery
As shown in Chapter 2, Section 2.7, there is a large pool of diagnosed women in the UK
and Ireland with a history of caesarean section delivery. UK guidelines allow for, and more
recently specifically recommend, vaginal deliveries for women on cART with undetectable
viral loads (de Ruiter et al, 2008; Hawkins et al, 2005; Taylor et al, 2012). The risks and
benefits of vaginal delivery after previous caesarean section(s) are, however, uncertain
among the general population and have been little explored among women living with HIV.
The objective of the second part of this chapter is to describe mode of delivery among
repeat pregnancies, explore patterns within women (VBAC for example), and document
serious adverse outcomes that may be related to mode of delivery (Objective 6).
7.2.1 Methods
Analyses were restricted to deliveries during 2005-2010 to women who had already
experienced at least one live or stillbirth since their HIV diagnosis (Figure 7.2) since UK
guidelines on the obstetric management of HIV in pregnancy have changed quite
substantially over the last decade, as discussed in Chapter 2, Section 2.7. If a woman had
more than one repeat delivery during the study period only her last was included (hereafter
referred to as her ‘subsequent’ or ‘current’ delivery’). Where a woman’s ‘previous’ delivery
is referred to this was her immediately preceding birth. The dataset was based on
deliveries, and for the purpose of these analyses multiple pregnancies were considered as
one delivery (based on information reported for the first born twin) in line with the way such
data are routinely recorded by the NSHPC. Some sub-analyses were restricted to women
who were nulliparous at the time of their first pregnancy reported to the NSHPC. Reasons
for emergency caesarean sections are collected via the obstetric scheme only. Viral load
was the reported measurement closest to delivery (within 28 days prior and up to seven
days after)58.
58 For most analyses in this thesis, an imputed viral load variable was used whereby if no viral load was
reported within 28 days prior and up to seven days after delivery but the woman had an undetectable viral
load reported earlier in that pregnancy then her delivery viral load was imputed as undetectable (as
described in Chapter 3, Section 3.4). It was not felt appropriate to use the imputed variable in these
analyses since actual viral load closest to the point of delivery (whether or not reported to the NSHPC)
could substantially influence the mode of delivery undertaken.
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Figure 7.2 Study population flow chart – mode of delivery analyses
*Information on these previous pregnancies was retained in the dataset for exploration of patterns in mode
of delivery within women
7.2.2 Study population
There were 1996 subsequent deliveries (1981 live and 15 stillbirths) eligible for inclusion in
the analysis; 1598 were second deliveries, 346 third, 46 fourth and six fifth (Table 7.8).
There were 1960 singletons and 36 pairs of twins. The majority of deliveries (86.2%) were
to women who were born abroad, with most of these originating from sub-Saharan Africa.
Women’s median age at delivery of their last reported infant was 32.5 years (IQR: 28.7-
36.0); most women were aged 25-34 years although almost one third were ≥35 years. The 
median birth-to-birth interval between women’s last birth and their previous birth was 2.2
years (IQR: 1.1-3.6). The last antenatal CD4 count measurement during that pregnancy
was <350 cells/µl in 29.0% of pregnancies, and viral load at delivery was undetectable in
77.4%.
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Table 7.8 Mode of delivery analyses - characteristics of subsequent pregnancies
Characteristic n %
Pregnancy (n=1996)
Second 1598 80.1
Third 346 17.3
Fourth 46 2.3
Fifth 6 0.3
Year of delivery (n=1996)
2005 179 9.0
2006 220 11.0
2007 322 16.1
2008 359 18.0
2009 474 23.7
2010 442 22.1
Age at delivery, yrs (n=1995)
<25 182 9.1
25-34 1179 59.1
≥35 634 31.8
World region of origin (n=1995)
UK/Ireland 276 13.8
Sub-Saharan Africa 1559 78.1
Elsewhere 160 8.0
Pregnancy outcome (n=1996)
Live birth 1981 99.2
Stillbirth 15 0.8
Pregnancy type (n=1996)
Singleton 1960 98.2
Twin/triplet 36 1.8
Gestational age, wks (n=1963)
≥37 1718 87.5
<37 245 12.5
Last CD4 count, cells/µl (n=1712)
≥500 677 39.5
350-499 540 31.5
200-349 393 23.0
<200 102 6.0
Viral load at delivery, copies/ml (n=1071)
≤50 829 77.4
>50 242 22.6
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Time trends in mode of delivery
Mode of delivery was reported for 98.7% (1970/1996) of live and stillbirths in this dataset.
Overall 47.0% (925/1970) were delivered by elective caesarean section, 31.2% (n=615)
vaginally, and 21.8% (n=430) by emergency caesarean section. Of note, the rate of
elective caesarean section among the last reported births was higher than that among
women having their first delivery during the same period (41.2% (2257/5480))59. Mode of
delivery was reported for 12 of the 15 stillbirths; there were five emergency caesarean
sections and seven vaginal deliveries (five planned and two unplanned). Figures 7.3 and
7.4 show trends in mode of delivery over time; the overall proportion of vaginal deliveries
increased significantly between 2005 and 2010 (from 21.0% to 39.3%, p<0.001). The
proportion of women who had a planned vaginal delivery more than doubled over the six
year study period (from 13.1% in 2005 to 29.0% in 2010 p<0.001). There was no significant
change in the proportion of unplanned vaginal deliveries (p=0.565). In line with the overall
increase in vaginal deliveries, the proportion of caesarean sections declined (from 79.0% to
60.7% p<0.001) driven by a decline in elective caesarean sections (from 58.5% to 39.5%,
p<0.001), while the proportion of emergency caesarean sections was stable; 20.5% in 2005
and 21.2% in 2010 (p=0.140).
59 This group of first reported pregnancies during 2005-2010 did not form part of the study population but
data is provided here for context.
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Figure 7.3 Mode of delivery for subsequent births, by year, 2005-2010
Figure 7.4 Subsequent births delivered vaginally according to whether they were
reported to have been planned, by year, 2005-2010
*Not specified whether planned or unplanned
Note: Figure 7.4 provides a breakdown of the vaginal deliveries shown in Figure 7.3.
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7.2.3 Planned and actual mode of delivery
Emergency caesarean sections
Among the 430 women delivering by emergency caesarean section during 2005-2010 the
planned mode of delivery was reported for 243, around half (51.4%) of whom had planned
for an elective caesarean section, and half for a vaginal delivery. Over a third (36.9%,
158/428) of emergency caesarean sections were delivered preterm. Information on the
reason for emergency caesarean section was reported for 208 women. The most common
reason was rupture of membranes (either ‘spontaneous’ or ‘premature’) accounting for a
quarter of cases (n=51, 24.5%), followed by fetal distress (n=42, 20.2%), labour (n=36,
17.3%), and failure to progress (n=25, 12.0%). All other reasons given each accounted for
<5% of the remaining deliveries.
Vaginal deliveries
Of those delivering vaginally this was reported as being the planned mode of delivery for
95.4% (477/500). Looking at this the other way around, of the 607 women who planned to
deliver vaginally 78.6% did deliver vaginally, 19.4% by emergency caesarean section. The
remaining small proportion (2.0%) were reported to have delivered by elective caesarean
section likely due to a change in the planned mode close to the time of delivery e.g. due to
an unsuppressed viral load late in pregnancy or emergent obstetric indications. Overall,
10.8% (66/609) of vaginal deliveries were preterm. The majority of women delivering
vaginally who had a viral load delivery measurement, reported had an undetectable viral
load (88.9%, 279/314); the proportion was 91.0% among the planned vaginal deliveries.
Although the NSHPC requests the viral load measurement closest to delivery, it is possible
that this is not always what is actually reported. Among the vaginal deliveries, viral load
measurements were taken at a median of 25 days (IQR: 14-44.5) prior to delivery, and of
those with a detectable viral load, the majority (85.7%, 30/35) were <400 copies/ml. It is
thus feasible that some of the women reported as having a detectable viral load may in fact
have become undetectable at the point of delivery. Furthermore, maternal choice may play
a role, particularly for women with a very low, but detectable, viral load.
Elective caesarean sections
Of the 499 women who had an elective caesarean section planned 70.3% delivered by this
route, 25.1% by emergency caesarean section (half of which were preterm deliveries), and
4.6% delivered vaginally. Among those who had an elective caesarean section, 73.4% had
an undetectable viral load (for context, the corresponding proportion among first reported
pregnancies was 60.6% (783/1292)). Among the last reported pregnancies, the proportion
262
of those delivered by elective caesarean section with an undetectable viral load did not
decrease over the study period (it was 78.6% in 2010), though this largely reflects
improvements in viral suppression by delivery over time. Viral load measurements were
taken at a median of 21 days (IQR: 9.0-41.5) prior to delivery.
7.2.4 Mode of delivery patterns within women
There were 1953 women with information available on the mode of delivery for both their
current (last reported) and previous birth. Figure 7.5 shows that among women delivering
vaginally 31.4% had delivered their previous infant by caesarean section (either elective or
emergency). Of the 1404 women who had delivered their previous infant by caesarean
section, 13.6% (n=191) subsequently had a VBAC, and this proportion increased
significantly from 8.3% in 2005 to 17.3% in 2010 (test for trend: p<0.001). Meanwhile, of
women delivering by elective caesarean section 94.5% had delivered their previous infant
by caesarean section (either elective or emergency). Among women delivering by
emergency caesarean section 33.3% delivered their previous infant by emergency
caesarean section.
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Figure 7.5 Mode of delivery for current and previous birth
CURRENT DELIVERY PREVIOUS DELIVERY
El CS – Elective caesarean section, Em CS – Emergency caesarean section
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Figure 7.6 shows patterns in women’s planned mode of delivery for their current pregnancy
according to the mode of delivery of their previous pregnancy. Of the 601 women who had
planned a vaginal delivery for their current pregnancy, over a third (37.6%) had delivered
their previous pregnancy by a caesarean section. Meanwhile, of the 494 women planning
to deliver their subsequent pregnancy by elective caesarean section, the vast majority had
previously delivered by a caesarean section with only 4.2% having previously delivered
vaginally. With regard to the success rate of VBAC, of the 226 women who had previously
delivered by caesarean section and planned to have a subsequent VBAC, 61.6% (n=138)
successfully delivered by this route (data not shown).
Figure 7.6 Planned mode of delivery for current birth and actual mode of delivery for
previous birth
CURRENT DELIVERY PREVIOUS DELIVERY
(PLANNED MODE)
El CS – Elective caesarean section, Em CS – Emergency caesarean section
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Sensitivity analyses: Patterns in mode of delivery within nulliparous women
Analyses restricted to women who were nulliparous at their first reported pregnancy
included 742 women, 725 (97.7%) of whom had known mode of delivery for both their
previous (first) reported pregnancy and current (second) pregnancy. Figure 7.7 shows that
the patterns in mode of delivery among this sub-group were similar to those among all
women. Among those delivering vaginally, 42.7% had delivered their previous infant by
caesarean section (either elective or emergency), this proportion remained stable between
2005 and 2010 (test for trend: p=0.619). Looking at this the other way around, of the 568
women who had delivered their previous infant by caesarean section, 15.5% (n=88)
subsequently had a VBAC, and this proportion increased significantly from 6.8% in 2005 to
18.0% in 2010 (test for trend: p=0.022). Of women delivering by elective caesarean section
the vast majority (95.6%) had delivered their previous infant by caesarean section (either
elective or emergency).
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Figure 7.7 Mode of delivery for current and previous birth, among women who were
reported to be nulliparous at their first reported pregnancy
CURRENT DELIVERY PREVIOUS DELIVERY
El CS – Elective caesarean section, Em CS – Emergency caesarean section
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7.2.5 Women with two or more caesarean sections
After their last reported delivery, 1235 women had experienced two or more caesarean
sections (1018 women had two, 197 had three, 19 had four, and one woman had five)60.
Only five women had had more than one previous caesarean section and then delivered an
infant vaginally during 2005-2010, of whom two were nulliparous at their first reported
pregnancy, and the remaining three were parous. An additional three women had more
than one previous caesarean section and then planned to deliver their last infant vaginally
(but actually delivered by emergency caesarean section), all of whom were parous at their
first reported pregnancy.
7.2.6 Adverse obstetric outcomes that may be related to mode of delivery
Uterine rupture
Among all 1996 deliveries four uterine ruptures were reported to have occurred
representing a risk of 0.20% (95% CI: 0.004-0.40), all resulting in an emergency caesarean
section. The risk was 0.28% (95% CI: 0.006-0.56) among the 1404 women who had
previously delivered by caesarean section. Three of these women had experienced one
previous caesarean section, and one woman had experienced two. Elective caesarean
section had been planned for two of the women, a vaginal delivery for one, and for the
remaining woman the planned mode of delivery was not reported. None of the four women
were reported to have died. Of the four infants two were stillborn; one at 32 weeks
gestation, and one at 41 weeks gestation, the latter was born to the one woman who was
planning to have a vaginal delivery. The remaining two deliveries were live births; one at 32
weeks and one at 39 weeks. Neither of the live born infants was known to have acquired
HIV.
MTCT
There were 10 HIV-positive infants delivered during the study period, of whom five were
delivered by elective caesarean section, two by emergency caesarean section, and the
remaining three vaginally, giving transmission rates of 0.65% (95% CI: 0.08-1.21, n=5/774),
0.58% (95% CI: -0.02-1.38, n=2/345) and 0.62% (95% CI: -0.08-1.31, n=3/487)
respectively. The very small number of HIV-positive infants in each of these three groups
makes it difficult to draw valid comparisons.
Table 7.9 shows the current and previous modes of delivery for the women whose infants
vertically acquired HIV together with relevant clinical and obstetric details for their current
60 Based on all their deliveries reported to the NSHPC during 1990-2010.
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pregnancy. Of the five women who delivered HIV-positive infants by elective caesarean
section, all had delivered their previous infant by caesarean section, three had a detectable
viral load at delivery (of the remaining two, one was undetectable (<50 copies/ml) and one
was missing), and three were reported to have been parous at the time of their first
pregnancy reported to the NSHPC. Of the two women who delivered an HIV-positive infant
by emergency caesarean section, both had delivered previously by caesarean section and
both had detectable viral loads. Finally, of the three women who delivered vaginally one
had planned for a caesarean section but planned mode of delivery was missing for the
remaining two (one of whom had a detectable viral load at delivery). Two of the women had
previous vaginal deliveries and one a previous elective caesarean section. None of the
women reported here had more than one HIV-positive infant.
269
Table 7.9 Current and previous mode of delivery among women who had HIV-positive infants in their last reported pregnancy
Woman Actual mode ofdelivery*
Planned mode of
delivery* Preterm delivery
Viral load,
copies/ml**
Mode of delivery for
previous pregnancies***
Parity at first
reported pregnancy
1 Elective CS n/a No ≥10,000 2x elective CS Not reported
2 Elective CS n/a Not reported Not reported 1x elective CS 2
3 Elective CS n/a No <50 1x elective CS 1
4 Elective CS n/a No 50-999 1x elective CS Nulliparous
5 Elective CS n/a No ≥10,000 1x emergency CS 1
6 Emergency CS Not reported No ≥10,000 1x emergency CS Nulliparous
7 Emergency CS Not reported No 50-999 1x elective CS Not reported
8 Vaginal Elective CS No Not reported 3 x vaginal Nulliparous
9 Vaginal Not reported Yes ≥10,000 1x emergency CS 2
10 Vaginal Not reported No <50 1x vaginal 2
CS - caesarean section
*For current (last reported) pregnancy
**Closest to delivery (in current pregnancy), restricted to measurements taken between 28 days before and seven days after delivery
***Previous pregnancies reported to the NSHPC
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7.3 Discussion
7.3.1 Adverse pregnancy and perinatal outcomes
Risk of adverse outcomes among HIV-positive women
Among the repeat pregnancies the overall risk of preterm delivery was 13%, which is
consistent with previous analyses of UK data on HIV-positive women (Cheshire et al, 2012;
Short et al, 2013; Townsend et al, 2007), but higher than the 7% recorded among the
general population in England and Wales (Office for National Statistics, 2011a), and across
Europe (6%) (Beck et al, 2010). Similarly, the risk of low birthweight, at 13%, was notably
higher than among the UK general population (6%) (Moser et al, 2008). Comparisons
between HIV-positive women and the general population should be made with caution. For
example, the socio-economic characteristics of HIV-positive women, who are largely
migrants from sub-Saharan Africa, will differ to those of the general population. However, it
is of note that among the general population of black African women living in the UK the
risk of pre-term delivery (8%) (Office for National Statistics, 2011a) and low birthweight
(7%) (Moser et al, 2008) were still considerably lower than among HIV-positive women.
The role of HIV-related factors cannot, therefore, be ruled out. The rate of congenital
abnormalities, at 2.9% during 2000-2010, was not dissimilar to the prevalence among the
general population (2.6% in 2007), though comparisons are difficult due to the differing
definitions, methodologies, and time periods for which data is available (see Chapter 2,
Section 2.6).
Adverse outcomes among repeat compared with index pregnancies
At their repeat pregnancies HIV-positive women did not appear to be at increased risk of
stillbirth, preterm delivery, having an infant with a low birthweight or congenital
abnormalities compared with index pregnancies. This largely allays concerns about a
potentially increased risk of adverse pregnancy outcomes in repeat pregnancies (see
Chapter 2, Section 2.6). The probability of having a low birthweight infant was in fact
significantly lower among the repeat pregnancies, tying in with the reduced risk of low
birthweight infants among parous women in the general population (Shah, 2010). Indeed,
being parous per se has been associated with a lower risk of a range of adverse outcomes
in the general population as detailed in Chapter 2, Section 2.6. Furthermore, the lack of
increased risk of adverse outcomes among the repeat pregnancies may reflect a
combination of factors which could be balancing out the risks among the two groups. For
example, although median maternal age was greater among the repeat pregnancies, the
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proportion aged ≥40 years was similar (5% vs. 4%) thus the impact of increased maternal
age may not be substantial. Maternal health was actually better among the repeat than first
pregnancy groups, likely because a higher proportion were on ART at conception (49% vs.
22%). However, associations are complex, with, for example, interactions between the
influence of parity and correlated exposures such as maternal age (Kozuki et al, 2013;
Lisonkova et al, 2010). These were not explored in detail here as the analyses largely
aimed to explore adverse outcomes among the repeat pregnancies specifically rather than
elucidate the mechanisms through which parity may influence pregnancy and perinatal
outcomes more generally.
In contrast to findings with respect to stillbirth, preterm birth, low birthweight and birth
defects, women were at significantly increased risk of reported miscarriage at their repeat
pregnancies (7% vs. 5%, p<0.001). As has been mentioned, this finding should be
interpreted with caution. Although reporting of late miscarriages (≥20 weeks) is likely to be 
reasonably complete, since over 80% of women book for antenatal care before 18 weeks
gestation (as shown in Chapter 5), early miscarriages are likely to be under-reported to the
NSHPC since information is generally collected at the time that women first book for
antenatal care, which in this population was at an average of around 13 weeks gestation
(also shown in Chapter 5). Furthermore, there may be some differential reporting of
miscarriage which could bias the findings; miscarriages might be more likely to be reported
among women who have already experienced a pregnancy as a diagnosed woman. Of
course another explanation that needs to be considered is toxicities of early pregnancy
exposure to ART. After adjusting for whether women were on ART at conception there was
no longer a significant difference in the risk of miscarriage, suggesting that this may play a
role. However, reporting (or selection) bias may also be relevant here with women on ART
from prior to conception potentially being more likely to have a miscarriage reported.
Relatively few studies have explored miscarriage as a potential adverse pregnancy
outcome in the cART era. An analysis of HIV-positive women enrolled in the US Women’s
Interagency HIV Study during 1994-2002 found no evidence of an increased risk among
those who were already on ART at their last study visit prior to conception (Massad et al,
2004). However, data from a single UK centre during 1997-2012, (which will thus also be
present in the national NSHPC dataset) showed that the odds of miscarriage among those
on cART prior to pregnancy was 9.75 (95% CI: 2.13-44.62) times that in women starting
cART during pregnancy. These findings should, however, be interpreted with caution; the
OR was not adjusted for confounding factors, and the number of miscarriages was small,
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with only 15 reported during the study period, hence the very wide confidence intervals.
Also, as per the NSHPC analyses, reporting bias is probable (Dale, 2013)61.
That women’s repeat pregnancies since diagnosis were less likely to result in a termination
than first pregnancies ties in with the decline in terminations among HIV-positive women
over time (Townsend et al, 2008b). It may also reflect the fact that these women have
already experienced a pregnancy as an HIV-positive woman in the era of very low rates of
MTCT (the study population was restricted to women whose first reported pregnancy was
from 2000 onwards), thus potentially allaying women’s fears around MTCT. Women’s
better health at their repeat pregnancies may also have had an impact. Other studies have
reported declining rates of termination in the cART era (Massad et al, 2004; van Benthem
et al, 2000). Furthermore, aside from the influence of an HIV diagnosis on decision-making,
already having children may influence decisions regarding the termination of subsequent
unintended pregnancies in the general population (Skjeldestad et al, 1994).
Risk factors for preterm delivery among repeat pregnancies
The following factors were associated with an increased risk of preterm delivery among
repeat pregnancies in adjusted analyses: previous preterm delivery, white ethnicity,
multiple pregnancy, and low antenatal CD4 count. In the multivariable model, women with a
previous preterm delivery reported to the NSHPC had over five times the odds of having a
subsequent preterm delivery. Although studies on the association between previous and
subsequent preterm delivery among HIV-positive women specifically are lacking in the
published literature, in the general population prior preterm delivery has been found to be a
strong predictor of subsequent preterm delivery, as highlighted in two large reviews
(Goldenberg et al, 2008; Slattery et al, 2002). In a recent Italian study among HIV-positive
women, a significant association was also detected, though the adjusted OR was lower
than in the present study (aOR: 2.22, 95% CI: 1.23–4.01) (Liuzzi et al, 2013). This could in
part reflect the higher overall risk of preterm delivery in the Italian study population (21%)
compared with HIV-positive women in the UK and Ireland. In the current analyses the
association was even stronger for women who had previously delivered very preterm
infants (<34 weeks or <32 weeks), a pattern that has also been noted in the general
population (Goldenberg et al, 2008; Mercer et al, 1999). The robustness of these findings
was assessed in several sensitivity analyses and remained after excluding multiple
pregnancies and women who were parous at their first reported pregnancy. This data
underscores the important influence of obstetric history. Such histories need to be borne in
61 Noteworthy, but of less relevance to the interpretation of the findings presented here, the Development
of AntiRetroviral Therapy in Africa (DART) trial reported no increased risk of miscarriage/termination (a
combined outcome) in women on long-term tenofovir-containing cART compared with without tenofovir
exposure during pregnancy (Gibb et al, 2012). As noted in Chapter 1, tenofovir is one of the WHO
recommended first-line drugs for adults.
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mind not only for the obstetric, but also for the therapeutic management of diagnosed
women. For example, prior preterm delivery may be an important indicator for the earlier
initiation of antenatal ART to ensure viral suppression by delivery.
Compared with white women, those of black African or ‘other’ ethnicity were at lower risk of
preterm delivery. A review of the international evidence-base pointed towards an increased
risk among black women living in the western world (Goldenberg et al, 2008), though
disentangling the influence of ethnicity from socio-economic factors is difficult. The findings
of other UK-based studies have varied. For example, a large cohort study of live singleton
births among 122,415 nulliparous women reported a preterm delivery odds ratio of 1.33
(95% CI: 1.15-1.56) for black compared with white women, after adjusting for deprivation
(Patel et al, 2004). Meanwhile, a study of over 36,000 live births in Birmingham did not find
an increased risk among black women, although there was some evidence of an increased
risk of very preterm delivery (both <34 weeks and <28 weeks), even after adjusting for
factors such as maternal deprivation. However, the number of black women included in the
study was relatively small (n=213) (Aveyard et al, 2002). Among HIV-positive women
specifically, studies from other European countries have suggested lower risks among
black women, though the difference was not always significant (Boer et al, 2007; Rudin et
al, 2011; Thorne et al, 2004). In the UK and Ireland, white HIV-positive women may have
other risks, for example over 90% of women with a history of injecting drug use belonged to
the white ethnic group. Smoking is another potential risk factor for preterm delivery
(Goldenberg et al, 2008), and is much more prevalent among white than black African
women (Karlsen et al, 2012). Meanwhile, the finding that women who were
immunocompromised had an increased risk of preterm delivery is consistent with other
studies both in African settings and the Western world (Ezechi et al, 2013; Thorne et al,
2004; Townsend et al, 2010a; Turner et al, 2013). This emphasises the need for good
clinical management of these women from early in pregnancy, as this may have benefits
beyond PMTCT, and indeed maternal health, by also influencing perinatal outcomes.
As outlined in Chapter 2, Section 2.6, there has been much discussion and debate
regarding the association between antenatal ART receipt, particularly cART, and preterm
delivery. The current analysis was not specifically designed to investigate this association
in detail and focused on the specific group of women experiencing repeat pregnancies.
However, although overall there was no significant association between the type of ART
received and the risk of preterm delivery (p=0.765), the direction of the odds ratios did
suggest that women who received cART (PI- or NNRTI-based) may be at increased risk,
consistent with previous studies from Europe and elsewhere (Short et al, 2014). Assessing
the association in more recent years is difficult as the majority of women reported to the
NSHPC are receiving cART (95% of treated women in this analysis), resulting in the lack of
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a valid comparison group. An important source of confounding, when considering the
association between PI-based cART and preterm delivery, is indication for treatment, as a
range of factors will influence the type of antenatal ART a woman receives. For example, it
is possible that women who have already experienced a preterm delivery may be less likely
to be put on a PI-based regimen in a subsequent pregnancy due to concerns that a PI-
based regimen might increase her already heightened risk of a preterm delivery. Although
there was little evidence of this in the NSHPC (58% of those with a previous preterm
delivery took PI-based cART in their subsequent pregnancy compared with 59% of those
with no history of preterm delivery), it cannot be ruled out in other settings.
Of course, the benefits of early initiation of ART need to be balanced with the potential
risks. In the present analysis although there was some evidence of an increased odds of
preterm delivery among those conceiving on PI-based cART compared with those starting
PI-based cART during pregnancy, this was nullified after adjusting for confounding factors.
This adds to the evidence-base in support of the early initiation of ART, or indeed lifelong
ART initiation, among pregnant women (i.e. suggesting that this would not lead to an
increased risk of preterm delivery in any future pregnancies which would consequently be
conceived on ART). However, these findings need to be corroborated by other studies, and
in other settings. Indeed, it is of concern that a number of previous studies have reported
an increased risk of preterm delivery among women on ART from before or early in
pregnancy, as detailed in Chapter 2, Section 2.6. More research is clearly required to
elucidate the relationship between timing of ART initiation and preterm delivery risk.
Since these analyses focused on repeat pregnancies it was possible to explore the
association between birth-to-pregnancy intervals and preterm delivery. This is an exposure
of interest since short, as well as very long, intervals have been associated with adverse
pregnancy outcomes, as documented in systematic reviews by Conde-Agudelo et al 2006
and Wednt et al 2012. Regarding the increased risk among those with very short intervals,
a potential biological mechanism is the “maternal nutritional depletion hypothesis” (i.e. it
takes some time for a woman’s nutrient stores to replenish post-natally), thus if she
becomes pregnant again during this time she may lack essential nutrients which are
important for a healthy pregnancy (King, 2003). Although in the univariable analyses
women with a short (<6 months) interval had an increased risk of preterm delivery, this was
no longer significant in adjusted analyses. Another European study also reported a lack of
an association (Di Renzo et al, 2011). It may be difficult to draw comparisons with data
from the general population since the characteristics of HIV-positive women with short
intervals may well differ to those of the broader population. The ability to capture birth-to-
pregnancy intervals also warrants some discussion here. Inevitably, shorter intervals are
more likely to be included in the analyses because women having a pregnancy in more
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recent years, but leaving several years before conceiving again, will not yet have had their
repeat pregnancy. Longer intervals will thus only be available for women who had a
previous pregnancy early in the study period while short intervals should be more evenly
distributed among the early and later pregnancies. Furthermore, migrant women with
longer intervals may potentially be more likely to have returned home by the time of their
subsequent pregnancy.
Limitations
In interpreting the descriptive analyses of the risk of adverse pregnancy and perinatal
outcomes in women’s first and repeat pregnancies, it should be noted that around half of
women were parous prior to their first pregnancy reported to the NSHPC. The analyses
were designed to document the frequency of adverse outcomes among women’s repeat
pregnancies since their diagnosis, and draw comparisons with the risk in their first
pregnancies as a diagnosed woman, rather than explore the association between parity
and pregnancy outcomes more broadly i.e. outside the context of HIV. However, the
potential influence of overall parity on the findings should not be overlooked. To consider
the impact that parity may have had, sensitivity analyses were carried out on women known
to be nulliparous at the time of their first pregnancy reported to the NSHPC, and the results
were generally comparable, as has been described.
An important limitation of the preterm delivery analyses is that because the NSHPC does
not collect information on some well-known important risk factors for preterm delivery such
as socio-economic status and smoking (Goldenberg et al, 2008; Slattery et al, 2002), these
could not be investigated or adjusted for in the analyses. The presence of other infections
has also been implicated in preterm deliveries (Slattery et al, 2002). However, this
information was only added to the NSHPC data collection form in mid-2008 and thus could
not be included as a covariate in the analyses without vastly reducing the power of the
analyses. It is not known whether women’s previous unreported pregnancies (e.g. those
occurring prior to diagnosis) were delivered preterm and this could be important in
predicting future preterm delivery risk given the strong associations reported here.
Furthermore, it was not possible to reliably distinguish idiopathic preterm deliveries from
those delivered early for reasons such as obstetric or fetal complications (indicated
deliveries), and this information is not specifically requested by the NSHPC. However, there
is likely to be some overlap between risk factors for idiopathic and ‘indicated’ preterm
delivery, and it has been suggested that some women who are delivered early for obstetric
reasons may also have been at increased risk of an idiopathic preterm delivery (Ananth et
al, 2006; Mazaki-Tovi et al, 2007).
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With regard to missing data, although gestational age at delivery was available for 98% of
births, information on potential predictors of preterm delivery was missing for some women.
Women with missing data on any explanatory variable had a higher probability of preterm
delivery, the reasons for which are likely to be multifactorial. For example, women arriving
at hospital in preterm labour may not have sufficient time for laboratory testing and are thus
more likely to have missing delivery CD4 counts. Meanwhile, history of previous preterm
delivery was missing if the women’s previous reported pregnancy did not result in a live or
stillbirth. Some studies have reported an increased risk of preterm delivery in women with a
history of adverse outcomes such as miscarriage and termination of pregnancy (Di Renzo
et al, 2011; Goldenberg et al, 1993; Swingle et al, 2009), though this was not investigated
here in light of the probable under-reporting of both miscarriages and terminations.
7.3.2 Mode of delivery
Temporal trends in mode of delivery
During 2005-2010 nearly half (47%) of sequential (last reported) deliveries were planned
caesarean sections (compared with 41% of first reported pregnancies during the same
period). However, the proportion of vaginal deliveries almost doubled (from 21% to 39%),
reflecting the move towards the normalisation of vaginal delivery among women living with
HIV. Similar trends have been observed across Europe following similar changes to
recommendations on mode of delivery (Aebi-Popp et al, 2013a). Nevertheless, the
proportion of caesarean section deliveries remained relatively high in 2010 (61%,
composed of 40% elective and 21% emergency). This needs to be considered in the
context of background rates of caesarean section deliveries in the general population. In
England during 2009-2010 one quarter of deliveries were by caesarean section (composed
of 10% elective and 15% emergency) (Health and Social Care Information Centre, 2010).
Similarly, the rate of caesarean section deliveries among HIV-positive women in France
during 2005-2010, at 53%, was reported to be twice that of the general population (Briand
et al, 2013).
Reasons for the higher rate of caesarean sections (both elective and emergency) among
HIV-positive women are likely to be complex and multifactorial. Although, as shown in the
first part of this chapter, at their repeat (compared with first reported) pregnancies women
were significantly more likely to achieve an undetectable viral load by delivery, still one
quarter of those delivering by elective caesarean section had unsuppressed virus at
delivery and were therefore not eligible for a vaginal delivery. Meanwhile, elective
caesarean section was the strongly recommended mode of delivery for those living with
HIV for over a decade and thus some women may still feel this is the safest choice, as may
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some obstetricians. This analysis focused on women’s repeat pregnancies which adds
another dimension to decisions around mode of delivery; many of these women will have
previously successfully delivered an HIV-negative infant by caesarean section which may
reinforce this as the ‘safest choice’ for the health of their baby. Indeed, of those women
delivering by elective caesarean section the vast majority (95%) had also delivered their
previous infant by caesarean section. Maternal request and prior obstetric history,
particularly having previously delivered by caesarean section, have been shown to be
important (Aebi-Popp et al, 2013a; Briand et al, 2013; Livingston et al, 2010; Mark et al,
2012; Suy et al, 2008), and data for the general UK population revealed that previous
caesarean section was the most common reason for delivering a subsequent baby by the
same route (Thomas et al, 2001). Furthermore, some studies have reported HIV-positive
women on cART to be at increased risk of pregnancy complications such as pre-eclampsia
(Suy et al, 2008; Wimalasundera et al, 2002) which may be an indication for an early
(caesarean section) delivery. Counselling women with repeat pregnancies about the very
low risk of vertical transmission associated with vaginal deliveries among those on
suppressive therapy, as well as options such as VBAC, will help enable them, together with
their obstetrician, to make an informed choice. It should also be borne in mind that mode of
delivery in the current pregnancy will impact on future obstetric management; for example,
in the general population VBAC is not recommended for women with more than three
previous caesarean section deliveries (Royal College of Obstetricians and Gynaecologists,
2007).
Mode of delivery patterns for women’s previous and subsequent births
Although the majority of women in this study population had a history of caesarean section
delivery in previous pregnancies, VBAC is now considered a safe option for most women
(Royal College of Obstetricians and Gynaecologists, 2007). Of those who had previously
delivered by caesarean section 14% had a VBAC. The success rate of VBAC was 62% (i.e.
the proportion of women planning a VBAC who successfully delivered by the route). This is
towards the lower end of success rates among the general population – a systematic
review and meta-analysis reported a range of 60-82% (Guise et al, 2004), with the RCOG
guideline quoting a narrower but not inconsistent range of 72-76% based on three key
studies (Royal College of Obstetricians and Gynaecologists, 2007). The potential risks of
VBAC among this population, uterine rupture for example, do however need consideration.
There were four uterine ruptures reported overall, a rate of 2.0 per 1000 (95% CI: 0.04-4.0),
and 2.8 (95% CI: 0.06-5.6) among those who delivered their previous infant by caesarean
section, although a vaginal delivery was only known to have been planned for one of these
four women. A national-level UK study reported a uterine rupture rate of 1.1 (95% CI: 0.9-
1.3) per 1000 maternities among women with a previous caesarean section delivery
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(Fitzpatrick et al, 2012). Although the rate appears to be higher in the NSHPC population,
the confidence intervals do overlap, and it is difficult to draw conclusions due to the small
number of events. The study by Fitzpatrick et al also reported that the risk of rupture
increased with number of previous caesarean sections, and was higher in those planning a
vaginal delivery rather than an elective caesarean section. Looking forwards, these are
factors relevant to HIV-positive women in the UK and Ireland in light of current guidelines.
However, the risk of uterine rupture is low and needs to be balanced against the risks of
having a repeat caesarean section.
Missed opportunities for vaginal deliveries
Of the women who delivered by elective caesarean section, nearly three quarters had an
undetectable viral load and were thus eligible for a vaginal delivery in the absence of
obstetric indications for caesarean section. The recent European pooled analysis (including
data from the UK and Ireland) highlighted the missed opportunities for vaginal delivery with
55% of those with an undetectable viral load delivering by caesarean section during 2000-
2010 (Aebi-Popp et al, 2013a). Possible reasons for the high rate of caesarean sections in
the current study population have been discussed above. However, that a quarter of
women delivering their repeat pregnancy by elective caesarean section were not eligible for
vaginal delivery also needs to be addressed. The most important factors influencing the
achievement of an undetectable viral load by delivery include baseline viral load and
duration of ART (see Chapter 1, Section 1.2.4). As shown in Chapter 5, women on ART at
conception had over five times the odds of having undetectable viral load at delivery than
those initiating ART during pregnancy. Implementation of more recent guidelines
recommending earlier initiation of antenatal ART (Taylor et al, 2012), together with efforts
to encourage and enable women to book earlier for antenatal care thus providing the
opportunity for earlier initiation of ART, should enable more women to be eligible for a
normal delivery.
Risk of emergency caesarean section delivery
One concern regarding the recommendation for vaginal delivery among eligible HIV-
positive women is the potential for the rate of emergency caesarean sections to increase.
An earlier analysis of the NSHPC data for 1999-2006 reported an increase in the rate of
emergency caesarean sections from 17% to 23%. At the time it was suggested this may be
attributable to the increasing number of women eligible to attempt a vaginal delivery in
which unforeseen complications may arise (Townsend et al, 2008b). Reassuringly, among
the repeat pregnancies there was no increase in the proportion of emergency caesarean
sections during 2005-2010 despite a significant increase in vaginal deliveries. The
previously observed increase might be explained by obstetricians being particularly
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cautious, and hence more frequently resorting to an emergency caesarean if complications
arose in women attempting a normal delivery, as the option of planned vaginal birth had
only been recently introduced (see Appendix II). As noted in Chapter 1, Section 1.2.4, there
is now increasing evidence that the risk of transmission is very low among women with an
undetectable viral load suggesting little additional benefit of caesarean section among
these women, which may impact on clinical decision-making.
Limitations of mode of delivery analyses
The classification of caesarean sections as elective or emergency is carried out by the
healthcare professional reporting to the NSHPC, with some data cleaning by the NSHPC
team. For example, an elective caesarean section reported to have been carried out after
the rupture of membranes will be reclassified as emergency. Definitions have not been
entirely consistent over time and this may lead to some misclassification, though it is not
clear how this may have influenced the findings. Limited data is currently available on
adverse outcomes associated with different modes of delivery as this is not specifically
requested on the NSHPC reporting forms. However, since uterine rupture is a very serious
outcome, associated with maternal and perinatal severe morbidity as well as mortality (Ofir
et al, 2003; Ronel et al, 2012), it was possible to search the free-text notes field of the
NSHPC database to identify occurrences with reasonable confidence that this outcome
was likely to be documented. This approach was not deemed appropriate for other less
serious adverse events which are less likely to be consistently reported. Also, although the
number of deliveries in the dataset was sufficiently large for most analyses, uterine rupture
is a rare event, reflected in the wide confidence intervals around the estimated rate.
Meanwhile, though information on the duration of rupture of membranes may be of
relevance to analyses of mode of delivery, this has only been collected by the NSHPC
since 2007 and insufficient data was available at the time of analysis.
As shown in the first part of this chapter, over half (57%) of women were parous at the time
of their first pregnancy reported to the NSHPC. The inclusion of such women, rather than
restricting the analysis to only those women who were nulliparous, could potentially
influence the findings. Details of these women’s prior obstetric history are not collected by
the NSHPC. However, most women in the NSHPC originate from Africa, many of whom will
have acquired their HIV infection in their country of origin (Health Protection Agency,
2011a). Therefore, any deliveries they had prior to their arrival in the UK are likely to have
been vaginal deliveries even if they had diagnosed HIV, since elective caesarean sections
have been little used for PMTCT in Africa (Aizire et al, 2013). To confirm that the inclusion
of these women did not substantially affect the findings on patterns of mode of delivery
within women, sensitivity analyses were conducted among those nulliparous at their first
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reported pregnancy and the findings were very similar. Related to this, the analyses were
restricted to women’s last reported live or stillbirth only, and consideration of their obstetric
history largely utilised only information on their immediately preceding delivery.
Nevertheless, it is women’s preceding delivery that is likely to have most bearing on the
subsequent delivery.
281
7.4 Key findings
Adverse pregnancy and perinatal outcomes
 Of the 3028 repeat pregnancies during 2000-2010 most (90.4%) resulted in a live
birth, 0.8% in a stillbirth, 6.6% a miscarriage, 2.2% in a termination
 Few women had repeated adverse outcomes; only one woman had two stillbirths,
33 had more than one miscarriage, and none had more than one HIV-positive infant
 Women were significantly more likely to conceive their repeat (as compared with
index) pregnancies on ART (48.8% vs. 21.9%, p<0.001), and the proportion of
repeat pregnancies conceived on ART increased significantly in more recent years
(from 40.7% in 2005 to 61.5% in 2010, test for trend: p<0.001).
 Overall, 13.1% of repeat births were preterm, 12.6% of infants were of low
birthweight, and 2.9% had a congenital abnormality
 Compared with first reported pregnancies, at their repeat pregnancies women did
not appear to be at increased risk of stillbirth (p=0.440), preterm delivery (p=0.240),
or having an infant with congenital abnormalities (p=0.908). They had a lower risk
of having a low birthweight infant (p=0.009), but an increased risk of reported
miscarriage (p<0.001)
 On multivariable analysis factors associated with preterm delivery among repeat
pregnancies were a previous preterm delivery, being white, having a multiple
pregnancy, and being immunosuppressed
 In a sub-analysis there was little evidence of an increased probability of preterm
delivery among women conceiving on cART
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Mode of delivery
 Almost half (47.0%) of the 2761 repeat live/stillbirths during 2005-2010 were
delivered by elective caesarean section, 31.2% vaginally, and 21.8% by emergency
caesarean section
 There was a significant increase in infants delivered vaginally between 2005 and
2010, from 21.0% to 39.3%, p<0.001, although, overall, 19.4% of women planning
to deliver vaginally actually delivered by emergency caesarean section
 Despite the increase in women planning vaginal deliveries there was no evidence
of an increase in emergency caesarean section deliveries (p=0.140)
 Almost a third (31.4%) of women delivering vaginally had delivered their previous
infant by caesarean section. Looking at this the other way around, 13.6% of women
who had delivered their previous infant by caesarean section subsequently had a
VBAC, and this proportion increased significantly, from 8.3% in 2005 to 17.3% in
2010 (test for trend: p<0.001)
 Among women delivering by elective caesarean section the vast majority (94.5%)
had delivered their previous infant via caesarean section
 Nearly three quarters (73.4%) of women delivering by elective caesarean section
had an undetectable viral load and were thus eligible for a vaginal delivery
 MTCT rates were 0.65% (95% CI: 0.08-1.21 n=5) for elective caesarean section
deliveries, 0.58% (95% CI: -0.02-1.38, n=2) for emergency caesarean section and
0.62% (95% CI:-0.08-1.31, n=3) for vaginal deliveries
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Chapter 8 Discussion
The overarching aim of this thesis was to investigate the epidemiology of sequential
pregnancies among HIV-positive women in the UK and Ireland, and to explore the health,
therapeutic and obstetric management, and pregnancy outcomes of the women
experiencing them. Such information will inform the care of HIV-positive women in the UK
and Ireland and other similar settings, in the context of current and potential future
pregnancies. The four results chapters of the thesis explored the frequency and predictors
of repeat pregnancies (Chapter 4), women’s engagement with HIV and pregnancy-related
care and the health and management of those experiencing sequential pregnancies
(Chapter 5), the influence of short-course cART for PMTCT on response to therapy in
subsequent pregnancies (Chapter 6), and pregnancy and perinatal outcomes, together with
mode of delivery (Chapter 7). A detailed discussion of the findings of these chapters,
contextualised within the published literature, is provided within each chapter. This final
chapter draws together key findings of the thesis under some broad themes, within the
context of contemporary issues around the management of HIV-positive women of
childbearing age. The implications of the findings for policy and practice are discussed. The
broader strengths and limitations of the NSHPC are reviewed, and areas for future work
highlighted.
8.1 Key findings and implications for policy and practice
8.1.1 High and increasing occurrence of repeat pregnancies
This thesis provides the first estimates of the rate of repeat pregnancies to diagnosed
women in a European setting, and the first detailed exploration of repeat pregnancies
among HIV-positive women in the UK and Ireland. The data clearly show that a substantial
and increasingly large proportion of pregnancies to diagnosed women in the UK and
Ireland are second and subsequent (accounting for 39% of pregnancies reported in 2009).
This proportion now appears to be levelling off, with repeat pregnancies accounting for just
under half of all pregnancies reported annually since 2011 (National Study of HIV in
Pregnancy and Childhood, 2014). These data underscore the need for clinicians to take
into account the high probability of future pregnancies among HIV-positive women who
have already experienced a pregnancy as a diagnosed woman. It is important that
demographic and clinical characteristics of these women, and the challenges that they
present for therapeutic and obstetric management in current and potential future
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pregnancies, are thoroughly understood. The analyses revealed clear variations in the
probability of repeat pregnancies according to demographic characteristics. Repeat
pregnancies were more likely in women who were younger, had fewer previous births, and
in women from Middle and Western Africa compared with women born in the UK or Ireland,
though there was no apparent association with clinical or immunological status. Such
variations are an important consideration when planning reproductive health services and
HIV care for people living with HIV.
The provision of on-going reproductive health care for HIV-positive women of childbearing
age is undoubtedly important. This needs to encompass contraceptive advice, the
avoidance of unintended pregnancies and pre-conception counselling including advice on
conception strategies for serodiscordant couples (Hoyt et al, 2012; Steiner et al, 2013).
Optimising maternal and infant health is of course an integral element, particularly for
women living with HIV. Women may also need advice regarding unplanned pregnancies
and access to termination of pregnancy services. Though information on contraceptive use
and/or whether pregnancies were planned is not collected by the NSHPC, it is likely that a
high proportion of pregnancies to HIV-positive women are unintended, as is the case
among the general UK population (see Chapter 4, Section 4.3). Unintended and mistimed
pregnancies are associated with adverse maternal and infant outcomes (Gipson et al,
2008; Shah et al, 2011), and the avoidance of these among HIV-positive women is one of
the four components of the WHO’s comprehensive approach for PMTCT (World Health
Organization, 2003). The provision of accessible and effective family planning, and
supporting women to make adequate use of such services, is therefore essential. Since
HIV-positive women appear to be at higher risk of several adverse perinatal outcomes than
the general population (see Chapter 2, Section 2.6 and Chapter 7, Section 7.1), identifying
and addressing modifiable risk factors for adverse outcomes among these women is
especially important. Two in five women conceived their repeat pregnancy less than 18
months after their previous delivery, with 11% conceiving in under six months. Short inter-
pregnancy intervals have been associated with a range of adverse outcomes among the
general population including preterm birth, low birthweight and stillbirth (Conde-Agudelo et
al, 2006; Wendt et al, 2012). Although not significant in adjusted analyses presented in this
thesis, there was an association between an inter-pregnancy interval of less than six
months and an increased preterm delivery risk. Supporting HIV-positive women to achieve
adequate birth spacing may thus be beneficial.
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8.1.2 Women’s engagement with HIV and pregnancy-related care
Several analyses presented in this thesis explored women’s engagement with HIV and
pregnancy-related care, and sought to identify variations in access to and uptake of care
according to demographic or clinical characteristics. Although the data demonstrated good
engagement with care overall (the majority of women received antenatal ART and MTCT
rates were low), they do raise some areas of concern (Chapter 5). For example, almost half
of women booked late for antenatal care at their repeat pregnancy. It is important that care
providers understand the high probability of pregnancy (particularly in some groups), and
ensure that women know how to access local antenatal services should they become
pregnant (again). Women also need to be counselled on the benefits of booking for
antenatal care early, even if they have safely delivered before. Close links between HIV
and reproductive care services are crucial.
Potential missed opportunities for the timely initiation of ART among this population of
previously diagnosed women were also apparent, during both pregnant and non-pregnant
periods. Antenatal ART commenced at a median of 24 weeks among those with CD4
counts of ≥350 cells/µl, and only one week earlier if CD4 was <350 cells/µl. The latter group 
raise some concern since they require prompt treatment initiation for their own health
(though may be deferred until after the first trimester) (Taylor et al, 2012), and are also a
group at greater risk of MTCT (e.g. see Chapter 6). Of course ART initiation during
pregnancy is to some extent dependent on timing of antenatal booking, but notable delays
were apparent even after women had booked (a median lag of 10 and seven weeks from
booking to starting ART in women with CD4 ≥350 cells/µl and <350 cells/µl respectively). 
These delays appear to be at least partly health service or provider-related; laboratory
testing delays were noted, with 30% of women having a delay of four or more weeks from
booking to laboratory testing. This is a potential area in which to improve practice.
Guidelines should recommend that all HIV-positive women who are not on treatment have
blood samples taken on the day that they book for antenatal care62. Education and efforts
to raise awareness in primary care, antenatal and HIV services may also be needed. The
benefits of earlier ART initiation in terms of PMTCT have been recently highlighted within
the NSHPC as a whole (Townsend et al, 2014). Although there was a trend towards earlier
antenatal ART initiation over time among women’s sequential pregnancies, booking delays
and the long interval between booking and starting ART in some women need to be
addressed. Recommendations for future research on this topic are outlined in Section 8.3
below.
62 UK National Screening Committee Programme Standards for the Infectious Diseases in Pregnancy
Screening Programme do indicate that pregnant women already known to be HIV-positive should have
prompt clinical evaluation (UK National Screening Committee, 2010).
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Analyses of the health of women presenting with a second pregnancy who were not on
ART at conception revealed that two-fifths had a CD4 count of <350 cells/µl, and 10% were
severely immunosuppressed. This underscores the need for careful monitoring of CD4
counts and emergence of HIV/AIDS symptoms in all women after pregnancy, particularly
those who discontinue ART after delivery. The data also raise concern as to the extent of
loss to follow-up of women from care after their pregnancy ends. Linked NSHPC-SOPHID
data revealed that 12% of women did not access HIV care during the calendar year after
delivery. It is reassuring that the majority of women engaged with HIV care after pregnancy,
though their motivation to continue this could wane over time. The reasons that these
women presenting with low CD4 counts have not yet started treatment need further
exploration. This should include an assessment of the contribution of disengagement from
care in both the short and longer-term, and an exploration of the underlying reasons for
delays in treatment initiation among those who are engaged in care (see Section 8.3
below). The healthcare sector has a vital role in ensuring HIV-positive women are
maintained in care. It is essential that healthcare providers make HIV care as accessible
as possible for women with children to care for. Important considerations include the
provision of appointments at convenient times and locations, as well as having
mechanisms in place to maintain women in care (e.g. follow-up of those who miss
appointments). Patients in care should be provided with appropriate and accessible
information, and engaged in a dialogue that takes into consideration their individual
circumstances, beliefs, concerns and level of health literacy, to help them to make informed
decisions about their care (Nunes et al, 2009). Patient organisations may have an
important part to play here. It is essential that patients have a good understanding of the
benefits of ART, and HIV care more broadly, even if they feel well. Prior exposure to short-
course ART for PMTCT may potentially create confusion around the need to initiate lifelong
treatment in the future. This needs to be clearly explained from the outset.
Analyses revealed that women with repeat pregnancies are a heterogeneous group.
Investigation of demographic characteristics associated with poorer engagement with care
(late booking for antenatal care, later initiation of antenatal ART, or having an indication for
treatment among those not on ART at conception of their second pregnancy) largely
demonstrated equality in the timeliness of care, consistent with the equity in care seen
among the UK HIV-positive population more generally (Delpech et al, 2013). However,
some variations were apparent, as highlighted in Chapter 5. For example, women
originating from sub-Saharan Africa started antenatal ART significantly later than those
born in the UK or Ireland, and there was also some indication of later booking for antenatal
care among this group. Migrants from sub-Saharan Africa face a multitude of potential
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barriers to accessing healthcare including stigma, discrimination and poverty (Elford et al,
2008a; Ibrahim et al, 2008; Prost, 2005). The provision of culturally appropriate, accessible
services is essential, though clearly a comprehensive approach is needed to reduce social
and economic disparities which may impact on many aspects of the lives of migrants. It is
important to note that only relatively broad socio-demographic categories can be explored
using the NSHPC data which may have concealed important variations between sub-
groups (see ‘strengths and limitations’ below). Treatment and health status were also
associated with women’s level of engagement with care. For example, women not on ART
at conception of their repeat pregnancies booked for antenatal care significantly later than
those conceiving on treatment. Meanwhile, women who received insufficient ART (none or
short duration) during their first pregnancy were at increased risk of presenting in a
subsequent pregnancy with a low CD4 count. Such groups may require particularly close
follow-up to ensure good engagement with care. Identifying women who are engaging
poorly with services in their first pregnancy, and providing additional support not only during
but also after pregnancy, may have benefits for their future pregnancies, as well as for their
health more generally. Although women with a history of injecting drug use now only
account for a small proportion of women reported to the NSHPC (the small sample size
potentially resulting in a lack of power to detect associations), studies in other settings have
found these women to be at increased risk of adverse outcomes such as insufficient
antenatal ART (Bailey et al, 2011). These women may require specialised outreach
services to help engage them with HIV and pregnancy care. The findings presented in this
thesis highlight the need for further research to help identify modifiable structural or
individual-level barriers to timely ART initiation among diagnosed women, both within and
outside the context of pregnancy (see Section 8.3 below).
8.1.3 Optimising management
Though the benefits of antenatal ART far outweigh the risks (Newell et al, 2013), the
optimisation of the care of HIV-positive childbearing women is a priority for both women
and their infants. Good maternal health likely has benefits for the outcomes of their current
and any future pregnancies. For example, women in poorer health (indicated by lower CD4
counts) had an increased probability of preterm delivery in their repeat pregnancies
(Chapter 7). Meanwhile, ensuring that HIV-positive women live as long and healthy lives as
possible, throughout and beyond their childbearing years, benefits both themselves and
their children. Since the first trials carried out in the 1990’s demonstrated the effectiveness
of ART taken during pregnancy for PMTCT (see Chapter 1, Section 1.2.4), short-course
antenatal ART for women not in need of treatment for their own heath has been a mainstay
of PMTCT interventions, recommended in both resource-rich and resource-limited settings
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(Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal
Transmission, 2012; Taylor et al, 2012; World Health Organization, 2013). However, the
landscape has changed dramatically since the early years of the epidemic, and during the
course of this PhD the WHO introduced ‘Option B+’ for HIV-positive pregnant women (see
Chapter 2, Section 2.4). The possibility of lifelong ART for all women is thus an emerging
theme in the management of HIV in pregnancy. The evidence-base for such an approach
is, however, lacking, with issues such as operational challenges, cost, equity in access,
retention in care, adherence, maternal health, drug resistance, and women’s views and
preferences requiring more research (Ahmed et al, 2013; Shaffer et al, 2014). Several
analyses presented in this thesis contribute new information to the evolving evidence-base.
In support of an argument for recommending lifelong ART for all pregnant women, analyses
revealed that a quarter of women with a CD4 count of ≥350 cells/µl at their first pregnancy 
had counts of <350 cells/µl at their second pregnancy (Chapter 5). These data indicate that
for many women there may be health benefits of initiating lifelong ART in their first
pregnancy, whether or not they experience future pregnancies. UK guidelines allow for,
rather than recommend, lifelong ART for pregnant women presenting with CD4 counts of
350-500 cells/µl (in the absence of other indications e.g. certain co-infections) (Taylor et al,
2012). A recommendation could be considered for this group in particular, as the probability
of having an indication for treatment at their second pregnancy was especially high (40%
had <350 cells/µl at their second pregnancy). Similar findings have been reported in other
settings (Coria et al, 2012; Ekouevi et al, 2012; Watts et al, 2013). Furthermore, the high
probability of repeat pregnancies in the contemporary population of HIV-positive women,
often within a relatively short time period (the median birth-to-pregnancy interval was less
than two years), calls into question the use of short-course therapy from a practical
perspective.
Data presented in this thesis also demonstrate that the initiation of lifelong ART may have
benefits for women’s future pregnancy outcomes. Women starting ART during their second
pregnancy had over four times the odds of having a detectable viral load at delivery
compared with those conceiving on treatment. Although the risk of MTCT is now very low in
appropriately managed women, it still exists and the unadjusted rate was three times higher
among those not on ART at conception compared with those conceiving on treatment
(Chapter 5). A further possible benefit of women conceiving their repeat pregnancies on
ART is that more women might then achieve an undetectable viral load by delivery, thus
enabling them to plan for a normal delivery (in the absence of other contraindications) (see
Chapter 7). Finally, around half of women presenting with a repeat pregnancy were not yet
on treatment. As noted in Chapter 1, viral load is highly correlated with the risk of onward
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transmission of HIV, not only for MTCT but also transmission to sexual partners. The role of
the treatment of HIV-positive women of childbearing age as an HIV prevention strategy in
the UK setting is difficult to assess as we do not know what proportion of HIV-positive
pregnant women in the UK are in serodiscordant partnerships or the contribution of this
group to the overall rate of HIV transmission in the UK. However, 45% of new infections in
the UK in 2012 were heterosexually acquired (Aghaizu et al, 2013), and an increasing
proportion are believed to have been acquired in the UK (it is estimated that over two-fifths
of infections in people born abroad were acquired in the UK, based on data for 2010) (Rice
et al, 2012). Since women with (repeat) pregnancies are a group who are likely to be
having unprotected sex, there is clearly potential for onward transmission which could be
reduced with effective treatment (Cohen et al, 2011).
These potential benefits of lifelong ART are, however, based on the assumption that
women adhere to treatment once initiated, and conceive any subsequent pregnancies on
suppressive therapy. Disengagement from HIV care is therefore of particular concern. Early
data from Malawi, where the Option B+ approach has been championed, indicate that
retention in care presents a challenge, particularly among women initiating ART during
pregnancy (i.e. those not yet needing treatment for their own health) (Tenthani et al, 2014).
Further to this, sub-optimal ART adherence has been noted in post-partum women
(Nachega et al, 2012), which can result in poor virological suppression thus creating an
environment in which drug resistance can develop (Clavel et al, 2004; Tang et al, 2012).
This may impact on women’s response to therapy and future treatment options.
Nonetheless, the analyses in Chapter 5 revealed that women conceiving their subsequent
pregnancies on treatment booked significantly earlier for antenatal care, suggesting
potentially higher levels of engagement with care among this group compared with those
not receiving ART prior to pregnancy. Supporting this assertion, not being on ART has
been associated with a greater risk of loss to follow-up from HIV care among the broader
UK HIV-positive population (Gerver et al, 2010; Rice et al, 2011), and among post-partum
women in other settings (Coria et al, 2012; Tenthani et al, 2014).
Around half of repeat pregnancies were conceived on ART (and the proportion increased
from 41% in 2005 to 62% in 2010). Should the Option B+ approach be adopted,
theoretically all women would eventually be conceiving their repeat pregnancies on ART.
Though there was no significant association between conceiving on ART and preterm
delivery risk (Chapter 7), the results should be interpreted with some caution as this was a
sub-analysis which may have been limited by small numbers. The situation needs ongoing
monitoring. Furthermore, with most women now receiving PI-based HAART during
pregnancy (Chapter 6), there is the potential for increasing preterm delivery rates among
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HIV-positive women in years to come as the current evidence-base points towards PI-
based cART as a particular risk for preterm delivery (see Chapter 2, Section 2.6).
Meanwhile, the potential adverse impact of earlier initiation of lifelong ART on women’s
longer-term health also needs consideration. As has been recently highlighted, though new
formulations of antiretrovirals have improved safety profiles, drug toxicities are still a
concern and need to be carefully balanced against the benefits of starting ART earlier in
women not needing treatment for their own health (Sabin et al, 2013). Finally, women’s
opinions and choices are an important consideration, and the HIV-positive community has
voiced concerns and reservations about lifelong ART for all women (Ngarina et al, 2014;
Welbourn, 2012).
Analyses revealed no evidence of an association between previous short-course PI-based
cART exposure and response to therapy in a subsequent pregnancy (Chapter 6). Looking
towards women’s future pregnancies, this finding is reassuring, indicating that short-course
PI-based therapy continues to be a viable option, thus supporting current recommendations
(Taylor et al, 2012). There was, however, some evidence that women previously exposed
to NNRTI-based regimens may have an increased probability of not adequately
suppressing the virus in future pregnancies. Women in receipt of these regimens during
pregnancy may require particularly careful monitoring after their pregnancy ends in order to
support them to continue to adhere to their treatment and ensure that any treatment
discontinuations are carefully managed.
In summary, analyses presented in this thesis suggest that lifelong ART may have benefits
for many women of childbearing age and their future pregnancy outcomes, but do also
support short-course therapy as an effective PMTCT intervention, even with future
pregnancies in mind. These findings add to the evidence-base to inform policy and clinical
decision-making in the UK and Ireland, and other resource-rich countries. It may be hard to
extrapolate the findings to resource-limited settings where the situation is very different and
the challenges presented by the epidemic are far greater. Equity in access to care is a
particular issue in settings such as sub-Saharan Africa where many people still do not have
access to the live-saving treatment that they require (UNAIDS, 2013)63. However, for
example, the clear association between conceiving subsequent pregnancies on ART and a
decreased risk of detectable viral load at delivery (Chapter 5) has broader applicability.
MTCT rates are still high in some low and middle-income countries with 260,000 new
infections in children during 2012 and, despite significant improvements in recent years,
nearly two-fifths of women are still not receiving effective antenatal ART (UNAIDS, 2013).
63 In 2012, HIV treatment coverage was 61% in low and middle-income countries (UNAIDS, 2013).
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Lifelong ART in this population has a potentially important role in reducing the risk of MTCT
in future pregnancies.
The data also need to be considered in light of the changing global situation with regards to
HIV treatment. The WHO now provides a programmatic recommendation for the treatment
of people with CD4 counts of ≤500 cells/µl, and all those with serodiscordant partners 
regardless of CD4 count (World Health Organization, 2013)64. Some other international
guidelines recommend that treatment is offered to all HIV-positive people (Panel on
Antiretroviral Guidelines for Adults and Adolescents, 2013; Thompson et al, 2012).
Although the UK remains more conservative in its recommendations (Williams et al,
2012)65, it seems likely that the current global move towards more HIV-positive people
being on treatment at higher CD4 counts will continue. In the UK and Ireland, and other
resource-rich settings, an individualised approach to the management of HIV in pregnancy
may be most appropriate, with all women starting ART in pregnancy enabled to make an
informed decision about whether to continue treatment for life on the basis of their CD4
count and viral load (without a specified minimum CD4 count at which lifelong treatment
can begin), plans for future pregnancies, the HIV status of their partner, and their personal
preference. It remains imperative that the risks and benefits of lifelong ART are carefully
assessed, with respect to both childbearing women and their infants, and the broader HIV-
positive population.
8.2 Strengths and limitations
Limitations relevant to specific analyses have been discussed within each results chapter of
this thesis. Here, some of the broader strengths and limitations of the NSHPC are
highlighted.
The NSHPC is a large, well established, active surveillance system which has been running
for over two decades, and reporting of pregnancies in women with diagnosed HIV is
comprehensive (Townsend et al, 2008b). It is a national study and all analyses in this thesis
were restricted to women diagnosed prior to delivery. Due to the routine offer and high
uptake of antenatal HIV screening since 2000, the number of pregnant women with
undiagnosed HIV by the time of delivery is low (Townsend et al, 2006). Findings are thus
highly generalisable to the population of HIV-positive women living in the UK and Ireland.
64 The WHO provides this as a programmatic recommendation (for resource-limited settings, typically in
the context of high HIV prevalence). It indicates that priority should be given to those with CD4 counts of
≤350 cells/µl.  
65 UK guidelines recommend treatment initiation in those with an AIDS-defining illness and/or CD4 counts
of ≤350 cells/µl (or at higher CD4 counts for those meeting certain criteria e.g. hepatitis B or C co-infection) 
(Williams et al, 2012).
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The major strength of the NSHPC for examining repeat pregnancies in HIV-positive women
compared with other similar data sources such as the ECS (sites in 10 European countries)
(Thorne et al, 2005) and the US WITS (six clinical consortia across the US) (Sheon et al,
1996), is that it has national coverage. This, together with high reporting rates, means that
the NSHPC provides reliable denominators for estimating the rate of repeat pregnancies.
Families with young children may be quite a mobile population in general, and migrants
particularly so (Creighton et al, 2004). Women who move to a different geographic location
in the UK or Ireland between pregnancies should still be reported to the NSHPC and can
be linked with their previously reported pregnancies. The NSHPC also seeks to collect
information on all pregnancies, not only live births, although there is likely to be under-
ascertainment of early miscarriages and terminations (as discussed in Chapter 7).
Furthermore, since it is an active surveillance study, rather than a consented cohort, there
is not an issue of under ascertainment of pregnancies due to women declining to
participate. As evidenced in this thesis, the NSHPC provides a rich source of data on the
health, management and pregnancy outcomes of women in the context of sequential
pregnancies.
The NSHPC is a voluntary and national scheme. It is therefore necessary to prioritise the
information requested in order to limit the number of data items collected, thus ensuring
reporting rates remain high and that data are as complete and high quality as possible. This
does, however, mean that it is not feasible to collect some specific data items that would
have been informative in the analyses and for the interpretation of the results. Although
around half of women were parous prior to their first pregnancy reported to the NSHPC,
detailed information on women’s previous pregnancies not reported to the NSHPC is not
collected. For example, no information is collected on the timing of previous pregnancies,
women’s total number of living children, mode of delivery or gestational age. This presents
a limitation for the analyses conducted in this thesis and may have resulted in some
confounding that could not be adjusted for in the analyses, as has been highlighted in the
relevant results chapters (in particular, Chapters 4 and 7). Meanwhile, factors related to
women’s social circumstances (e.g. socio-economic status, relationship status and
migration status) would be useful. For example, the vast majority of diagnosed women in
the UK and Ireland are migrants from sub-Saharan Africa who represent a very diverse
population. In the context of comprehensive reporting, it is difficult to request additional
highly sensitive information which could depress reporting rates or respondents’ ability to
provide timely information. Therefore, the NSHPC does not allow specific investigation of
groups such as undocumented migrants and asylum seekers who may experience
particular difficulties in accessing healthcare (Rechel et al, 2013). Other behavioural
characteristics, such as smoking during pregnancy, would be helpful for analyses of
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perinatal outcomes, though potentially difficult to collect as the information would be self-
reported and desirability bias66 may be an issue. Indeed, unmeasured factors that could not
be either explored as predictors of outcomes of interest in their own right, or adjusted for as
confounding factors, present a limitation for the analyses.
By its nature, the NSHPC only requests information during the antenatal (and immediate
post-partum) period which makes it difficult to explore the longer-term health of childbearing
women. However, unique to those women with more than one pregnancy reported to the
study, the dataset allows the assessment of some clinical and immunological trajectories
between women’s pregnancies. This could be utilised further in the future given the large
number of repeat pregnancies now being reported. Furthermore, the feasibility and utility of
linking the NSHPC with SOPHID, enabling the attainment of additional information on
women after their pregnancy ends (and hence prior to any future pregnancies), has been
demonstrated here with >85% of women matched to SOPHID.
Finally, missing data is an issue for any study and can potentially lead to biased findings if
missingness is not random. The extent of missing data on key exposure and outcome
variables was assessed within each chapter. Any bias that may have been introduced by
missing data was explored by comparing the characteristics of those with and without
missing data on the outcome of interest. On the whole, the proportion of missing data on
key variables was low, except for some clinical and immunological variables. For example,
viral load at delivery was missing for around 45% of pregnancies. However, the use of an
imputed variable (see Chapter 3, Section 3.4) proved effective in increasing available data.
The robustness of analyses conducted on the imputed variable was confirmed by running
concurrent sensitivity analyses on the non-imputed variable. Furthermore, an advantage of
focusing on women with repeat pregnancies reported is that there is more than one
opportunity for woman-specific (though not pregnancy-specific) characteristics to be
collected, thus further reducing the amount of missing data. This could, however, also
potentially introduce some bias when drawing comparisons with women who have only had
one pregnancy reported.
8.3 Conclusions and recommendations for future research
This thesis informs the evidence-base for the effective management of HIV-positive women
in the context of current and potential future pregnancies. It also identifies several areas for
further work on sequential pregnancies, as well as the broader health and management of
women of childbearing age.
66 Desirability bias results from people’s responses being biased towards those that are considered more
socially acceptable (Fisher, 1993).
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The high probability of repeat pregnancies among HIV-positive women emphasises the
importance of ongoing reproductive care which needs to take account of demographic
variations in the likelihood of future pregnancies. With regard to future NSHPC analyses,
the findings highlight that women experiencing repeat pregnancies since their HIV
diagnosis are no longer simply a ‘sub-group’ that require investigation in their own right but
a large, integral part of the NSHPC population. The impact of these repeat pregnancies e.g.
the clustering of pregnancies within women which requires statistical adjustment, need
consideration with respect to all future analyses of the dataset. Meanwhile, information on
whether or not pregnancies were planned would be informative on a range of issues
relevant to the contemporary population of HIV-positive women. For example,
understanding whether the high probability of repeat pregnancies among women
originating from Middle and Western Africa is related to a higher prevalence of unplanned
pregnancy among these groups would help inform the provision of family planning services
tailored to women most in need. However, attempting to collect such information through
an ongoing national study such as the NSHPC could be problematic, not least because of
the range of ways in which a ‘planned’ or ‘unplanned’ pregnancy may be understood and
interpreted, as noted in Chapter 4, Section 4.3. Information on pregnancy planning may
therefore be best collected by means of a specific survey, for example a short
questionnaire left in clinics for women to complete.
Late booking for antenatal care and delays in antenatal ART initiation, particularly among
those requiring treatment, are an issue for some women. In order to address these delays,
further research is required to elucidate the reasons behind them including potential
structural barriers (e.g. the socio-economic environment of HIV-positive women) and those
related to women’s individual circumstances, beliefs and choices. Assessment of the
contribution of disengagement from HIV care after pregnancy, as well as any inequalities in
access to or uptake of care that cannot be explored using the NSHPC data alone (e.g. in
relation to immigration status), will be important. Mixed methods research including
interviews or focus groups with women could help draw out some of the more nuanced
differences between sub-groups and identify common themes around women’s reasons for
delaying ART initiation. Reasons such as concerns about side-effects of ART or safety for
the unborn baby, for example, might be targeted via interventions such as patient
information leaflets addressing women’s key concerns. A questionnaire-based survey
and/or interviews with clinicians could also help to identify any health system or provider-
related barriers to timely laboratory assessment and ART initiation.
Pregnancies reported to the NSHPC are predominantly in black African women with a likely
heterosexual route of HIV exposure. Notwithstanding the heterogeneity within this
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population, it should also be remembered that the small numbers of pregnancies in some
other population sub-groups precluded detailed analyses. One emerging sub-group is that
of young women who acquired HIV vertically from their own mothers (Kenny et al, 2012;
Thorne et al, 2007b). Recent analyses have shown that 45 of these women have had
pregnancies, a third of whom have had more than one (NSHPC, unpublished data reported
by end of June 2013). These women may have particularly complex treatment histories,
and (repeat) pregnancies in this group will need assessing as numbers increase.
As has been highlighted, there are many unanswered questions around the Option B+
approach for the management of HIV in pregnancy. Analyses presented in this thesis add
to the evidence-base for such an approach, indicating potential benefits of lifelong ART for
both maternal health and future pregnancy outcomes. The NSHPC dataset, especially
when linked to other data sources such as SOPHID, can continue to contribute to the
evidence-base for the UK and other similar settings. For example, though analyses showed
high levels of attendance for HIV care during the year after delivery, monitoring longer-term
retention in care will be important, including how retention differs between those who
remain on ART and those who discontinue after delivery. This could be carried out by
means of ongoing linkage with SOPHID. The linked data could also provide information on
diagnosed women’s use of HIV care prior to conception. Adherence to ART, both during
and outside of pregnancy, is likely to be difficult to collect through an ongoing national-level
study. However, longer-term viral suppression in post-partum women could be assessed
through the linkage with SOPHID which collects information on a range of indicators among
those attending HIV care, including viral loads and CD4 counts. Again, monitoring
differences between women who remain on ART after pregnancy and discontinuers would
be helpful. It would also be informative to examine whether women who start and stop ART
with each pregnancy have a faster rate of CD4 count decline than those who have never
received ART (potentially utilising a ‘control’ group of as-yet untreated women present in
SOPHID). Additionally, the UK CHIC study, which has now been successfully linked with
the NSHPC, provides a rich source of data on patterns of ART use and clinical and
immunological trajectories during and outside of women’s pregnancies (Huntington et al,
2012). However, only a proportion of women reported to the NSHPC are captured by UK
CHIC, which is not a national study. Recent US data demonstrated that women who
maintained viral suppression between pregnancies had improved health at delivery of their
sequential pregnancies, as well as reduced rates of vertical transmission (Stewart et al,
2014). It would be interesting to explore this in the UK setting.
Given expanded access to ART in resource-limited settings and the global shift towards
earlier initiation of HIV treatment, together with the findings of this thesis, it seems
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inevitable that women will present in pregnancy with increasingly complex treatment
histories (either in the context of previous pregnancies or prior treatment for their own
health). There was no evidence that the use of short-course PI-based cART impacted on
response to therapy in subsequent pregnancies, supporting current UK recommendations
for the management of HIV in pregnancy. However, the lack of drug resistance data
hampered interpretation of the findings. There are currently no data on the prevalence of
drug resistance among HIV-positive pregnant women in the UK and Ireland, or the
contribution of short-course therapy for PMTCT to the development of resistance. This
thesis highlights the utility of data linkage; the high level of matching achieved between the
NSHPC and SOPHID paves the way for future linkages, particularly with other national
level datasets. Linkage with the UK Drug Resistance Database (currently underway) will
enable assessment of the prevalence of antiretroviral drug resistance in women’s index
pregnancies, and emergence of resistance in subsequent pregnancies. Investigation and
ongoing monitoring of drug resistance will be important to inform best clinical management
of women, with a view to the impact of current treatment decisions on future pregnancies
as well as women’s longer-term health and management.
Repeat pregnancies were more likely to be conceived on ART than index pregnancies, and
the proportion of all pregnancies conceived on treatment may increase given the move
towards earlier initiation of HIV treatment. Although the analyses showed that women were
not at increased risk of adverse perinatal outcomes at their repeat, as compared with index,
pregnancies, the risk of outcomes such as preterm delivery was high (13%). There is a
need for careful monitoring of perinatal outcomes, particularly for pregnancies conceived on
cART, in light of the uncertainties in the evidence-base for preterm delivery risk. This
should include assessment of the outcomes of antenatal exposure to newer antiretrovirals
and those used in third-line regimens. Information on co-infections (e.g. hepatitis B,
hepatitis C, syphilis) has been collected by the NSHPC since 2008 and future analyses
should explore how such co-infections may impact on pregnancy outcomes. The analyses
on preterm delivery risk also demonstrated the importance of women’s obstetric histories;
previous preterm delivery emerged as a very strong risk factor for preterm delivery in
subsequent pregnancies. This finding has implications for future analyses of preterm
delivery, an area of ongoing interest and research, which should be adjusted for prior
obstetric history. Such adjustments may also be an important consideration for analyses of
other adverse perinatal outcomes such as low birthweight. With respect to future NSHPC
data collection, requesting information on whether or not women’s previous unreported
pregnancies (e.g. those occurring prior to HIV diagnosis) were delivered preterm would aid
future analyses.
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Finally, there are complexities in the obstetric management of women’s repeat
pregnancies. This thesis provides the first national-level exploration of patterns in mode of
delivery in women’s sequential pregnancies. Almost a third of women delivering vaginally
had delivered their previous infant by caesarean section. The large pool of women with a
history of caesarean section birth(s), together with more recent guidelines specifically
recommending a vaginal delivery among eligible women (Taylor et al, 2012), means the
rate of vaginal deliveries in women with a history of caesarean section is likely to increase
in the coming years. Adverse outcomes such as uterine rupture, and the potential impact
on the risk of MTCT, should be closely monitored.
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Appendix II British HIV Association guidelines – key recommendations
Guidelines for the management of HIV in adults
2001 guideline 2005 guideline 2008 guideline 2012 guideline
CD4 count
threshold at
which to start
lifelong ART (in
patients with
chronic infection
and no other
indication for
treatment)
Before CD4 count falls to <200
cells/µl
Before CD4 count falls to <200
cells/µl
In patients with a CD4 count of
<350 cells/µl
In patients with a CD4 count of
≤350 cells/µl (note: ART 
initiation should not be delayed if
CD4 count is close to the
threshold)
Guidelines for the management of HIV in pregnancy
2001 guideline 2005 guideline 2008 guideline 2012 guideline
When to start
ART in
pregnancy
i) Women not
requiring
treatment for their
own health
No specific recommendation
regarding timing
Short-term ART
starting in the second trimester
with standard cART
regimens
Aim to start by 28 weeks, with a
possible earlier start between 20
and 24 weeks for women with
high baseline viral loads wanting
a vaginal delivery
All women should start by week
24 of pregnancy. Start at the
beginning of the second
trimester if baseline viral load is
>30,000 copies/ml, and
consider starting earlier if
>100,000 copies/ml
Continued overleaf
357
*The guideline allows for consideration of vaginal delivery in women on ART with an undetectable viral load, but notes that there is insufficient evidence for a recommendation.
Notes: This table provides an overview of changes over time in key recommendations that are of relevance to issues explored within this thesis. The guidelines themselves are
comprehensive and include contain further details, including specific recommendations for a range of clinical scenarios.
List of references to British HIV Association guidelines:
Adult guidelines: (BHIVA Writing Committee on behalf of the BHIVA Executive Committee, 2001; Gazzard, 2005; Gazzard et al, 2008; Williams et al, 2012)
Pregnancy guidelines: (de Ruiter et al, 2008; Hawkins et al, 2005; Lyall et al, 2001; Taylor et al, 2012)
Guidelines for the management of HIV in pregnancy
2001 guideline 2005 guideline 2008 guideline 2012 guideline
ii) Women
needing treatment
for their own
health (according
to adult
guidelines)
No specific recommendation
regarding timing. It is noted
that women should be
managed as if they were not
pregnant
No specific recommendation
regarding timing
Start ART early, although can
usually be deferred until after the
first trimester
Start ART as soon as possible
as per adult guidelines, but may
be delayed until after the first
trimester unless patient has an
opportunistic infection
What to start (in
women not
needing
treatment for
their own health)
Zidovudine monotherapy
(assuming low viral load of
<10,000-20,000 copies/ml).
Alternatively, short-course
cART may be considered
A protease inhibitor based
combination is recommended.
Alternatively, zidovudine
monotherapy in women with
viral loads of <10,000
copies/ml willing to deliver by
elective caesarean section
Standard cART regimens; to
contain zidovudine and
lamivudine if no contraindications.
Regimen should also contain a
boosted protease inhibitor
Boosted protease inhibitor-
based cART. Alternatively,
zidovudine monotherapy in
women with viral loads of
<10,000 copies/ml willing to
deliver by elective caesarean
section
Mode of delivery
(assuming no
contraindication)
Pre-labour caesarean section
for all women*
Elective caesarean section for
all women on zidovudine
monotherapy, and women on
cART with a detectable (≥50 
copies/ml) viral load
Elective caesarean section for all
women on zidovudine
monotherapy, and women on
cART with a detectable (≥50 
copies/ml) viral load
Vaginal delivery for women on
cART with a viral load <50
copies/ml plasma at 36 weeks.
Elective caesarean section for
all women on zidovudine
monotherapy
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Appendix III NSHPC data collection forms
i) Obstetric notification form (page 359)
ii) Obstetric outcome form (page 360)
iii) Paediatric notification form (page 361)
iv) Paediatric follow-up form (page 362)
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Appendix IV Log-log plots of time to second pregnancy
Figure A.1 Log-log plot of time to second pregnancy stratified by age group at first
reported pregnancy
Notes:
Log-log plot shows the probability of experiencing a repeat pregnancy against time since first pregnancy
on the log-log scale.
Analyses adjusted for the other variables in the multivariable model, namely year, region of origin and
parity (see Chapter 4, Table 4.5).
Comment on parallelism
Broadly speaking, the four lines in Figure A.1 may be considered to be reasonably parallel,
though overlapping. It should be remembered that the number of repeat pregnancies
experienced by women who were aged ≥35 years at their first reported pregnancy (the 
main contributor to the crossing of lines) was small (n=26).
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Figure A.2 Log-log plot of time to second pregnancy stratified by parity at first reported
pregnancy
Notes:
Log-log plot shows the probability of experiencing a repeat pregnancy against time since first pregnancy
on the log-log scale.
Analyses adjusted for the other variables in the multivariable model, namely year, maternal age, and
maternal world region of origin (see Chapter 4, Table 4.5).
Comment on parallelism
The four lines in Figure A.2 may be considered to be reasonably parallel, though
overlapping. The crossing of lines early in the analysis time occurs in the presence of
relatively few data points.
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Appendix V Log-log plots of time to initiation of antenatal ART
Figure A.3 Log-log plot of time to initiation of antenatal ART stratified by time period
Notes:
Log-log plot shows the probability of not initiating ART against time to treatment initiation on the log-log
scale.
Analyses adjusted for the other variables in the multivariable model, namely earliest antenatal CD4 count,
region of report, and earliest antenatal viral load (Chapter 5, Table 5.7).
Comment on parallelism
The four lines in Figure A.3 may be considered to be parallel. There are however some
crossing of lines, likely reflecting changes in guidelines and clinical practice over time in the
timing of ART initiation. It should be remembered that relative to later years, the number of
pregnancies during the earliest time period (2000-2002), which is the main contributor to
the crossing of lines, is small (n=40), with just two data points causing this data line to cross
the other three. Similarly, where the lines for 2006-2008 and 2009-2010 cross the number
of data points are small, after this, the lines consist of a much larger number of data points
and the two lines run parallel to each other.
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Figure A.4 Log-log plot of time to initiation of antenatal ART stratified by earliest
antenatal CD4 count
Notes:
Log-log plot shows the probability of not initiating ART against time to treatment initiation on the log-log
scale.
Analyses adjusted for the other variables in the multivariable model, namely time period, region of report,
and earliest antenatal viral load (see Chapter 5, Table 5.7).
Comment on parallelism
Similar to the previous figure, in Figure A.4, the early crossing of the lines for CD4 count
≥500 cells/µl and 350-499 cells/µl groups occurs in the presence of relatively few data 
points in both categories. That all lines appear to converge late in the analysis time should
be considered in context of the fact that only a very small proportion of women did not
receive antenatal ART (3% overall). The differences between groups at the end of the
analysis time will therefore be small (i.e. a matter of a percentage point or two).
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Appendix VI Algorithm used to match NSHPC with SOPHID
Match
level
Sex Date of
birth
Postcode/region Other
1 x x Full/part PC (PS+) at Notification
2 x x Full/part PC (PS+) at Delivery
3 x x Part PC (PS) at Notification
4 x x Part PC (PS) at Delivery
5 x x Scotland
6 x x Part PC (PD) at Notification Country of birth via new HIV
diagnosis
7 x x Part PC (PD) at Delivery Country of birth via new HIV
diagnosis
8 x x Part PC (PD) at Notification Site of treatment
9 x x Part PC (PD) at Delivery Site of delivery
10 x x Part PC (PD) at Notification Date diagnosis within 30 days
of date of first positive test
11 x x Part PC (PD) at Delivery Date diagnosis within 30 days
of date of first positive test
Definitions:
PC (postcode)
PS+ (postcode sector plus): full postcode minus the last character e.g. NW9 5E
PS (postcode sector): full postcode minus the last two characters e.g. NW9 5
PD (postcode district): 1st half of postcode e.g. NW9
Source: Provided by Cuong Chau, HIV and STI Department, Public Health England.
